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Culture-Derived Human Platelets for Clinical Transfusion
Abstract
Platelets are a vital component of human blood due to their role in clotting. Despite the incredible importance
of platelets for human survival, there is very little supply of platelets to meet the clinical demand. Currently,
platelets are only supplied from donations, whether through whole blood or apheresis. Therefore, there is a
need for ex vivo means of producing platelets at a price that is competitive with the current market price. This
project seeks to meet 65% of the demand for platelets in Philadelphia by producing platelets ex vivo in a
process that utilizes shear stress to induce platelet formation from megakaryocytes. To begin this batch
process, induced pluripotent stem cells derived from bone marrow are proliferated over the course of 10 days.
During a 20-day differentiation phase that occurs in 2 parallel 2000 L stirred single-use bioreactors, a number
of growth factors are supplied to the stem cell culture to induce differentiation of the cells into
megakaryocytes. The megakaryocytes, once mature, are exposed to shear stress in a specially developed
microfluidic device, inspired by the work done in Dr. Daeyeon Lee’s lab, to induce platelet formation. Once
platelets have been generated, they are processed over the course of 5 days to be separate, washed, and
concentrated in a resuspension solution via a series of centrifugation and mixing steps, after which they will be
packaged into platelet units and transported to surrounding hospitals for clinical transfusion. This process
design results a yearly production of 69,550 300 mL platelet units each year, with a platelet count of 5.5x1010
platelets in each unit. For this process, the IRR is 28.99%, the NPV is 14.4 million in the year 2030, and ROI is
23.21%.
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April	23,	2019	University	of	Pennsylvania	School	of	Engineering	and	Applied	Science	Department	of	Chemical	and	Biomolecular	Engineering	220	S.	33rd	Street	Philadelphia,	PA	19104		Dear	Professors	Vrana	and	Wattenbarger,		Enclosed	is	a	process	design	to	produce	ABO-compatible	culture-derived	human	platelets	for	clinical	transfusion.	The	proposed	design	aims	to	supply	65%	of	the	annual	platelet	need	for	the	city	of	Philadelphia.	Platelets	are	required	for	patients	experiencing	severe	blood	loss	due	to	trauma	and	patients	experiencing	conditions	associated	with	low	platelet	count,	such	as	cancer	and	immune	disorders.	Platelets	are	in	high	demand	and	have	a	traditionally	low	supply,	as	platelet	supply	comes	entirely	from	donations,	and	the	platelet	donation	process	is	lengthy	and	can	have	undesirable	side	effects.		The	enclosed	design	aims	to	use	induced	pluripotent	stem	cells	(iPSCs)	as	a	starting	point	for	producing	platelets.	iPSCs	will	be	proliferated	in	a	series	of	seed	bioreactors	and	then	differentiated	into	megakaryocytes	(MKs),	the	precursor	cell	to	platelets.	A	microfluidic	shear	device	will	then	be	used	to	convert	the	MKs	into	proplatelets	and	then	platelets.	The	platelets	will	then	undergo	a	series	of	downstream	processes	including	washing	and	six	disk-stack	centrifugation	steps	to	purify	the	product.	It	will	then	undergo	viral	inactivation	and	be	packaged	for	use	in	platelet	transfusions	in	hospitals	in	the	Philadelphia	area.		The	proposed	process	yields	0.669	kg	of	platelets	per	batch,	the	equivalent	of	1215	units	of	platelets.	A	new	batch	is	produced	every	five	days.	The	internal	rate	of	return	is	28.99%.	The	net	present	value	(NPV)	is	14.4	million	in	2030,	and	the	return	on	investment	(ROI)	is	23.21%.		The	information	within	stems	from	literature	on	platelet	formation	as	well	as	guidance	from	Dr.	Wattenbarger,	Dr.	Scott	Diamond,	Dr.	Daeyeon	Lee,	and	various	industrial	consultants.	Should	any	questions	or	need	for	supplemental	information	arise,	please	do	not	hesitate	to	reach	out	to	our	group.		Sincerely,					________________________________						________________________________									________________________________		 Alayna	Choo	 	 															Gabrielle	Leon	 	 							Susanna	Jaramillo				 	
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I.	Abstract	
	 Platelets	are	a	vital	component	of	human	blood	due	to	their	role	in	clotting.	Despite	the	incredible	importance	of	platelets	for	human	survival,	there	is	very	little	supply	of	platelets	to	meet	the	clinical	demand.	Currently,	platelets	are	only	supplied	from	donations,	whether	through	whole	blood	or	apheresis.	Therefore,	there	is	a	need	for	ex	vivo	means	of	producing	platelets	at	a	price	that	is	competitive	with	the	current	market	price.	This	project	seeks	to	meet	65%	of	the	demand	for	platelets	in	Philadelphia	by	producing	platelets	ex	
vivo	in	a	process	that	utilizes	shear	stress	to	induce	platelet	formation	from	megakaryocytes.	To	begin	this	batch	process,	induced	pluripotent	stem	cells	derived	from	bone	marrow	are	proliferated	over	the	course	of	10	days.	During	a	20-day	differentiation	phase	that	occurs	in	2	parallel	2000	L	stirred	single-use	bioreactors,	a	number	of	growth	factors	are	supplied	to	the	stem	cell	culture	to	induce	differentiation	of	the	cells	into	megakaryocytes.	The	megakaryocytes,	once	mature,	are	exposed	to	shear	stress	in	a	specially	developed	microfluidic	device,	inspired	by	the	work	done	in	Dr.	Daeyeon	Lee’s	lab,	to	induce	platelet	formation.	Once	platelets	have	been	generated,	they	are	processed	over	the	course	of	5	days	to	be	separate,	washed,	and	concentrated	in	a	resuspension	solution	via	a	series	of	centrifugation	and	mixing	steps,	after	which	they	will	be	packaged	into	platelet	units	and	transported	to	surrounding	hospitals	for	clinical	transfusion.	This	process	design	results	a	yearly	production	of	69,550	300	mL	platelet	units	each	year,	with	a	platelet	count	of	5.5x1010	platelets	in	each	unit.	For	this	process,	the	IRR	is	28.99%,	the	NPV	is	14.4	million	in	the	year	2030,	and	ROI	is	23.21%.		 	
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II.	Introduction	and	Objective-Time	Chart	
2.1	Introduction		 Platelets	are	the	primary	agents	in	the	blood	that	aid	with	clotting.	When	a	healthy	person	cuts	him	or	herself,	platelets	are	activated,	which	causes	the	blood	to	clot	at	the	laceration	and	wound	repair	to	begin.	If	someone	experiences	severe	trauma,	however,	they	may	require	a	larger	supply	of	platelets	than	their	body	is	producing	to	improve	the	wound	repair	process.	Additionally,	there	are	a	number	of	different	diseases	or	medicines	that	can	lead	to	low	platelet	counts	or	poorly-functioning	platelets,	including	cancer	and	thrombocytopenia.	People	in	any	of	these	situations	may	require	a	platelet	donation,	but	because	platelet	supply	for	transfusions	relies	solely	on	donations,	there	is	a	great	lack	in	availability.	At	any	given	time,	platelet	supply	operates	at	a	margin	of	10%	supply	versus	demand.1	Additionally,	platelet	donations	are	time-consuming	and	can	cause	undesirable	side	effects	in	donors.	A	donor-independent	source	of	platelets	would	greatly	alleviate	these	issues.	
2.2	Biological	Background		 Platelets	are	formed	in	the	body	from	megakaryocytes	(MKs)	in	the	final	stage	of	megakaryocyte	development.2	MKs	are	specialized	cells	derived	from	hematopoietic	stem	cells,	which	are	stem	cells	that	will	differentiate	into	various	blood	cells.	Via	the	addition	of	various	growth	factors,	proteins,	cytokines,	and	other	reagents,	stem	cells	can	be	forced	to	differentiate	into	MKs	in	vitro.				 The	ex	vivo	process	of	generating	platelets	on	an	industrial	scale	will	begin	with	the	proliferation	of	induced	pluripotent	stem	cells,	or	iPSCs.	During	this	process,	the	iPSCs	will	be	inhibited	from	differentiating,	and	will	instead	be	induced	to	remain	in	their	pluripotent	
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state.	iPSCs	are	pluripotent	cells,	meaning	that	they	have	the	ability	to	differentiate	into	many	different	cells.	iPSCs	can	be	derived	from	various	adult	stem	cells.	When	those	stem	cells	are	cultured,	they	are	reverted	back	to	their	pluripotent	state,	creating	iPSCs.	The	differentiation	process	from	iPSCs	to	MKs	can	be	controlled	based	on	the	molecules	involved	in	formation	of	hematopoietic	stem	cells	and	MKs	in	vivo.	After	proliferation	to	large	cell	counts,	the	iPSCs	will	be	differentiated	to	hematopoietic	progenitor	cells,	which	are	precursors	to	MKs,	and	then	will	be	further	differentiated	into	megakaryocytes.		 After	MKs	have	been	formed,	they	will	be	flowed	through	a	bioreactor	designed	specifically	for	this	process	that	has	higher	levels	of	shear	stress	than	the	stirred	tank	bioreactor.	In	vivo,	platelets	are	formed	when	MKs	travel	from	the	bone	marrow	to	the	bloodstream.	As	the	MKs	flow	out	of	the	bone	marrow,	long	branches	called	proplatelets	begin	to	extend	from	the	MK	molecule.2	Eventually,	platelets	are	released	from	the	tips	of	the	proplatelets,	a	process	that	happens	spontaneously	in	the	body	but	can	be	aided	ex	vivo	by	applying	shear	stress.		
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Figure	2.2.1.	Platelet	Formation	from	Megakaryocytes.	This	figure	demonstrates	the	formation	of	platelets	from	MKs	in	the	body.	Proplatelets,	or	long	tubules,	form	on	the	MK,	and	then	the	proplatelets	are	sheared	off	in	the	body	to	form	platelets.3	
	
2.3	Motivation	Platelets	are	specialized	blood	cells	that	help	the	body	form	clots	to	stop	bleeding.	In	instances	such	as	serious	injuries,	surgeries,	and	chemotherapy,	platelet	counts	can	reach	dangerously	low	levels,	putting	patients	at	risk	of	heavy	bleeding.	In	these	cases,	platelet	transfusions	are	performed	to	replenish	the	platelet	count	in	these	patients.	Approximately	2.2	million	units	of	platelets	are	used	in	transfusions	each	year	in	the	United	States,	with	an	estimated	7,000	units	of	platelets	being	used	every	day.4 However,	the	current	platelet	supply	meets	only	10%	of	the	demand	on	average.1	This	means	that	whenever	there	is	an	accident	or	natural	disaster,	platelet	supply	drops	to	dangerously	low	levels.	An	additional	platelet	source	would	help	mitigate	these	types	of	issues.		
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Additionally,	the	only	source	for	platelets	currently	is	donation.	The	donation	process	is	much	more	involved	than	regular	blood	donation	because	it	involves	removing	blood	from	the	body,	filtering	out	the	platelets,	and	returning	the	blood	and	other	fluids	to	the	donor’s	body.	Collection	takes	roughly	two	hours,	and	some	donors	report	undesired	side	effects	such	as	dizziness	and	stomach	pain	afterward.5	Introducing	a	donor-independent	platelet	source	would	reduce	the	number	of	these	arduous	procedures	required.	 	
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2.4	Project	Charter	
Project	Name	 Culture-Derived	Human	Platelets	for	Clinical	Transfusion	
Leaders	 Alayna	Choo,	Gabrielle	Leon,	Susanna	Jaramillo	
Project	Scope	 In	Scope	
● Manufacturing	process	to	produce	69,550	units	of	ABO-compatible	platelets	each	year	to	supply	65%	of	the	annual	need	in	Philadelphia	
● Post-manufacturing	separation	and	purification	process	to	ensure	safety	of	manufactured	platelets	
● Testing	of	final	product	to	ensure	safety	and	efficacy	
● Design	of	manufacturing	equipment	and	facilities	
● Rigorous	economic	analysis	to	determine	feasibility	of	venture	
● Adherence	to	health	and	safety	guidelines		Out	of	Scope	
● Laboratory	research	and	development		○ Kinetics	of	differentiation	under	variable	conditions	○ Yield	of	platelets	from	megakaryocytes	under	variable	conditions	
● Design,	funding,	and	performance	of	clinical	trials	
● Obtaining	FDA	approval	for	a	Biologic	License	Application	
● Harvesting	of	unused	megakaryocytes	from	spent	media	streams	as	a	potential	byproduct	
● Pilot	plant	study	to	analyze	optimal	conditions	for	cell	growth	and	differentiation	
Deliverables	 Business	Opportunity	Assessment	
● What	are	the	current	and	projected	market	and	competitive	landscapes	for	universally	compatible	platelets?	
● What	advantages	do	culture-derived	platelets	provide	over	traditional	donated	platelets?	
● What	are	the	ROI,	IRR,	and	NPV	for	this	project?	Technical	Feasibility	Assessment	
● Is	it	possible	to	produce	69,550	units	of	platelets	each	year	to	supply	65%	of	need	in	Philadelphia?	Manufacturing	Capability	Assessment		
● What	capital	investment	will	be	required	to	build	the	platelet	production	facility?	
● Will	this	process	and	its	products	meet	FDA	requirements?	
Timeline	 Design	of	the	process,	equipment	and	facility	as	well	as	a	rigorous	economic	analysis	will	be	completed	in	four	months.	
	 	
7	
2.5	Objective-Time	Chart	
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III.	Innovation	Map	
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IV.	Market	and	Competitive	Assessment	
4.1	Choice	of	Production	Level	and	Plant	Location		 A	2013	Blood	Survey	Report	by	the	AABB,	a	not-for-profit	organization	that	develops	standards	and	provides	accreditation	for	transfusion	medicine	and	cellular	therapies,	found	that	1.24	million	platelet	apheresis	procedures	were	conducted	across	all	AABB	registered	centers	in	the	United	States.6	This	amounts	to	2.2	million	units	of	platelets.	At	any	given	time,	platelet	supply	meets	roughly	10%	of	demand,1	indicating	that	22	million	units	of	platelets	are	required	annually	in	the	United	States.	Since	a	singular	facility	cannot	feasibly	service	the	entire	country,	we	have	decided	to	limit	the	scope	of	this	project	to	one	large	metropolitan	area.	Philadelphia	was	chosen	because	there	are	sixteen	hospitals	containing	cancer	treatment	and	trauma	centers	within	its	city	limits,	allowing	the	facility	to	impact	a	large	number	of	patients	requiring	platelet	apheresis	procedures.	Assuming	platelet	demand	in	Philadelphia	is	proportional	to	overall	platelet	demand	in	the	United	States,	approximately	107,000	platelet	units	are	required	annually.		 Platelet	donation	is	currently	the	only	method	of	platelet	production,	so	there	is	no	major	competition	in	the	immediate	future.	One	other	company,	Platelet	BioGenesis,	has	patented	a	specialized	bioreactor	to	manufacture	man-made	platelets,	but	it	is	still	in	the	preclinical	stages	of	development.7	Given	the	scarce	competitive	landscape	and	the	constant	shortage	of	donated	platelets,	our	facility	will	aim	to	produce	65%	of	annual	demand	in	the	Philadelphia	area,	or	69,550	units	of	platelets	per	year.	One	unit	of	whole-blood-derived	platelets	contains	approximately	5.5x1010	platelets	in	a	300	mL	bag.	These	platelets	will	then	be	concentrated	and	pooled	together	with	other	platelets	before	transfusion.	Apheresis	platelet	units	have	a	higher	concentration	and	are	usually	diluted	
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before	platelet	transfusion.	For	this	project,	the	platelet	unit	that	are	generated	will	be	similar	to	the	pre-pooled	platelet	unit	and	will	contain	the	same	concentration	as	whole-blood	units.8	 	
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V.	Customer	Requirements	
5.1	Customer	Analysis		 Patients	receive	platelet	transfusions	under	several	different	circumstances.	Platelets	are	often	required	when	patients	experience	severe	trauma	and	major	bleeding.	There	are	also	several	medical	conditions	associated	with	low	platelet	count.	Thrombocytopenia,	a	condition	in	which	patients	have	abnormally	low	platelet	counts,	can	result	from	a	number	of	conditions	such	as	immune	diseases	or	leukemia.9	Cancer	patients	in	general	often	need	to	receive	platelet	transfusions	because	chemotherapy	destroys	platelet	precursor	cells	in	the	bone	marrow.10	Overall,	almost	7,000	platelet	units	are	required	in	the	United	States	every	day.4	
5.2	ABO	Compatibility	While	ABO	blood	type	matching	is	required	for	safe	blood	transfusions,	platelets	do	not	need	to	be	ABO	matched	for	a	transfusion	to	be	successful.	A	2007	survey	by	Fung	et	al.	found	that	17%	of	hospitals	do	not	have	formal	ABO	policies	regarding	platelet	transfusions,	and	roughly	half	of	hospitals	with	such	policies	give	ABO	incompatible	platelets	if	compatible	platelets	are	unavailable.11	Though	not	necessary,	it	is	still	ideal	for	patients	to	receive	platelet	transfusions	from	their	same	blood	group	because	major	mismatches	in	blood	group	can	sometimes	lead	to	hemolysis	or	reduced	platelet	count	depending	on	the	health	of	the	recipient.	It	would	be	ideal	to	circumvent	such	blood	group	mismatch	issues	by	developing	a	universally	compatible	platelet.	This	will	be	possible,	given	the	existence	of	a	naturally	occurring	nearly-universal	platelet	from	the	blood	type	A	subgroup	A2,	which	does	not	
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express	the	A	antigen.12	In	order	to	improve	ABO	compatibility	of	the	platelet	product,	the	iPSC	source	will	be	from	bone	marrow	donated	from	a	person	with	type	A2	blood.		
5.3	Decreasing	Alloimmune	Response	to	Platelets	
	 While	ABO	compatibility	is	not	a	huge	concern,	HLA	compatibility	is.	HLA	is	a	surface	protein	on	platelets	that	can	elicit	a	major	alloimmune	response	during	transfusion	when	the	person	receiving	the	transfusion	has	platelets	from	a	different	HLA	class	than	the	platelets	themselves.	In	order	to	overcome	this	issue,	the	iPSCs	will	be	gene	edited	to	delete	an	HLA	Class	I-associated	molecule,	beta-2	microglobulin.	Deletion	of	this	gene	creates	an	HLA	downregulated	cell	and	therefore	platelet,	which	should	aid	in	the	universal	compatibility	of	the	platelet	product.13	
5.4	Hospital	Storage	Requirements		 While	the	eventual	user	of	the	product	is	a	hospital	patient,	the	hospitals	are	the	primary	customer	for	this	process.	The	platelet	units	exiting	downstream	processing	each	day	will	be	distributed	to	nearby	hospitals.	The	shelf	life	of	a	platelet	is	a	mere	five	to	seven	days,	so	the	it	is	vital	that	the	hospitals	receive	the	platelet	product	as	rapidly	as	possible.	In	the	current	design,	platelets	will	reach	the	hospital	less	than	48	hours	after	being	produced,	so	the	platelets	will	still	have	three	to	five	days	of	vitality.	Additionally,	platelets	must	be	produced	in	accordance	with	hospital	safety	requirements	and	must	be	stored	in	the	conditions	necessary	to	retain	vitality.	Platelets	must	be	stored	at	temperatures	ranging	from	20°C	to	24°C	in	a	clean	environment.27,28	 	
13	
VI.	CTQ	Variables	-	Product	Requirements	N/A		 	
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VII.	Product	Concepts	
7.1	Selection	of	Stem	Cell	Source		 Induced	pluripotent	stem	cells	(iPSCs)	were	selected	as	the	cell	source	for	this	process.	iPSCs	are	adult	cells	derived	from	skin	or	blood	cells	that	have	been	reprogrammed	back	into	a	pluripotent	state.	iPSCs	are	a	recent	development,	having	been	isolated	by	researchers	in	2007.	Since	their	discovery,	they	have	been	successfully	differentiated	into	neurons,	egg	and	sperm	cell	precursors,	and	blood	cells,	among	other	cell	types.14	iPSCs	are	an	ideal	candidate	for	platelet	formation	because	they	can	be	cultured	into	hematopoietic	stem	cells	that	are	precursors	to	megakaryocytes.	They	are	also	highly	proliferative	and	have	a	relatively	short	doubling	time	of	18-20	hours.24	iPSCs	are	readily	available	and	reasonably	priced	at	roughly	$1000/vial	from	several	vendors	such	as	Sigma	Aldrich	and	ThermoFisher,	though	iPSCs	will	be	banked	in	a	cell	bank	specific	to	this	process	once	the	project	moves	past	the	bench	scale.	Each	vial	contains	a	one	milliliter	suspension	of	one	million	cells.		 Several	alternatives	to	iPSCs	were	considered	for	selection	because,	while	promising,	iPSCs	are	a	relatively	recent	development	that	have	not	yet	been	used	in	any	FDA-approved	therapies.	Cell	sources	such	as	hematopoietic	stem	cells,	human	embryonic	stem	cells,	and	megakaryocytes	were	also	considered.		 Hematopoietic	stem	cells	(HSCs)	are	found	in	the	peripheral	blood	and	blood	marrow.	They	have	been	successfully	differentiated	into	all	types	of	blood	cells,	including	platelets,	making	them	an	attractive	candidate.15	However,	availability	of	HSCs	is	dependent	upon	donations	of	blood	marrow,	an	invasive	and	burdensome	process.	Since	
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the	purpose	of	this	project	is	to	provide	platelets	while	circumventing	the	lengthy	and	unreliable	donor	process,	HSCs	were	not	selected	for	this	process.		 Human	embryonic	stem	cells	(hESCs)	were	also	considered.	hESCs	are	derived	from	embryos	that	develop	from	eggs	that	have	undergone	in	vitro	fertilization	and	been	donated	for	research.16	While	hESCs	are	attractive	candidates	due	to	their	virtually	unlimited	development	potential,	many	groups	have	expressed	ethical	concerns	with	using	hESCs	because	it	involves	the	destruction	of	a	human	embryo.	Given	that	iPSCs	have	also	showed	promise	for	platelet	formation	and	do	not	come	with	the	ethical	qualms	attached	to	hESCs,	iPSCs	were	selected	over	hESCs.		 Megakaryocytes	(MKs),	large	bone	marrow	cells	that	are	precursors	to	platelets,	were	also	considered	as	a	cell	source	for	platelet	formation.	MKs	would	be	a	convenient	choice	because	they	are	further	along	in	the	differentiation	pathway	than	stem	cells.	This	would	eliminate	several	upstream	steps,	cutting	the	cost	of	raw	materials	such	as	growth	and	differentiation	media	as	well	as	the	time	required	for	platelet	formation.	However,	MKs	are	not	very	proliferative,	and	the	amount	of	MKs	required	to	produce	the	desired	number	of	platelets	would	be	extraordinarily	high.	Additionally,	nearly	all	peer-reviewed	studies	of	producing	platelets	have	used	stem	cells	further	back	in	the	differentiation	process	than	MKs,	so	rather	than	devote	extra	resources	to	figuring	out	how	to	start	with	MKs,	iPSCs	were	selected.	
7.2	Alternative	Products	
	 Though	the	question	statement	for	this	project	specifically	requested	a	process	for	producing	platelets,	an	alternative	product	concept	we	considered	was	simply	producing	megakaryocytes.	This	would	eliminate	the	need	for	the	microfluidic	shear	device	and	some	
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of	the	downstream	processing	separation	steps.	However,	there	would	be	a	time	lag	between	megakaryocytes	being	transfused	and	platelets	being	formed	and	available	for	use.	Transfusing	full	cells	into	humans	could	also	potentially	be	tumorigenic,	which	would	lead	to	more	challenging	FDA	approval	and	a	riskier	product.	Additionally,	after	conducting	a	literature	search,	no	studies	were	found	in	which	megakaryocytes	were	transfused	into	patients.	This	lack	of	precedent	and	the	corresponding	research	that	would	have	to	be	done	to	determine	the	worthiness	of	this	idea	coupled	with	the	time	lag	between	transfusion	and	platelet	production	made	this	a	less	attractive	alternative	product	concept	for	this	project,	and	it	was	abandoned	early	on	in	the	development	process.		 An	additional	alternative	we	looked	at	was	the	creation	of	synthetic	platelets	using	poly(lactic-co-glycolic	acid)-poly-L-lysine	(PLGA-PLL)	conjugated	with	PEG	arms.	An	experiment	conducted	by	scientists	from	four	American	universities	tested	the	efficacy	of	PEGylated	PGLA-PLL	for	application	in	blood	clotting.	The	synthetic	platelets	were	tested	in	
vitro	to	test	for	binding	efficiency	to	activated	platelets	and	in	vivo	using	a	major	femoral	artery	injury	in	a	rate.	The	nanospheres	used	in	the	rate	testing	led	to	a	significant	reduction	in	bleeding	time,	which	paralleled	the	in	vitro	findings.	The	synthetic	platelets	were	observed	in	the	animal	system	over	the	course	of	7	days,	and	the	findings	indicated	that	all	synthetic	platelets	had	cleared	from	circulation	after	7	days,	no	adverse	effects	were	observed	in	any	animals	tested,	and	the	platelet	efficacy	was	increased.	While	this	option	seemed	promising,	this	method	relied	heavily	on	activated	platelets	already	present	within	the	body.	Additionally,	the	synthetic	platelets	were	only	tested	over	a	7-day	period	in	rats,	and	used	materials	that	were	not	already	FDA-approved	for	use	in	humans.17	Additionally,	the	ability	for	scale-up	of	the	process	was	unclear.	Thus,	this	particular	
17	
process	was	ultimately	taken	out	of	consideration	and	only	became	of	note	for	competitive	analysis	of	our	process.		 	
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VIII.	Superior	Product	Concepts	
	 The	final	process	design	-	to	produce	universally	compatible	platelets	from	induced	pluripotent	stem	cells	-	provides	many	final	product	advantages	as	compared	to	other	possibilities.	One	of	the	most	important	qualities	of	a	biological	product	is	whether	or	not	it	is	carcinogenic	or	tumorigenic.	Stem	cell	therapy	often	sounds	like	an	attractive	option	because	it	would	allow	for	a	patient	to	produce	their	own	platelets	as	needed	and	would	be	a	cheaper,	quicker,	and	less	complex	process.	However,	stem	cells	and	even	multipotent	or	fully-differentiated	daughter	cells	have	the	ability	to	be	tumorigenic	in	humans.	Unlike	cells,	however,	platelets	do	not	have	nuclei.	Consequently,	platelets	developed	in	vitro	have	shown	to	not	possess	tumorigenic	capabilities.			 Additionally,	platelet	transfusions	are	often	performed	during	emergency	traumas.	Transfusing	platelets	would	allow	for	nearly	immediate	clotting	action	to	occur	and	would	likely	be	one	of	the	most	effective	ways	to	treat	a	patient	with	severe	bleeding.			 	
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IX.	Competitive	(Patent)	Analysis	
	 Only	one	company	currently	holds	a	patent	related	to	producing	ABO-compatible	platelets	in	a	specialized	bioreactor.	The	patent	is	held	by	Jonathan	Thon,	the	Chief	Executive	Officer	of	Platelet	Biogenesis.	The	company’s	mission	is	to	produce	immunoprivileged	platelets	on-demand	from	induced	pluripotent	stem	cells.7	The	company	is	still	in	the	preclinical	stages	of	development	but	has	raised	over	$14.6	million	in	five	rounds	of	funding	from	several	investors,	including	the	United	States	Department	of	Defense.18		 Dr.	Thon’s	patent,	entitled	“System	and	Method	for	Producing	Blood	Platelets,”	details	a	microfluidic	device	used	to	convert	megakaryocytes	into	platelets.	The	device	consists	of	two	substrates	separated	by	a	permeable	membrane	that	creates	a	network	of	microfluidic	channels.	The	first	substrate	contains	several	inlet	channels	extending	in	the	longitudinal	direction,	while	the	second	substrate	contains	the	same	number	of	outlet	channels	also	extending	longitudinally.	The	permeable	membrane	is	arranged	between	the	two	substrates,	with	the	first	substrate	containing	the	inlet	channels	stacked	on	top	of	the	second	substrate	containing	the	outlet	channels.19	Proplatelets,	the	elongations	extending	from	megakaryocytes	in	the	final	stages	of	platelet	formation,	extend	through	the	permeable	membrane,	and	the	shear	they	experience	as	the	megakaryocytes	flow	through	the	device	causes	platelets	to	be	released	from	the	proplatelets.	The	bioreactor	is	designed	to	be	stackable	so	that	platelet	production	can	be	scaled	up	relatively	quickly.		Each	device	can	process	between	5,000	and	150,000	microliters	per	hour.	The	bioreactor	can	be	scaled	to	different	sizes,	but	the	base	of	the	bioreactor	chip	assembly	is	the	size	of	a	standard	96	well	microplate	(127.8	mm	x	81.1	mm	x	14.4	mm).	While	the	
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overall	concept	of	Thon’s	patent	is	similar	to	the	microfluidic	device	designed	for	this	project,	a	device	of	this	flow	capacity	would	not	be	sufficient	for	our	process,	which	aims	to	produce	69,550	units	of	platelets	per	year.	This	evens	out	to	roughly	500	liters	that	need	to	be	processed	by	the	microfluidic	device	each	day.	Our	design	will	thus	be	different	in	that	it	is	able	to	process	higher	flow	rates	and	produce	more	platelets	per	device.	 	
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X.	Preliminary	Process	Synthesis	
An	alternative	option	to	the	shear	vessel	presented	in	the	previous	section	was	a	silk	bone	marrow	niche	based	on	a	3D	silk	niche	developed	by	researchers	from	the	University	of	Pavia	in	Italy	and	Tufts	University.	In	the	body,	bone	marrow	is	comprised	of	hematopoietic	tissue	and	adipose	cells	surrounded	by	vascular	sinuses.	These	structures	are	interspersed	in	a	mesh	of	spongy,	trabecular	bone.20	In	a	lab	setting,	the	paper	authors	were	able	to	create	a	silk	scaffold	comprised	of	a	1%	weight	by	volume	silk	solution	using	silkworm	cocoons	cast	on	polydimethylsiloxane	in	varying	patterns.	The	scaffold	structures	were	dried	for	16	hours	at	22°C.	These	formations	were	water	annealed	for	varying	lengths	of	time	at	various	temperatures	in	order	to	achieve	high,	medium,	and	low	silk	film	mechanical	properties.	The	researchers	additionally	created	an	extracellular	matrix	composed	of	25	µg/mL	type	I	collagen,	100	µg/mL	fibrinogen,	25	µg/mL	fibronectin,	and	25	µg/mL	type	IV	collagen	or	laminin,	depending	on	the	test.	In	some	experiments,	the	ECM	was	mixed	with	500	ng/mL	VCAM-1,	a	vascular	cell	adhesion	molecule	and	vascular	endothelial	growth	factor	(VEGF).	This	ECM	was	then	added	to	the	silk	film.		In	order	to	replicate	the	microvasculature	of	the	bone	marrow,	gel-spun	microtubes	were	created	using	a	15%	aqueous	silk	solution	mixed	with	fibronectin,	type	IV	collagen,	and	laminin	at	a	final	concentration	of	25	µg/mL	with	300	ng/mL	stromal	cell-derived	factor.	The	tubes	were	perforated	with	pores	using	a	6%	weight	by	volume	PEO.	The	pores	created	were	large	enough	to	allow	platelets	to	pass	through	while	being	too	small	for	megakaryocytes	to	pass.		Similar	to	the	silk	scaffold,	the	synthetic	microvasculature	was	
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mixed	with	VCAM-1	and	VEGF	for	some	experiments.		The	final	silk	tubes	were	subsequently	trimmed	to	~1.5	cm	and	secured		within	their	reactor	chamber.		Finally,	through	a	salt-leaching	process,	a	porous	silk	sponge	was	assembled	around	the	silk	microtube.	An	8%	silk	solution	was	dispensed	around	the	tubing,	and	sodium	chloride	particles	were	added	to	the	solution.	The	scaffolds	and	tubing	were	then	left	at	room	temperature	for	48	hours	and	soaked	in	DI	water	for	an	additional	48	hours	in	order	to	leach	out	the	NaCl	particles.						 			 The	structure	they	were	able	to	generate	provided	a	relatively	direct	analogue	to	bone	marrow	and	the	production	of	platelets	in	the	body.	The	mesh	system	was	seeded	with	2.5x105	megakaryocytes,	and	the	silk	microtube	was	then	perfused	with	culture	media	at	a	shear	rate	of	60s-1,	which	is	analogous	to	the	shear	rate	in	the	body.	On	average,	they	were	able	to	retrieve	1.4x106	platelets	per	perfusion	system,	and	the	product	platelets	were	directly	collected	into	platelet	collection	bags.21	This	design	initially	seemed	promising	given	a	few	key	factors,	the	first	being	that	this	design	would	provide	a	very	direct	analogue	to	the	way	that	platelets	are	formed	in	the	bone	marrow,	mimicking	the	spongy	matrix	very	directly.	Additionally,	the	use	of	silk	in	the	process	would	likely	not	have	provided	difficulties	in	FDA	approval,	since	silk-based	
Figure	10.1.	Illustration	of	the	overall	platelet	production	process	and	the	structure	of	the	silk	bone	marrow	niche. 
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materials,	such	as	stitches,	are	already	used	in	medical	procedures	and	all	additional	materials	used	in	the	process	were	biological	materials	that	are	commonly	used	in	the	medical	field.	Finally,	the	residence	time	of	megakaryocytes	in	the	flow	system	was	relatively	short	at	just	24	hours.		Despite	its	potential	benefits,	however,	it	was	ultimately	decided	that	this	particular	design	would	not	be	suitable	for	this	process.	The	first	reason	for	this	was	largely	based	on	the	fact	that	the	scalability	of	the	system	would	have	been	very	difficult.	The	niche	system	did	not	provide	a	high	enough	platelet	yield,	when	compared	to	the	estimates	for	the	number	of	platelets	that	can	be	achieved	from	an	individual	megakaryocyte	in	a	shear	vessel.	Additionally,	the	preparation	time	of	the	shear	unit	itself	would	have	to	span	multiple	days,	which	would	further	complicate	scale-up.	Furthermore,	the	niche	would	be	nearly	impossible	to	sterilize	between	uses,	thus	rendering	it	unusable	after	one	production	cycle.	This	would	mean	that	lab	staff	would	have	to	prepare	the	silk	niche	network	prior	to	each	cycle,	which	would	be	a	relatively	time	and	resource-intensive	process.	Thus,	it	was	concluded	that	this	particular	proposed	design	would	be	infeasible	given	the	nature	of	the	process.			 	
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XI.	Assembly	of	Database	
For	calculations	regarding	utilities,	physical	properties	of	water	were	used	at	the	selected	temperature	and	pressure	–	this	includes	viscosity,	density,	and	other	similar	properties.	 	
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XII.	Process	Flow	Diagram	and	Material	Balances	
12.1	Summary	of	Process	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	 	
Figure	12.1.1.	Shown	above	is	the	overall	process	flow	diagram,	simplified	and	separated	into	the	major	processes.	After	platelet	formation,	the	process	is	split	into	two	parallel	streams	for	downstream	processing.	The	shear	vessel	for	platelet	formation	will	operate	over	the	course	of	5	days	for	8	hours	each	day.	So,	one-fifth	of	the	total	platelet	suspension,	or	513.4	L,	will	be	processed	downstream	each	day.	
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Material	 Total	Mass	In	(kg)	 Total	Mass	Generated	(kg)	 Total	Mass	Out	in	Product	(kg)	 Total	Mass	Consumed	(kg)	 Total	Mass	in	Waste	(kg)	
Platelets	 0	 1.137	 0.670	 0	 0.468	
iPSCs	 0	 0.103	 0	 0.103	 0	
MKs	 0	 2.583	 0	 1.133	 1.450	
IMDM	+	Nutrients	 2703.254	 0	 1.378	 1.123	 2700.753	Tyrode's	Soln	+	Trisodium	Citrate	 3786.748	 0	 20.171	 0	 3766.578	
PAS-E/Plasma	 5447.326	 0	 343.546	 0	 5103.780	
Oxygen	 1.044	 0	 0.016	 0.421	 0.607	
TOTAL	 11938.372	 3.824	 365.780	 2.780	 11573.635	
	
	 	
Table	12.1.1.	This	is	the	overall	mass	balance	that	shows	the	mass	input	of	each	material	into	the	entire	batch	process	and	the	total	mass	output	of	each	material	from	the	entire	batch	process.	The	total	waste	represents	the	total	amount	of	waste	collected	from	each	batch	that	will	be	treated	with	bleach	according	to	NIH	guidelines.	
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12.2	Upstream	Process	Design	
	
	
	
	
	
	
	
	
	
	
	
	
	
	 					 	
Figure	12.2.1.	This	figure	shows	the	detailed	process	flow	diagram	for	the	upstream	process,	which	includes	iPSC	proliferation,	differentiation	into	MKs,	and	platelet	development	collection.	
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	Table	12.2.1a	and	12.2.1b.	In	these	tables,	all	of	the	masses,	flow	rates,	pressures,	and	compositions	of	each	stream	in	the	upstream	process	are	described.	(a)	
(b)	
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12.3	Downstream	Process	Design	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	 	
Figure	12.3.1.	This	figure	shows	the	detailed	process	flow	diagram	for	the	downstream	process,	which	platelet	separation,	washing,	and	resuspension.	In	the	final	steps,	the	platelets	will	undergo	viral	inactivation	and	will	then	be	stored	and	prepared	for	distribution.	
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Table	12.3.1.	In	these	tables,	all	of	the	masses,	flow	rates,	pressures,	and	compositions	of	streams	19	through	27	in	the	downstream	process	are	described.	
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Table	12.3.2.	In	these	tables,	all	of	the	masses,	flow	rates,	pressures,	and	compositions	of	streams	28	through	36	in	the	downstream	process	are	described.	
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Table	12.3.3.	In	these	tables,	all	of	the	masses,	flow	rates,	pressures,	and	compositions	of	streams	37	through	45	in	the	downstream	process	are	described.	
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	 	Table	12.3.4.	In	these	tables,	all	of	the	masses,	flow	rates,	pressures,	and	compositions	of	streams	46	and	47	in	the	downstream	process	are	described.	
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XIII.	Process	Descriptions	
Shown	in	Figures	12.2.1	and	12.3.1	are	the	process	flow	diagrams	for	the	platelet	production	and	purification	process.	The	process	can	be	divided	into	a	number	of	subprocesses,	as	shown	in	Figure	12.1.1:	iPSC	proliferation,	iPSC	differentiation	into	MKs,	platelet	formation,	platelet	accumulation,	platelet	separation,	platelet	washing,	platelet	resuspension,	viral	inactivation,	and	storage	and	distribution.	For	each	step	of	the	process,	different	reactors,	vessels,	and	separation	equipment	are	used	that	are	best	suited	for	the	needs	of	the	cells	and	products	contained	within.	Tables	detailing	the	mass	balance	performed	on	each	unit	can	be	found	in	Appendix	C.	
13.1	Proliferation	of	iPSCs	The	iPSCs	will	be	proliferated	in	a	ten-day,	three-step	seed	train.	In	this	seed	train,	the	volumes	of	the	bioreactors	will	be	10	L,	50	L,	and	250	L.	A	seed	train	has	been	selected	because	it	allows	for	easy	testing	and	control	of	the	cells.	By	limiting	the	volume	of	cells	in	each	step,	any	contamination	or	issues	can	be	controlled	for,	and	the	process	can	start	over	without	losing	much	time.	Additionally,	the	volume	constraints	ensure	that	cell	growth	will	not	be	limited	by	lack	of	nutrients	or	space	to	proliferate.	The	working	volumes	of	culture	media	in	each	bioreactor	have	been	determined	by	capping	the	concentration	of	the	iPSCs	in	each	bioreactor	to	1x106	cells/mL.	During	every	step	of	proliferation,	the	iPSCs	will	be	cultured	in	a	mammalian	cell	media	composed	of	FDA-approved	components.	Specifically,	Iscove’s	Modified	Dulbecco’s	Medium	(IMDM)	will	be	the	basis	of	the	culture.	Plasbumin,	which	is	a	recombinant	form	of	the	protein	albumin,	will	be	added	in	a	concentration	of	50	g/L,	and	Rock	Inhibitor	(Y-27632)	will	be	added	to	the	media	in	a	concentration	of	10	
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micromolar	to	increase	single	cell	survival.22	The	IMDM	media	will	be	prepared	by	mixing	it	with	the	powder	nutrients	in	a	large	vessel.	To	begin	the	process,	10x106	cells	will	be	seeded	into	a	10	L	stirred-bioreactor	with	a	5	L	working	volume	(stream	1	in	Figure	12.2.1)	containing	the	growth	media.	5.25001	kg	of	IMDM	and	nutrient	rich	growth	media	will	have	been	loaded	into	the	vessel	via	stream	2	prior	to	inoculation.	Sterilized	oxygen	gas	will	also	be	supplied	to	the	culture	as	needed	to	maintain	a	5%	pO2	(relative	to	ambient	oxygen	pressure)	because	it	has	been	found	that	for	optimal	stem	cell	growth,	the	partial	pressure	of	oxygen	(pO2)	should	be	maintained	at	5%	of	the		pO2	of	air.23	To	determine	the	mass	of	oxygen	to	be	supplied	to	the	cells,	Equation	B.2	was	used,	in	which	the	first	term	determines	the	baseline	mass	of	oxygen	required	to	reach	the	desired	partial	pressure	and	the	second	term	accounts	for	the	oxygen	uptake	rate	of	the	cells.	Additionally,	iPSCs	have	been	shown	to	have	a	doubling	time	of	18-20	hours.24	From	Equation	B.1,	it	was	determined	that	the	growth	rate	of	iPSCs	is	0.0385	hours-1.		Based	on	this,	the	cells	must	be	cultured	in	the	5	L	culture	for	6.5	days	to	reach	a	final	concentration	of	1x106	cells/mL,	or	a	mass	of	5	grams.	Then	using	equation	B.2	and	the	known	oxygen	uptake	rate	of	mammalian	stem	cells,	which	is	approximately	0.00576	kg-O2/h/kg-cell,25	it	was	found	that	0.8173	g	of	oxygen	gas	will	have	to	be	supplied	as	the	cells	grow	and	proliferate.	Oxygen	flow	is	shown	in	stream	3	in	Figure	12.2.1.	A	10	L	bioreactor	with	a	working	volume	of	5	L	has	been	selected	for	the	first	step	because	it	is	small	so	that	the	inoculated	cells	will	not	be	too	dilute	but	large	enough	so	that	there	will	be	enough	cells	to	inoculate	the	next	bioreactor.	Additionally,	a	smaller	size	and	relatively	fast	proliferation	period	implies	that	if	the	cells	were	to	become	contaminated	or	did	not	
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exhibit	standard	growth,	the	batch	could	still	be	completed,	but	on	a	slightly	delayed	or	slightly	reduced	scale.	This	bioreactor,	as	well	as	all	of	the	other	bioreactors	in	the	upstream	process	before	platelet	formation,	will	be	a	single-use	bioreactor.	For	this	step,	the	bioreactor	is	the	Xcellerex	XDR	Single-Use	10	L	Bioreactor	(more	information	on	the	bioreactor	can	be	found	in	Sections	15.1	and	16.1).	A	stainless	steel	vessel	is	fitted	with	a	sterile	polymer	bag	that	will	be	used	for	one	batch	only.	Single-use	bioreactors	decrease	downtime	of	bioreactors	from	two	weeks	to	approximately	two	days,	which	eliminates	much	of	the	cost	and	time	associated	with	cleaning	the	bioreactors.	It	will	also	ensure	that	there	is	no	contamination	between	batches,26	which	is	vital	to	secure	FDA	approval	of	the	process.	The	bioreactor	has	a	built-in	oxygen	pump	and	easy	control	mechanisms	for	measuring	the	pO2.	Additionally,	the	entire	platelet	production	process	will	be	maintained	at	22°C,	since	temperatures	between	22°C	and	24°C	have	been	shown	to	be	ideal	for	platelet	production	and	storage	and.27,28	The	bioreactor	similarly	has	easy	measurement	and	controls	for	temperature.	There	is	also	a	probe	for	measuring	the	pH.	Throughout	this	entire	process,	the	pH	in	all	fluids	must	be	maintained	at	7.2.	While	the	media	is	buffered,	standard	acids	and	bases	will	be	kept	in	stock	to	supply	as	need	for	to	maintain	the	desired	pH.	 The	culture	in	the	10	L	bioreactor	will	be	mixed	at	speed	of	30	rpm.	The	mixing	speeds	of	all	bioreactors	were	determined	based	on	the	fluid	properties	of	the	culture	(assumed	to	be	similar	to	that	of	water)	and	the	desired	Reynolds	number.	It	was	found	that	for	the	highest	rate	of	human	cell	growth,	a	bioreactor	with	a	3-blade	impeller	such	as	those	utilized	by	the	bioreactors	in	this	process	should	maintain	a	Reynolds	number	near	17,500.29	With	these	values,	Equation	B.4	was	used	to	determine	the	rate	of	mixing	for	this	
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bioreactor	as	well	as	all	of	the	others.	For	this	step,	the	ideal	rotation	speed	was	found	to	be	near	the	minimum	speed	capable	in	this	bioreactor,	so	the	minimum	rotation	speed	of	30	rpm	was	selected.	As	the	iPSCs	are	nearing	the	end	of	their	6.5	day	period	of	proliferation	in	the	10	L	bioreactor,	the	47.5001	kg	of	media	will	be	added	to	the	50	L	bioreactor	via	stream	5	(Figure	15.2.1)	to	prepare	for	inoculation	from	the	first	bioreactor.	This	bioreactor	will	be	a	HyPerforma	Single-Use	50	L	Bioreactor	produced	by	Thermoscientific,	and	it	will	operate	with	a	working	volume	of	50	L.	It	has	similar	features	to	the	previous	bioreactor,	and	more	information	can	be	found	in	Sections	15.2	and	16.2.	Once	the	iPSCs	have	reached	a	mass	of	5	grams	in	the	first	bioreactor,	they	will	be	pumped	into	the	50	L	bioreactor	via	stream	4	to	begin	the	second	step	of	the	seed	train.	Stream	4,	which	has	a	total	mass	of	5.2508	kg,	has	been	split	up	into	parts	A	and	B	to	show	that	in	stream	4,	there	will	be	a	peristaltic	pump	that	increase	the	flow	rate	of	the	cell	culture	to	64.2	L/h.	The	peristaltic	pump	used	is	Thermo	Scientific	Masterflex	(see	Sections	15.9	and	16.19	for	more	details),	and	it	will	be	operated	at	a	pressure	of	2	atm.	Temperature	and	oxygen	content	will	be	maintained	at	22°C	and	5%	pO2	relative	to	air,	respectively.	To	maintain	this	oxygen	content,	0.0081	kg	of	oxygen	will	be	delivered	to	the	bioreactor	during	the	culture,	shown	as	stream	6.	The	culture	will	remain	in	this	bioreactor	for	2.5	days,	until	the	cells	have	reached	a	total	mass	of	50	grams.	The	culture	will	be	stirred	at	a	speed	of	75	rpm.	Similar	to	the	second	step	of	the	seed	train,	the	final	proliferation	bioreactor,	which	is	the	HyPerforma	250	L	Single-Use	Bioreactor	(see	Sections	15.3	and	16.3	for	more	information),	will	operate	with	a	working	volume	of	103	L	and	will	be	loaded	with	58.1503	kg	of	IMDM	and	nutrients	(shown	as	stream	8	in	Figure	12.2.1)	before	the	end	of	day	9.	
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Then,	the	culture	in	the	50	L	bioreactor,	which	at	the	end	of	the	culture	period	will	have	a	mass	of	52.7591	kg,	will	be	pumped	via	peristaltic	pump	into	the	250	L	single-use	bioreactor	for	the	last	step	of	the	seed	train,	shown	as	stream	7.	The	culture	will	be	pumped	into	the	bioreactor	using	a	peristaltic	pump	at	a	volumetric	flow	rate	of	64.2	L/h.	Once	completely	loaded	in	the	bioreactor,	it	will	take	one	day	for	the	cells	to	reach	a	final	mass	of	0.103	kg,	or	a	cell	count	of	1.03x1011	iPSCs.	The	temperature	and	oxygen	content	in	this	bioreactor	will	be	maintained	in	the	same	way	as	the	previous	bioreactors,	and	this	bioreactor	is	similarly	outfitted	with	probes	and	pumps	to	load	and	control	the	flow	of	all	material.	The	mass	of	oxygen	to	be	supplied	to	this	bioreactor	is	0.01614	kg,	shown	as	stream	9	in	Figure	12.2.1.	The	culture	will	be	stirred	at	30	rpm	while	in	this	bioreactor.	
13.2	Differentiation	into	MKs		 At	the	end	of	the	tenth	day	of	iPSC	proliferation,	the	110.925	kg	of	cells	and	media	in	the	250	L	bioreactor	(shown	in	stream	10	in	Figure	12.2.1)	will	then	be	pumped	to	a	flow	rate	of	64.2	L/h	and	then	split	equally	into	streams	11A	and	11B	to	be	transferred	into	two	separate	2000	L	stirred	single-use	bioreactors.	This	is	shown	in	Figure	12.2.1	as	streams	10a	and	10b.	The	2000	L	bioreactors	will	be	HyPerforma	2000	L	Single	Use	Bioreactors,	and	they	can	also	regulate	temperature,	pH,	and	oxygen	content	and	control	them	when	necessary	(more	information	can	be	found	in	Sections	15.4	and	16.4).	There	are	two	main	reasons	that	two	separate	bioreactors	will	be	used	for	this	step.	Firstly,	the	current	maximum	volume	of	single-use	bioreactors	is	2000	L.26	Additionally,	two	bioreactors	will	also	ensure	that	if	one	of	the	two	parallel	batches	gets	contaminated	or	if	there	are	any	other	kind	of	errors	in	the	batch,	there	will	still	be	a	remaining	supply	of	MKs	that	can	be	used	further	downstream.		
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The	two	bioreactors	will	each	be	preloaded	with	1344.95	kg	of	media	to	induce	iPSC	differentiation	into	MKs,	depicted	as	streams	12A	and	12B	in	Figure	12.2.1.	The	basis	of	the	media	will	again	be	IMDM.	Plasbumin	and	Rock	Inhibitor	will	be	added	in	the	same	concentrations	as	the	proliferation	bioreactors:	50	g/L	and	10	uM,	respectively.	To	induce	differentiation,	additional	FDA-approved	nutrients	are	added	to	the	culture.	Human	fibroblast	growth	factor-2	(FGF-2),	bone	morphogenic	protein	4	(BMP4),	vascular	endothelial	growth	factor-A	(VEGF-A),	oprelvekin	(interleukin-11),	and	PEGylated	recombinant	human	megakaryocyte	growth	and	development	factor	(PEG-rHuMGDF)	will	all	be	added	to	the	culture	in	concentrations	of	10	ng/mL.22,30	Additionally,	stem	cell	factor	(SCF)	will	be	added	at	a	concentration	of	50	ng/mL,	and	an	analog	to	thrombopoietin	(TPO)	known	as	Nplate	or	romiplostim	will	be	added	to	the	culture	at	a	concentration	of	20	ng/mL	All	of	these	nutrients	have	been	shown	to	aid	in	the	differentiation	of	iPSCs	to	MKs	and	the	formation	of	platelets	from	MKs,	especially	TPO	and	PEG-rHuMGDF.22,30	While	PEG-rHuMGDF	is	mostly	necessary	for	improved	platelet	yield	from	mature	MKs,	it	has	been	shown	that	added	PEG-rHuMGDF	earlier	in	the	process	will	help	to	increase	the	platelet	yield	further.	Therefore,	it	will	be	added	at	the	beginning	of	the	differentiation	process.30	All	nutrients	will	have	been	added	to	the	media	prior	to	loading	the	media	into	the	bioreactor.	Once	the	media,	nutrients,	and	iPSCs	have	been	loaded	into	the	bioreactors,	the	20	day	differentiation	period	will	begin.	During	this	time,	the	batches	will	be	monitored	for	growth	progress,	contamination,	temperature,	pH,	and	nutrient	and	oxygen	levels.	Samples	will	be	taken	and	tested	daily	to	ensure	that	the	cells	are	differentiating	on	the	expected	path.	From	literature,	it	is	expected	that	during	this	time,	the	cells	will	not	only	
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differentiate,	but	they	will	proliferate	as	well.	It	has	been	shown	that	from	each	iPSC,	25	MKs	are	expected	to	be	produced.	However,	of	those	25	MKs,	only	44%	or	11	MKs,	will	be	pre-platelet	forming	MKs.22		During	the	first	14	days	of	culture,	it	is	expected	that	the	iPSCs	will	be	differentiating	into	hematopoietic	progenitor	cells	(HPCs).	Since	these	are	still	stem	cells,	the	pO2	will	be	maintained	at	5%	during	this	time	period.	For	the	last	6	days	of	culture,	the	HPCs	will	further	differentiate	into	mature	MKs,	and	the	MKs	are	expected	to	have	begun	bearing	proplatelets,	the	precursors	to	platelets,	by	the	end	of	day	20.	For	this	6	day	period,	the	pO2	will	be	adjusted	to	20%,	which	has	been	shown	to	be	ideal	for	MKs	and	platelets.	At	this	point,	MKs	will	be	ready	to	begin	generating	platelets.	3.8	w/v%	trisodium	citrate,	or	48.772	kg,	will	be	added	to	each	of	the	two	bioreactors	to	prevent	platelet	aggregation	during	the	formation	process.31	The	total	mass	of	oxygen	that	will	be	supplied	to	each	bioreactor	via	streams	13A	and	13B	(Figure	12.2.1)	is	estimated	to	be	0.225	kg.	Additionally,	the	bioreactor	will	be	stirred	at	a	rate	of	20	rpm	for	the	duration	of	the	20	day	culture.	The	two	cell	cultures,	which	will	each	contain	1.2875	kg	of	MKs	in	a	total	volume	of	1283.5	L	will	be	pumped	out	of	the	bioreactors	using	a	peristaltic	pump	and	passed	through	a	microfluidic	shear	device	to	induce	platelet	formation.	The	streams	flowing	into	the	shear	vessel	are	shown	by	the	merging	of	streams	14A	and	14B	exiting	the	two	2000	L	bioreactors	into	stream	15	in	Figure	12.2.1.	The	MK	culture	will	be	pumped	into	the	shear	device	at	a	rate	of	64.2	L/h	for	8	hours,	which	will	result	in	513.4	L,	or	560.255	kg,	of	MK	culture	flowing	into	the	shear	vessel	in	8	hours.	This	will	be	repeated	4	more	times	over	the	next	4	days.	On	day	3,	the	first	bioreactor	will	be	empty	of	culture,	so	culture	from	the	
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second	bioreactor	will	begin	flowing	into	the	shear	vessel.	Beginning	with	stream	15	in	Figure	12.2.1	and	continuing	on	for	the	duration	of	the	process,	the	masses	shown	are	the	masses	flowing	to	each	unit	each	day.	
13.3	Platelet	Formation		 Platelet	formation	from	megakaryocytes	will	take	place	in	a	specialty	microfluidic	shear	device.	The	device	used	is	meant	to	simulate	platelet	production	in	the	body	by	mimicking	the	shear	stress	experienced	by	platelets	in	the	bone	marrow.	While	platelets	have	been	shown	to	form	from	megakaryocytes	spontaneously	without	the	application	of	shear	stress	in	the	laboratory,	shear	will	be	applied	by	this	device	to	accelerate	platelet	formation.		 The	microfluidic	shear	device	used	will	be	an	adaptation	of	a	device	designed	by	a	multidisciplinary	team	at	the	University	of	Pennsylvania.	The	device	is	a	four-by-four	inch	square	chip	constructed	from	a	silicon	and	glass	composite.	Over	10,000	microfluidic	channels	are	directly	etched	into	the	chip,	all	of	which	are	connected	to	one	inlet	port	and	one	outlet	port.	Fifty	of	these	chips	will	be	arranged	on	a	flat	benchtop	surface	and	be	used	in	parallel	to	process	each	batch	of	platelets.		Megakaryocytes	will	be	perfused	through	the	assembly	of	chips	at	1.28	L/h	per	chip	for	eight	hours	per	day,	with	the	remainder	of	the	solution	being	stored	in	the	2000	L	bioreactors	until	it	is	processed.	The	throughput	of	both	2000	L	bioreactors	will	take	a	total	of	five	days	to	process,	which,	as	mentioned	previously,	results	in	a	total	mass	of	560.16	kg	of	MK	culture	flowing	through	the	shear	vessel	each	day.	The	outlet	from	the	assembly	of	shear	devices	is	collected	in	two	repurposed	wave	bioreactors	that	act	as	mixed	storage	vessels	until	the	downstream	processing	begins.	The	streams	carrying	the	output	are	
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shown	as	streams	17A	and	17B	in	Figure	12.2.1,	and	they	each	have	a	mass	that	is	half	of	the	total	mass	passing	through	the	shear	vessel,	or	280.128	kg.	More	information	about	the	microfluidic	devices	can	be	found	in	Sections	15.5	and	16.5.	The	remaining	MK	culture	in	the	2000	L	bioreactor	will	have	further	time	to	develop	and	bear	proplatelets.	Based	on	various	studies,	the	additional	two	to	five	days	of	storage	experienced	by	some	of	the	MKs	before	entering	the	shear	vessel	to	produce	platelets	will	not	harm	the	MKs	in	any	way	and	could	actually	increase	the	maturity	and	number	of	proplatelets	expressed	on	each	MK.30,31	100	platelets	are	expected	to	form	from	each	proplatelet-bearing	MK	during	the	one-hour	residence	time	in	the	microfluidic	channels.30	This	will	result	in	a	total	mass	of	0.2266	kg	of	platelets	flowing	into	the	storage	vessels	each	day	(or	0.1133	kg	into	each).	Additionally,	a	total	remaining	mass	of	0.2884	MKs	will	also	be	present	in	the	culture	because	only	44%	of	the	MKs	will	be	producing	platelets.		
13.4	Storage	Vessels		 The	storage	vessels	for	the	shear	vessel	output	will	be	GE	WAVE	500	Bioreactors,	which	are	made	up	of	disposable	bag	on	a	rocker.	Rather	than	using	the	WAVE	500’s	as		bioreactors,	they	will	simply	be	used	in	this	step	to	gently	rocky	the	accumulated	platelets	until	all	platelets	have	been	collected.	To	prepare	for	the	platelet	product,	the	WAVE	bags	will	be	inflated	with	sterile	air	at	a	rate	of	10	liters	per	minute.	The	air	pump	is	a	part	of	the	WAVE	bioreactor	system.	This	process	will	take	50	minutes,	so	the	bag	inflation	will	begin	10	minutes	after	the	MKs	begin	flowing	through	the	microfluidic	channels.		 All	WAVE	bioreactors	will	be	rocked	at	an	angle	of	2	degrees	and	15	rpm	(rocks	per	minute)	as	a	baseline.	These	conditions	have	been	selected	in	order	to	ensure	that	the	
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platelets	will	be	well	mixed	in	the	solution	at	each	stage.	This	rocking	angle	and	speed	will	be	gentle	enough	to	limit	platelet	activation	as	much	as	possible	but	allow	for	oxygen	transfer.	More	information	regarding	these	two	storage	vessels	can	be	found	in	Sections	15.8	and	16.6.	The	oxygen	uptake	rate	of	platelets	is	rather	low	compared	to	that	of	cells,	so	the	main	concern	when	selecting	the	rpm	and	rocking	angle	of	the	WAVE	vessels	and	mixers	is	ensuring	a	well-mixed	solution	is	achieved	at	the	end	of	the	storage	or	mixing	period.	These	parameters	will	be	further	explored	during	the	research	and	development	period	(see	Section	20.3).		 As	mentioned	previously,	280.128	kg	of	platelets	and	MKs	in	media	will	enter	each	storage	vessel	via	streams	17A	and	17B	over	an	8-hour	period.	Additionally,	0.0118	kg	of	sterile	oxygen	gas	will	be	supplied	to	each	of	the	storage	vessels	via	streams	18A	and	18B	in	Figure	12.2.1.	Since	the	platelets	are	not	proliferating	like	the	cells	were,	the	oxygen	requirement	for	this	step	as	well	as	the	next	steps	was	calculated	using	Equation	B.3.	Once	all	of	the	platelets	have	flowed	into	the	storage	vessel,	they	are	ready	for	downstream	processing.	
13.5	Separation	via	Centrifugation		 Downstream	processing	will	begin	immediately	at	the	end	of	each	day	of	platelet	formation,	after	all	of	the	platelet	and	MK	product	have	been	collected	in	the	two	storage	vessels	from	the	shear	vessels.	There	will	be	two	lines	of	downstream	processing	occurring	in	parallel	-	each	line	will	begin	with	the	GE	500	WAVE	storage	vessel.	To	better	understand	the	scheduling,	refer	to	Section	20.4.	To	begin	processing	the	platelets	in	one	line	(the	exact	same	masses	and	procedure	will	be	employed	on	the	other	parallel	line),	the	256.7	L	of	platelets	and	MKs	suspended	in	culture	media	will	be	pumped	out	of	the	storage	
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vessel	at	a	flow	rate	of	80	L/h	(stream	19	in	Figure	12.3.1)	and	will	enter	the	first	centrifuge	to	separate	out	any	cells	that	may	have	escaped	into	the	platelet	product	in	the	shear	device.	80	L/h	has	been	selected	as	a	relatively	low	flow	rate	of	platelets	because	the	platelets	can	activate	at	high	flow	rates	when	there	are	high	levels	of	shear	stress.	The	tubing	connecting	the	outlet	flow	from	the	storage	vessel	to	the	inlet	of	the	centrifuge	will	have	a	1	inch	inner	diameter.	A	peristaltic	pump	placed	after	the	GE	WAVE	500	bioreactor	(breaking	stream	19	in	Figure	12.3.1	to	streams	19A	and	19B)	will	pump	the	fluid	at	the	aforementioned	flow	rate.	Disc	stack	centrifugation	will	be	used	during	this	step	as	well	as	in	all	other	centrifugation	steps.	Disc	stack	centrifuges,	specifically	the	MBPX	Centrifuge	be	Alfa	Laval,	are	gentle	enough	to	limit	platelet	activation.	More	information	on	all	of	the	disc	stack	centrifuges	can	be	found	in	Section	15.6,	and	specific	information	regarding	this	centrifuge	can	be	found	in	Section	16.7.	Additionally,	trisodium	citrate	has	been	added	to	the	platelet	product	to	limit	activation.		To	remove	the	remaining	MKs	from	the	platelets,	the	platelet	product	from	the	storage	vessel	will	be	centrifuged	at	300g	while	flowing	continuously	into	and	out	of	the	centrifuge	at	a	constant	flow	rate.31	This	step	will	take	3.21	hours	to	completely	process	the	platelets.	The	MKs,	much	heavier	than	the	platelets,	will	be	removed	in	the	sludge	exiting	the	bottom	of	the	centrifuge	(stream	21	in	Figure	12.3.1),	while	the	liquid	platelet	product	(stream	20	in	Figure	12.3.1),	containing	approximately	70%	of	the	liquid	that	entered	the	centrifuge,	will	be	continuously	removed	from	the	top	for	further	processing.	It	has	been	assumed	that	during	this	step,	80%	of	the	platelets	will	be	recovered	in	the	liquid	product	and	no	MKs	will	remain	in	the	liquid	product,	which	is	consistent	with	related	literature	discussing	the	separation	of	red	blood	cells	from	blood	to	form	platelet-rich	plasma.31	
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13.6	Centrifugation	and	Washing	The	liquid	platelet	product	that	has	been	cleaned	of	MKs	will	be	centrifuged	again	at	the	same	flow	rate	to	concentrate	the	platelets.	For	this	centrifugation	step,	the	platelet	culture	will	be	centrifuged	at	700g.	As	indicated	previously,	it	has	been	assumed	that	the	disc	stack	centrifuges,	all	operating	with	the	same	fluid	flow	rates,	will	produce	sludge	that	has	retained	30%	of	the	total	liquid	mixed	with	the	solids.	Additionally,	all	centrifugation	steps	operating	at	700g	are	assumed	to	have	a	95%	platelet	yield.	A	rotational	force	of	700g	has	been	selected	because	it	this	has	been	shown	to	minimize	platelet	loss	when	separating	platelets	from	platelet	poor-plasma	on	the	lab	scale.31	At	this	higher	g-force,	the	platelets	will	be	forced	to	the	bottom	of	the	centrifuge,	so	the	slurry	leaving	the	disc	stack	centrifuge,	which	contains	only	30%	of	the	original	liquid	content,	will	be	richer	in	platelets	and	will	flow	into	a	repurposed	GE	WAVE	500	for	mixing.	At	a	flow	rate	of	80	L/h,	this	step	will	take	2.25	hours	to	complete,	at	which	time	all	of	the	platelet	slurry	-	which	will	have	a	volume	of	53.91	L	-	will	have	been	added	to	the	mixer	(stream	23	in	Figure	12.3.1).	See	Section	16.8	for	additional	centrifuge	details	and	Section	15.7	for	additional	mixer	details.	The	mixer	will	be	prepared	for	platelets	before	the	platelets	leave	the	storage	vessel.	The	bag	will	be	filled	with	sterile	air	at	a	rate	of	10	L/min	for	50	minutes.	Then,	the	mixer	will	be	filled	via	stream	24	in	Figure	12.3.1	with	161.721	L,	or	172.16	kg,	of	Tyrode’s	salt	solution,	which	will	create	a	25%	volume	dilution	of	the	platelet	culture	(1	part	platelets	in	the	original	IMDM	media	and	3	parts	Tyrode’s	solution).	Tyrode’s	salt	solution	is	a	physiologically	compatible	buffer	that	is	used	in	the	blood	industry	to	wash	platelets	prior	to	testing	or	transfusion.27	3.8	w/v%	trisodium	citrate	will	be	included	in	the	salt	solution	to	help	prevent	platelet	activation.	Additionally,	oxygen	gas	will	be	supplied	to	the	mixer	as	
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needed	to	maintain	a	pO2	of	20%.	The	expected	mass	of	oxygen	to	be	supplied	is	0.00906	kg	throughout	the	one	hour	mixing	process	(stream	25	in	Figure	12.3.1).	Once	the	all	of	the	platelet	slurry	has	been	fully	loaded	into	the	mixer,	the	platelets	will	gently	mix	with	Tyrode’s	solution	for	1	hour	to	ensure	that	the	platelet	product	is	well	mixed	with	the	wash	buffer.	Additional	information	on	this	mixing	step	can	be	found	in	Section	16.9.	It	has	been	assumed	that	for	all	centrifugation	steps,	30%	of	the	liquid	entering	the	centrifuge	will	remain	in	the	platelet	slurry.	After	an	hour	of	mixing,	the	215.628	L	of	fluid	and	platelets	in	the	mixer	will	be	pumped	at	a	flow	rate	of	80.0	L/h	to	a	third	centrifuge	(shown	as	stream	26	in	Figure	12.3.1,	and	additional	information	is	described	in	Section	16.10),	where	they	will	again	be	spun	at	700g.	This	centrifugation	step	will	take	2.70	hours	to	complete.	As	the	platelet	exits	the	bottom	of	the	centrifuge,	it	will	be	delivered	to	a	second	mixer	(see	Section	16.11	for	more	details)	that	has	been	inflated	with	sterile	air	and	loaded	with	194.07	L,	or	196.76	kg,	of	Tyrode’s	solution	(stream	29	in	Figure	12.3.1).	The	total	mass	of	the	platelet	slurry	exiting	the	centrifuge	and	entering	this	mixer	-	which	is	shown	in	stream	28	-	will	be	69.3651	kg	and	the	volume	will	be	68.6884	L,	such	that	the	addition	of	the	wash	buffer	will	create	a	suspension	that	is	25%	platelet	slurry	by	volume	and	75%	wash	buffer	by	volume.	For	this	step,	trisodium	citrate	is	not	added	to	the	wash	because	very	little	trisodium	citrate	must	be	present	in	the	final	platelet	product.	Further	dilutions	will	ensure	that	the	remaining	mass	of	trisodium	citrate	is	minimized.	Once	all	68.6884	L	of	platelet	slurry	have	entered	the	mixer,	the	platelets	will	be	washed	for	one	hour.	The	mass	of	oxygen	gas	required	to	maintain	a	pO2	of	20%	is	0.01085	kg	(stream	30	in	Figure	12.3.1).	
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13.7	Centrifugation	and	Resuspension		 After	the	second	washing	step,	the	266.136	kg	mixture	from	the	wave	mixer	-	depicted	as	stream	31	in	Figure	12.3.1	-	will	be	pumped	through	a	fourth	centrifuge	at	a	flow	rate	of	80.0	L/h.	Additional	information	regarding	this	centrifugation	step	can	be	found	in	Section	16.12.	The	liquid	product	exiting	the	top,	which	will	contain	just	5%	of	the	total	platelets	entering	the	centrifuge	and	a	total	mass	of	186.242	kg,	will	be	discarded,	as	shown	by	stream	32.	The	platelet	slurry	exiting	the	bottom	of	the	centrifuge	will	contain	95%	of	the	platelets,	for	a	total	platelet	mass	of	0.07796	kg	and	a	total	slurry	mass	of	79.894	kg,	will	flow	into	a	third	mixer	(shown	as	stream	33	in	Figure	12.3.1).	It	will	take	3.23	hours	to	completely	process	all	of	the	mixture	(see	Section	16.13	for	more	details).	During	the	previous	(second)	mixing	step,	the	third	mixer	will	be	prepared	for	the	platelet	slurry	by	inflating	it	with	sterile	air	for	50	minutes	at	a	flow	rate	of	10	L/h	and	then	filled	with	232.878	grams	of	the	resuspension	fluid	(stream	34	in	Figure	12.3.1).	The	resuspension	fluid	will	be	composed	of	80%	of	a	standard	platelet	additive	solution	(PAS-E)	and	20%	mock	plasma.28	The	mock	plasma	is	made	up	of	some	of	the	most	essential	components	of	plasma.	To	prepare	the	mock	plasma,	water	is	mixed	with	Plasbumin	and	potassium	salt	to	create	a	mixture	that	is	92%	by	weight	water,	5%	by	weight	Plasbumin,	and	3%	by	weight	potassium.	The	mock	plasma	will	then	be	mixed	with	PAS-E	to	create	resuspension	fluid.	In	this	mixer,	the	platelet	slurry	will	again	be	diluted	to	25%	by	volume	of	the	platelet	slurry.	0.01301	kg	of	sterile	oxygen	will	be	supplied	during	the	one	hour	mixing	period	via	stream	35	to	maintain	a	pO2	of	20%.	After	mixing,	the	platelet	and	resuspension	mixture,	shown	in	stream	36	and	having	a	total	mass	of	312.785	kg,	will	be	pumped	through	another	disc	stack	centrifuge	at	a	flow	rate	of	80	L/h	(Section	16.14).	The	
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93.886	kg	platelet	slurry	(stream	38	in	Figure	12.3.1)	will	flow	into	the	fourth	and	final	wave	mixer	over	the	course	of	3.88	hours	(Section	16.15).	Like	the	previous	wave	mixer,	this	mixer	will	have	been	pre-inflated	and	loaded	with	311.854	kg	of	resuspension	fluid	(stream	39	in	Figure	12.3.1).	The	platelets	will	be	mixed	in	the	resuspension	fluid	for	one	hour,	during	which	time	0.01214	kg	of	oxygen	will	be	added	to	maintain	a	pO2	20%.	Unlike	the	previous	steps,	the	platelet	slurry	will	be	diluted	to	25%	by	volume.	The	volume	of	resuspension	fluid	was	determined	based	on	the	desired	final	platelet	concentration	of	1.83x1011	platelets/L.	Since	the	centrifuges	are	all	assumed	to	output	a	platelet	slurry	with	30%	of	the	liquid	remaining,	the	dilution	in	mixer	4	was	determined	assuming	that	there	would	be	two	final	centrifugation	steps	in	series	to	concentrate	the	platelets	to	the	desired	volume.	
13.8	Concentration		 A	two-step	centrifugation	step	will	be	utilized	to	concentrate	the	platelets	to	the	final	desired	volume.	These	disc-stack	centrifuges	will	process	the	resuspended	platelets	at	a	flow	rate	of	80	L/h	and	a	force	of	700g,	just	like	the	previous	four	centrifuges.	All	405.73	kg	of	resuspended	platelets	leaving	the	fourth	mixing	via	stream	41	will	be	pumped	into	the	sixth	centrifuge	of	the	course	of	5.06	hours	(see	Section	16.16	for	more	details).	The	121.774	kg	platelet	slurry	collected	from	the	bottom	(stream	43	in	Figure	12.3.1)	will	then	flow	directly	into	the	seventh	and	final	centrifuge.	The	final	centrifuge	(additional	details	available	in	Section	16.17)	will	process	the	platelets	over	the	course	of	1.52	hours,	after	which	time,	a	total	mass	of	36.578	kg	of	resuspended	platelets	containing	0.06696	kg	of	platelets,	will	be	directed	into	the	viral	inactivation	step	(shown	as	stream	45	in	Figure	12.3.1)	and	then	will	be	packaged	before	transportation	to	surrounding	hospitals.	
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13.9	Waste	Streams	
	 The	streams	exiting	the	centrifuges	that	are	not	flowing	into	the	next	unit	contain	waste	that	must	be	disposed	of	properly.	These	streams	are	shown	in	Figure	12.3.1	as	streams	21,	22,	27,	32,	37,	42,	and	44.	The	total	mass	of	waste	produced	from	each	batch	will	thus	be	11421.2	kg.	The	waste	from	these	streams,	containing	a	mixture	of	MKs,	platelets,	culture	media,	Tyrode’s	salt	solution,	and	PAS-E	and	mock	plasma,	will	be	disposed	of	in	accordance	with	guidelines	(see	Section	20.2).	
13.10	Viral	Inactivation		 Any	trace	amounts	of	viral	DNA	need	to	be	removed	from	the	platelets	before	they	can	be	packaged	and	administered	to	human	patients.	There	are	several	commercially	available	methods	of	viral	inactivation	for	platelets	already	in	existence.	The	INTERCEPT	Blood	System	will	be	used	in	this	process	because	it	has	received	FDA	approval	and	is	able	to	process	up	to	forty	units	of	platelets	per	hour	per	device.32		 The	INTERCEPT	system	consists	of	four	main	steps.	First,	the	platelets	are	flowed	through	a	container	of	amotosalen,	a	photosensitizer	that	penetrates	cell	membranes	and	viral	envelopes	and	forms	crosslinks	between	pyrimidine	residues	in	DNA	and	RNA.	The	amotosalen,	when	treated	with	UV-A	light,	undergoes	a	photochemical	reaction	that	converts	the	crosslinks	into	covalent	bonds,	thus	preventing	replication	of	viral	DNA.33	Amotosalen	has	a	high	specificity	for	nucleic	acids	and	does	not	interfere	with	the	function	of	the	platelets	themselves.32	The	amotosalen	solution	used	is	3	mM	amotosalen	in	0.924%	NaCl.	The	container	itself	is	made	of	flexible,	heat-sealed	plastic.		 Following	treatment	with	amotosalen,	the	platelets	are	flowed	into	an	illumination	container.	The	container	is	a	heat-sealed	plastic	bag.	Two	illumination	containers	can	be	
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simultaneously	inserted	into	a	device	called	the	INT100,	which	treats	platelets	with	UV-A	light	at	320-400	nm.	Two	platelet	units	fit	in	each	illumination	container,	and	since	it	takes	one	hour	to	process	forty	units	(inclusive	of	the	loading	and	unloading	time),	each	unit	receives	approximately	five	minutes	of	UV	treatment.	UV-A	light	is	used	because	light	of	shorter	wavelengths	such	as	UV-B	and	UV-C	light	can	damage	platelets.32		 The	platelets	are	then	flowed	into	a	compound	adsorption	device	(CAD)	to	reduce	the	levels	of	residual	amotosalen	and	any	of	its	byproducts.	The	CAD	consists	of	immobilized	beads	in	a	mesh	pouch.34	The	platelets	are	treated	in	this	container	for	four	to	sixteen	hours.	In	this	process,	the	platelets	will	be	treated	for	four	hours,	as	studies	have	shown	that	there	is	no	clinically	significant	difference	in	platelet	function	when	treated	for	four	hours	and	those	treated	for	sixteen	hours.35			 Following	the	CAD	step,	the	platelets	will	be	flowed	into	their	storage	bags.	Platelets	are	stored	in	gas-permeable	bags	made	from	plasticized	PVC.36	Each	bag	holds	one	unit	of	platelets,	or	5.5x1010	platelets	in	300	mL.	More	information	regarding	viral	inactivation	can	be	found	in	Section	15.10.	
13.11	Irradiation		 In	some	cases,	platelets	need	to	be	irradiated	with	gamma	rays	prior	to	transfusion.	This	process	is	necessary	for	immunocompromised	patients,	such	as	those	with	cancer,	to	prevent	the	transmission	of	Transfusion	Associated	Graft-Versus	Host	Disease	(TA-GVHD).	TA-GVHD	results	from	blood	transfusions	when	lymphocytes	from	the	blood	donor	engraft	in	the	recipient.	This	process	can	shorten	the	shelf	life	of	the	platelets,	so	it	is	done	when	the	platelets	are	already	in	storage	bags	and	are	about	to	be	used.37	However,	since	the	proposed	process	does	not	use	donors,	gamma	irradiation	should	not	be	a	necessary	step.	
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13.12	Storage	and	Distribution		 After	the	platelets	have	undergone	viral	inactivation,	they	will	flow	via	stream	46	in	Figure	12.3.1	into	one	final	GE	500	WAVE	Bioreactor	(described	in	Section	16.18),	which	will	again	act	as	a	storage	vessel.	The	platelets	will	be	rocked	at	an	angle	of	2	degrees	and	a	rate	of	12	rpm.	From	here,	the	platelets	will	be	packaged	and	transported	to	surrounding	hospitals.	It	has	been	determined	that	the	packaging	and	distribution	requirements	are	out	of	the	scope	of	this	project.	
13.13	Yield	per	Batch		 At	the	end	of	each	batch,	0.669	kg	of	platelets	will	have	been	generated	in	364.5	L	of	PAS-E/mock	plasma.	This	is	the	equivalent	of	1215	units	per	batch,	where	each	unit	contains	5.5x1010	platelets	in	300	mL.	A	new	batch	will	begin	every	5	days,	1215	units	of	platelets	will	be	produced	every	5	days.	This	is	actually	83%	of	the	market	demand,	however,	it	is	assumed	that	platelet	yield	may	decrease	in	real	practice,	so	an	excess	platelet	supply	has	been	built	in.	Finally,	because	this	process	is	so	novel,	constant	optimization	will	be	required.	Therefore,	excess	platelets	can	be	tested	in	the	quality	control	lab	in	order	to	find	new	ways	to	improve	the	platelet	production	process.	It	is	also	expected	that	approximately	10-15%	of	the	total	platelet	batches	will	be	bad.	Often	times,	contamination	can	occur	in	bioprocesses.	Additionally,	sometimes	cells	may	not	grow	or	differentiate	along	the	desired	pathway.	Taking	into	account	all	of	these	possibilities,	it	is	assumed	that	the	final	platelet	supply	and	number	of	high-quality	platelet	units	that	will	be	sold	each	year	is	69,550	units,	which	meets	65%	of	the	total	market	demand	in	Philadelphia.		 	
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XIV.	Energy	Balance	and	Utility	Requirements	
14.1	Energy	Utilities	
	 The	energy	requirements	for	each	unit	were	determined	from	the	equipment	data	sheets	provided	by	the	unit	vendors	shown	in	Appendix	E.	Details	regarding	power	requirements	for	operation	of	each	unit	are	also	shown	in	Section	11.	The	impellers	in	the	stirred	bioreactors,	the	WAVE	mixers	and	storage	vessels,	and	the	pumps	all	require	various	amounts	of	electricity	for	operation.	As	mentioned	in	Section	13,	the	impellers	with	mix	the	tanks	at	rates	varying	from	20	rpm	to	75	rpm,	the	WAVE	reactors	for	storage	and	mixing	will	rock	at	an	angle	of	2	degrees	and	a	rate	of	15	rpm,	and	the	pumps	will	be	operated	at	a	pressure	change	of	2	atm.	The	annual	energy	requirements	for	the	stirred	bioreactors,	the	WAVE	mixers	and	storage	vessels,	and	the	disc	stack	centrifuges,	and	the	pumps	are	191,756.4	kWh,	1,949.1	kWh,	24,984.25	kWh,	and	131.4	kWh,	respectively.	Additionally,	it	has	been	estimated	that	the	power	requirement	for	lighting	and	HVAC	for	the	facility	will	be	40.8	kWh	annually.	Since	the	industrial	cost	of	electricity	in	the	city	of	Philadelphia	is	$0.085/kWh,	the	annual	cost	of	energy	has	been	determined	to	be	$29,268.	
14.2	Mass	Utilities	There	are	a	number	of	important	utilities	that	will	be	required	for	this	process.	65.59	kg	(or	27,500	L)	of	sterile	air	are	required	to	fill	the	GE	WAVE	Bioreactor	bags	for	each	batch.	There	are	11	total	GE	WAVE	Bioreactors	used	as	either	mixers	or	storage	vessels,	and	each	must	be	filled	with	an	air	volume	of	500	L	5	times	per	batch.	The	cost	of	sterile	air	is	$0.10	per	kg,	and	there	are	73	batches	run	in	the	facility	per	year,	so	the	total	cost	of	sterile	air	per	year	is	$478.81.	The	total	oxygen	requirement	has	been	determined	based	on	the	required	pO2	in	each	vessel	and	the	rate	of	consumption	of	oxygen	gas	of	the	
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cells	and	platelets.	As	discussed	in	Section	23,	the	total	sterile	oxygen	requirement	per	batch	is	0.8188	kg.	To	see	detailed	oxygen	requirements	for	each	bioreactor,	see	Appendix	C.	The	cost	of	sterilized	oxygen	gas	is	$0.17/kg,	and	there	are	73	batches	per	year,	so	the	total	cost	of	sterile	oxygen	gas	per	year	is	$10.16.		The	fourteen	centrifuges	that	are	used	during	the	downstream	processing	of	platelets	as	well	as	the	microfluidic	shear	vessel	for	platelet	formation	will	be	flushed	with	sterile	water	and	then	steam	sterilized.	Each	of	the	centrifuges	has	a	bowl	volume	of	15	L	and	must	be	flushed	with	sterile	water	a	flow	rate	of	200	L/h	for	30	minutes.	Each	centrifuge	is	used	5	times	per	batch,	which	means	that	a	total	volume	of	7,000	L	of	water	will	be	used	to	flush	the	centrifuges	per	batch.	The	same	process	is	used	to	flush	the	microfluidic	device	between	uses,	however	the	flow	rate	of	water	in	this	case	will	be	1.28	L/h.	These	sterilization	procedures	must	occur	5	times	per	batch	because	downstream	processing	is	done	over	the	course	of	5	days.	This	results	in	a	total	required	volume	of	320	L	of	sterile	water	per	batch	for	cleaning	the	shear	devices.	At	a	cost	of	$0.005/L,	the	total	cost	of	sterile	water	per	year	is	$2,578.	After	flushing	with	water,	the	centrifuges	and	the	microfluidic	shear	vessel	will	be	steam	sterilized	at	the	same	flow	rates	as	the	water	flush	for	30	minutes.	The	pressure	and	temperature	of	steam	for	sterilization	will	be	1.02	atm	and	404	K.38	As	a	result,	the	total	mass	of	steam	required	is	a	combined	304.2	kg	annually,	so	at	a	cost	of	$0.013/kg,	the	total	cost	of	steam	for	sterilization	is	$3.95	per	year.	Non-sterile	water	is	also	required	to	maintain	a	temperature	of	22°C	in	the	50	L,	250	L,	and	2000	L	bioreactors.	Assuming	that	the	maximum	temperature	drift	is	5°C	and	that	the	flow	rate	of	water	in	the	cooling	jacket	is	equal	to	the	values	described	in	the	equipment	information	sheets	(see	Appendix	E),	the	total	mass	of	cooling	water	expected	
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to	be	required	per	year	is	386,403,600	L,	and	at	a	price	of	$0.00054/kg,	this	results	in	a	total	yearly	cost	of	$207,498.	Table	19.2.1	in	Section	19.2	contains	detailed	cost	information	regarding	all	utilities.		 	
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XV.	Equipment	List	and	Unit	Descriptions	
	 The	quantity	of	each	type	of	equipment	has	been	determined	based	on	the	period	of	use	and	down	time	required	to	prepare	the	equipment	for	the	next	period	of	use.	Additionally,	spare	units	were	deemed	necessary	for	the	bioreactors	because	often	times,	contamination	or	break	down	of	equipment	can	occur.	Due	to	the	nature	of	platelet	demand,	production	cannot	be	halted	due	to	equipment	failure,	so	spares	were	deemed	a	necessary	cost	to	incur.	Table	15.1	shows	in	detail	the	number	of	each	unit	as	well	as	the	purchase	cost	and	the	bare	module	cost,	which	was	determined	using	the	bare	module	factors	provided	in	Product	and	Process	Design	Principles.39	
Table	15.1.	This	table	details	the	quantity	of	each	unit	of	equipment	that	will	be	purchased.	
Equipment	Name	(Number)	 Equipment	Type	 Purchase	Cost	 Bare	Module	Factor	 Bare	Module	Cost	10	L	single	use	bioreactor	(2)	 Process	Machinery	 $139,440	 3.21	 $447,602	10	L	single	use	bioreactor	(1)	 Spares	 $69,720	 3.21	 $223,801	50	L	single	use	bioreactor	(1)	 Process	Machinery	 $71,245	 3.21	 $228,696	50	L	single	use	bioreactor	(1)	 Spares	 $71,245	 3.21	 $228,696	250	L	single	use	bioreactor	(1)	 Process	Machinery	 $79,798	 3.21	 $256,152	250	L	single	use	bioreactor	(1)	 Spares	 $79,798	 3.21	 $256,152	2000	L	single	use	bioreactor	(10)	 Process	Machinery	 $2,151,720	 3.21	 $6,907,021	2000	L	single	use	bioreactor	(1)	 Spares	 $215,172	 3.21	 $690,702	Microfluidic	Shear	Device	(100)	 Fabricated	Equipment	 $300,000	 2.00	 $600,000	Peristaltic	Pumps	(9)	 Process	Machinery	 $39,195	 3.30	 $129,344	Disc	Stack	Centrifuge	(14)	 Process	Machinery	 $420,000	 3.21	 $1,348,200	GE	Wave	Reactor	-	Mixer	(8)	 Process	Machinery	 $240,000	 3.21	 $770,400	GE	Wave	Reactor	-	Storage	(3)	 Process	Machinery	 $90,000	 3.21	 $288,900	INTERCEPT	Blood	System	(2)	 Process	Machinery	 $100,000	 2.00	 $200,000			 	 $4,067,333	 		 $12,575,666	
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15.1	10	L	Single-Use	Seed	Bioreactor		 The	first	step	in	the	iPSC	proliferation	seed	train	will	use	a	10	L	single-use	bioreactor.	The	Xcellerex	XDR-10	Bioreactor	System	from	GE	Healthcare	Life	Sciences	will	be	used.	An	exact	price	quote	from	GE	was	unavailable,	but	based	on	a	correlation	between	single-use	bioreactor	size	and	purchase	cost	provided	by	industrial	consultant	Jeffrey	Cohen	of	Johnson	&	Johnson,	a	similarly	sized	single-use	bioreactors	from	Thermo	Fisher	would	cost	$69,720.	The	corresponding	single-use	bioprocess	container	bag	would	cost	roughly	$3,254	per	bag	based	on	another	provided	correlation,	though	the	real	price	would	likely	be	lower	since	a	50	L	bag	from	Thermo	Fisher	costs	$2,981.	The	bioreactor	is	composed	of	three	main	parts:	the	vessel	frame,	instrument	tower,	and	Xcellerex	Disposable	Single-Use	Bioreactor	Bag	Assembly	(XDA).	The	vessel	itself	is	stainless	steel,	and	the	bag	is	made	from	flexible	low-density	polyethylene	film	and	includes	a	bottom-mounted	impeller	and	sparger	assembly	that	connects	into	the	vessel	frame	via	magnetic	coupling.	The	instrument	tower	includes	mass	flow	controllers,	peristaltic	pumps,	and	probe	transmitters	that	measure	temperature,	pH,	and	dissolved	oxygen	content.	The	XDR-10	is	suitable	for	working	volumes	from	4.5	L	to	10	L;	the	volume	used	in	this	process	will	be	5	L.	10x106	cells	will	be	seeded	in	the	reactor	and	proliferated	for	6.5	days,	at	which	point	the	mass	of	cells	will	be	5	grams.	The	reactor	will	be	maintained	at	22°C	and	5%	pO2.	The	vessel	impeller	will	rotate	as	a	speed	of	30	rpm.	At	the	end	of	the	culture	period,	the	outlet	tubing,	which	has	an	inner	diameter	of	1	inch,	connecting	this	bioreactor	with	the	next	bioreactor	will	be	connected	to	a	peristaltic	pump.	This	pump	will	push	the	culture	into	the	next	bioreactor	at	a	volumetric	flow	rate	of	64.2	L/h.	For	more	information	on	the	pump,	see	Section	15.9.	
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15.2	-	50	L	Single-Use	Seed	Bioreactor		 The	second	step	in	the	iPSC	seed	train	uses	a	50	L	single-use	bioreactor.	The	HyPerforma	2:1	Single-Use	50	L	Bioreactor	from	Thermo	Fisher	will	be	used.	This	unit	will	be	purchased	for	$71,245,	and	the	single-use	bags	used	inside	the	reactor	can	be	purchased	for	$2,981	per	bag.	The	unit	consists	of	a	stainless	steel	bioreactor	tank	and	a	single-use	BioProcess	Container	(BPC)	composed	of	Aegis	5-14	Film,	a	five-layer	blend	of	polymers.	A	complete	mixing	system	with	a	cooling	water	jacket	is	included	in	the	hardware	unit.	The	rated	liquid	working	volume	is	50	L,	which	is	what	will	be	used	in	this	process.	The	total	bioreactor	volume	is	65.5	L.	The	BPC	chamber	is	13.75	inches	in	diameter	and	31.5	inches	high.	This	unit	will	operate	at	22°C	and	5%	pO2.	The	cells	will	proliferate	in	this	reactor	for	2.5	days,	at	which	point	there	will	be	50	grams	of	iPSC	cells.	The	same	pump	setup	will	be	used	at	the	outlet	harvest	tubing	as	in	the	10	L	bioreactor.		
15.3	-	250	L	Single-Use	Seed	Bioreactor		 The	final	seed	bioreactor	used	to	proliferate	the	iPSCs	is	a	250	L	vessel.	The	HyPerforma	5:1	Single-Use	250	L	Bioreactor	from	Thermo	Fisher	will	be	used.	This	unit	will	be	purchased	for	$83,154,	and	the	single-use	bags	used	inside	the	reactor	can	be	purchased	for	$3,631	per	bag.	The	components	of	this	unit	are	the	same	as	those	in	the	50	L	model.	The	unit	consists	of	a	stainless	steel	bioreactor	tank	and	a	single-use	BPC	composed	of	Aegis	5-14		Film.	It	is	equipped	with	a	complete	mixing	system	and	water	jacket	and	is	available	for	purchase	in	turnkey	format.	The	system	utilizes	traditional	stirred-tank	bioreactor	design	principles	to	optimize	cell	viability	and	performance.	The	total	reactor	volume	is	316	L,	but	the	rated	liquid	working	volume	is	250	L,	and	the	minimum	working	volume	is	50	L.	This	process	will	use	a	working	volume	of	103	L,	which	is	safely	in	the	
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middle	of	this	range.	The	BPC	chamber	diameter	is	23.5	inches	in	diameter	and	59.7	inches	high.	The	unit	will	operate	at	22°C	and	5%	pO2.	The	cells	will	remain	in	the	reactor	for	24	hours,	at	which	point	there	will	be	0.103	kg	of	iPSCs	(1.03x1011	cells).	At	the	harvest	exit	there	will	be	a	peristaltic	pump	that	will	increase	the	flow	rate	of	the	exiting	iPSC	culture	to	64.2	L/h.		
15.4	-	2000	L	Single-Use	Bioreactor	
	 The	iPSC	cells	generated	by	the	seed	train	bioreactors	will	be	differentiated	into	megakaryocytes	in	single-use	2000	L	bioreactors.	The	unit	used	will	be	the	HyPerforma	2:1	Single-Use	2000	L	Bioreactor,	which	can	be	purchased	from	Thermo	Fisher	for	$215,172.	The	corresponding	single-use	bag	can	be	purchased	for	$10,286	per	bag.	The	unit	consists	of	a	stainless	steel	bioreactor	tank	and	a	single-use	BioProcess	Container	(BPC)	composed	of	Aegis	5-14		Film.	A	complete	mixing	system	with	a	cooling	water	jacket	is	included	in	the	hardware	unit.	The	rated	liquid	working	volume	is	2000	L;	the	working	volume	that	will	be	used	in	this	process	is	1283.5	L.	The	BPC	chamber	is	47	inches	in	diameter	and	90.5	inches	high.	This	unit	will	operate	at	22°C.	The	cells	will	remain	in	this	reactor	for	20	days.	For	the	first	14	days,	the	iPSCs	will	differentiate	into	HPCs	while	the	reactor	is	maintained	at	5%	pO2.	For	the	last	six	days,	the	HPCs	will	differentiate	into	megakaryocytes	while	the	reactor	is	maintained	at	20%	pO2.	
15.5	-	Microfluidic	Shear	Device		 The	microfluidic	shear	device	used	in	this	process	is	adapted	from	a	device	designed	by	a	multidisciplinary	team	at	the	University	of	Pennsylvania	consisting	of	Daeyeon	Lee,	David	Issadore,	Sagar	Yadavali,	and	Heon-Ho	Jeong.	The	team	designed	a	highly	parallelized	microfluidic	platform	to	mass-produce	microparticles.	While	typical	
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microfluidic	devices	have	been	challenging	to	use	in	commercial	applications	due	to	low	production	rates,	the	device	designed	by	the	Penn	team	consists	of	10,260	microfluidic	droplet	generators,	allowing	them	to	process	over	10,000	times	more	throughput	than	other	microfluidic	devices.40		 This	new	device	that	serves	as	a	basis	for	our	shear	device	is	a	4	inch	square	wafer	constructed	from	silicon	and	glass,	allowing	it	to	handle	high	pressures	(over	1000	PSI)	and	temperatures	(over	500°C).	It	has	been	named	the	VLSDI,	or	very	large	scale	droplet	integration.	The	droplet	generators	on	the	device	are	etched	directly	into	the	wafer	using	deep	reactive	ion	etching.	The	VLSDI	was	fabricated	at	the	Singh	Center	for	Nanotechnology	at	the	University	of	Pennsylvania.	An	image	of	the	device	is	shown	in	Appendix	D.		 The	VLSDI	has	only	one	set	of	inlet	ports	and	one	set	of	outlet	ports.	1	mm	holes	were	laser	cut	into	the	bottom	of	the	wafer	to	create	vias	that	serve	as	the	inlet	and	outlet	channels.	The	efficacy	of	the	wafer	was	demonstrated	by	generating	polycaprolactone	microparticles.	The	researchers	were	able	to	achieve	a	production	rate	of	277	grams	per	hour,	or	328	billion	particles	per	hour,	at	a	flow	rate	of	2.09	liters	per	hour.		 This	process	will	use	an	assembly	of	fifty	of	these	shear	devices	acting	in	parallel	to	process	the	throughput	from	the	2000	L	bioreactors.	The	working	volume	exiting	the	two	reactors	combined	is	2567	L.	This	volume	will	be	processed	over	the	course	of	five	eight-hour	days	(513.4	L	per	day).	The	outlet	from	the	2000	L	reactors	will	be	connected	directly	to	the	inlet	ports	of	the	devices,	with	a	series	of	sterile	Y-splitters	dividing	the	solution	into	fifty	equal	parts	(each	reactor	will	be	connected	to	twenty-five	microfluidic	devices).	The	device	used	in	our	process	will	be	operated	slightly	differently	from	the	original	VLSDI	
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design;	instead	of	flowing	a	dispersed	phase	through	one	inlet	port	and	a	continuous	phase	through	the	other	inlet	port,	the	solution	containing	MKs	will	be	flowed	through	both	inlet	ports.	 The	shear	stress	experienced	by	the	MKs	as	they	flow	through	the	device	will	induce	platelet	formation.	A	high	level	of	shear	stress	on	MKs	that	already	exhibit	proplatelet	formation	has	been	shown	to	allow	platelets	to	form	in	as	little	as	20	minutes.41	For	this	project,	platelet	generation	must	be	maximized,	so	the	solution	containing	MKs	will	be	flowed	through	the	device	at	a	flow	rate	lower	than	the	allowed	maximum	flow	rate	to	increase	the	amount	of	time	each	MK	spends	in	the	device;	a	flow	rate	of	1.28	L/h	through	each	device	will	be	used.	The	output	from	these	devices	will	exit	through	tubing	connected	to	the	outlet	ports	and	be	collected	in	a	repurposed	wave	mixer	used	as	a	storage	vessel.		The	temperature	will	be	maintained	at	22°C	throughout	the	process.	The	oxygen	pressure	will	be	maintained	at	20%.		
15.6	-	Centrifuge	
	 A	series	of	six	centrifuges	will	be	used	in	the	downstream	processing	steps	to	isolate	the	platelets	from	any	residual	megakaryocytes	and	other	cellular	material.	The	centrifuge	used	will	be	the	MBPX	404S	separation	system	sold	by	Alfa	Laval.	This	unit	can	be	purchased	for	$30,000.	This	centrifuge	is	non-hermetic	and	is	designed	for	laboratory	and	pilot	scale	production;	it	can	process	between	100	L/h	and	150	L/h.	The	feed	will	be	introduced	into	the	centrifuge	bowl	by	a	stationary	inlet	pipe.	It	then	enters	the	distributor,	where	it	is	accelerated	by	the	disc	inlet	before	entering	the	disc	stack.	The	separation	occurs	between	the	discs.	The	liquid	phase	exits	the	centrifuge	through	an	outlet	at	the	top	of	the	bowl,	while	the	solids	phase	collects	in	the	periphery	of	the	bowl	and	is	released	at	
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preset	intervals	through	solids	ports.42	Each	centrifuge	used	during	this	process	will	be	operated	at	22°C.	Pumps	are	built	into	the	centrifuge	to	push	out	the	liquid	and	slurry	from	their	respective	exit	ports.		
15.7	-	Mixer		 During	downstream	processing,	the	iPSCs	will	undergo	washing	and	resuspension	in	various	volumes	between	the	second	and	third,	third	and	fourth,	fourth	and	fifth,	and	fifth	and	sixth	centrifugation	steps.	The	“mixers”	used	will	be	repurposed	500	L	WAVE	Bioreactors,	which	can	be	purchased	from	GE	Healthcare	Life	Sciences	for	an	estimated	$30,000	per	unit.	The	corresponding	single-use	bag	can	be	purchased	for	an	estimated	$300	per	bag.		The	mixers	will	operate	at	a	rocking	angle	of	2	degrees	and	a	rocking	speed	of	15	rpm.	The	volumes	of	fluid	in	the	mixers	will	vary	based	on	each	step	(more	information	can	be	found	in	Section	13).	Oxygen	will	be	supplied	via	pump	that	is	built	into	the	mixer.		
15.8	-	Storage	Units		 Three	storage	units	are	required	for	the	overall	production	process	–	two	will	be	at	the	exits	of	the	microfluidic	shear	vessels	and	one	will	be	at	the	end	of	the	process	to	collect	the	platelet	product	before	packaging	and	distribution.	The	storage	units,	like	the	mixers	discussed	in	Section	15.7,	will	be	GE	500	L	WAVE	Bioreactors.	They	will	similarly	be	operated	at	a	rocking	angle	of	2	degrees	and	a	rocking	speed	of	15	rpm.	Oxygen	will	be	supplied	via	a	pump	built	into	the	WAVE	Bioreactor.	The	storage	units	after	the	microfluidic	shear	device	will	contain	a	liquid	volume	of	256.7	L,	and	the	storage	unit	at	the	end	of	the	process	will	contain	a	liquid	volume	of	72.9	L	at	the	end	of	each	day	of	downstream	processing.	
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15.9	-	Peristaltic	Pumps		 Throughout	the	process,	a	series	of	peristaltic	pumps	will	be	used	to	push	fluid	through	the	system.	The	pumps	used	will	be	Masterflex	P/S	Pump	Systems,	which	can	be	purchased	from	Thermo	Fisher	for	an	estimated	$4,355	per	unit.	The	pump	has	an	RPM	range	of	0.1	to	600,	and	using	P/S	18	precision	pump	tubing	(which	has	an	inner	diameter	of	0.31	inches),	the	pump	is	able	to	function	at	flow	rates	between	0.38	to	2300	mL/min.	The	fluid	passing	through	the	pump	will	have	a	volumetric	flow	rate	ranging	between	64.2	L/h	and	80.0	L/h,	which	is	well	within	the	range	of	the	pump’s	possible	flow	rates.	The	material	in	the	pump	tubing	throughout	the	process	will	be	maintained	at	22°C,	which	is	well	within	the	operating	range,	0-40°C,	of	the	pump.	The	pump	will	be	operated	at	a	pressure	of	2	atm.	The	power	requirement	of	the	pump	is	0.2	kW.		
15.10	-	INTERCEPT	Blood	System	for	Viral	Inactivation	Following	the	series	of	centrifugation	and	mixing	downstream	processing	steps,	a	viral	inactivation	step	will	be	carried	out	using	the	INTERCEPT	Blood	System,	which	can	be	purchased	for	an	estimated	$50,000	per	unit.	The	INTERCEPT	system	has	three	main	components.	The	first	is	a	container	of	3	mM	amotosalen	in	0.924%	NaCl.	Amotosalen	penetrates	cell	membranes	and	viral	envelopes	and	forms	crosslinks	between	pyrimidine	residues	in	DNA	and	RNA	to	prevent	viral	replication.	The	container	is	made	of	flexible,	heat-sealed	plastic.	The	second	is	an	illumination	container,	which	is	a	heat-sealed	plastic	bag,	that	is	inserted	into	a	device	called	the	INT100.	The	INT100	treats	platelets	with	UV-A	light	at	320-400	nm,	with	each	platelet	unit	receiving	approximately	five	minutes	of	UV	treatment.	The	third	piece	of	the	system	is	a	compound	adsorption	device	(CAD)	used	to	reduce	the	levels	of	residual	amotosalen	and	any	of	its	byproducts.	The	CAD	consists	of	
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immobilized	beads	in	a	mesh	pouch.	The	platelets	are	treated	in	this	container	for	four	hours.	 	
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XVI.	Specification	Sheets	
The	following	pages	contain	the	specification	sheets	for	each	of	the	units	used	in	this	process.	The	purpose	of	each	unit,	its	vendor,	price,	physical	description,	and	required	operating	conditions	are	included.	 	
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16.1	-	10	L	Single-Use	Bioreactor	Description	and	Function	 The	10	L	single-use	bioreactor	will	be	a	flexible,	stirred-tank		reactor	system	consisting	of	a	stainless	steel	reactor	vessel,	process	instrumentation	built	into	a	cabinet	adjacent	to	the	vessel,	a	fully	integrated	control	console,	and	a	single-use	bioreactor	bag	assembly.	This	unit	will	be	used	as	the	first	step	in	a	seed	train	used	to	proliferate	iPSCs.	The	rated	working	volume	is	10	L;	the	volume	used	in	this	process	will	be	5	L.	Cells	will	be	seeded	in	the	reactor	and	proliferated	for	6.5	days	until	reaching	a	total	mass	of	5	grams	of	cells.		Vendor	 	 	 GE	Healthcare	Life	Sciences		Operation	 	 	 Batch		Materials	Handled	 	 	 	 	 Input	(g/batch)	 Output	(g/batch)	
	 	 	 	 iPSC	cells	 	 0.01	 	 	 5		 	 	 	 IMDM	 	 	 5000	 	 	 4995.758		 	 	 	 Plasbumin	 	 250	 	 	 250		 	 	 	 Rock	Inhibitor	 0.012367	 	 0.012367		 	 	 	 Oxygen	 	 0.817296	 	 0.069399		Characteristics	 	 Model:		 	 	 Xcellerex	XDR	10		 	 	 	 Construction	Material:		 Plastic	and	304	stainless	steel		permanent	vessel,	USP	Class	VI-compliant	LDPE	single-use	bag	assembly	Dimensions:	 	 	 Vessel:	13	x	32	x	14	in		 	 	 	 Instrument	tower:	15	x	28	x	28	in		 	 	 	 Balance:	18	x	3	x	18	in	Sterilization:	 	 	 Disposable	bag	assembly;	clean		permanent	vessel	with	a	non-abrasive	cloth	with	mild	detergent	and	water	Agitation	speed:	 	 30	rpm	Impeller	configuration:	 M40E	pitched-blade	type	with		medical-grade	ceramic	bearings;	3	blades	at	40°	pitch	Volume:	 	 	 10	L	
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	Operating	Conditions	 Temperature:		 	 22°C		 	 	 	 Pressure:	 	 	 1	atm		 	 	 	 pH:	 	 	 	 7.2		 	 	 	 pO2:	 	 	 	 5%		 	 	 	 Growth	time:	 	 	 6.5	days		Purchase	Cost	 	 $69,720	(estimate)	 	
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16.2	-	50	L	Single-Use	Bioreactor	Description	and	Function	 The	50	L	single-use	bioreactor	will	consist	of	a	stainless	steel		reactor	vessel	and	a	single-use	bioreactor	bag	assembly.	This	unit	will	be	used	as	the	second	step	in	the	seed	train	used	to	proliferate	iPSCs.	The	rated	working	volume	is	50	L;	the	volume	used	in	this	process	will	be	50	L.	Cells	will	be	seeded	in	the	reactor	and	proliferated	for	2.5	days	until	reaching	a	total	mass	of	50	grams	of	cells.		Vendor	 	 	 Thermo	Fisher	Scientific		Operation	 	 	 Batch		Materials	Handled	 	 	 	 	 Input	(kg/batch)	 Output	(kg/batch)	
	 	 	 	 iPSC	cells	 	 0.0050	 	 0.0500		 	 	 	 IMDM	 	 	 49.996	 	 49.958		 	 	 	 Plasbumin	 	 2.750	 	 	 2.750		 	 	 	 Rock	Inhibitor	 0.00013604	 	 0.00013504		 	 	 	 Oxygen	 	 0.00817293	 	 0.00069399		Characteristics	 	 Model:		 	 	 HyPerforma	2:1	50	L	Single-Use		Bioreactor		 	 	 	 Construction	Material:		 Stainless	steel	permanent	vessel,		Thermo	Scientific	Aegis	5-14	Film	disposable	bag	assembly	Dimensions:	 	 	 BPC	Chamber	Diameter:	13.75	in		 	 	 	 BPC	Chamber	Height:	31.5	in		 	 	 	 Overall	Reactor	Geometry:	1.9:1	Sterilization:	 	 	 Disposable	bag	assembly;	clean		permanent	vessel	with	a	non-abrasive	cloth	with	mild	detergent	and	water	Agitation	speed:	 	 75	rpm	Impeller	configuration:	 Single-use	polyethylene	impeller		with	4.375	inch	diameter;	3	blades	with	45°	pitch	Volume:	 	 	 50	L		Operating	Conditions	 Temperature:		 	 22°C	
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	 	 	 	 Pressure:	 	 	 1	atm		 	 	 	 pH:	 	 	 	 7.2		 	 	 	 pO2:	 	 	 	 5%		 	 	 	 Growth	time:	 	 	 2.5	days		Purchase	Cost	 	 $71,245	
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16.3	-	250	L	Single-Use	Bioreactor	
	Description	and	Function	 The	250	L	single-use	bioreactor	will	consist	of	a	stainless	steel		reactor	vessel	and	a	single-use	bioreactor	bag	assembly.	This	unit	will	be	used	as	the	second	step	in	the	seed	train	used	to	proliferate	iPSCs.	The	rated	working	volume	is	250	L;	the	volume	used	in	this	process	will	be	103	L.	Cells	will	be	seeded	in	the	reactor	and	proliferated	for	1	day	until	reaching	a	total	mass	of	103	grams	of	cells.		Vendor	 	 	 Thermo	Fisher	Scientific		Operation	 	 	 Batch		Materials	Handled	 	 	 	 	 Input	(kg/batch)	 Output	(kg/batch)	
	 	 	 	 iPSC	cells	 	 0.05	 	 	 0.103		 	 	 	 IMDM	 	 	 102.958	 	 102.770		 	 	 	 Plasbumin	 	 7.90	 	 	 7.90		 	 	 	 Rock	Inhibitor	 0.0003908	 	 0.0003908		 	 	 	 Oxygen	 	 0.0168362	 	 0.00142963		Characteristics	 	 Model:		 	 	 HyPerforma	5:1	250	L	Single-Use		Bioreactor		 	 	 	 Construction	Material:		 Stainless	steel	permanent	vessel,		Thermo	Scientific	Aegis	5-14	Film	disposable	bag	assembly	Dimensions:	 	 	 BPC	Chamber	Diameter:	23.5	in		 	 	 	 BPC	Chamber	Height:	45.5	in		 	 	 	 Overall	Reactor	Geometry:	1.9:1	Sterilization:	 	 	 Disposable	bag	assembly;	clean		permanent	vessel	with	a	non-abrasive	cloth	with	mild	detergent	and	water	Agitation	speed:	 	 30	rpm	Impeller	configuration:	 Single-use	polyethylene	impeller		with	7.88	inch	diameter;	3	blades	with	45°	pitch	Volume:	 	 	 250	L		Operating	Conditions	 Temperature:		 	 22°C	
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	 	 	 	 Pressure:	 	 	 1	atm		 	 	 	 pH:	 	 	 	 7.2		 	 	 	 pO2:	 	 	 	 5%		 	 	 	 Growth	time:	 	 	 1	day		Purchase	Cost	 	 $79,798	(estimate)				 	
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16.4	-	2000	L	Single-Use	Bioreactor	
	Description	and	Function	 The	two	2000	L	single-use	bioreactors	run	in	parallel	will		consist	of	a	stainless	steel	reactor	vessel	and	a	single-use		bioreactor	bag	assembly.	This	unit	will	be	used	to	differentiate	iPSCs	into	HPCs	and	finally	megakaryocytes.	The	rated	working	volume	is	2000	L;	the	volume	used	in	this	process	will	be	1283.5	L.	Cells	will	be	seeded	in	the	reactor	and	differentiated	for	20	days	until	reaching	a	total	mass	of	1.2875	kilograms	of	megakaryocytes.		Vendor	 	 	 Thermo	Fisher	Scientific		Operation	 	 	 Batch		Materials	Handled	 	 	 	 	 Input	(kg/batch)	 Output	(kg/batch)	
	 	 	 	 iPSC	cells	 	 0.0515	 	 0		 	 	 	 Megakaryocytes	 0	 	 	 1.2875	IMDM	 	 	 1283.460	 	 1282.417		 	 	 	 Plasbumin	 	 68.125	 	 68.125		 	 	 	 Rock	Inhibitor	 0.00178271	 	 0.00178271		 	 	 	 Oxygen	 	 0.2265021	 	 0.0339197		 	 	 	 FGF-2	 	 	 0.000012835		 0.000012835		 	 	 	 BMP	 	 	 0.000012835		 0.000012835		 	 	 	 SCF	 	 	 0.000064175		 0.000064175		 	 	 	 VEG-F	A	 	 0.000012835		 0.000012835		 	 	 	 Romiplostim	 	 0.00002567	 	 0.00002567		 	 	 	 Oprelvekin	 	 0.000012835		 0.000012835		 	 	 	 PEG-rHuMGDF	 0.000012835		 0.000012835		 	 	 	 Sodium	Citrate	 48.773	 	 48.773		Characteristics	 	 Model:		 	 	 HyPerforma	2:1	2000	L	Single-Use		Bioreactor		 	 	 	 Construction	Material:		 Stainless	steel	permanent	vessel,		Thermo	Scientific	Aegis	5-14	Film	disposable	bag	assembly	Dimensions:	 	 	 BPC	Chamber	Diameter:	47	in		 	 	 	 BPC	Chamber	Height:	90.5	in		 	 	 	 Overall	Reactor	Geometry:	1.9:1	Sterilization:	 	 	 Disposable	bag	assembly;	clean		
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permanent	vessel	with	a	non-abrasive	cloth	with	mild	detergent	and	water		Agitation	speed:	 	 20	rpm	Impeller	configuration:	 Single-use	polyethylene	impeller		with	15.7	inch	diameter;	3	blades	with	45°	pitch	Volume:	 	 	 2000	L		Operating	Conditions	 Temperature:		 	 22°C		 	 	 	 Pressure:	 	 	 1	atm		 	 	 	 pH:	 	 	 	 7.2		 	 	 	 pO2:	 	 	 	 5%	for	first	14	days,	20%	for	final		6	days		 	 	 	 Growth	time:	 	 	 20	days		Purchase	Cost	 	 $215,172			 	
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16.5	-	Microfluidic	Shear	Device	
	Description	and	Function	 An	array	of	microfluidic	chips	are	used	to	induce	shear	stress		on	megakaryocytes	and	promote	platelet	formation.	Fifty	4x4	inch	chips	are	arranged	on	a	flat	surface	and	the	outlet	from	the	2000	L	bioreactors	is	directed	into	the	array	using	a	series	of	splitters.	The	shear	induced	by	flow	through	the	channels	causes	megakaryocytes	to	release	platelets.	Each	device	is	a	chip	composed	of	a	silicon	and	glass	composite	with	channels	etched	directly	into	it	using	deep	reactive	ion	etching.		Vendor	 	 	 N/A;	fabricated	at	the	Singh	Center	of	Nanotechnology	at	the		University	of	Pennsylvania		Operation	 	 	 Continuous		Materials	Handled	 	 	 	 	 Input	(kg/batch)	 Output	(kg/batch)		 	 	 	 Megakaryocytes	 2.575	 	 	 1.442		 	 	 	 Platelets	 	 0	 	 	 1.133	IMDM	 	 	 2564.83	 	 2564.83		 	 	 	 Plasbumin	 	 136.25	 	 136.25		 	 	 	 Rock	Inhibitor	 0.0035654	 	 0.0035654		 	 	 	 Oxygen	 	 0.0339197	 	 0.0339197	FGF-2	 	 	 0.00002567	 	 0.00002567		 	 	 	 BMP	 	 	 0.00002567	 	 0.00002567		 	 	 	 SCF	 	 	 0.00012835	 	 0.00012835		 	 	 	 VEG-F	A	 	 0.00002567	 	 0.00002567		 	 	 	 Romiplostim	 	 0.00005134	 	 0.00005134		 	 	 	 Oprelvekin	 	 0.00002567	 	 0.00002567		 	 	 	 PEG-rHuMGDF	 0.00002567	 	 0.00002567		 	 	 	 Sodium	Citrate	 97.546	 	 97.546		Characteristics	 	 Model:		 	 	 N/A		 	 	 	 Construction	Material:		 Silicon	and	glass	Dimensions:	 	 	 4	x	4	inch	square	Sterilization:	 	 	 Steam	sterilization			Operating	Conditions	 Temperature:		 	 22°C		 	 	 	 Pressure:	 	 	 1	atm		 	 	 	 pH:	 	 	 	 7.2	
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	 	 	 	 pO2:	 	 	 	 20%		 	 	 	 Run	time:	 	 	 5	days;	8	hours	per	day		Purchase	Cost	 	 $3,000	per	device			 	
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16.6	-	Storage	Vessel	(WAVE	Reactor)	
	Description	and	Function	 A	repurposed	500	L	WAVE	single-use	bioreactor	will	consist	of		a	stainless	steel	rocking	unit	and	a	single-use	bioreactor	bag		assembly.	This	unit	will	be	used	to	store	unprocessed	platelets	emerging	from	the	shear	vessel.	The	rated	working	volume	is	500	L;	the	volume	used	in	this	process	will	be	256.7	L.	Product	will	be	collected	in	the	vessel	for	8	hours.	A	second	500	L	WAVE	single-use	bioreactor	will	be	used	to	collect	another	256.7	L	of	solution,	for	a	total	volume	of	513.4	L.		Vendor	 	 	 General	Electric		Operation	 	 	 Batch		Materials	Handled	 	 	 	 	 Input	(kg/batch)	 Output	(kg/batch)		 	 	 	 Megakaryocytes	 0.1442	 	 0.1450		 	 	 	 Platelets	 	 0.1133	 	 0.1134	IMDM+Nutrients	 270.11	 	 270.11		 	 	 	 Oxygen	 	 0.015193	 	 0.014252		 	 	 	 Sodium	Citrate	 9.7546	 	 9.7546		Characteristics	 	 Model:		 	 	 WAVE	Bioreactor	500/1000		System		 	 	 	 Construction	Material:		 Stainless	steel	permanent	vessel,		multilayer	laminated	clear	USP	class	VI	plastic	disposable	bag	assembly	Dimensions:	 	 	 Base	Unit:	79	×	49	×	63	in		 	 	 	 With	KIT500EH:	89	×	49	×	63	in	Sterilization:	 	 	 Disposable	bag	assembly;	CIP/SIP		for	base	Rocking	Details:	 	 Adjustable	Rocking	Angle:	0.5°-4°		 	 	 	 Rocking	Speed:	4	-	25	rocks/min	Rocking	Speed:	 	 15	rocks/min	Rocking	Angle:	 	 2°	Volume:	 	 	 500	L		Operating	Conditions	 Temperature:		 	 22°C		 	 	 	 Pressure:	 	 	 1	atm	
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	 	 	 	 pH:	 	 	 	 7.2		 	 	 	 pO2:	 	 	 	 20%		 	 	 	 Residence	Time:	 	 8	Hours		Purchase	Cost	 	 $30,000/unit		 	 	 	 $300/bag			 	
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16.7	-	Disc	Stack	Centrifuge	1	
	Description	and	Function	 The	MBPX	810H	disk	stack	centrifuge	will	be	used	to	separate		the	platelets	from	the	process	waste	(sludge	stream),	which	includes	unused	MKs.	There	is	about	an	80%	recovery	of	platelets	from	the	process	in	the	liquid,	platelet-rich	stream.	The	resulting	platelet	stream	is	0.046%	platelets	by	mass.				Vendor	 	 	 Alfa	Laval		Operation	 	 	 Batch		Materials	Handled	 	 	 	 	 Input	(kg/batch)	 Output	(kg/batch)		 	 	 	 IMDM+Nutrients	 270.11	 	 189.08	Sodium	Citrate	 9.7546	 	 6.8282	Megakaryocytes	 0.1450	 	 0 	 	 	 	 Platelets	 	 0.1134	 	 0.09073 	 	 	 	 Oxygen	 	 0.014252	 	 0.0099763	 		  Characteristics	 	 Model:		 	 	 MBPX	810H		 	 	 	 Centrifuge	Type:		 	 Disc	Stack	Construction	Materials:	 Corrosion	resistant	stainless	steel		EN	1.4462	Max	Throughput	Capacity:	 15	m3/h	Solids	Handling	Capacity:	 300-540	L/h	G-Force:	 	 	 300	g	Bowl	Speed:	 	 	 6,250	rpm	maximum	Percent	yield:		 	 80%	Sterilization:	 	 	 CIP/SIP		Operating	Conditions	 Temperature:		 	 22°C		 	 	 	 Pressure:	 	 	 1	atm		 	 	 	 Flow	Rate:	 	 	 80	L/h		 	 	 	 Residence	Time:	 	 3.2	Hours		Purchase	Cost	 	 $30,000/unit		
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16.8	-	Disc	Stack	Centrifuge	2	
	Description	and	Function	 The	MBPX	810H	disk	stack	centrifuge	will	be	used	to	separate		the	platelets	from	the	process	waste	(liquid	stream),	which	includes	unused	MKs.	There	is	about	an	95%	recovery	of	platelets	from	the	process	in	the	platelet-rich	slurry	stream.	The	resulting	platelet	stream	is	0.146%	platelets	by	mass.				Vendor	 	 	 Alfa	Laval		Operation	 	 	 Batch		Materials	Handled	 	 	 	 	 Input	(kg/batch)	 Output	(kg/batch)		 	 	 	 IMDM+Nutrients	 189.08	 	 56.723	Sodium	Citrate	 6.82822	 	 2.048466		 	 	 	 Platelets	 	 0.09072875469	 0.08619231695 	 	 	 	 Oxygen	 	 0.009976303408	 0.002992891022 	 	 	 	  Characteristics	 	 Model:		 	 	 MBPX	810H		 	 	 	 Centrifuge	Type:		 	 Disc	Stack	Construction	Materials:	 Corrosion	resistant	stainless	steel		EN	1.4462	Max	Throughput	Capacity:	 15	m3/h	Solids	Handling	Capacity:	 300-540	L/h	G-Force:	 	 	 700	g	Bowl	Speed:	 	 	 6,250	rpm	maximum	Percent	yield:		 	 95%	Sterilization:	 	 	 CIP/SIP		Operating	Conditions	 Temperature:		 	 22°C		 	 	 	 Pressure:	 	 	 1	atm		 	 	 	 Flow	Rate:	 	 	 80	L/h		 	 	 	 Residence	Time:	 	 2.25	Hours		Purchase	Cost	 	 $30,000/unit		
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16.9	-	Mixing	and	Washing	1	(WAVE	Reactor)	
	Description	and	Function	 A	repurposed	500	L	WAVE	single-use	bioreactor	will	consist	of		a	stainless	steel	rocking	unit	and	a	single-use	bioreactor	bag		assembly.	This	unit	will	be	used	to	re-suspend	and	wash	platelets	emerging	from	the	second	centrifuge.	The	rated	working	volume	is	500	L;	the	volume	used	in	this	process	will	be	215.628	L.		Vendor	 	 	 General	Electric		Operation	 	 	 Batch		Materials	Handled	 	 	 	 	 Input	(kg/batch)	 Output	(kg/batch)		 	 	 	 Platelets	 	 0.0861923	 	 0.0861923	IMDM+Nutrients	 56.723	 	 56.723		 	 	 	 Oxygen	 	 0.01206	 	 0.011972		 	 	 	 Sodium	Citrate	 10.2423	 	 10.2423	Sterile	Water	 	 161.721	 	 161.721	NaCl	 	 	 1.725	 	 	 1.725	MgCl2-6H2O	 	 0.046144	 	 0.046144	KCl	 	 	 0.043126	 	 0.043126	Sodium	Carbonate	 0.21563	 	 0.21563	Glucose	 	 0.21563	 	 0.21563		Characteristics	 	 Model:		 	 	 WAVE	Bioreactor	500/1000		System		 	 	 	 Construction	Material:		 Stainless	steel	permanent	vessel,		multilayer	laminated	clear	USP	class	VI	plastic	disposable	bag	assembly	Dimensions:	 	 	 Base	Unit:	79	×	49	×	63	in		 	 	 	 With	KIT500EH:	89	×	49	×	63	in	Sterilization:	 	 	 Disposable	bag	assembly;	CIP/SIP		for	base	Rocking	Details:	 	 Adjustable	Rocking	Angle:	0.5°-4°		 	 	 	 Rocking	Speed:	4	-	25	rocks/min	Rocking	Speed:	 	 15	rocks/min	Rocking	Angle:	 	 2°	Volume:	 	 	 500	L	
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	Operating	Conditions	 Temperature:		 	 22°C		 	 	 	 Pressure:	 	 	 1	atm		 	 	 	 pH:	 	 	 	 7.2		 	 	 	 pO2:	 	 	 	 20%		 	 	 	 Residence	Time:	 	 1	Hour		Purchase	Cost	 	 $30,000/unit		 	 	 	 $300/bag		
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16.10	-	Disc	Stack	Centrifuge	3	
	Description	and	Function	 The	MBPX	810H	disk	stack	centrifuge	will	be	used	to	separate		the	platelets	from	the	process	waste	(liquid	stream),	which	includes	unused	MKs.	There	is	about	an	95%	recovery	of	platelets	from	the	process	in	the	platelet-rich	slurry	stream.	The	resulting	platelet	stream	is	0.118%	platelets	by	mass.				Vendor	 	 	 Alfa	Laval		Operation	 	 	 Batch		Materials	Handled	 	 	 	 	 Input	(kg/batch)	 Output	(kg/batch)		 	 	 	 IMDM+Nutrients	 56.723	 	 17.017	Wash	Buffer	 	 174.21	 	 52.263		 Platelets	 	 0.086277	 	 0.081963		 	 	 	 Oxygen	 	 0.011972	 	 0.0035915 	 	 	 	  Characteristics	 	 Model:		 	 	 MBPX	810H		 	 	 	 Centrifuge	Type:		 	 Disc	Stack	Construction	Materials:	 Corrosion	resistant	stainless	steel		EN	1.4462	Max	Throughput	Capacity:	 15	m3/h	Solids	Handling	Capacity:	 300-540	L/h	G-Force:	 	 	 700	g	Bowl	Speed:	 	 	 6,250	rpm	maximum	Percent	yield:		 	 95%	Sterilization:	 	 	 CIP/SIP		Operating	Conditions	 Temperature:		 	 22°C		 	 	 	 Pressure:	 	 	 1	atm		 	 	 	 Flow	Rate:	 	 	 80	L/h		 	 	 	 Residence	Time:	 	 2.75	Hours		Purchase	Cost	 	 $30,000/unit		 	
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16.11	-	Mixing	and	Washing	2	(WAVE	Reactor)	
	Description	and	Function	 A	repurposed	500	L	WAVE	single-use	bioreactor	will	consist	of		a	stainless	steel	rocking	unit	and	a	single-use	bioreactor	bag		assembly.	This	unit	will	be	used	to	re-suspend	and	wash	platelets	emerging	from	the	second	centrifuge.	The	rated	working	volume	is	500	L;	the	volume	used	in	this	process	will	be	258.7536	L.		Vendor	 	 	 General	Electric		Operation	 	 	 Batch		Materials	Handled	 	 	 	 	 Input	(kg/batch)	 Output	(kg/batch)		 	 	 	 Platelets	 	 0.081963	 	 0.081963	IMDM+Nutrients	 17.017	 	 17.017	Wash	Buffer   52.263	 	 52.263	Oxygen	 	 0.01445	 	 0.01437	Sterile	Water	 	 194.07	 	 194.07	NaCl	 	 	 2.0700	 	 2.0700	MgCl2-6H2O	 	 0.055373	 	 0.055373	KCl	 	 	 0.051751	 	 0.051751	Sodium	Carbonate	 0.25875	 	 0.25875	Glucose	 	 0.25875	 	 0.25875		Characteristics	 	 Model:		 	 	 WAVE	Bioreactor	500/1000		System		 	 	 	 Construction	Material:		 Stainless	steel	permanent	vessel,		multilayer	laminated	clear	USP	class	VI	plastic	disposable	bag	assembly	Dimensions:	 	 	 Base	Unit:	79	×	49	×	63	in		 	 	 	 With	KIT500EH:	89	×	49	×	63	in	Sterilization:	 	 	 Disposable	bag	assembly;	CIP/SIP		for	base	Rocking	Details:	 	 Adjustable	Rocking	Angle:	0.5°-4°		 	 	 	 Rocking	Speed:	4	-	25	rocks/min	Rocking	Speed:	 	 15	rocks/min	Rocking	Angle:	 	 2o	Volume:	 	 	 500	L	
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	Operating	Conditions	 Temperature:		 	 22°C		 	 	 	 Pressure:	 	 	 1	atm		 	 	 	 pH:	 	 	 	 7.2		 	 	 	 pO2:	 	 	 	 20%		 	 	 	 Residence	Time:	 	 1	Hour		Purchase	Cost	 	 $30,000/unit		 	 	 	 $300/bag		
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16.12	-	Disc	Stack	Centrifuge	4	
	Description	and	Function	 The	MBPX	810H	disk	stack	centrifuge	will	be	used	to	separate		the	platelets	from	the	process	waste	(liquid	stream),	which	includes	unused	MKs.	There	is	about	an	95%	recovery	of	platelets	from	the	process	in	the	platelet-rich	slurry	stream.	The	resulting	platelet	stream	is	0.0976%	platelets	by	mass.				Vendor	 	 	 Alfa	Laval		Operation	 	 	 Batch		Materials	Handled	 	 	 	 	 Input	(kg/batch)	 Output	(kg/batch)		 	 	 	 IMDM	+	Nutrients	 17.017	 	 5.1051	Wash	 	 	 249.02	 	 74.707	Platelets	 	 0.082043	 	 0.077941	Oxygen	 	 0.014366	 	 0.0043098	 		 	  Characteristics	 	 Model:		 	 	 MBPX	810H		 	 	 	 Centrifuge	Type:		 	 Disc	Stack	Construction	Materials:	 Corrosion	resistant	stainless	steel		EN	1.4462	Max	Throughput	Capacity:	 15	m3/h	Solids	Handling	Capacity:	 300-540	L/h	G-Force:	 	 	 700	g	Bowl	Speed:	 	 	 6,250	rpm	maximum	Percent	yield:		 	 95%	Sterilization:	 	 	 CIP/SIP		Operating	Conditions	 Temperature:		 	 22°C		 	 	 	 Pressure:	 	 	 1	atm		 	 	 	 Flow	Rate:	 	 	 80	L/h		 	 	 	 Residence	Time:	 	 3.23	Hours		Purchase	Cost	 	 $30,000/unit	
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16.13	-	Mixing	and	Washing	3	(WAVE	Reactor)	
	Description	and	Function	 A	repurposed	500	L	WAVE	single-use	bioreactor	will	consist	of		a	stainless	steel	rocking	unit	and	a	single-use	bioreactor	bag		assembly.	This	unit	will	be	used	to	re-suspend	and	wash	platelets	emerging	from	the	second	centrifuge.	The	rated	working	volume	is	500	L;	the	volume	used	in	this	process	will	be	310.504	L.		Vendor	 	 	 General	Electric		Operation	 	 	 Batch		Materials	Handled	 	 	 	 	 Input	(kg/batch)	 Output	(kg/batch)		 	 	 	 IMDM	+	Nutrients	 5.1051	 	 5.1051	Wash	Buffer	 	 74.707	 	 74.707	Platelets	 	 0.077941	 	 0.078017	Oxygen	 	 0.017315	 	 0.017239	PAS-E	 	 	 186.30	 	 186.30	Synthetic	Plasma	 46.576	 	 46.576		Characteristics	 	 Model:		 	 	 WAVE	Bioreactor	500/1000		System		 	 	 	 Construction	Material:		 Stainless	steel	permanent	vessel,		multilayer	laminated	clear	USP	class	VI	plastic	disposable	bag	assembly	Dimensions:	 	 	 Base	Unit:	79	×	49	×	63	in		 	 	 	 With	KIT500EH:	89	×	49	×	63	in	Sterilization:	 	 	 Disposable	bag	assembly;	CIP/SIP		for	base	Rocking	Details:	 	 Adjustable	Rocking	Angle:	0.5°-4°		 	 	 	 Rocking	Speed:	4	-	25	rocks/min	Rocking	Speed:	 	 15	rocks/min	Rocking	Angle:	 	 2°	Volume:	 	 	 500	L		Operating	Conditions	 Temperature:		 	 22°C		 	 	 	 Pressure:	 	 	 1	atm		 	 	 	 pH:	 	 	 	 7.2	
86	
	 	 	 	 pO2:	 	 	 	 20%		 	 	 	 Residence	Time:	 	 1	Hour		Purchase	Cost	 	 $30,000/unit		 	 	 	 $300/bag		
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16.14	-	Disc	Stack	Centrifuge	5	
	Description	and	Function	 The	MBPX	810H	disk	stack	centrifuge	will	be	used	to	separate		the	platelets	from	the	process	waste	(liquid	stream),	which	includes	unused	MKs.	There	is	about	an	95%	recovery	of	platelets	from	the	process	in	the	platelet-rich	slurry	stream.	The	resulting	platelet	stream	is	0.0788%	platelets	by	mass.				Vendor	 	 	 Alfa	Laval		Operation	 	 	 Batch		Materials	Handled	 	 	 	 	 Input	(kg/batch)	 Output	(kg/batch)		 	 	 	 IMDM	+	Nutrients	 5.1051	 	 1.5315	Wash	Buffer		 	 74.707	 	 22.412	PAS-E	 	 	 186.30	 	 55.891	Synthetic	Plasma	 46.576	 	 13.973	Platelets	 	 0.078017	 	 0.074116	Oxygen	 	 0.017239	 	 0.0051717	 		  Characteristics	 	 Model:		 	 	 MBPX	810H		 	 	 	 Centrifuge	Type:		 	 Disc	Stack	Construction	Materials:	 Corrosion	resistant	stainless	steel		EN	1.4462	Max	Throughput	Capacity:	 15	m3/h	Solids	Handling	Capacity:	 300-540	L/h	G-Force:	 	 	 700	g	Bowl	Speed:	 	 	 6,250	rpm	maximum	Percent	yield:		 	 95%	Sterilization:	 	 	 CIP/SIP		Operating	Conditions	 Temperature:		 	 22°C		 	 	 	 Pressure:	 	 	 1	atm		 	 	 	 Flow	Rate:	 	 	 80	L/h		 	 	 	 Residence	Time:	 	 3.88	Hours		Purchase	Cost	 	 $30,000/unit	
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16.15	-	Mixing	and	Washing	4	(WAVE	Reactor)	
	Description	and	Function	 A	repurposed	500	L	WAVE	single-use	bioreactor	will	consist	of		a	stainless	steel	rocking	unit	and	a	single-use	bioreactor	bag		assembly.	This	unit	will	be	used	to	re-suspend	and	wash	platelets	emerging	from	the	second	centrifuge.	The	rated	working	volume	is	500	L;	the	volume	used	in	this	process	will	be	405.001	L.		Vendor	 	 	 General	Electric		Operation	 	 	 Batch		Materials	Handled	 	 	 	 	 Input	(kg/batch)	 Output	(kg/batch)		 	 	 	 IMDM	+	Nutrients	 1.5315	 	 1.5315	Wash	Buffer	 	 22.412	 	 22.412	PAS-E	 	 	 305.37	 	 305.37	Synthetic	Plasma	 76.344	 	 76.344	Platelets	 	 0.074116	 	 0.074189	Oxygen	 	 0.017312	 	 0.017239		Characteristics	 	 Model:		 	 	 WAVE	Bioreactor	500/1000		System		 	 	 	 Construction	Material:		 Stainless	steel	permanent	vessel,		multilayer	laminated	clear	USP	class	VI	plastic	disposable	bag	assembly	Dimensions:	 	 	 Base	Unit:	79	×	49	×	63	in		 	 	 	 With	KIT500EH:	89	×	49	×	63	in	Sterilization:	 	 	 Disposable	bag	assembly;	CIP/SIP		for	base	Rocking	Details:	 	 Adjustable	Rocking	Angle:	0.5°-4°		 	 	 	 Rocking	Speed:	4	-	25	rocks/min	Rocking	Speed:	 	 15	rocks/min	Rocking	Angle:	 	 2°	Volume:	 	 	 500	L		Operating	Conditions	 Temperature:		 	 22°C		 	 	 	 Pressure:	 	 	 1	atm		 	 	 	 pH:	 	 	 	 7.2	
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	 	 	 	 pO2:	 	 	 	 20%		 	 	 	 Residence	Time:	 	 1	Hour		Purchase	Cost	 	 $30,000/unit		 	 	 	 $300/bag		
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16.16	-	Disc	Stack	Centrifuge	6	
	Description	and	Function	 The	MBPX	810H	disk	stack	centrifuge	will	be	used	to	separate		the	platelets	from	the	process	waste	(liquid	stream),	which	includes	unused	MKs.	There	is	about	an	95%	recovery	of	platelets	from	the	process	in	the	platelet-rich	slurry	stream.	The	resulting	platelet	stream	is	0.0579%	platelets	by	mass.				Vendor	 	 	 Alfa	Laval		Operation	 	 	 Batch		Materials	Handled	 	 	 	 	 Input	(kg/batch)	 Output	(kg/batch)		 	 	 	 IMDM	+	Nutrients	 1.5315	 	 0.459456	Wash	Buffer	 	 22.412	 	 6.7236	PAS-E	 	 	 305.37	 	 91.612	Synthetic	Plasma	 76.344	 	 22.903	Platelets	 	 0.074189	 	 0.070480	Oxygen	 	 0.017239	 	 0.0051717	 		  Characteristics	 	 Model:		 	 	 MBPX	810H		 	 	 	 Centrifuge	Type:		 	 Disc	Stack	Construction	Materials:	 Corrosion	resistant	stainless	steel		EN	1.4462	Max	Throughput	Capacity:	 15	m3/h	Solids	Handling	Capacity:	 300-540	L/h	G-Force:	 	 	 700	g	Bowl	Speed:	 	 	 6,250	rpm	maximum	Percent	yield:		 	 95%	Sterilization:	 	 	 CIP/SIP		Operating	Conditions	 Temperature:		 	 22°C		 	 	 	 Pressure:	 	 	 1	atm		 	 	 	 Flow	Rate:	 	 	 80	L/h		 	 	 	 Residence	Time:	 	 5.06	Hours		Purchase	Cost	 	 $30,000/unit	
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16.17	-	Disc	Stack	Centrifuge	7	
	Description	and	Function	 The	MBPX	810H	disk	stack	centrifuge	will	be	used	to	separate		the	platelets	from	the	process	waste	(liquid	stream),	which	includes	unused	MKs.	There	is	about	an	95%	recovery	of	platelets	from	the	process	in	the	platelet-rich	slurry	stream.	The	resulting	platelet	stream	is	0.183%	platelets	by	mass.				Vendor	 	 	 Alfa	Laval		Operation	 	 	 Batch		Materials	Handled	 	 	 	 	 Input	(kg/batch)	 Output	(kg/batch)		 	 	 	 IMDM	+	Nutrients	 0.45946	 	 0.13784	Wash	Buffer	 	 6.7236	 	 2.0171	PAS-E	 	 	 91.6121	 	 27.484	Synthetic	Plasma	 22.903	 	 6.8709	Platelets	 	 0.070480	 	 0.066956	Oxygen	 	 0.0051717	 	 0.0015515	 		  Characteristics	 	 Model:		 	 	 MBPX	810H		 	 	 	 Centrifuge	Type:		 	 Disc	Stack	Construction	Materials:	 Corrosion	resistant	stainless	steel		EN	1.4462	Max	Throughput	Capacity:	 15	m3/h	Solids	Handling	Capacity:	 300-540	L/h	G-Force:	 	 	 700	g	Bowl	Speed:	 	 	 6,250	rpm	maximum	Percent	yield:		 	 95%	Sterilization:	 	 	 CIP/SIP		Operating	Conditions	 Temperature:		 	 22°C		 	 	 	 Pressure:	 	 	 1	atm		 	 	 	 Flow	Rate:	 	 	 80	L/h		 	 	 	 Residence	Time:	 	 1.52	Hours		Purchase	Cost	 	 $30,000/unit	
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16.18	-	Storage	Vessel	(WAVE	Reactor)	
	Description	and	Function	 A	repurposed	500	L	WAVE	single-use	bioreactor	will	consist	of		a	stainless	steel	rocking	unit	and	a	single-use	bioreactor	bag		assembly.	This	unit	will	be	used	to	store	unprocessed	platelets	emerging	from	the	shear	vessel.	The	rated	working	volume	is	500	L;	the	volume	used	in	this	process	will	be	183.572	L.	Product	will	be	collected	in	the	vessel	and	held	for	2.5	hours,	assuming	the	ability	to	have	overnight	delivery.			Vendor	 	 	 General	Electric		Operation	 	 	 Batch		Materials	Handled	 	 	 	 	 Input	(kg/batch)	 Output	(kg/batch)		 	 	 	 IMDM	+	Nutrients	 0.13784	 	 0.13784	Wash	Buffer	 	 2.0171	 	 2.0171	PAS-E	 	 	 27.484	 	 27.484	Synthetic	Plasma	 6.8709	 	 6.8709	Platelets	 	 0.066956	 	 0.066956	Oxygen	 	 0.0015515	 	 0.0015515		Characteristics	 	 Model:		 	 	 WAVE	Bioreactor	500/1000		System		 	 	 	 Construction	Material:		 Stainless	steel	permanent	vessel,		multilayer	laminated	clear	USP	class	VI	plastic	disposable	bag	assembly	Dimensions:	 	 	 Base	Unit:	79	×	49	×	63	in		 	 	 	 With	KIT500EH:	89	×	49	×	63	in	Sterilization:	 	 	 Disposable	bag	assembly;	CIP/SIP		for	base	Rocking	Details:	 	 Adjustable	Rocking	Angle:	0.5o-4o		 	 	 	 Rocking	Speed:	4	-	25	rocks/min	Rocking	Speed:	 	 15	rocks/min	Rocking	Angle:	 	 2o	Volume:	 	 	 500	L		Operating	Conditions	 Temperature:		 	 22°C		 	 	 	 Pressure:	 	 	 1	atm	
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	 	 	 	 pH:	 	 	 	 7.2		 	 	 	 pO2:	 	 	 	 20%		 	 	 	 Residence	Time:	 	 2.5	Hours		Purchase	Cost	 	 $30,000/unit		 	 	 	 $300/bag			 	
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16.19	-	Peristaltic	Pumps	(All	Pumps	in	PFD)	Description	and	Function	 Peristaltic	pumps	are	used	throughout	the	process	in	order	to		transport	contents	throughout	the	process.	Particularly,	the		pumps	are	used	between	bioreactors	in	the	upstream	process	and	following	mixing	steps	in	downstream	processing.	The	consistent	flow	is	needed	to	maintain	consistent	flow	from	unit	to	unit.		Vendor	 	 	 Thermo	Fisher		Operation	 	 	 Batch		Characteristics	 	 Model:		 	 	 Masterflex	P/S	18	Pump	Systems		 	 	 	 Construction	Material:		 Stainless	Steel	and	Plastic	Polymer	Flow	Rate	Range:	 	 0.3	-	2300	mL/min	Maximum	Pressure	Drop:	 2.66	atm	Power	Requirement:		 250	W		Operating	Conditions	 Temperature:		 	 0-40°C		 	 	 	 Pressure:	 	 	 2	atm		 	 	 	 	Purchase	Cost	 	 $4,355/unit	
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XVII.	Equipment	Cost	Summary	
17.1	Major	Unit	Operation	Costs	The	estimated	total	purchase	cost	for	the	major	equipment	required	for	this	process	is	$4,067,333.	This	includes	all	of	the	seed	bioreactors,	the	2000	L	bioreactors	used	for	differentiation	of	iPSCs	into	megakaryocytes,	the	microfluidic	shear	devices,	centrifuges,	mixers,	and	INTERCEPT	viral	inactivation	system.	The	estimated	bare	module	cost	for	this	equipment	is	$12,575,666.	A	bare	module	factor	of	3.21	was	used	for	the	majority	of	the	equipment	(the	bioreactors,	the	centrifuges,	and	mixers).	This	was	calculated	assuming	the	cost	of	installation	materials	is	71%	of	the	equipment	purchase	cost,	the	cost	of	installation	labor	is	54%	of	the	equipment	purchase	cost,	the	cost	of	freight,	insurance,	and	taxes	is	9%	of	the	equipment	purchase	cost,	the	cost	of	construction	overhead	is	57%	of	the	equipment	purchase	cost,	and	the	cost	of	contractor	engineering	expenses	is	30%	of	the	equipment	purchase	cost.	A	different,	lower	bare	module	factor	was	used	for	the	microfluidic	shear	device	and	the	INTERCEPT	blood	system	because	these	units	are	benchtop-sized	and	will	not	invoke	such	substantial	installation	costs.	A	bare	module	factor	of	2.00	was	used	for	these	units	assuming	that	the	cost	of	installation	materials	is	20%	of	the	equipment	purchase	cost,	the	cost	of	installation	labor	is	40%	of	the	equipment	purchase	cost,	the	cost	for	freight,	insurances,	and	taxes	is	9%	of	the	equipment	purchase	cost,	the	cost	of	construction	overhead	is	21%	of	the	equipment	purchase	cost,	and	the	cost	of	contractor	engineering	expenses	is	10%	of	the	equipment	purchase	cost.	A	bare	module	factor	of	3.30	was	used	for	the	peristaltic	pumps.39	It	is	likely	that	this	is	a	high,	conservative	estimate	for	the	equipment	costs	because	the	majority	of	the	equipment	involved	in	this	plant	is	off-the-shelf	and	will	not	require	
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nearly	as	much	money	for	installation	materials	and	contractor	engineering	expenses	as	estimated.	Nonetheless,	for	the	purposes	of	this	report,	this	conservative	cost	estimate	will	be	used	to	gauge	the	feasibility	of	the	process.	The	overall	breakdown	of	the	equipment	costs,	bare	module	costs,	and	number	of	units	required	is	detailed	in	Table	17.1.1	below.		
Table	17.1.1.	The	types	of	equipment,	number	of	each	unit,	purchase	cost,	and	bare	module	cost	are	shown	below.	The	total	purchase	and	bare	module	costs	are	also	provided.	
		 The	most	expensive	process	units	are	the	single-use	bioreactors,	the	2000	L	reactor	being	the	most	expensive,	followed	by	the	250	L	reactor	and	the	50	L	reactor.	Despite	being	highly	specialized	and	novel	technology,	the	microfluidic	shear	devices	themselves	are	not	expensive	relative	to	the	other	process	units	-	a	2019	estimate	from	Dr.	Daeyeon	Lee	places	each	chip	at	roughly	$3,000.	The	majority	of	the	costs	associated	with	the	microfluidic	devices	come	in	the	form	of	licensing	fees,	which	are	accounted	for	in	the	profitability	analysis.		
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It	should	be	noted	that	for	some	processing	units,	spare	equipment	will	be	purchased	so	that	the	facility	can	maintain	production	goals	even	in	cases	of	contamination	or	equipment	malfunctions.	One	spare	of	each	bioreactor	will	be	purchased	(the	10	L,	the	50	L,	the	250	L,	and	the	2000	L)	for	this	purpose.	Additionally,	two	sets	of	fifty	microfluidic	devices	will	be	purchased	so	that	the	time	required	to	steam	sterilize	the	devices	between	batches	will	not	interfere	with	meeting	production	targets	and	staying	on	schedule;	one	of	the	sets	will	be	used	every	other	batch	while	the	other	set	is	sterilized	and	prepared	for	the	next	batch.	Spares	of	the	downstream	processing	equipment	such	as	centrifuges,	mixers,	and	storage	vessels	will	not	be	purchased,	as	there	is	already	a	large	quantity	of	these	units	in	the	facility	and	maintenance	on	these	small	units	should	be	fairly	routine.	It	should	be	noted	that	the	polymer	bags	used	in	the	single-use	bioreactors	are	crucial	pieces	of	equipment	but	are	not	included	in	the	equipment	costing	summary	list	because	they	are	not	a	one-time	investment;	a	new	bag	is	used	for	each	reactor	for	each	batch.	The	bags	range	in	price	from	$3,000	per	bag	for	the	50	L	reactors	to	$3,500	per	bag	for	the	250	L	reactors	to	$10,000	per	bag	for	the	2000	L	reactors.	The	repurposed	single-use	wave	bioreactors	used	as	mixers	and	storage	vessels	also	require	disposable	bags	that	cost	$300	per	bag.	These	costs	are	accounted	for	in	the	variable	costs	section	of	the	profitability	analysis;	it	is	estimated	that	the	bags	will	cost	$2.3	million	per	year.	 	
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XVIII.	Fixed	Capital	Investment	Summary	
A	summary	of	the	total	capital	investment	required	for	this	project	is	shown	below	in	Table	21.1.	A	total	of	$20.1	million	will	be	required	to	build	the	production	facility.		 	
Table	18.1.	Summary	of	the	total	capital	investment	required	for	the	facility.
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XIX.	Operating	Cost	
19.1	Variable	Costs	
	 The	annual	cost	of	purchasing	raw	materials	for	this	process	is	estimated	to	be	$2.06	million,	which	evens	out	to	$29.76	per	platelet	unit	produced.	These	values	are	shown	in	Table	19.1.			
Table	19.1.1.	The	cost	of	raw	materials	required	for	this	process	are	shown	on	a	per	platelet	unit	basis	and	on	an	annual	basis. 
	
		 The	cost	of	raw	materials	for	this	process	was	calculated	using	prices	quoted	by	vendors	online	as	well	as	estimates	from	industrial	consultants	on	this	project.	There	are	several	high-value	raw	materials	required	for	the	very	specific	growth	and	differentiation	media	required	for	this	process.	Many	of	these	materials	are	recombinant	proteins	that	are	required	in	small	quantities	but	are	either	not	readily	available	for	purchase	or	cost	an	exorbitant	amount	when	purchased	in	the	required	quantity,	such	as	PEG-rHuMGDF	and	Oprelvekin.	Price	quotes	from	online	vendors	were	unavailable	for	these	components,	so	it	
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was	decided	after	speaking	with	several	consultants	that	it	would	be	more	reasonable	to	assume	that	the	manufacture	of	these	proteins	and	growth	factors	could	be	contracted	out	to	laboratories	that	research	them	or	already	produce	them.	The	production	of	these	components	would	ideally	be	integrated	into	our	process	in	the	future	once	the	venture	has	grown	enough	to	support	it.	It	was	assumed	that	since	FGF-2,	BMP,	VEG-F	A,	Romiplostim,	Oprelvekin,	and	PEG-rHuMGDF	are	only	required	in	the	range	of	1-4	grams	each	per	year,	we	could	easily	pay	a	laboratory	(or	several	different	laboratories)	a	fee	to	make	these	products	for	our	process.	An	annual	payment	of	$3,000	per	component	was	assumed	in	the	calculations.	Slightly	higher	annual	payment	estimates	of	$5,000	and	$10,000	for	SCF	and	rock	inhibitor,	respectively,	were	assumed	since	9.37	g	of	SCF	and	260.3	g	of	rock	inhibitor	are	required	each	year.	For	plasbumin,	another	protein	that	was	not	able	to	be	purchased	for	a	reasonable	price	and	quantity	online,	it	was	decided	that	a	contracting	fee	of	$100,000	could	be	paid	to	a	laboratory	to	cover	the	costs	of	supplies,	an	employee	whose	full-time	job	was	to	make	this	protein,	and	an	additional	fee	for	the	product	because	9,946.25	g	of	it	are	required	each	year.		 All	other	raw	materials	can	be	purchased	normally	from	vendors	such	as	Sigma	Aldrich	and	Thermo	Fisher.	The	most	significant	raw	material	cost	is	IMDM	due	to	the	large	amount	of	it	consumed	(187,391	L)	per	year.	IMDM	can	be	purchased	for	between	approximately	$10	to	$60	per	liter	from	the	aforementioned	vendors	depending	on	the	quantity	purchased.	Since	the	required	quantity	for	this	process	is	so	large,	it	was	assumed	that	a	substantial	bulk	discount	could	be	negotiated,	and	a	value	of	$10	was	used	in	the	calculations.	
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	 Additionally,	iPSCs	are	a	significant	cost	in	this	analysis.	It	is	desired	to	purchase	the	cells	once	and	then	spend	the	years	dedicated	to	research	and	development	before	the	plant	begins	operation	banking	these	cells	to	ensure	uniformity	of	the	platelet	product.	The	price	used	in	the	cost	analysis	accounts	for	the	initial	purchase	of	the	cells,	and	it	is	included	each	year	because	there	is	a	cost	associated	with	maintaining	the	cell	bank,	and	new	cell	lines	may	occasionally	need	to	be	purchased.		The	overall	variable	costs,	including	the	raw	materials,	utilities,	and	additional	general	expenses,	are	detailed	in	Table	19.1.2.		
Table	19.1.2.	Summary	of	the	variable	costs	associated	with	plant	operation.		
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19.2	Utilities	
	 The	total	annual	cost	of	utilities	is	$239,837,	or	$3.45	per	platelet	unit.	The	cost	breakdown	of	the	various	utilities	is	shown	in	Table	19.2.1.	The	utilities	include	electricity,	steam,	water,	oxygen,	and	sterile	air.	Electricity	is	required	to	operate	each	of	the	process	units	as	well	as	the	plant	facility	itself.	The	electricity	requirements	for	each	unit	were	calculated	using	specification	sheets	provided	by	the	equipment	vendors,	and	the	requirements	for	the	plant	itself	were	calculated	by	assuming	that	40.8	kWh	of	lighting	and	HVAC	utility	are	required	for	each	square	foot	annually,	a	value	obtained	from	a	“Commercial	Buildings	Energy	Consumption	Survey”	conducted	by	the	US	Energy	Information	Administration.	The	industrial	cost	of	electricity	in	Philadelphia	is	$0.085	per	kWh,	so	the	annual	cost	of	electricity	for	the	processing	units	is	$18,600	and	$10,668	for	lighting	and	HVAC	requirements.	The	plant	also	requires	a	substantial	amount	of	steam	for	sterilization	of	the	centrifuges	and	the	microfluidic	shear	devices;	the	reactors,	mixers,	and	storage	vessels	do	not	require	steam	sterilization	because	they	have	disposable	bags.	Each	centrifuge	and	microfluidic	shear	device	will	be	treated	with	steam	at	a	pressure	of	1.02	atm	and	121°C	for	thirty	minutes	after	each	use,	as	outline	by	the	CDC.38	This	process	requires	304.2	kg	of	steam	annually.	Steam	is	priced	at	$0.013	per	kg,	leading	to	an	annual	cost	of	steam	of	$3.95.	Sterile	water	is	also	required	for	this	process	to	clean	each	centrifuge	and	microfluidic	device.	This	sterile	water	will	be	flowed	through	the	centrifuge	at	200	L/h	for	thirty	minutes	and	through	the	microfluidic	device	at	a	flow	rate	of	1.28	L/h	for	thirty	minutes.	It	is	priced	at	$0.005	per	liter,	and	515,672	liters	are	required	annually	for	a	total	cost	of	$2,578	per	year.	Some	non-sterile	cooling	water	is	also	required	to	keep	the	reactors	at	room	temperature;	386,403,600	L	are	required	annually	at	$0.00054	per	L,	
103	
leading	to	a	total	annual	cost	of	$207,498.	Sterile	oxygen	is	required	in	each	of	the	bioreactors,	the	shear	devices,	and	mixers.	It	is	priced	at	$0.170	per	kg,	and	this	process	will	require	59.8	kg	annually	for	a	total	cost	of	$10.16.	Sterile	air	is	required	to	inflate	the	WAVE	bioreactor	bags	used	as	mixers	and	storage	vessels.	It	is	priced	at	$0.10	per	kg,	and	4788	kg	are	required	annually	for	a	total	cost	of	$478.81	per	year.	
	
Table	19.2.1.	List	of	utilities	required	for	this	process.	
		
19.3	Fixed	Operating	Costs	The	inputs	used	to	calculate	the	fixed	operating	cost	of	this	process	are	detailed	in	Table	19.3.1.	They	include	operations,	maintenance,	overhead,	property	taxes	and	insurance,	depreciation,	and	other	annual	expenses	such	as	licensing	fees	and	rental	space.	
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Table	19.3.1.	Inputs	to	the	fixed	cost	calculations	performed	for	this	process.	
		 It	was	decided	that	four	daily	operating	shifts	of	six	hours	each	would	be	necessary	for	successful	operation.	For	the	majority	of	the	time,	no	human	intervention	is	necessary	to	operate	the	equipment;	the	operators	will	be	most	involved	only	when	the	disposable	bags	in	the	bioreactors	and	mixers	need	to	be	changed	and	the	vessels	need	to	be	cleaned.	
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Therefore,	having	three	operators	per	shift	as	well	as	one	control	laboratory	specialist	and	one	manager	with	some	engineering	training	was	deemed	appropriate	for	this	process.	Since	the	microfluidic	technology	used	in	the	platelet	formation	step	belongs	to	the	University	of	Pennsylvania,	a	licensing	fee	will	have	to	be	paid	to	use	this	technology	in	our	process.	Based	on	advice	from	the	industrial	consultants,	a	value	of	$400,000	annually	was	decided	upon	as	a	reasonable	value	to	assume	for	the	purposes	of	economic	calculations.	The	actual	value	could	be	negotiated	once	the	facility	is	built	and	ready	to	actually	use	the	technology.	The	cost	of	renting	space	is	also	included	in	the	fixed	cost	analysis.	The	space	required	for	this	facility	was	determined	to	be	3,076	square	feet	based	on	estimates	of	space	required	for	a	media	prep	room,	a	main	production	room,	a	biological	lab,	and	an	analytical	lab	for	quality	control	testing.	Based	on	advice	from	the	industrial	consultants,	it	was	assumed	that	a	12x24	foot	room	would	be	required	for	media	prep.	For	the	main	production	room	that	will	house	all	of	the	processing	units,	it	was	calculated	that	855	square	feet	would	be	required	for	the	equipment	itself.	Space	will	also	be	needed	in	that	room	to	move	between	the	units	and	connect	the	required	tubing	between	the	units,	so	2500	square	feet	were	allotted	for	this	room.	A	12x12	foot	room	was	allotted	for	a	biological	lab,	which	will	eventually	be	used	for	cell	culture	and	cell	bank	maintenance	once	a	cell	bank	is	established.	An	additional	lab	for	analytical	testing	of	batches	was	also	included	and	12x12	foot	room	was	allocated	for	this	purpose.	In	Philadelphia,	rental	space	goes	for	an	average	of	$40	per	square	foot,	so	this	value	was	used	to	obtain	an	estimate	of	$123,040	spent	per	year	on	space	rental.43	
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The	disposable	bags	required	for	the	single-use	bioreactors	and	mixers	are	included	in	the	fixed	operating	costs	as	well.	The	annual	cost	of	the	disposable	bags	is	$2,300,000,	or	$33.07	per	platelet	unit.	The	costs	were	obtained	from	online	quotes	for	the	wave	bioreactors	used	as	mixers	and	storage	vessels	as	well	as	a	correlation	provided	by	Jeffrey	Cohen	(Johnson	&	Johnson)	for	the	Thermo	Fisher	HyPerforma	line	of	bioprocess	containers.	While	this	cost	is	significant,	the	benefits	of	employing	single-use	technology	outweigh	the	costs	because	the	downtime	between	batches	is	significantly	reduced,	as	is	the	required	amount	of	steam	for	equipment	sterilization.	The	complete	fixed	cost	is	$9.99	million,	and	a	summary	of	the	cost	breakdown	is	shown	below	in	Table	19.3.2.	Operations	comprise	the	majority	of	the	fixed	costs.		 	
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Table	19.3.2.	Summary	of	the	fixed	operating	costs	associated	with	this	facility.	
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XX.	Other	Important	Considerations	
20.1	Regulatory	Requirements		 The	use	of	culture-derived	platelets	in	transfusions	rather	than	donor	platelets	will	require	approval	from	the	FDA.	The	product	will	have	to	successfully	undergo	clinical	trials	before	being	used	in	human	patients	to	ensure	its	safety	and	efficacy.	Prior	to	receiving	approval	to	begin	clinical	trials,	an	Investigational	New	Drug	(IND)	application	will	have	to	be	submitted	to	the	FDA.	The	FDA	will	use	this	application	to	evaluate	the	manufacturing	process,	any	available	safety	and	toxicity	data,	and	clinical	protocols	before	issuing	their	approval	to	begin	clinical	studies.44			 Given	that	the	average	hematology-related	clinical	trial	lasts	roughly	10-15	years	and	costs	$65.2	million,	the	design	and	performance	of	clinical	trials	have	been	deemed	out	of	scope	for	this	project.45	However,	it	is	important	to	note	the	parameters	that	will	be	evaluated	during	these	trials.	In	Phase	I	trials,	healthy	volunteers	will	be	used	to	assess	how	the	platelets	interact	with	the	body.	This	phase	will	test	dose	escalation	and	any	associated	side	effects.	Phase	II	and	III	trials	will	then	use	patients	with	the	disease	being	treated	-	in	this	case,	thrombocytopenia	(low	platelet	count)	-	to	assess	efficacy.	In	Phase	II	trials,	researchers	will	collect	additional	safety	data	and	begin	to	evaluate	the	efficacy	of	the	product.	Phase	III	trials	will	then	be	performed	in	a	larger	sample	population	to	evaluate	the	performance	of	the	culture-derived	platelets	compared	to	traditional	donor	platelets	and	assess	long-term	side	effects.	Phase	IV,	also	known	as	post-marketing	surveillance,	will	take	place	after	FDA	approval	has	been	received	and	will	continue	to	monitor	the	safety	of	the	platelets	as	well	as	test	for	more	nuanced	phenomena,	such	as	the	interaction	of	the	platelets	with	various	medications.44	
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	 Once	production	has	begun,	the	platelets	produced	at	the	end	of	each	day	will	have	to	undergo	testing	in	the	on-site	biochemical	laboratory	to	ensure	that	there	is	no	contamination	and	the	platelet	count	and	function	have	been	maintained	within	an	acceptable	range.	Packaging	and	distribution	to	surrounding	hospitals	will	begin	immediately	at	the	end	of	the	downstream	processing	steps.	Hospitals	will	receive	the	platelets	but	will	not	be	able	to	use	them	until	the	quality	has	been	confirmed.	This	testing	is	expected	to	take	24	hours.	
20.2	Waste	Disposal		 As	mentioned	in	the	mass	balance,	11412.2	kg	of	liquid	waste	with	a	small	mass	of	platelets	and	MKs	will	be	produced	each	batch	and	must	be	disposed	of	in	accordance	with	guidelines.	At	the	end	of	each	day	of	downstream	processing,	there	will	be	228.45	kg	of	liquid	biohazard	waste	to	treat,	or	2241.5	L.	In	accordance	with	NIH	guidelines,	the	waste	will	be	stored	in	a	15000	L	tank	and	then	treated	with	5.25%	sodium	hypochlorite	(bleach).	The	bleach	will	be	added	in	a	1:10	ratio,	meaning	that	224.15	L	of	5.25%	bleach	will	be	added	to	the	waste	produced	from	each	day	of	downstream	processing.46	Each	day	for	5	days,	the	waste	produced	at	the	end	of	the	day	will	be	added	to	the	tank	and	bleached,	creating	a	total	waste	and	bleach	volume	of	12328.25	L.	The	waste	will	be	picked	up	every	5	days	by	personnel	to	be	disposed	of	properly.		
20.3	Research	and	Development		 Four	years	have	been	allocated	before	production	begins	for	research	and	development	due	to	the	nature	of	this	project	-	four	years	of	design	and	one	year	of	construction.	Platelet	production	ex	vivo	has	only	been	done	on	the	lab	scale	thus	far,	so	commercial-scale	processing	must	be	optimized.	Firstly,	acquired	iPSC	stocks	must	be	gene	
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edited	according	to	standard	protocol	so	that	the	platelets	developed	will	be	universally	compatible.	While	ABO	compatibility	is	not	a	widespread	issue	with	platelet	donations,	HLA	alloimmune	response	is	a	major	concern.	HLA	is	a	surface	protein	similar	to	ABO	that	is	present	on	the	surface	of	cells.	Immune	responses	to	foreign	a	foreign	HLA	type	is	common	and	could	be	harmful.	To	decrease	the	possibility	of	an	alloimmune	response,	the	HLA	gene	will	be	deleted	to	decrease	its	surface	expression.	For	this	procedure,	the	iPSCs	will	undergo	gene	editing	to	delete	the	beta-2	microglobulin	gene.13	This	process	will	take	a	short	period	to	complete,	and	after	the	iPSCs	have	been	successfully	altered,	they	will	need	to	be	proliferated	and	stocked	up	so	that	there	will	be	a	ready	available	supply	of	frozen	gene-edited	iPSCs	for	each	batch.		 The	iPSCs	must	also	be	adapted	to	feeder-free	conditions	so	that	they	can	proliferate	without	feeder	cells.	Similar	to	the	gene-editing	step,	this	is	a	well-defined	process	and	is	not	predicted	to	be	a	challenge.	However,	it	is	vital	for	this	step	to	be	performed	so	that	the	iPSCs	will	be	able	to	grow	in	the	conditions	for	this	process.22	For	this	step,	cells	will	have	to	be	seeded	in	the	feeder-free	Essential	8	Medium	on	Matrigel-coated	plates.	After	the	cells	are	have	grown,	they	will	be	ready	for	culture.			 Time	must	also	be	dedicated	to	perfecting	the	shear	device	for	platelet	formation.	Research	during	this	period	will	be	dedicated	to	optimizing	the	device	conditions,	such	as	flow	rate,	to	achieve	the	highest	yield	possible	of	platelets	-	the	goal	yield	of	platelets	is	100	functional	platelets	per	pre-platelet	MK.		 The	separation	and	downstream	processing	techniques	employed	in	this	project	are	common	in	the	biotechnological	industry,	but	they	have	not	been	used	on	this	scale	with	platelets	before.	Thus,	the	disc-stack	centrifugation	and	the	washing	and	resuspension	
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steps	must	be	tested	and	developed.	The	volume	of	liquid	remaining	in	the	concentrated	platelet	product	post-centrifugation	must	be	determined	experimentally.	Estimates	of	30%	liquid	retention	in	the	slurry	have	been	used	for	the	purpose	of	this	design	based	on	literature	values,	but	it	is	likely	that	the	true	liquid	content	in	the	platelet	slurry	will	vary,	especially	because	the	rotation	speed	of	the	centrifuges	is	relatively	low	compared	to	many	other	disc	stack	centrifugation	processes.		The	wash	and	resuspension	steps	must	undergo	similar	testing	to	ensure	that	the	final	platelet	product	has	minimal	quantities	of	media	and	other	materials	used	in	the	stages	of	production.	Additionally,	the	rocking	angle	and	rate	of	the	wave	mixers	must	be	tested	to	ensure	that	platelet	activation	in	minimal	but	that	the	platelets	and	wash	solution	are	becoming	well	mixed.	The	process	used	on	this	scale	to	wash	and	store	the	platelets	is	different	from	the	procedure	done	for	individual	platelet	donations,	so	no	information	about	the	yield	or	likelihood	of	platelet	activation	is	available.	The	platelet	product	yielded	from	each	production	step	will	be	tested	for	platelet	and	cell	count	and	level	of	platelet	viability	and	activation.	
20.4	Scheduling	
	 Because	the	production	of	platelets	is	a	batch	process	system	and	a	new	platelet	supply	must	be	generated	every	day,	careful	scheduling	was	done	to	help	with	minimizing	costs.	By	determining	the	period	of	time	that	the	cells	and	platelets	spend	in	each	step	of	the	process	and	the	time	to	clean	the	unit	before	the	next	batch,	the	number	of	employees	as	well	as	the	number	of	units	required	were	determined.	The	schedules	shown	in	Figure	20.4.1	demonstrate	the	timeline	for	a	single	batch	-	it	shows	the	downtime	for	each	piece	of	equipment	as	well	as	the	amount	of	time	that	the	iPSCs,	MKs,	or	platelets	spend	in	each	
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unit.	(a)	shows	the	overall	process	timeline,	and	(b)	gives	a	more	detailed	look	at	the	timeline	for	the	downstream	process	because	it	is	very	involved	and	on	a	shorter	time	period	than	the	rest	of	the	process.		Figure	20.4.2	shows	that	many	batches	run	simultaneously	but	at	different	parts	of	the	batch	process.	A	new	batch	begins	every	5	days	because	new	platelets	are	produced	once	each	day	for	five	days	for	one	batch.	This	schedule	demonstrates	why	there	is	a	need	for	more	than	one	of	each	unit,	especially	in	the	upstream	process.		 	
113	
			 	
Fi
gu
re
	2
0.
4.
1a
	a
nd
	2
0.
4.
1b
.	Figure
	(a)	sho
ws	the
	overal
l	sched
ule	for	
the	ups
tream	a
nd	dow
nstream
	proces
ses.	Ea
ch	step
	in	the	
proces
s	occur
s	
for	a	sp
ecific	p
eriod	o
f	time,	
as	show
n	by	th
e	brigh
t	colors
.	At	the
	end	of
	
each	pr
ocess,	t
he	clea
ning	tim
e	is	sho
wn	in	a
	light	p
ink.	Fig
ure	(b)
	shows
	
the	det
ailed	sc
hedule
	of	the	
downs
tream	p
rocessi
ng	step
s.	In	ad
dition	t
o	
the	cle
aning	p
eriods	
for	eac
h	unit,	
the	tim
e	when
	the	mi
xers	ar
e	prepp
ed	
with	ai
r	and	m
edia	is	
shown
	in	ligh
t	green
.	(a)	 (b)	
114	
	 	
Fi
gu
re
	2
0.
4.
2.
	This	sc
hedule
	demon
strates
	clearly
	that	di
fferent
	steps	o
f	the	en
tire	
batch	
proces
s	are	a
lways	
occurr
ing	sim
ultaneo
usly	in
	the	p
lant	to
	maxim
izes	
equipm
ent	use
	and	en
sure	a	
new	pl
atelet	p
roduct
	is	prod
uced	d
aily.	A	
new	ba
tch	
begins
	every	
5	days.
	
115	
XXI.	Profitability	Analysis	
21.1	Market	Analysis	and	Basic	Approach		 Approximately	107,000	units	of	platelets	are	used	in	transfusions	in	the	city	of	Philadelphia	annually.	Given	the	chronic	shortage	of	donated	platelets	experienced	in	Philadelphia	and	across	the	country,	it	would	be	ideal	for	this	facility	to	be	capable	of	providing	a	large	portion	of	the	platelet	need	for	the	city.	There	is	no	current	competition	in	the	market,	since	the	only	current	source	of	platelets	is	donations.	When	operating	at	full	capacity,	this	facility	is	able	to	produce	83%	of	the	city’s	annual	need.	However,	assuming	that	10%	of	the	batches	are	bad	and	that	some	platelet	products	will	be	used	for	sampling,	the	facility	will	more	realistically	provide	65%	of	the	city’s	need,	or	69,550	units	of	platelets	annually.	If	this	venture	is	successful	in	Philadelphia,	this	process	could	be	developed	further	and	have	the	potential	to	expand	into	other	major	cities	and	service	a	larger	portion	of	the	population.	
21.2	Pricing	of	Platelets		 One	unit	of	platelets	costs	an	average	of	$533.90,	excluding	the	costs	of	storage	and	transfusion.47	While	there	is	no	current	competition	in	the	market	for	manufactured	platelets	at	this	time,	it	is	assumed	that	there	will	be	other	players	in	the	market	by	the	time	this	process	receives	FDA	approval,	especially	with	the	work	being	pioneered	by	Platelet	BioGenesis	and	the	likely	emergence	of	similar	ventures	in	the	future.	Based	on	this	assumption,	a	price	of	$400	per	unit	was	settled	upon.	This	value	was	used	in	the	cash	flow	analysis	for	each	year	the	facility	is	in	operation,	though	when	other	competitors	do	enter	the	market	in	the	future,	this	price	will	likely	have	to	be	adjusted	for	this	venture	to	stay	competitive.	
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21.3	Profitability	Analysis	and	Metrics	
	 This	facility	will	require	an	initial	total	capital	investment	of	$20.1	million.	The	working	capital	required	for	this	project	is	detailed	below	in	Table	21.3.1.	Prior	to	beginning	plant	operation,	it	was	assumed	that	three	years	would	be	required	to	finalize	the	design	and	allow	for	further	research	and	development	to	determine	optimal	operating	conditions	and	culture	techniques.	An	additional	year	to	allow	for	facility	construction	was	also	assumed.	The	facility	will	be	active	for	15	years,	for	a	total	of	19	years	including	the	design	and	construction	time.	The	design	and	construction	is	slated	to	begin	in	2030	to	allow	enough	time	to	complete	clinical	trials	and	obtain	FDA	approval	for	the	product.	It	was	assumed	that	the	facility	will	not	immediately	begin	operating	at	full	capacity,	and	a	conservative	estimate	of	50%	production	capacity	was	assumed	for	the	first	year	of	operation.		
Table	21.3.1.	Working	capital	requirements	for	this	project.	
			 An	overview	of	several	key	profitability	metrics	is	provided	in	Table	21.3.2.	This	plant	will	have	a	return	on	investment	(ROI)	of	23.21%	and	an	internal	rate	of	return	(IRR)	of	28.99%.	The	net	present	value	of	the	project	in	2030	(the	first	year	of	the	project)	is	$14.4	million.		
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Table	21.3.2.	Important	profitability	metrics	for	this	venture.	The	internal	rate	of	return,	net	present	value	in	2030,	and	return	on	investment	are	provided.	
			 This	analysis	suggests	that	this	project	is	financially	feasible	and	has	the	potential	to	become	profitable.	Given	the	profitability	of	this	project	on	the	relatively	small	scale	of	Philadelphia,	this	venture	has	the	opportunity	to	become	even	more	lucrative	if	it	expands	into	other	cities’	platelet	markets.	Additionally,	given	more	time	for	research	and	development,	it	is	hopeful	that	higher	yields	of	platelets	per	megakaryocyte	will	be	achieved.	This	would	increase	production	capacity	and	allow	the	facility	to	service	more	hospitals	in	the	area,	perhaps	expanding	out	of	Philadelphia	proper	and	starting	to	move	into	supplying	suburban	and	other	regional	hospitals.	Furthermore,	it	is	likely	that	raw	material	costs	can	be	reduced	in	the	future.	Several	of	the	proteins	and	growth	factors	used	in	this	process	currently	need	to	be	outsourced	to	research	labs	and	are	a	significant	annual	cost.	Once	this	venture	grows	enough	to	support	additional	laboratory	space	and	
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personnel,	a	handful	of	laboratory	staff	could	be	hired	to	produce	these	components	in-house	for	a	fully	integrated	process.		
21.4	Clinical	Trial	Considerations	
	 The	platelets	produced	in	this	process	will	require	approval	from	the	FDA	before	they	can	safely	be	used	in	transfusions.	The	approval	process	will	require	the	successful	completion	of	clinical	trials	in	order	to	ensure	the	safety	and	efficacy	of	the	platelets.			 As	mentioned	previously,	the	average	hematology-related	clinical	trial	lasts	roughly	10-15	years	and	costs	$65.2	million.45	The	design	and	performance	of	these	clinical	trials	has	been	deemed	out	of	scope	of	this	project,	though	it	has	been	assumed	that	the	product	will	successfully	gain	FDA	approval	at	the	end	of	the	process.	As	a	result,	clinical	trials	have	been	left	out	of	the	profitability	analysis	discussed	above.	
21.5	Sensitivity	Analysis	-	MK	Platelet	Yield		 One	way	in	which	this	venture	could	become	more	profitable	is	if	the	yield	of	platelets	from	each	megakaryocyte	was	improved.	While	this	process	aims	to	achieve	100	functional	platelets	per	megakaryocyte,	it	has	been	shown	that	between	2,000	and	11,000	platelets	per	megakaryocyte	can	be	achieved	in	vivo.41	If	the	research	and	development	period	discussed	above	were	to	be	used	to	determine	the	optimal	conditions	for	increased	platelet	yield	from	each	megakaryocyte,	each	batch	produced	from	this	process	could	supply	far	more	platelets	than	originally	thought.		A	sensitivity	analysis	was	performed	to	determine	the	profitability	of	this	venture	depending	on	the	platelet	yield	per	megakaryocyte.	Assuming	the	lower	end	of	the	in	vivo	range	was	achieved	and	each	MK	yielded	2,000	platelets,	24,300	platelet	units	could	be	produced	in	each	batch.	This	would	allow	the	production	facility	to	provide	1.77	million	
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platelet	units	per	year,	more	than	the	total	annual	demand	in	Philadelphia.	If	this	were	the	case,	prices	could	be	set	even	lower,	and	the	venture	could	still	be	more	profitable	than	it	is	with	the	current	platelet	yield.	A	detailed	sensitivity	analysis	was	performed	to	determine	how	low	prices	could	be	set	while	still	attaining	desirable	profits.	The	results	demonstrate	that	if	prices	were	kept	at	the	current	level	of	$400	per	bag,	the	IRR	would	be	423%,	and	the	ROI	would	be	430%.	However,	a	detailed	sensitivity	analysis	revealed	that	the	price	could	be	set	as	low	as	$52.50	and	still	achieve	an	IRR	of	29.64%	and	ROI	of	24.06%.	These	values	are	extremely	close	to	the	IRR	and	ROI	of	the	proposed	design,	though	with	a	much	higher	NPV	in	2030	of	$16.2	million.	The	profitability	metrics	at	this	lower	price	are	detailed	in	Table	21.5.1.	Figure	21.5.1	shows	the	relationship	between	NPV	in	2030	and	platelet	yield	when	the	price	of	the	platelets	from	the	higher	yield	process	is	adjusted	to	maintain	an	IRR	and	ROI	similar	to	those	of	the	original	process;	the	NPV	increases	with	platelet	yield	even	with	the	sharp	decline	in	price,	suggesting	that	devoting	resources	to	achieving	higher	platelet	yields	would	be	valuable.	
Table	21.5.1.	Profitability	metrics	for	a	process	with	a	higher	platelet	yield	of	2,000	platelets	per	MK	when	the	price	for	one	unit	of	platelets	is	$52.50.		
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Figure	21.5.1.	NPV	in	2030	vs.	the	yield	of	platelets	per	megakaryocyte.	NPV	increases	linearly	with	platelet	yield	per	MK,	suggesting	that	research	into	attaining	higher	platelet	yields	would	benefit	this	process	financially.		 	
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XXII.	Conclusions	and	Recommendations	
	 Based	on	the	IRR	of	28.99%,	ROI	of	23.21%,	and	NPV	of	$14.4	million	in	2030,	we	would	recommend	that	this	project	be	implemented	for	ex	vivo	platelet	production	to	be	supplied	for	clinical	transfusions.	Introducing	a	new	culture-derived	source	for	platelets	would	greatly	alleviate	the	need	for	platelet	donations	and	reduce	the	strain	put	on	hospitals	awaiting	platelet	supply.	It	is	recommended	that	before	actually	implementing	this	process	and	building	the	facility,	several	years	be	dedicated	to	further	research	and	development.	There	are	several	areas	in	which	we	lack	information	that	could	greatly	improve	the	efficiency	of	the	process.	For	example,	research	into	improving	platelet	yield	from	cultured	megakaryocytes	could	increase	the	number	of	platelet	units	produced	each	year	and	result	in	higher	profits.		Additionally,	it	is	recommended	that	partnerships	with	large	biotechnology	companies	be	explored	in	the	future.	There	will	be	significant	clinical	trial	costs	associated	with	bringing	this	product	to	market,	so	partnering	with	larger	firms	who	could	provide	this	venture	with	more	capital	would	be	beneficial.	This	venture	should	be	an	attractive	partner	to	these	companies,	as	this	project	addresses	a	critical	need	in	the	medical	community	and	shows	promising	economic	potential.	 	
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XXV.	Appendix	
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Appendix	B	–	Equations	Growth	Rate	of	Cells:		 	 ! = XY	(@)Z[ 	 Equation	B.1		Mass	of	Oxygen	Gas	Required	for	Proliferating	Cells:	
(mass	to	reach	desired	concentration)	+	(mass	consumed	by	growing	cells)		 	 \×]^_×`a(^_)b×c + e×^fbg = E*..	?@	H+<-6$+3	 Equation	B.2	Mass	of	Oxygen	Gas	Required	for	Platelets:		 	 \×]^_×`a(^_)b×c + 8 × ?QH = E*..	H+<-6$+3	 Equation	B.3	Required	Mixing	Rate	of	CSTR:		 	 S = bh×ij×2_	 Equation	B.4	
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Appendix	C	–	Detailed	Mass	Balance	Tables	
Mass	Balance	Tables	for	Individual	Units:	Upstream		
Table	C.1.	Detailed	Mass	Balance	for	10	L	Bioreactor.	Proliferation:	10	L	Bioreactor	
Component	 Mass	in	(g)	 Mass	out	(g)	 Mass	generated	(g)	 Mass	consumed	(g)	 Mass	Accumulated	(g)	iPSC	Cells	 0.0100	 5.00	 4.99	 0	 0	IMDM	 5000	 4995.8	 0	 4.2421	 0	Plasbumin	 250.00	 250.00	 0	 0	 0	Rock	Inhibitor	 0.012367	 0.012367	 0	 0	 0	Oxygen	 0.81729	 0.069399	 0	 0.74789	 0	OVERALL	 5250.8	 5250.8	 4.990	 4.990	 0		
Table	C.2.	Detailed	Mass	Balance	for	50	L	Bioreactor.	Proliferation:	50	L	Bioreactor	
Component	 Mass	in	(g)	 Mass	out	(g)	 Mass	generated	(g)	 Mass	consumed	(g)	 Mass	Accumulated	(g)	iPSC	Cells	 5.000	 50.000	 45.000	 0	 0	IMDM	 4995.8	 4995.8	 0	 0	 0	Plasbumin	 250.00	 250.00	 0	 0	 0	Rock	Inhibitor	 0.012367	 0.012367	 0	 0	 0	Oxygen	 0.069399	 0.069399	 0	 0	 0	Overall	from	Previous	Reactor	 5250.8	 5295.8	 45.00	 0	 0	IMDM	 45000	 44962.5	 0	 37.521	 0	Plasbumin	 2500	 2500	 0	 0	 0	Rock	Inhibitor	 0.12367	 0.12367	 0	 0	 0	Oxygen	 8.1035	 0.62459	 0	 7.4789	 0	OVERALL	 52759.1	 52759.1	 45.00	 45.00	 0			 	
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Table	C.3.	Detailed	Mass	Balance	for	250	L	Bioreactor.	Proliferation:	250	L	Bioreactor	
Component	 Mass	in	(kg)	 Mass	out	(kg)	 Mass	generated	(kg)	 Mass	consumed	(kg)	 Mass	Accumulated	(kg)	iPSC	Cells	 0.05000	 0.10300	 0.05300	 0	 0	IMDM	 49.958	 49.958	 0	 0	 0	Plasbumin	 2.750	 2.750	 0	 0	 0	Rock	Inhibitor	 0.0001360	 0.0001360	 0	 0	 0	Oxygen	 0.00069399	 0.00069399	 0	 0	 0	Overall	from	Previous	Reactor	 52.759	 52.812	 0.053	 0	 0	IMDM	 53.000	 52.962	 0	 0.037593	 0	Plasbumin	 5.150	 5.150	 0	 0	 0	Rock	Inhibitor	 0.0002548	 0.0002548	 0	 0	 0	Oxygen	 0.016142	 0.00073563	 0	 0.015407	 0	OVERALL	 110.91	 110.92	 0.05300	 0.037593	 0			 	
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Table	C.4.	Detailed	Mass	Balance	for	2000	L	Bioreactor.	MK	Development:	2000	L	Bioreactor	
Component	 Mass	in	(kg)	 Mass	out	(kg)	 Mass	generated	(kg)	 Mass	consumed	(kg)	 Mass	Accumulated	(kg)	iPSC	Cells	 0.05150	 0	 0	 0.05150	 0	IMDM	 51.460	 51.460	 0	 0	 0	Plasbumin	 3.9500	 3.9500	 0	 0	 0	Rock	Inhibitor	 0.0001954	 0.0001954	 0	 0	 0	Oxygen	 0.00142963	 0.00142963	 0	 0	 0	Overall	from	Previous	Reactor	 55.463	 55.412	 0	 0.05150	 0	IMDM	 1232.0	 1231.0	 0	 1.0434	 0	MKs	 0	 1.2875	 1.2875	 0	 0	Plasbumin	 64.175	 64.175	 0	 0	 0	Rock	Inhibitor	 0.0015873	 0.0015873	 0	 0	 0	FGF-2	 1.2835E-05	 1.2835E-05	 0	 0	 0	BMP	 1.2835E-05	 1.2835E-05	 0	 0	 0	SCF	 6.4175E-05	 6.4175E-05	 0	 0	 0	VEG-F	A	 1.2835E-05	 1.2835E-05	 0	 0	 0	Romiplostim	 0.000025670	 0.000025670	 0	 0	 0	Oprelvekin	 1.2835E-05	 1.2835E-05	 0	 0	 0	PEG-rHuMGDF	 1.2835E-05	 1.2835E-05	 0	 0	 0	Sodium	Citrate	 48.773	 48.773	 0	 0	 0	Oxygen	 0.22507	 0.032490	 0	 0.19258	 0	OVERALL	 1400.6	 1400.6	 1.2875	 1.2875	 0			 	
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Table	C.5.	Detailed	Mass	Balance	for	Microfluidic	Shear	Vessel.	Microfluidic	Shear	Vessel	
Component	 Mass	in	(kg)	 Mass	out	(kg)	 Mass	generated	(kg)	 Mass	consumed	(kg)	 Mass	Accumulated	(kg)	IMDM	 2564.8	 2564.8	 0	 0	 0	MKs	 2.5750	 1.4420	 0	 1.1330	 0	Plasbumin	 136.25	 136.25	 0	 0	 0	Rock	Inhibitor	 0.00356543	 0.00356543	 0	 0	 0	FGF-2	 0.00002567	 0.00002567	 0	 0	 0	BMP	 0.00002567	 0.00002567	 0	 0	 0	SCF	 0.00012835	 0.00012835	 0	 0	 0	VEG-F	A	 0.00002567	 0.00002567	 0	 0	 0	Romiplostim	 0.00005134	 0.00005134	 0	 0	 0	Oprelvekin	 0.00002567	 0.00002567	 0	 0	 0	PEG-rHuMGDF	 0.00002567	 0.00002567	 0	 0	 0	Sodium	Citrate	 97.546	 97.546	 0	 0	 0	Oxygen	 0.03392	 0.03392	 0	 0	 0	Overall	from	Previous	Reactor	 2801.2	 2800.1	 0	 1.1330	 0	Platelets	 0	 1.1330	 1.1330	 0	 0	OVERALL	 2801.2	 2801.2	 1.1330	 1.1330	 0			 	
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Table	C.6.	Detailed	Mass	Balance	for	500	L	WAVE	Storage	Vessel.	Storage	Vessel	(Wave	Mixer)	
Component	 Mass	in	(kg)	 Mass	out	(kg)	 Mass	generated	(kg)	 Mass	consumed	(kg)	 Mass	Accumulated	(kg)	IMDM	+	Nutrients	 270.11	 270.11	 0	 0	 0	Sodium	Citrate	 9.7546	 9.7546	 0	 0	 0	MKs	 0.1442	 0.14503	 0.00083059	 0	 0	Platelets	 0.1133	 0.11341	 0.00011094	 0	 0	Oxygen	 0.0033920	 0.0033920	 0	 0	 0	Overall	from	Previous	Reactor	 280.12	 280.13	 0.00094154	 0	 0	Oxygen	 0.011801	 0.010860	 0	 0.00094154	 0	OVERALL	 280.14	 280.14	 0.00094154	 0.00094154	 0		
Mass	Balance	Tables	for	Individual	Units:	Downstream		
Table	C.7.	Detailed	Mass	Balance	for	Centrifuge	1.	Platelet	Separation	-	Gentle:	Centrifuge	1	
Component	 Mass	in	(kg)	 Mass	out	in	platelet	(top)	stream	(kg)	
Mass	out	in	sludge		stream	(kg)	 Mass	Accumulated	(kg)	IMDM	+	Nutrients	 270.11	 189.08	 81.033	 0	Sodium	Citrate	 9.7546	 6.8282	 2.9264	 0	MKs	 0.14503	 0	 0.14503	 0	
Platelets	 0.11341	 0.090729	 0.022682	 0	
Oxygen	 0.014252	 0.0099763	 0.0042756	 0	OVERALL	 280.14	 196.01	 84.131	 0			 	
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Table	C.8.	Detailed	Mass	Balance	for	Centrifuge	2.	Platelet	Concentration:	Centrifuge	2	
Component	 Mass	in	(kg)	 Mass	out	in	liquid	stream	(kg)	 Mass	out	in	sludge		stream	(kg)	 Mass	Accumulated	(kg)	IMDM	+	Nutrients	 189.08	 132.35	 56.723	 0	Sodium	Citrate	 6.8282	 4.7798	 2.0485	 0	MKs	 0	 0	 0	 0	
Platelets	 0.090729	 0.0045364	 0.086192	 0	Oxygen	 0.0099763	 0.0069834	 0.0029929	 0	OVERALL	 196.01	 137.14	 58.860	 0				 	
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Table	C.9.	Detailed	Mass	Balance	for	WAVE	Mixer	1.	Wash	in	Tyrode's	Buffer:	Wave	Mixer	1	
Component	 Mass	in	(kg)	 Mass	out	(kg)	 Mass	generated	(kg)	 Mass	consumed	(kg)	 Mass	Accumulated	(kg)	IMDM	+	Nutrients	 56.723	 56.723	 0	 0	 0	Sodium	Citrate	 2.0485	 2.0485	 0	 0	 0	MKs	 0	 0	 0	 0	 0	Platelets	 0.086192	 0.086277	 8.44E-05	 0	 0	Oxygen	 0.0029929	 0.0029929	 0	 0	 0	Overall	from	Previous	Reactor	 58.860	 58.861	 8.44E-05	 0	 0	Sterile	Water	 161.721	 161.721	 0	 0	 0	
NaCl	 1.725	 1.725	 0	 0	 0	
MgCl2-6H2O	 0.046144	 0.046144	 0	 0	 0	KCl	 0.043126	 0.043126	 0	 0	 0	Sodium	Carbonate	 0.21563	 0.21563	 0	 0	 0	Glucose	 0.21563	 0.21563	 0	 0	 0	Sodium	Citrate	 8.1939	 8.1939	 0	 0	 0	Oxygen	 0.0090631	 0.0089787	 0	 8.44E-05	 0	
OVERALL	 231.03	 231.03	 8.44E-05	 8.44E-05	 0			 	
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Table	C.10.	Detailed	Mass	Balance	for	Centrifuge	3.	Platelet	Concentration:	Centrifuge	3	
Component	 Mass	in	(kg)	 Mass	out	in	liquid	stream	(kg)	 Mass	out	in	sludge		stream	(kg)	 Mass	Accumulated	(kg)	IMDM	+	Nutrients	 56.723	 39.706	 17.017	 0	Wash	Buffer	(Water	+	salts/sugar)	 174.21	 121.95	 52.263	 0	Platelets	 0.086277	 0.0043138	 0.081963	 0	Oxygen	 0.011972	 0.0083801	 0.0035915	 0	OVERALL	 231.030	 161.665	 69.365	 0		
Table	C.11.	Detailed	Mass	Balance	for	WAVE	Mixer	2.	Wash	in	Tyrode's	Buffer:	Wave	Mixer	2	
Component	 Mass	in	(kg)	 Mass	out	(kg)	 Mass	generated	(kg)	 Mass	consumed	(kg)	 Mass	Accumulated	(kg)	IMDM	+	Nutrients	 17.017	 17.017	 0	 0	 0	Wash	Buffer	(Water	+	salts/sugar)	 52.263	 52.263	 0	 0	 0	Platelets	 0.081963	 0.082043	 8.0258E-05	 0	 0	Oxygen	 0.0035915	 0.0035915	 0	 0	 0	Overall	from	Previous	Reactor	 69.365	 69.365	 8.0258E-05	 0	 0	Sterile	Water	 194.07	 194.07	 0	 0	 0	NaCl	 2.0700	 2.0700	 0	 0	 0	MgCl2-6H2O	 0.055373	 0.055373	 0	 0	 0	KCl	 0.051751	 0.051751	 0	 0	 0	Sodium	Carbonate	 0.25875	 0.25875	 0	 0	 0	Glucose	 0.25875	 0.25875	 0	 0	 0	Oxygen	 0.010855	 0.010774	 0	 8.0258E-05	 0	OVERALL	 266.14	 266.14	 8.0258E-05	 8.0258E-05	 0			 	
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Table	C.12.	Detailed	Mass	Balance	for	Centrifuge	4.	Platelet	Concentration:	Centrifuge	4	
Component	 Mass	in	(kg)	 Mass	out	in	liquid	stream	(kg)	 Mass	out	in	sludge		stream	(kg)	 Mass	Accumulated	(kg)	IMDM	+	Nutrients	 17.017	 11.912	 5.1051	 0	Wash	Buffer	(Water	+	salts/sugar)	 249.02	 174.32	 74.707	 0	
Platelets	 0.082043	 0.0041022	 0.077941	 0	
Oxygen	 0.014366	 0.010056	 0.0043098	 0	OVERALL	 266.14	 186.24	 79.894	 0		
Table	C.13.	Detailed	Mass	Balance	for	WAVE	Mixer	3.	Wash	in	Resuspension	Solution:	Wave	Mixer	3	
Component	 Mass	in	(kg)	 Mass	out	(kg)	 Mass	generated	(kg)	 Mass	consumed	(kg)	 Mass	Accumulated	(kg)	IMDM	+	Nutrients	 5.1051	 5.1051	 0	 0	 0	Wash	Buffer	(Water	+	salts/sugar)	 74.707	 74.707	 0	 0	 0	Platelets	 0.077941	 0.078017	 7.632E-05	 0	 0	Oxygen	 0.0043098	 0.0043098	 0	 0	 0	Overall	from	Previous	Reactor	 79.894	 79.894	 7.632E-05	 0	 0	PAS-E	 186.30	 186.30	 0	 0	 0	Synthetic	Plasma	 46.576	 46.576	 0	 0	 0	Oxygen	 0.013006	 0.012929	 0	 7.632E-05	 0	OVERALL	 312.79	 312.79	 7.632E-05	 7.632E-05	 0			 	
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Table	C.14.	Detailed	Mass	Balance	for	Centrifuge	5.	Platelet	Concentration:	Centrifuge	5	
Component	 Mass	in	(kg)	 Mass	out	in	liquid	stream	(kg)	 Mass	out	in	sludge		stream	(kg)	 Mass	Accumulated	(kg)	IMDM	+	Nutrients	 5.1051	 3.5735	 1.5315	 0	Wash	Buffer	(Water	+	salts/sugar)	 74.707	 52.295	 22.412	 0	PAS-E	 186.30	 130.41	 55.891	 0	Synthetic	Plasma	 46.576	 32.603	 13.973	 0	Platelets	 0.078017	 0.0039009	 0.074116	 0	Oxygen	 0.017239	 0.012067	 0.0051717	 0	OVERALL	 312.79	 218.90	 93.886	 0		
Table	C.15.	Detailed	Mass	Balance	for	WAVE	Mixer	4.	Resuspension:	Wave	Mixer	4	
Component	 Mass	in	(kg)	 Mass	out	(kg)	 Mass	generated	(kg)	 Mass	consumed	(kg)	 Mass	Accumulated	(kg)	IMDM	+	Nutrients	 1.5315	 1.5315	 0	 0	 0	Wash	Buffer	(Water	+	salts/sugar)	 22.412	 22.412	 0	 0	 0	PAS-E	 55.891	 55.891	 0	 0	 0	Synthetic	Plasma	 13.973	 13.973	 0	 0	 0	Platelets	 0.074116	 0.074189	 7.2575E-05	 0	 0	Oxygen	 0.0051717	 0.0051717	 0	 0	 0	Overall	from	Previous	Reactor	 93.886	 93.886	 7.2575E-05	 0	 0	PAS-E	 249.48	 249.48	 0	 0	 0	Synthetic	Plasma	 62.371	 62.371	 0	 0	 0	Oxygen	 0.012140	 0.012067	 0	 7.2575E-05	 0	OVERALL	 405.75	 405.75	 7.2575E-05	 7.2575E-05	 0			 	
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Table	C.16.	Detailed	Mass	Balance	for	Centrifuge	6.	Platelet	Concentration:	Centrifuge	6	
Component	 Mass	in	(kg)	 Mass	out	in	liquid	stream	(kg)	 Mass	out	in	sludge		stream	(kg)	 Mass	Accumulated	(kg)	IMDM	+	Nutrients	 1.5315	 1.0721	 0.45946	 0	Wash	Buffer	(Water	+	salts/sugar)	 22.412	 15.688	 6.7236	 0	PAS-E	 305.37	 213.76	 91.612	 0	Synthetic	Plasma	 76.344	 53.440	 22.903	 0	Platelets	 0.074189	 0.0037095	 0.070480	 0	Oxygen	 0.017239	 0.012067	 0.0051717	 0	OVERALL	 405.75	 283.98	 121.77	 0		
Table	C.17.	Detailed	Mass	Balance	for	Centrifuge	7.	Platelet	Concentration:	Centrifuge	7	
Component	 Mass	in	(kg)	 Mass	out	in	liquid	stream	(kg)	 Mass	out	in	sludge		stream	(kg)	 Mass	Accumulated	(kg)	IMDM	+	Nutrients	 0.45946	 0.32162	 0.13784	 0	Wash	Buffer	(Water	+	salts/sugar)	 6.7236	 4.7065	 2.0171	 0	PAS-E	 91.612	 64.129	 27.484	 0	Synthetic	Plasma	 22.903	 16.032	 6.8709	 0	Platelets	 0.070480	 0.0035240	 0.066956	 0	Oxygen	 0.0051717	 0.0036202	 0.0015515	 0	OVERALL	 121.77	 85.196	 36.578	 0		
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between the substrates , forming microfluidic pathways 
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SYSTEM AND METHOD FOR PRODUCING 
BLOOD PLATELETS 
CROSS - REFENCE TO RELATED 
APPLICATIONS 
[ 0001 ] This application is based on , claims the benefit of , and incorporates by reference U . S . Provisional Application No . 61 / 215 , 369 filed Sep . 8 , 2015 , and entitled “ PLATELET BIOREACTOR . ” 
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH 
10002 ] This disclosure was made with government support 
under ROOHL114719 awarded by the National Institutes of 
Health . The government has certain rights in the disclosure . 
embryonic stem cells , umbilical cord blood stem cells and induced pluripotent stem cells . Other stem cell sources have 
included stem cells found in bone marrow , fetal liver and peripheral blood . However , despite successful production of functional platelets in the laboratory , many limitations 
remain to use in a clinical setting . [ 0007 ] For instance , only approximately 10 % of human megakaryocytes have been shown to initiate proplatelets 
production using state - of - the art culture methods . This has 
resulted in yields of 10 to 100 platelets per CD34 + cord 
blood - derived or embryonic stem cell - derived megakaryo 
cyte , which are themselves of limited availability . For example , the average single human umbilical cord blood unit can produce roughly 5 . 10º CD34 + stem cells . This 
poses a significant bottleneck in ex vivo platelet production . 
In addition , cell cultures have been unable to recreate physiological microenvironments , providing limited indi 
vidual control of extracellular matrix composition , bone 
marrow stiffness , endothelial cell contacts , and vascular 
shear rates . Moreover , cell cultures have been unsuccessful in synchronizing proplatelet production , resulting in non 
uniform platelet release over a period of 6 to 8 days , which 
is on the order of platelet shelf - life . [ 0008 ] Therefore , in light of the above , there remains a need for efficient ways to produce clinically relevant platelet yields that can meet growing clinical demands , and avoid the risks and costs associated with donor harvesting and storage . 
BACKGROUND OF THE DISCLOSURE 
[ 0003 ] The present disclosure generally relates to fluid systems , including microfluidic devices , systems that 
include such devices , and methods that use such devices and systems . More particularly , the present disclosure relates to devices , systems , and methods for generating biological products . 
[ 0004 ] Blood platelets , or thrombocytes , are irregular , disc 
shaped cell fragments that circulate in the blood and are 
essential for hemostasis , angiogenesis , and innate immunity . 
In vivo , platelets are produced by cells , known as mega karyocytes . As illustrated in FIG . 1 , megakaryocytes gen 
erated in the bone marrow migrate and contact endothelium cells that line blood vessels . There they extend long , branch 
ing cellular structures called proplatelets into the blood vessel space through gaps in the endothelium . Experiencing 
shear rates due to blood flow , proplatelets extend and release platelets into the circulation . In general , normal platelet counts range between 150 , 000 and 400 , 000 platelets per 
microliter of blood . However , when blood platelet numbers fall to low levels , a patient develops a condition known as 
thrombocytopenia and becomes at risk for death due to 
hemorrhage . Known causes for thrombocytopenia include 
malignancy and chemotherapy used to treat it , immune 
disorders , infection , and trauma . [ 0005 ] Despite serious clinical concerns for deleterious immune system response , risk due to sepsis and viral con tamination , treatment of thrombocytopenia generally involves using replacement platelets derived entirely from 
human donors . However , the process of obtaining platelets 
from transfusions is lengthy , costly , and often requires finding multiple matching donors . In addition , the usability 
of harvested platelets are limited due to a short shelf - life on account of bacterial testing and deterioration . Moreover , screening for viruses not known to exist is not possible . 
Combined with shortages created by increased demand and near - static pool of donors , it is becoming harder for health care professionals to provide adequate care for patients with 
thrombocytopenia , and other conditions related to low plate 
let counts . Alternatives to transfusion have included use of artificial platelet substitutes , these have thus far failed to replace physiological platelet products . 
[ 0006 In some approaches , production of functional 
human platelets has been attempted using various cell cul 
ture techniques . Specifically , platelets have been produced in the laboratory using megakaryocytes obtained from various 
stem cells . Stem cells utilized have typically included 
SUMMARY OF THE DISCLOSURE 
[ 0009 ] The present disclosure overcomes the drawbacks of aforementioned technologies by providing a system and 
method capable of efficient and scalable production of platelets , and other biological products . Specifically , the 
disclosure describes various bioreactor embodiments that 
include a number of features and capabilities aimed at 
generating clinically and commercially relevant biological 
products . In some aspects , the system and method described 
herein may be used to generate high platelet yields usable for 
platelet infusion . As such , many significant drawbacks of 
present replacement therapies can be overcome , since these 
predominantly rely on transfusions from human donors . [ 0010 ] As will be described , in some aspects , provided 
bioreactor embodiments can be configured to recreate physi ological conditions and processes associated with platelet 
production in the human body . Specifically , provided bio 
reactor embodiments can be configured for selective func 
tionalization using various materials and substances that can facilitate platelet production . Also , by including capabilities 
for uniform biological material trapping and controllable 
shear stresses , efficient production of platelets , and other 
biological products , can be achieved using the bioreactor 
embodiments described . In some designs , provided biore 
actor embodiments are configured for rapid assembly and disassembly , and adaptable to thermoplastic molding and 
other large scale manufacturing processes . 
[ 0011 ] In accordance with one aspect of the disclosure , a 
system and method for generating biological products is 
provided . The system includes a first substrate having 
formed therein a plurality of inlet channel extending sub 
stantially along a longitudinal direction , and a second sub 
strate having formed therein a plurality of outlet channel 
corresponding to the plurality of inlet channel and extending 
substantially along the longitudinal direction , the second 
substrate configured to releasably engage the first substrate . 
US 2018 / 0334652 A1 Nov . 22 , 2018 
The system also includes a permeable membrane , arranged between the substrates , forming microfluidic pathways 
between respective inlet and outlet channels and configured to selectively capture biological source material capable of generating biological products , wherein at least one channel is tapered transversally to control a pressure differential profile regulating perfusion through the permeable mem 
brane . [ 0012 ] In accordance with another aspect of the disclo sure , a method for generating biological products is pro 
vided . The method includes seeding a bioreactor assembly with biological source material capable of generating 
desired biological products , the bioreactor assembly a first 
substrate having formed therein a plurality of inlet channel extending substantially along a longitudinal direction , and a 
second substrate , configured to releasably engage the first 
substrate , and having formed therein a plurality of outlet 
channel corresponding to the plurality of inlet channel and extending substantially along the longitudinal direction , 
wherein at least one channel is tapered transversally to 
control a pressure differential profile therein . The bioreactor assembly also includes , a permeable membrane , arranged 
between the substrates , forming microfluidic pathways 
between respective inlet and outlet channels and configured to selectively capture biological source material . The 
method also includes introducing fluid media into the bio reactor assembly at predetermined flow rates to generate the desired biological products , and harvesting the desired bio 
logical products from the bioreactor assembly . [ 0013 ] The foregoing and other aspects and advantages of the disclosure will appear from the following description . In 
the description , reference is made to the accompanying 
drawings which form a part hereof , and in which there is 
shown by way of illustration a preferred embodiment of the disclosure . Such embodiment does not necessarily represent 
the full scope of the disclosure , however , and reference is made therefore to the claims and herein for interpreting the 
scope of the disclosure . 
[ 0024 ] FIG . 7A shows an embodiment of a bioreactor 
assembly that is disassembled , in accordance with aspects of the present disclosure . [ 0025 ] FIG . 7B shows the bioreactor assembly of FIG . 7A 
assembled . [ 0026 ] FIG . 8 shows another embodiment of a system , in accordance with aspects of the present disclosure . 
10027 ] FIG . 9A shows yet another embodiment of a bio 
reactor , in accordance with aspects of the present disclosure . 
[ 0028 ] FIG . 9B shows yet another embodiment of a bio 
reactor , in accordance with aspects of the present disclosure . 
[ 0029 ] FIG . 10 is a schematic showing a system , in 
accordance with aspects of the present disclosure . 
( 0030 ) FIG . 11 shows yet another embodiment of a bio 
reactor , in accordance with aspects of the present disclosure . 
( 0031 ) FIG . 12 shows yet another embodiment of a bio 
reactor , in accordance with aspects of the present disclosure . 
10032 ] FIG . 13 is a flowchart setting forth steps of a 
process , in accordance with aspects of the present disclo 
sure . [ 0033 ] FIG . 14A is a graph showing megakaryocytes produced using a static culture . [ 0034 ] FIG . 14B is a graph showing proplatelets and 
platelets produced using a static culture . [ 0035 ] FIG . 14C is a graph showing megakaryocytes 
produced in accordance with aspects of the present disclo 
sure . 0036 ] FIG . 14D is a graph showing proplatelets and 
platelets produced in accordance with aspects of the present 
disclosure . [ 0037 ] FIG . 15 is a graph showing a timeline of platelet production , in accordance with aspects of the present dis 
closure . 
[ 0038 ] FIG . 16 shows yet another embodiment of a bio reactor , in accordance with aspects of the present disclosure . 
BRIEF DESCRIPTION OF THE DRAWINGS 
[ 0014 ] The present disclosure will hereafter be described with reference to the accompanying drawings , wherein like 
reference numerals denote like elements . [ 0015 ) FIG . 1 is an illustration showing in vivo platelet production in bone marrow . 
[ 0016 ] . FIG . 2 is a schematic diagram of a system for producing biological products , in accordance with aspects of 
the present disclosure . 
100171 . FIG . 3 is an illustration showing an embodiment of 
a bioreactor , in accordance with aspects of the present 
disclosure . [ 0018 ] FIG . 4A is a perspective view showing one embodiment of a bioreactor assembly including the biore actor of FIG . 3 . [ 0019 ] FIG . 4B is a cross - sectional view of the embodi 
ment shown in FIG . 4A . 
[ 0020 ] FIG . 4C is another cross - section view of the 
embodiment shown in FIG . 4A . 
[ 0021 ] FIG . 5A shows an example system , in accordance with aspects of the present disclosure . 
[ 0022 ] FIG . 5B shows the bioreactor included in the system of FIG . 5A . 
10023 ] FIG . 6 shows an embodiment of a bioreactor , in accordance with aspects of the present disclosure . 
DETAILED DESCRIPTION OF THE 
DISCLOSURE 
[ 0039 ] The present disclosure provides systems and meth ods capable of efficient and scalable production of platelets , and other biological products . 
[ 0040 ] Turning now to FIG . 2 , a schematic diagram of an 
example system 100 for producing platelets , and other 
biological products , is shown . In general , the system 100 
includes a biological source 102 , a bioreactor assembly 104 , 
and an output 106 , where the biological source 102 and 
output 106 are connectable to various inputs and outputs of the assembly 104 , respectively . [ 0041 ] Specifically , the biological source 102 may be configured with various capabilities for introducing into the 
assembly 104 different biological source materials , sub stances , gas , or fluid media , to efficiently produce desirable biological products , such as platelets . For instance , the 
biological source 102 may include one or more pumps for 
delivering or sustaining fluid media in the bioreactor assem 
bly 104 . Examples include microfluidic pumps , syringe pumps , peristaltic pumps , and the like . 
[ 0042 ] As shown in FIG . 2 , in some implementations , the system 100 may also include a controller 108 for controlling 
the biological source 102 . Specifically , the controller 108 may be a programmable device or system configured to 
control the operation of the bioreactor assembly 104 , includ 
ing the timings , amounts , and types of biological source 
material , substances , fluid media or gas introduced therein . 
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In some aspects , the controller 108 may be configured to 
selectively functionalize and / or operate the assembly 104 to 
recreate physiological conditions and processes associated with platelet production in the human body . For example , 
the controller 108 may be programmed to deliver a selected 
number of megakaryocytes to the assembly 104 . In addition , 
the controller 108 may control fluid flow rates or fluid pressures in the bioreactor assembly 104 to facilitate pro 
platelet extension and platelet production . For instance , the 
controller 108 may establish flow rates up to 150 , 000 
microliters / hr in various channels configured in the biore 
actor assembly 104 . 
[ 0043 ] Although the controller 108 is shown in FIG . 2 as separate from the biological source 102 , it may be appreci 
ated that these may be combined into a single unit . For 
instance , the biological source 102 and controller 106 may 
be embodied in a programmable microfluidic pump or injection system . In addition , in some implementations , the controller 108 and / or biological source 102 may also 
include , communicate with , or received feedback from sys 
tems or hardware ( not shown in FIG . 2 ) that can regulate the 
temperature , light exposure , vibration , and other conditions 
of the bioreactor assembly 104 . By way of example , FIG . 8 
shows a bioreactor system 800 that includes a controller 802 
connected to heaters 804 and a thermocouple 806 for monitoring and controlling temperature . It may be appreci 
ated that the configuration shown in FIG . 8 is non - limiting , 
and any number of heaters , and heater arrangements may be possible . 
10044 ] Referring again to FIG . 2 , in general , the output 
106 is configured to receive fluid media containing various 
biological products generated in the bioreactor assembly 
104 . However , in some implementations , as will be 
described , such effluent may be redirected or circulated back 
into the bioreactor assembly 104 . In this manner , less fluid 
volume may be utilized , and the biological products gener 
ated can be more concentrated . In some aspects , the output 
106 may also include capabilities for collecting , storing 
and / or further processing received fluid media . 
[ 0045 ] It may be appreciated that the above - described 
system 100 has a broad range of functionality , and need not 
be limited to replicating physiological conditions or pro cesses , nor producing platelets . That is , the system 100 may be used to generate a wide variety of biological products . 
For instance , the system 100 may be used to separate , break up or dissolve various biological source materials or sub 
stances , such as megakaryocytes and other cells , and collect their product or content . Specifically , by controlling fluid 
flow and pressures , as well as other conditions , various 
contents of captured biological source materials may be 
released and subsequently harvested . In some aspects , the 
system 100 may also be utilized to differentiate and / or 
culture various cells , biological substances or materials , 
such as megakaryoctytes , for obtaining biological source 
material needed to generate desirable biological products . 
Example biological products include growth factors , and 
other components found in cells . Produced biological prod 
ucts , in accordance with the present disclosure , in addition 
to clinical use , may find use in a variety of applications 
including as components of cell culture medias and cosma ceuticals , such as cosmetics , shampoos , skin additives , creams , or cleaners , and so forth . 
[ 0046 ] Various embodiments of the above system 100 will now be described . It may be appreciated that these are 
non - limiting examples , and indeed various modifications or 
combinations are possible and considered by one of ordinary 
skill in the art to be within the intended scope of the present application . 
[ 0047 ] Referring now to FIG . 3 , an non - limiting micro 
fluidic bioreactor 300 , in accordance with aspects of the 
present disclosure , is shown . In general , the bioreactor 300 
includes a first substrate 302 , a second substrate 306 , and a permeable membrane 304 arranged therebetween . 
[ 0048 ] In particular , the first substrate 302 can include a 
number of inlet channels 308 , or inlet chambers , formed 
therein . As shown in FIG . 3 , in some embodiments , the 
channels can be arranged generally parallel to one another 
and extending substantially along a longitudinal direction 
( for example , the x direction ) . However it may be appreci ated that any channel arrangement capable of achieving 
platelet and other biological product production , as 
described in the present disclosure , may be possible . Also , 
the inlet channels 308 may be connected to an inlet port 310 
by way of an inlet manifold 312 formed in the first substrate 302 , where the inlet manifold 312 is configured to provide similar or comparable fluid pathways for fluid media tra 
versing therethrough . Such configuration may be advanta 
geous for distributing various biological substances or mate 
rials uniformly across the bioreactor 300 , or can be 
manipulated to distribute various biological substances or 
materials selectively or differentially within different fluid 
pathways . For instance , a concentration of platelet - produc ing megakaryocyte cells dispersed in a fluid medium can be introduced in one infusion step into the inlet port 310 to achieve a similar density or spatial distribution across the 
permeable membrane 304 . In alternative configurations , 
each inlet channel 308 may include different sized or sepa 
rate inlet ports . 
[ 0049 ] The second substrate 306 can include a plurality of outlet channels 310 , or outlet chambers , each corresponding 
to a respective inlet channel , and also extending substan tially parallel along the longitudinal direction . Similarly , the 
second substrate 304 may also include an outlet manifold 
316 formed therein , the outlet manifold 316 connected to the 
outlet channels 314 and configured to direct fluid media , including various biological products , substances or mate 
rials , to an output via an outlet port 318 . 
[ 0050 ] By way of example , the substrates described above 
may have lateral dimensions in a range between 10 mm and 
100 mm , and a thickness in a range between 1 and 10 mm , although other dimensions may also be possible . Also , a longitudinal dimension of the inlet channels 308 and / or 
outlet channels 314 be in the range of 1000 to 30 , 000 micrometers or , more particularly , in the range of 1000 to 
3000 micrometers , while at least one transverse dimension may be in the range of 100 to 3 , 000 micrometers or , more particularly , in the range of 100 to 300 micrometers . Other 
dimensions are also possible . As will be described , in some 
embodiments , the inlet channels 308 or outlet channels 314 
may also be tapered transversally either entirely or over a 
portion of the longitudinal dimension to control shear rates 
or pressure differentials between the channels , over an active 
contact area , regulating perfusion through the permeable 
membrane 304 . 
[ 0051 ] Various implementations of the bioreactor 300 are possible depending upon specific uses or applications . In 
particular , in some embodiments , the inlet channels 308 and 
outlet channels 314 , along with other microfluidic elements 
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of bioreactor 300 , may be longitudinally ( for example , along 
the x - direction shown in FIG . 3 ) and transversally ( y - and 
z - direction ) shaped and dimensioned to reproduce physi 
ological conditions , such as those found in bone marrow and 
blood vessels . For instance , channel shapes and dimensions 
may be selected to achieve physiological flow rates , shear 
rates , fluid pressures or pressure differentials similar to those 
associated with in vivo platelet production , as described 
with reference to FIG . 1 . In addition , configurations of the bioreactor 300 may be chosen to allow cooperation with 
other instrumentation , such as microscopes or cameras . For instance , the bioreactor 300 may be configured to adhere to 
standard microplate dimensions . 
[ 0052 ] In some configurations of the bioreactor 300 , the 
inlet channels 308 and outlet channels 314 terminate in their 
respective substrates to create a single fluid conduit 320 
from the inlet port 310 to the outlet port 318 , as shown in 
FIG . 3 . That is to say , fluid medium introduced into the inlet 
port 310 is necessarily extracted from the outlet port 318 . 
However , it may appreciated that additional inlet and outlet ports may also be possible with the bioreactor 300 . For 
example , the first substrate 302 may also include one or 
more outputs connected to the inlet channels 308 . Similarly , 
the second substrate 306 may also include one or more 
inputs connected to the outlet channels 314 . In this manner , multiple fluid pathways can be possible , which would allow 
for selectively preparing various portions of the bioreactor 300 independently . 
[ 0053 ] Although not shown in FIG . 3 , the bioreactor 300 
may also include a number of microfluidic filtration and 
resistive elements , connected to the channels and arranged at 
various points along the various fluid pathways extending 
between the inlet port 310 and outlet port 318 . For instance , 
one or more filtration elements may be placed proximate to 
the inlet port 310 to capture contaminants or undesirable 
substances or materials from an inputted fluid medium . In 
addition , one or more resistive elements may also be 
included to control flow forces or damp fluctuations in flow 
rates . In addition to resistive and filtration elements , ele 
ments may also be included . For example , air bubbles traps 
may be configured with one or more inputs to eliminate any 
air bubbles from entering the bioreactor 300 . 
[ 0054 ] By way of example , FIG . 6 illustrates a microflu idic connector 602 coupled to an input 604 of an example 
bioreactor 600 , in accordance with the above descriptions . 
As shown , the input 604 includes an expansion region 606 
and a conical region 608 separated by a mesh 610 . For example , the mesh 610 may have a size of approximately 
140 micrometers , although other values may be possible . As configured , the input 604 is capable of preventing air 
bubbles from entering the bioreactor 600 . [ 0055 ] Referring again to the bioreactor 300 of FIG . 3 , 
each substrate is shown to include 16 inlet channels 312 and 16 outlet channels 314 . It may be readily appreciated that 
more or fewer channels or chambers may be possible . For 
example , as illustrated in the bioreactor 900 shown in FIG . 
9A , two inlet channels 902 and two outlet channels 904 may 
be utilized . In addition to inlet and outlet channels , addi tional conduits may also be formed in the substrates of the 
bioreactor 300 of FIG . 3 . For instance , as shown in FIGS . 9A 
and 9B , a perfusion channel 906 may also be included in the 
bioreactor 900 . Specifically , the perfusion channel 906 would allow the flow of gas , which can subsequently perfuse through the substrate materials and into the bioreactor 900 
inlet / outlet channels . For example , a 5 % CO2 gas mixture may be perfused into the channels . 
[ 0056 ] In general , the permeable membrane 304 of FIG . 3 can include any rigid or flexible layer , film , mesh or material 
structure configured to connect corresponding inlet channel 
308 and outlet channel 314 via microfluidic pathways 
formed therein . In one embodiment , microfluidic pathways 
in the permeable membrane 304 may be formed using pores , 
gaps or microchannels , distributed with any density , either periodically or aperiodically , about permeable membrane 
304 . In another embodiment , the permeable membrane 304 
can include a three - dimensional structure formed using 
interwoven micro - or nano - fibers arranged to allow fluid 
therethrough . Although shown in FIG . 3 as rectangular in 
shape , it may be appreciated that the permeable membrane 
304 may have any shapes , including circular shapes , oval 
shapes , and so forth . In accordance with aspects of the 
disclosure , the permeable membrane 304 may be configured 
to selectively capture specific biological source materials or substances to produce desired biological products . For 
instance , the permeable membrane 304 may be configured to selectively capture platelet - producing cells and allow pro 
platelet extensions therethrough . 
[ 0057 ] By way of example , the permeable membrane 304 may include longitudinal and transverse dimensions in a 
range between 1 and 100 millimeters , and have a thickness 
in a range between 0 . 1 to 20 micrometers , although other dimensions are possible . Also , the permeable membrane 304 may include pores , gaps or microchannels sized in a range 
approximately between 3 micrometers and 10 micrometers , and more specifically approximately between 5 and 8 
micrometers . In some aspects , pore , gap or microchannel 
size , number , and density may depend on a number of factors , including desired biological products and product 
yields , as well as flow impedances , shear rates , pressure differentials , fluid flow rates , and other operational param 
eters . 
[ 0058 ] As appreciated from FIG . 3 , the inlet channels 308 
and outlet channels 314 overlap to define an active contact 
area in the permeable membrane 304 . For example , an active 
contact area 326 may be in a range between 1 mm² to 20 
mm ” , although other values are possible , depending upon 
the dimensions and number of channels utilized . In some 
implementations , the active contact area along with perme 
able membrane 304 characteristics may be optimized to 
obtain a desired biological product yield . For example , a 
permeable membrane 304 with 47 mm diameter , 5 % active contact area , and pore density of 1 . 109 pores / cm² could provide 200 , 00 potential sites for generating a desired bio logical product yield , such as a desired platelet yield . In 
some applications , the active contact area may be configured 
to trap at least approximately 1 . 104 megakaryocytes . 
[ 0059 ] The bioreactor 300 may be manufactured using any combination of biocompatible materials , inert materials , as well as materials that can support pressurized gas and fluid 
flow , or gas diffusion , and provide structural support . In 
some aspects , materials utilized in the bioreactor 300 may be 
compatible with specific manufacturing processes , such as 
injection molding . In addition , materials utilized may opti 
cally clear to allow visualization of fluid media , and other 
substances , present or flowing in various portions of the 
bioreactor 300 . 
[ 0060 ] By way of example , the first substrate 302 , or second substrate 306 , or both , or portions thereof , may be 
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manufactured using cell - inert silicon - based organic polymer 
materials , such as polydimethylsiloxane ( “ PDMS ” ) , thermo 
plastic materials , such as zeonor cyclo olefin polymer 
( “ COP ” ) , glass , acrylics , and so forth . On the other hand , the 
permeable membrane 304 may be manufactured using 
PDMS , thermoplastics , silk , hydrogels , extracellular matrix proteins , polycarbonate materials , polyesthersulfone mate 
rials , polyvinyl chloride materials , polyethyleneterephthalat 
materials , and other synthetic or organic materials . 
[ 0061 ] In accordance with aspects of the present disclo 
sure , the bioreactor 300 may be selectively functionalized using various biological substances and materials . Specifi 
cally , the bioreactor 300 may be selectively functionalized by way of fluid media , containing desired biological sub 
stances and materials , being introduced therein . Alterna tively , or additionally , the bioreactor 300 , or components 
thereof , may be functionalized using various preparation or manufacturing processes . For example , the permeable mem 
brane 304 may be pre - prepared with platelet - producing cells 
prior to assembly of the bioreactor 300 . In some aspects , the 
bioreactor 300 may be utilized to differentiate and / or culture megakaryocytes , as well as other cells , biological substances 
or materials . 
[ 0062 ] As described , in some aspects , the bioreactor 300 may be advantageously functionalized to replicate in vivo physiological conditions in order to produce platelets , or 
other biological products . For instance , in one application , a top surface 322 of the permeable membrane 304 may be selectively coated with extracellular matrix proteins , for 
example , while a bottom surface 322 can be left without , or can be coated with different proteins or substances . This can be achieved , for instance , by infusing a first fluid medium containing extracellular matrix proteins , using inputs and 
outputs in the first substrate 302 . At substantially the same 
time , a second fluid medium flow can be maintained in the 
second substrate 306 using respective inputs and outputs , 
where the second fluid medium would either contain no proteins , or different proteins or substances . Preferably , flow 
rates of the first and second fluid media would be configured 
such that little to no fluid mixing would occur . Such selec tive functionalization would ensure that introduced platelet producing cells , for example , coming to rest on the top 
surface 322 would contact extracellular matrix proteins , 
while proplatelets extended through the permeable mem 
brane 304 , and platelets released therefrom , would not 
contact extracellular matrix proteins , or would contact dif ferent proteins or biological substances . 
[ 0063 ] Non - limiting examples of biological substances 
and materials for functionalizing the bioreactor 300 may 
include human and non - human cells , such as megakaryo 
cytes , endothelial cells , bone marrow cells , osteoblasts , 
fibroblasts , stem cells , blood cells , mesenchymal cells , lung 
cells and cells comprising basement membranes . Other 
examples can include small molecules , such as CCL5 , 
CXCL12 , CXCL10 , SDF - 1 , FGF - 4 , S1PR1 , RGDS , Meth ylcellulose . Yet other examples can include , extracellular 
matrix proteins , such as bovine serum albumin , collagen 
type I , collagen type IV , fibrinectin , fibrinogen , laminin , 
vitronectin . In particular , to replicate three - dimensional extracellular matrix organization and physiological bone 
marrow stiffness , cells may be infused in a hydrogel solu 
tion , which may subsequently be polymerized . The hydrogel 
solution may include , but is not limited to alginate , matrigel , agarose , collagen gel , fibrin / fibrinogen gel . 
[ 0064 In some aspects , various portions of the bioreactor 300 may be configured to allow for assembly and disassem 
bly . Specifically , as shown in FIG . 3 , the first substrate 302 , 
permeable membrane 304 , and second substrate 306 may be configured to be removably coupled to one another . When engaged using fasters , clips , or other releasable locking 
mechanisms , for example , a hermetic seal can then be 
formed between various surfaces of the substrates and permeable membrane 304 to reinstate fluid pathway integ rity between the input 310 and output 318 . This capability 
can facilitate preparation , as described above , as well as 
cleaning for repeated use . In addition , disassembly allows for quick exchange of various components , for repurposing or rapid prototyping . For instance , a permeable membrane 304 having different pore sizes , or different preparations , may be readily swapped . 
[ 0065 ) Alternatively , the bioreactor 300 may be manufac 
tured as a single device , for sample using an injection 
molding technique , where the permeable membrane 304 
would be molded into the substrates . Such implementations may be advantageously integrated into large scale manufac turing techniques . By way of example , FIG . 16 shows a 
bioreactor 1600 generated using a molding technique . The 
bioreactor 1600 may be formed using PDMS , thermoplastic , such as copolymer ( “ COP ” ) , cyclic clefin copolymer 
( “ COC ” ) , polymethylmethacrylate ( “ PMMA " ) , polycarbon 
ate ( “ PC ” ) , and other materials . As shown in FIG . 16 , in 
some embodiments , the bioreactor 1600 may be include a glass substrate 1602 either on the top , or the bottom , of the 
bioreactor 1600 or both . Alternatively , the bioreactor 1600 may include an acrylic top substrate 1604 , alone or in 
combination with a glass or acrylic substrate . These sub 
strates could be used provide structural support to the 
bioreactor 1600 . 
[ 0066 ] By way of example , FIGS . 7A - B show an example 
bioreactor assembly 700 both disassembled and assembled , respectively . As shown in FIG . 7A , the bioreactor assembly 700 in general includes a base plate 702 , a clamp arm 704 , 
a top clamp frame 706 , fastener 708 , and bioreactor 710 . When assembled , as shown in FIG . 7B , a compression is provided to the bioreactor 710 bringing respective substrates 
of the bioreactor 710 to form a hermetic seal therebetween . In some designs , the bioreactor assembly 700 may incorpo 
rate hard stops with springs to be able to apply an even pressure across top and bottom surfaces of the bioreactor 710 to prevent leaks and avoid over - compression . Other 
fastening mechanisms or variations thereof are also possible , 
for example , as shown in FIG . 5A , or FIG . 8 . 
[ 0067 ] Referring now to FIGS . 4A - 4C , a non - limiting 
embodiment of a microfluidic bioreactor assembly 400 , in 
accordance with aspects of the present disclosure , is illus 
trated . Referring specifically to the cross - sectional view of 
FIG . 4B , the bioreactor assembly 400 can include a top 
substrate 402 , a bottom substrate 404 , and a membrane 406 
therebetween that connects a number of corresponding inlet channels 408 and outlet channels 410 formed in respective 
substrates . As described , the membrane 406 is configured to 
form fluid pathways between the substrates , for instance , via 
pores included therein . As shown in the perspective view of 
FIG . 4A , the bioreactor assembly 400 can also include a base portion 412 and top portion 414 configured to fasten the 
membrane 406 and substrates together , for example using 
screws . For simplicity , FIG . 4A shows only a portion of the 
bioreactor assembly 400 . When fastened , the base portion 
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412 and top portion 414 bring the substrates into an aligned engagement ( for example using guides , grooves , or holes ) 
capable of forming a hermetic seal therebetween in order to 
allow fluid or gas flow , or both , in the channels without leaks . Conversely , when unfastened , various portions of the bioreactor assembly 400 can be individually prepared , 
exchanged , cleaned and reused . 
[ 0068 ] As described , in some configurations , the bioreac tor assembly 400 may be configured to allow visualization during operation . Referring specifically to FIG . 4B , each 
substrate may have a glass layer 416 arranged proximate 
thereto , forming a stack that includes glass / substrate / mem 
brane / substrate / glass . In alternative configurations , the glass 
layers may be excluded , with the substrates and / or mem brane 406 configured to have appropriate structural integrity 
and desired material characteristics , such as transparency appropriate for allowing visualization of fluid media there through . As may be appreciated , the specific configurations 
of the bioreactor assembly 400 and portions thereof , as well as manner of assembly , may be modified or adapted to the specifics of the particular application . 
[ 0069 ] The inlet channels 408 and outlet channels 410 of the bioreactor assembly 400 need not have equal dimen 
sions . That is , as shown in FIG . 4B , the inlet channels 408 
can be larger ( or smaller ) in at least one transverse ( or 
longitudinal ) dimension compared to the outlet channels 
410 . By way of example , the inlet channels may have a first 
transverse dimension , or channel height of approximately 
0 . 1 mm , a second transverse dimension , or channel width of 
approximately 0 . 7 mm , while the outlet channels may have 
a channel height of approximately 0 . 1 mm and a channel 
width of approximately 0 . 5 mm . The channels may have a 
longitudinal dimension or length of approximately 25 mm . 
Various other dimensions may be possible . In some aspects , 
dimensions , including channel depths and widths , may be configured such that megakaryocytes experience desired 
shear stress in the center of the channels , and avoid trapping 
at channel walls . 
[ 0070 ] In addition , in some aspects , at least some of the 
inlet channels 408 or outlet channels 410 , or both , may also 
be tapered transversally over at least a portion of the 
longitudinal dimension forming the active contact area 422 . By way of example , a channel depth may begin at 0 . 5 mm 
and taper to a point . As described , such configurations may be advantageous for controlling a pressure differential pro 
file in the channels in order to regulate perfusion through the 
membrane 406 in the active contact area 422 . 
[ 0071 ] Referring particularly to the cross - sectional view 
of FIG . 4C , an inlet channels 408 and outlet channels 410 are 
shown to be tapered transversally , forming a taper angle a 
with the longitudinal direction x . That is , a surface 424 of the 
inlet channels 408 , or outlet channel 410 , or both , forms the 
taper angle with the longitudinal direction , or x direction , as 
shown . By way of example , the taper angle a can have 
values between 0 and 5 degrees , although other taper angles 
values may be possible . In some aspects , the taper angle 
associated with inlet channels 408 and outlet channels 410 
need not be the same . As a result of the taper in the channels , 
fluid media introduced via the inlet 418 and extracted via the 
outlet 420 would experience a uniform differential pressure 
profile across the active contact area 422 , as indicated by the 
arrows . Herein , the pressure differential profile refers to the 
various pressure differences between the inlet channels 408 
and outlet channels 410 present different points along the 
longitudinal direction x . 
[ 0072 ] By way of example , FIG . 5A - B show one embodi 
ment of the bioreactor system described with reference to FIG . 2 . Specifically referring to FIG . 5A , the system 500 
may include a syringe pump 502 fluidly connected , using plastic tubing 504 , to a bioreactor chip assembly 506 , as 
described with reference to FIGS . 4A - 4C . In particular , the 
tubing 504 may be fitted using Luer Lock connectors 508 in 
order to provide detachable , leak - proof connections to the 
syringe pump 502 as well as to an external output . As shown , 
the bioreactor chip assembly 506 includes a bioreactor 550 
fastened to a standard microplate - sized base 510 using a 
chip clamps 512 . Referring particularly to FIG . 5B , the 
bioreactor 550 is shown to include a plurality of channels 
552 , or chambers , formed in PDMS substrates included therein , and connected to respective inlet 554 and outlet 556 
ports . As described , inlet and outlet channels 552 are sepa rated by a permeable membrane 558 . The bioreactor 550 
also includes glass slides 560 , with or without holes , 
arranged on the top and bottom of the PDMS substrates . The 
bioreactor 550 further includes a PDMS molded track 562 
for achieving a hermetic seal . 
[ 0073 ] Another embodiment the bioreactor system 
described with reference to FIG . 2 is shown in FIG . 10 . Specifically , the system 1000 includes a biological input 
source 1002 , a bioreactor 1004 , an output 1006 , a controller 
1008 , and a recirculator 1010 . As described , the input source 
1002 is fluidly connected to a plurality of inlet channels 
1012 , while the output 1006 is fluidly connected to a 
plurality of outlet channels 1014 , with the inlet and outlet 
channels being separated by a permeable membrane ( not 
shown in FIG . 10 ) . As described , effluent containing pro 
duced biological products , such as platelets , may be received 
by the output 1006 . 
[ 0074 ] In addition to the outlet port 1016 configured to 
direct effluent from the outlet channels 1014 to the output 
1006 for collection , storage or further processing , the bio 
reactor 1004 shown in FIG . 10 also includes another outlet 
port 1018 connected to the outlet channels 1014 . Such 
configuration allows effluent flowing out of the outlet chan 
nels 1014 to be redirected , using the recirculator 1010 , back into the outlet channels 1014 by way of an inlet port 1020 
connected to the outlet channels 1014 , as indicated by arrows in FIG . 10 . This allows for reduced operational 
volumes as well as the ability to concentrate produced 
biological products . In addition , pressure differentials and 
shear stress profiles in the channels can be independently 
controlled by the controller 1008 . By way of example , the 
recirculator 1010 may be a peristaltic pump , which may be 
configured to achieve physiologically relevant conditions . 
[ 0075 ] Although not shown , the bioreactor 1004 may also include a perfusion channel for perfusing gas , such as CO2 , into the channels . In addition , the bioreactor 1004 may be included in a bioreactor assembly capable of assembly and disassembly 
[ 0076 ] Embodiments of bioreactor systems described thus far need not be limited to planar geometries . For example , as 
shown in FIGS . 11 and 12 , cylindrical geometries may also be implemented . Specifically referring to FIG . 11 , a cross 
section of an example cylindrical bioreactor 1100 is shown , 
which includes an outer chamber 1102 and inner chamber 
1104 formed in a substrate 1106 . As shown , the chambers are 
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separated a porous membrane 1108 , which is configured to 
form microfluidic pathways connecting the chambers , as 
described . The chambers are each connected to various inlet 
and outlet ports ( not shown in FIG . 11 ) that may facilitate infusion and collection of fluid media flowing therethrough , 
as indicated by the arrows . In some aspects , as shown in 
FIG . 11 , an inner surface 1110 of the substrate 1112 includes 
a curvature , or continuous taper , configured to control fluid 
flow between the chambers . In some aspects , the curvature 
may be configured to achieve a uniform pressure differential 
across an active area of the permeable membrane 1108 . 
[ 0077 ] In another example , FIG . 12 shows a cross - section of a cylindrical bioreactor assembly 1200 . In general , the 
bioreactor assembly 1200 includes a first substrate 1202 
separated from a second substrate 1204 by a permeable 
membrane 1206 . As may be appreciated , this configuration 
is similar to the one described with reference to FIG . 4B , but adapted to a cylindrical geometry . Specifically , the first 
substrate 1202 includes a plurality of inlet channels 1208 
formed therein . Similarly , the second substrate 1204 
includes a plurality of outlet channels 1210 formed therein , 
wherein the inlet channels 1208 and outlet channels 1210 extend substantially along a longitudinal direction perpen 
dicular to the cross - section shown in FIG . 12 , and overlap 
over an active contact area . The channels may or may not be 
tapered . A fluid medium flowing in the inlet channels 1208 
would then traverse the permeable membrane 1206 radially 
into the outlet channels 1210 , as indicated by the arrows . 
[ 0078 ] The channels of the bioreactor assembly 1200 may 
be connected to various inlet / outlet ports , and inlet / outlet 
manifolds ( not shown in FIG . 12 ) , similar to configurations 
described with reference to FIG . 3 . In addition , in some aspects , the channels may be tapered transversally over at least a portion of the longitudinal direction in order to 
control a pressure differential regulating perfusion through 
the permeable membrane 1206 . When the substrates are brought into engagement , by way of a base plate 1212 and 
fastener 1214 , an even pressure is applied across the per 
meable membrane 1206 , forming a hermetic seal between 
the substrates and permeable membrane 1206 . 
[ 0079 ] Turning now to FIG . 13 , a flowchart setting forth steps of a process 1300 , in accordance with aspects of the 
present disclosure , is shown . The process 1300 may begin at 
process block 1302 with providing biological source mate rial , such as megakaryocytes or progenitor cells or stem 
cells . In some aspects , biological source material may also 
be generated at process block 1302 . For instance , mega karyocytes may be generated by first isolating stem cells from umbilical cord blood , for example , and expanding them using various reagents . Such expanded cells may then be differentiated into megakaryocytic lineage , followed by a step of inducing polyploidization to generate mature mega karyocytes usable producing platelets . Alternatively , mega karyocytes may be obtained from induced pluripotent cells . 
[ 0080 ] As indicated by process block 1304 , the provided or generated biological source material may then be seeded 
in a bioreactor assembly , for instance , as described with 
reference to FIGS . 3 - 5 . In some aspects , this step may include preparing various components bioreactor assembly . For example , a permeable membrane may be seeded with biological source material using various culture and plating techniques prior to device assembly . Alternatively , or addi 
tionally , a number of infusion , incubation , and other steps may also be performed to prepare the bioreactor assembly 
with the biological source material . For instance , mega karyocytes dispersed in a fluid medium may be selectively 
infused in the bioreactor assembly . By virtue of appropri ately sized pores or microchannels , megakaryocytes may 
then be captured in a permeable membrane . 
[ 0081 ] In some aspects , as described , the bioreactor assembly may be functionalized with various biological 
substances and compositions to optimize the production of 
desired biological product . For example , physiological con 
ditions found in bone marrow and blood vessels may be 
reproduced to replicate in vivo platelet production . This may 
be achieved by selective infusion , or other preparation , as 
described steps . For instance , the bioreactor assembly may 
be functionalized with various cells including endothelial 
cells , bone marrow cells , blood cells , and cells comprising 
basement membranes . The bioreactor assembly may also be functionalized with various small molecules including 
CCL5 , CXCL12 , CXCL10 , SDF - 1 , FGF - 4 , S1PR1 , REDS , Methylcellulose , and extracellular matrix proteins , including 
collagen , fibrinectin , fibrinogen , laminin , vitronectin , and 
combinations thereof . Such selective infusion of various biological compositions may be achieved sequentially or in 
parallel . In some aspects , parallel infusion may be per 
formed , using multiple inlets and outlets , such that laminar flow media streams do not mix . Any of above biological 
substances or compositions may be infused using various 
fluid media , including cell culture media , whole blood , 
plasma , platelet additive solutions , suspension media , and so 
on . In some aspects , the above infusion and seeding pro 
cesses may be visually monitored using a camera , a micro 
scope , and the like , to verify adequate conditioning and 
coverage . In addition , various conditions , including tem perature , light or vibration may be adjusted during perform 
ing either process block 1302 or process block 1304 . 
[ 0082 ] Referring again to FIG . 13 , at process block 1306 
fluid media may then be introduced into a seeded and functionalized bioreactor assembly in order to produce desired biological products , such as platelets . By controlling 
fluid media flow rates and pathways in a selected bioreactor 
assembly embodiment , as described , conditions can con 
trolled to facilitate or optimize production of desired bio 
logical products . In particular , perfusion rates through the 
permeable membrane , along with shear stresses due to the 
traversing fluid can be controlled . By way of example , flow 
rates may be in a predetermined range approximately 
between 5 , 000 and 150 , 000 microliters per hour , although 
other values are possible , depending upon the application , 
specific bioreactor assembly embodiment , and desired bio 
logical products . For instance , flow rates may vary depend 
ing whether the bioreactor assembly is being prepared , or 
being operated to generate desired biological products . 
[ 0083 ] . In some aspects , flow rates may be configured to 
maintain shear rates in a predetermined range advantageous 
for efficient production of desired biological products , such as platelets . In general , such predetermined range may be 
between 10 s - and 10 , 000 s - 4 , although other values may be possible . In some aspects , physiological shear rates consis 
tent with proplatelet extension and platelet production in 
vivo may be desirable . For example , physiological shear 
rates may be between 500 s - and 2500 s - . [ 0084 ] Then , at process block 1308 , biological products 
generated in the bioreactor assembly may then be harvested . For instance , generated biological products carried by tra 
versing fluid media and may be collected and separated from 
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the effluent for subsequent use . In some aspects , post 
collection processing may be performed . For instance , pro 
cess block 1308 may also include a process to dialyze the 
bioreactor - derived platelets in an FDA - approved storage 
media , such as platelet additive solution . In particular , a dynamic dialysis system may be used , for instance , using 
continuous flow at low shear through a 0 . 75 mm , 0 . 65 um 
PES lumen ( Spectrum Labs ) . Thus , the culture media may 
be replaced with a media that can be infused into human 
patients . In addition , in some aspects , the post - collection 
processing at process block 1308 may also include a process 
to irradiate the biological products generated . Such step is 
often required by the FDA before platelets can be used on human patients . 
[ 0085 ] In summary , the present disclosure provides a novel approach for efficient and scalable production of platelets , and other biological products . By way of example , FIG . 14A - D show flow cytometry graphs comparing animal results of mature megakaryocyte , and proplatelet / platelet production using previous static culture techniques with 
those obtained using the approach of the present disclosure . 
In particular , FIGS . 14A and 14B show mature megakaryo cytes and proplatelets / platelets produced in static cultures , 
respectively , while FIGS . 14C and 14D show mature mega karyocytes and proplatelets / platelets successfully produced 
using the present approach , respectively . In addition , FIG . 
14C illustrates successful confinement of megakaryocytes . As another example , FIG . 15 shows a graph illustrating a 
timeline of cell yield using a bioreactor and method , as 
described . As shown , a significant number of platelets 
( “ PLT ” ) can be generated within the first hour of operation 
of the bioreactor . These results indicate that the present approach can be successfully implemented to produce clini 
cally - relevant numbers of platelets . 
10086 ] The various configurations presented above are 
merely examples and are in no way meant to limit the scope 
of this disclosure . Variations of the configurations described 
herein will be apparent to persons of ordinary skill in the art , 
such variations being within the intended scope of the 
present application . In particular , features from one or more 
of the above - described configurations may be selected to create alternative configurations comprised of a sub - combi 
nation of features that may not be explicitly described above . 
In addition , features from one or more of the above - de 
scribed configurations may be selected and combined to 
create alternative configurations comprised of a combination 
of features which may not be explicitly described above . 
Features suitable for such combinations and sub - combina tions would be readily apparent to persons skilled in the art upon review of the present application as a whole . The 
subject matter described herein and in the recited claims 
intends to cover and embrace all suitable changes in tech nology . 
arranged between the substrates , a permeable membrane 
forming microfluidic pathways between respective inlet and outlet channels and configured to selectively capture biological source material capable of generat ing biological products , 
wherein at least one channel is tapered transversally to 
control a pressure differential profile regulating perfu 
sion of a fluid medium through the permeable mem 
brane . 
2 . The system of claim 1 , wherein the substrates , when 
engaged , are configured to form a hermetic seal between 
respective inlet and outlet channels . 
3 . The system of claim 1 , wherein a taper angle formed 
between a surface of the at least one channel and the longitudinal direction is in a range approximately between 0 and 5 degrees . 
4 . The system of claim 1 , wherein the plurality of inlet 
channels are connected to an inlet manifold formed in the 
first substrate , the inlet manifold being configured to uni 
formly or differentially distribute across the plurality of inlet 
channels the biological source material introduced therein . 
5 . The system of claim 1 , wherein the system further comprises an outlet manifold formed in the second surface , 
the outlet manifold connected to the outlet channels and 
configured to at least direct the fluid medium comprising generated biological products to an output . 
6 . The system of claim 4 , wherein the biological source material includes megakaryocytes and the biological prod ucts include platelets or megakaryocyte component prod 
ucts . 
7 . The system of claim 1 , wherein the system further comprises a source configured to selectively introduce into 
the channels fluid media comprising one or more biological 
substances . 
8 . The system of claim 7 , wherein the source is further configured to selectively introduce fluid media comprising 
cells including megakaryocytes , endothelial cells , bone mar 
row cells , blood cells , lung cells and cells comprising 
basement membranes , small molecules including CCL5 , 
CXCL12 , CXCL10 , SDF - 1 , FGF - 4 , S1PR1 , RGDS , Meth ylcellulose , and extracellular matrix proteins , including col 
lagen , fibrinectin , fibrinogen , laminin , vitronectin , and com 
binations thereof . 9 . The system of claim 7 , wherein the source is further configured to selectively introduce cell culture media , whole 
blood , plasma , platelet additive solutions , suspension media , 
and combinations thereof . 10 . The system of claim 7 , wherein the source is further configured to control flow of the fluid medium in the channels to generate shear rates within a predetermined 
range that is selected to facilitate production of biological 
products . 
11 . The system of claim 1 , wherein the substrates com prise PDMS , thermoplastics , zeonor cyclo olefin polymers , 
glass , and combinations thereof . 
12 . The system of claim 1 , wherein the permeable mem 
brane comprises PDMS , thermoplastics , silk , hydrogels , or 
polycarbonate . 
13 . The system of claim 1 , wherein the permeable mem brane comprises pores sized in a range approximately 
between 3 micrometers and 10 micrometers . 
14 . The system of claim 1 , wherein the at least one channel is tapered transversally such that the pressure dif 
ferential profile is substantially uniform over at least a 
1 . A system for generating biological products , the system comprising : 
a first substrate having formed therein a plurality of inlet channel extending substantially along a longitudinal 
direction ; 
a second substrate having formed therein a plurality of outlet channels corresponding to the plurality of inlet channels and extending substantially along the longi 
tudinal direction , the second substrate configured to releasably engage the first substrate ; and 
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portion of an active area defined in the permeable membrane by an overlap of respective inlet and outlet channels . 15 . A method for generating biological products , the method comprising : 
seeding a bioreactor assembly with biological source material capable of generating desired biological prod 
ucts , the bioreactor assembly comprising : 
a first substrate having formed therein a plurality of 
inlet channels extending substantially along a longi 
tudinal direction ; a second substrate , configured to releasably engage the 
first substrate , and having formed therein a plurality of outlet channel corresponding to the plurality of inlet channels and extending substantially along the 
longitudinal direction , wherein at least one channel is tapered transversally to control a pressure differ 
ential profile therein ; 
arranged between the substrates , a permeable mem 
brane forming microfluidic pathways between 
respective inlet and outlet channels and configured to 
selectively capture biological source material ; 
introducing fluid media into the bioreactor assembly at 
flow rates suitable for generating the desired biologi cal products from the biological source material captured by the permeable membrane ; and 
harvesting the desired biological products from the 
bioreactor assembly . 
16 . The method of claim 15 , wherein the desired biologi cal products comprise platelets . 
17 . The method of claim 15 , wherein the biological source material comprises megakaryocytes . 
18 . The method of claim 15 , wherein the method further comprises generating the biological source material from 
bone marrow , peripheral blood , umbilical cord blood , fetal liver , yolk sack , spleen , or pluripotent stem cells . 
19 . The method of claim 15 , wherein the method further comprises functionalizing the bioreactor assembly with one or more biological substances by selectively introducing 
fluid media comprising the one or more biological sub 
stances into the channels . 20 . The method of claim 19 , wherein one or more biological substances comprises cells including endothelial cells , bone marrow cells , blood cells and cells comprising 
basement membranes , small molecules including CCL5 , 
CXCL12 , CXCL10 , SDF - 1 , FGF - 4 , S1PR1 , RGDS , Meth ylcellulose , and extracellular matrix proteins including col 
lagen , fibrinectin , fibrinogen , laminin , vitronectin , and com 
binations thereof . 21 . The method of claim 19 , wherein the fluid media 
comprises cell culture media , whole blood , plasma , platelet 
additive solutions , suspension media , and combinations 
thereof . 
22 . The method of claim 15 , wherein the method further comprises introducing the fluid media at a predetermined 
flow rate that is configured to induce physiological shear 
rates in the outlet channels sufficient to generate platelets . 
23 . The method of claim 22 , wherein the physiological 
shear rates are in a range approximately between 10 sec - 1 
and 2000 sec - 1 . 24 . The method of claim 22 , wherein the predetermined 
flow rate is in a range approximately between 5 , 000 and 
150 , 000 microliters per hour . 25 . The method of claim 15 , wherein a taper angle formed 
between a surface of the at least one channel and the longitudinal direction is in a range approximately between 0 
and 5 degrees . 
26 . The method of claim 15 , wherein the pressure differ ential profile is substantially uniform over at least a portion 
of an active area defined in the permeable membrane by an overlap of respective inlet and outlet channels . 
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Silicon and glass very large scale microﬂuidic
droplet integration for terascale generation of
polymer microparticles
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Microﬂuidic chips can generate emulsions, which can be used to synthesize polymer
microparticles that have superior pharmacological performance compared to particles pre-
pared by conventional techniques. However, low production rates of microﬂuidics remains a
challenge to successfully translate laboratory discoveries to commercial manufacturing. We
present a silicon and glass device that incorporates an array of 10,260 (285 × 36) microﬂuidic
droplet generators that uses only a single set of inlets and outlets, increasing throughput by
>10,000× compared to microﬂuidics with a single generator. Our design breaks the tradeoff
between the number of generators and the maximum throughput of individual generators by
incorporating high aspect ratio ﬂow resistors. We test these design strategies by generating
hexadecane microdroplets at >1 trillion droplets per h with a coefﬁcient of variation CV <3%.
To demonstrate the synthesis of biocompatible microparticles, we generated 8–16 µm
polycaprolactone particles with a CV <5% at a rate of 277 g h−1.
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In 1959, Richard Feynman famously proposed the use ofmicrometer- and nanometer-scale particles for medicine, aswell as the creation of enormous numbers of microfabricated
“factories” to generate large quantities of these engineered mate-
rials1. In the last two decades, signiﬁcant progress has been made
toward accomplishing this vision. In particular, microﬂuidics has
been used to enable precise control of multiphasic ﬂows to gen-
erate micrometer- and nanometer-scale materials with control and
uniformity not possible using conventional techniques2–6. These
micro- and nano-engineered materials have generated particular
enthusiasm in the pharmaceutical industry, as well as the food and
cosmetics industries, where they have created new opportunities to
generate novel drug formulations that offer unprecedented spatial
and temporal control of drug delivery within the body7–9. In
comparison to conventional particle formation techniques, such as
spray drying or ball milling10, microﬂuidic-generated formulations
have demonstrated increased particle monodispersity, more uni-
form composition of drug within the particles, increased drug
yield, longer lasting formulations that are still injectable, and
reduced burst release of drug2,6,11.
The low production rate of microﬂuidic devices for the gen-
eration of microparticles (<10 mL h−1 for the dispersed phase,
<100 mg h−1 of particles) has remained a key challenge to suc-
cessfully translate the many promising laboratory-scale results of
microﬂuidics to commercial-scale production of microﬂuidic-
generated materials. In previous work, architectures have been
developed that make it possible to operate many microﬂuidic
droplet generators in parallel11–22. While great progress has been
made in these approaches, current chips with parallelized devices
are limited to production rates ϕmax⪍ 1 L h−1, have droplet
homogeneities set by three-dimensional (3D) soft-lithography
fabrication15, are limited to low temperature and pressure
operation, can only be used with the solvents compatible with the
device’s polymer construction, or are unable to be adapted to
produce higher-order emulsions and particles that require multi-
step processing23–25.
To address these challenges, we present the all silicon and glass
very large scale droplet integration (VLSDI), in which we incor-
porate an array of 10,260 (285 × 36) microﬂuidic droplet gen-
erators onto a 3D-etched single silicon wafer that is operated using
only a single set of inlets and outlets. The monolithic construction
from a single silicon wafer obviates the alignment and bonding
challenges of prior multilayer approaches and allows high pressure
use. To demonstrate the power of this approach, we generate
polycaprolactone (PCL) solid microparticles, a biodegradable
material approved by the United States Food and Drug Admin-
istration (US FDA), with a coefﬁcient of variation CV <5%, and an
emulsion production rate that results in 277 g h−1 particle pro-
duction (2.09 L h−1 dispersed phase, 328 billion particles per h).
Key to achieving this throughput lies in a design strategy that
breaks the tradeoff between the number of integrated droplet
generators Nmax and the maximum throughput of each droplet
generator ϕimax. Our design includes a high aspect ratio ﬂow
resistor into each droplet generator, which decouples the design of
the individual droplet generator from the high ﬂuidic resistance
requirement necessary for parallelization. Moreover, because of
the VLSDI’s all silicon and glass construction, it can operate at
high pressure (Pmax > 1000 PSI (pounds per square inch)) and
high temperature (Tmax > 500 °C), use solvents prevalent in the
pharmaceutical industry but that are incompatible with polymer
devices, and achieve a uniformity not possible using soft-
lithography based devices (CV <3%). Because of the VLSDI’s
3D fabrication strategy, it can be scaled to the 10,000 droplet
generators that we demonstrate in this study and beyond using
conventional semiconductor fabrication, in contrast to prior
approaches that have used either two-dimensional microﬂuidic or
two-dimensional microﬂuidics attached to macroscopically
deﬁned manifolds. Because our device allows arbitrary micro-
ﬂuidic droplet generators to be parallelized, it can produce higher-
order emulsions and particles that require multi-step processing.
Results
Very large scale droplet integration fabrication. We fabricate
the VLSDI using a single microfabricated 500 µm thick 4″ Si
wafer encapsulated in glass, resulting in a robust, monolithic
construction.(Supplementary Fig. 2 for step by step fabrication)
(Fig. 1a, b) This design enables the production of highly
monodispersed PCL solid microparticles (CV <5%), >1000×
faster than previously reported parallelized microﬂuidic
approaches (Fig. 1c, d).
We use four steps of lithography and deep reactive ion etch
(DRIE) to deﬁne the droplet generators (hµF= 22.5 µm), under-
passes (hUP= 26 µm), vias (hV= 130 µm), and delivery channels
(hD= 360 µm) (Fig. 1e). Underpasses are channels that are
required to allow ﬂuid to pass underneath the arterial lines that
deliver ﬂuid to each of the rows (Supplementary Fig. 1b). The
microfabricated Si wafer is anodically bonded to two 4″
Boroﬂoat33 glass wafers on its top and its bottom. Anodic
bonding results in microﬂuidic channels that can operate at a
maximum pressure of >1000 PSI, enabling high-throughput
operation even on highly viscous samples. To make ﬂuid
connections to the VLSDI, we drill 1.5 mm holes in the top glass
plate before anodic bonding using an excimer laser micro-
machining tool (IPG Photonics IX-255). We use steel compres-
sion ﬁttings to avoid the creation of debris in the device that can
occur using pressure ﬁt tubing (Supplementary Fig. 4). The
ﬁttings are bonded to our device using chemically resistant epoxy
(Mater Bond Epoxy EP41S-5) and connected to polytetraﬂuor-
oethylene (PTFE) tubing (1/8″ OD (outter diameter), 1/16″ ID
(inner diameter)). The dispersed and continuous phases are
delivered to the device from N2 gas pressured steel pressure
vessels (Alloy Products) through the PTFE tubings. All of the
parts and tubing are chemically resistant, allowing our platform
to generate particles using a wide range of temperatures,
pressures, and solvents (Supplementary Figs 3–5).
Design principles. There are three main design goals for our
parallelized device: to ensure uniform ﬂow across each of the N
microﬂuidic droplet generators, such that each generator supplies
the same shear stresses to produce droplets with the same dia-
meter. To minimize the footprint of each individual microﬂuidic
droplet generator, such that the greatest number N can be
incorporated onto a given wafer. To maximize the production
rate (droplets per s) of each individual droplet generator, while
keeping the microﬂuidic device in a low ﬂow velocity regime
where each device produces uniform droplets (i.e., a dripping
regime not a jetting regime)26. These design goals and the ﬂuid
physics of microﬂuidic droplet generators provide tradeoff rela-
tionships and constraints that guide the VLSDI’s design.
The droplet generators on our device use a ﬂow-focusing
geometry (Fig. 1b) and are organized in a ladder architecture13–16
(Fig. 1f) (Supplementary Fig. 1). In the ladder design, the
individual generators are connected in a line along a single set of
liquid distribution channels. A two-dimensional array of micro-
ﬂuidic droplet generators is created by connecting multiple rows
of droplet generators, also in a ladder geometry, using a single set
of arterial lines. In previous work, it has been shown that liquids
can be uniformly distributed over N ﬂow-focusing generators
(FFGs) connected using a single set of distribution channels, such
that the ﬂow resistance in the distribution channel between
droplet generators RD is small relative to that of each individual
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microﬂuidic droplet generator RDev, resulting in a design rule16:
2N ðRD=RDevÞ<0:01: ð1Þ
In previous work, this design rule has been satisﬁed for large
numbers of microﬂuidic droplet generators by taking advantage
of the hydrodynamic resistance of a microﬂuidic channel’s R∝1/
h3 dependence on the height h of the microﬂuidic channel, using
delivery channels with a height hD > 100 µm and droplet
generators with a height hDev ~10 µm13 –16. Using these design
principles for parallelizing microﬂuidic droplet generators, there
is a tradeoff between the number of droplet generators that can be
incorporated onto a given chip area N and the maximum
throughput ϕ of each individual droplet generator. The origin of
this tradeoff comes from two competing goals: a to keep the ﬂuid
velocity low at high volumetric ﬂow rates, thus decreasing the
device’s ﬂuidic resistance RDev, such that each device produces
uniform droplets (i.e., a dripping regime not a jetting regime)26
and b to increase the ﬂuidic resistance RDev of each droplet
generator to satisfy Eq. 1 for the largest possible number of
droplet generators N .
The transition from dripping to jetting is a well-studied
phenomenon, and depends on the capillary number of the
continuous phase of each individual ﬂow-focusing droplet
generator Cao= µv/σ (where µ is the ﬂow viscosity, v is the
velocity, and σ is the interfacial tension), representing the relative
importance of surface tension to viscous forces, as well as the
Weber number WeD of the dispersed phase, which represents the
relative magnitudes of inertial and surface tension forces. When
Ca and We <O(100), surface tension force dominates the droplet
break-up and uniform droplets are formed via the dripping
mechanism26. For the application of high-throughput particle
production, the dripping to jetting transition deﬁnes a maximum
throughput ϕimax for the individual droplet generators.
To overcome the tradeoff between increasing the number of
droplet generators N and the maximum ﬂow rate at which each
device can be operated ϕimax, we incorporated ﬂow resistors for
both the dispersed and continuous phase upstream of the droplet
generators (Fig. 2a). Each of these ﬂow resistors has a width less
than their height w < h (w= 10 µm, h= 22.5 µm), such that the
dependence of resistance on the channel dimensions become RR∝1/
hw3 . By adding these ﬂow resistors, the resistance of the individual
droplet generators RDev decreases as a function of h at a rate less
than that of a traditional parallelization design RDev∝1/wh3 13 ,14,16.
Thus, the minimum resistance Rmindev necessary to incorporate 10,260
FFGs to satisfy Eq. 1 can be achieved at a greater height h (Fig. 2e)
and thus enable the droplet generators to operate at a higher
volumetric ﬂow rate before transitioning from the dripping to
jetting regime. This work, wherein we have decoupled the design of
individual ﬂow-focusing droplet generators in massively paralle-
lized chips, builds on earlier reports where ﬂow resistors were used
to control the ﬂow rate and decouple droplet generators in chips
that contain several droplet generators27,28.
Validation of design principles. To validate the design principles
described above, we analyzed the performance of three VLSDI
devices whose channel dimensions satisfy the design rule for
10,260 FFGs (Eq. 1) (Fig. 2a). For each design, the footprint of the
individual droplet generator is identical (175 µm × 1475 µm) and
10,260 FFGs are incorporated using the same ladder geometry.
Device I: we built this device without the beneﬁt of our decou-
pling strategy, using upstream ﬂow resistors, with height h= 10
µm and the width w= 20 µm immediately downstream of the
droplet generator and w= 10 µm upstream. Device II: here, we
incorporated ﬂow resistors and increased the dimensions of the
droplet generators to h= 22.5 µm and w= 80 µm immediately
downstream of the droplet generator and w= 40 µm upstream in
the dispersed and continuous phases, and Device III: we increased
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Fig. 1 All silicon and glass VLSDI for high-throughput microparticle production. a A photograph of the VLSDI chip, which consists of 10,260 (285 × 36)
ﬂow-focusing droplet generators (FFGs). b An optical micrograph of two individual droplet generators producing droplets. Scale bar: 140 µm. c Organic
phase in water emulsion (3.5 L) generated from VLSDI in 30min on a chip operated at a dispersed ﬂow rate Φd= 2.09 L h−1 (10 wt% polycaprolactone in
dichloromethane) and a continuous ﬂow rate Φc= 5 L h−1(2 wt% polyvinylalcohol in water). The inset shows an SEM (scanning electron microscope)
image of polycaprolactone microparticles obtained after evaporation of dichloromethane. Scale bar: 8 µm. The 2mL tube represents the emulsion collected
from a conventional microﬂuidic droplet generator in 1 h. d Moore’s Law of polymer microparticle generation. Yellow11, green19, orange12, blue: this work. e
An SEM micrograph of the cross section of the VLSDI chip. Scale bar: 90 µm. f The ladder design architecture that our chip uses to incorporate 10,260
parallel droplet generators. Φo emulsion output, Φc,Φd supply channels for continuous and dispersed phase
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the dimensions of the droplet generator further, such that h=
22.5 µm and w= 140 µm immediately downstream of the droplet
generator and w= 40 µm upstream in the dispersed and con-
tinuous phases. The ﬂow resistors, with width w = 10 µm and
height h = 22.5 µm, are incorporated in the same layer as the
microﬂuidic droplet generators. The channel length between the
ﬂow resistor and the droplet generator is deﬁned by the low
Reynold’s number entrance length (length= 0.06 × Re)29.
We ﬁrst evaluated these devices by generating hexadecane
droplets in water (2 wt% Tween 80). We conﬁrmed that at all ﬂow
rates droplets are generated in every one of the 10,260 droplet
generators (Supplementary Movie 1). As expected, we found that
Device I transitioned from making uniform droplets to
polydisperse droplets at a low dispersed ﬂow rate of ϕdmax=
0.35 L h−1 (Fig. 2f), Device II with its increased channel
dimensions produced uniform droplets at a maximum dispersed
ﬂow rate of ϕdmax= 3.5 L h−1, and Device III with its even larger
downstream channel dimensions produced uniform droplets up
to a maximum dispersed ﬂow rate of ϕdmax= 7.3 L h−1. For each
of the three devices, at ﬂow rates where the device was in the
dripping regime, the droplets were highly monodispersed (CV
<5%) (Fig. 2g). And, at ﬂow rates where the droplet generator
were in the jetting regime, the droplets became highly
polydisperse (CV »5%) (Fig. 2h). All three devices transitioned
from dripping to jetting at approximately the same Capillary
number Ca immediately downstream of the droplet generator
oriﬁce (Ca≅0.08).
We tested the mass production of oil-in-water emulsion by
using pressure-driven ﬂow (Supplementary Figs. 4 and 5 for
experimental setup) and the size of emulsion droplets could be
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changed by varying the ratio of the ﬂow rates of the dispersed and
continuous phases (Supplementary Movie 2). For example, by
changing the dispersed oil phase ﬂow rate over the range of ϕd=
0.5 L h−1 (10 PSI) to 7.3 L h−1 (59 PSI) and the continuous
aqueous phase over the range of ϕc= 0.8 L h−1 (12 PSI) to 9.2 L h−1
(62 PSI), the average droplet size could be controlled over a range of
d= 22.5–37.5 μm (Fig. 3a, Supplementary Fig. 6). The generated
droplets were highly monodisperse at all ﬂow rates, with the
coefﬁcient of variation CV <3% (Fig. 3b) at a throughput >1 trillion
droplets per h (Supplementary Movie 3). Because our device is
fabricated using anodically bonded silicon and glass, it can operate at
extremely high pressures (>1000 PSI), making it very well suited for
high-throughput processing of highly viscous ﬂuids. We demon-
strated the high-throughput production of mineral oil droplets (30
cP), which is an order of magnitude more viscous than the
hexadecane (3.0 cP) and dichloromethane (DCM) (0.41 cP). We
achieved a dispersed phase throughput of ϕD= 2.2 L h−1 (d= 24.3
µm droplets, CV <3%) (Supplementary Fig. 7 and Supplementary
Movie 4). The size of the droplets that could be produced by each of
the chips were comparable to that of the oriﬁce dimensions, as has
been shown in previous work30. Using our Device III chip, which
had oriﬁce dimensions of height h= 22.5 µm and width w= 20 µm,
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we were able to produce droplets with diameters d= 22.5–37.5 μm.
With the Device I chip that had oriﬁce dimensions of height h= 10
µm and width w= 10 µm, we were able to produce droplets with
diameters d= 14.5–18.4 μm.
VLSDI integration of T-junctions. To demonstrate the mod-
ularity of the VLSDI architecture, we designed, fabricated, and tested
a version of the chip that incorporates 10,260 (285 × 36) T-junction
devices (Fig. 4a). We designed ﬂow resistors (width w= 10 µm and
height h= 18 µm) upstream of the T-junctions, following the same
design rules used on our FFG device (Fig. 4b). We ﬁrst evaluated
these devices by generating hexadecane droplets in water (2 wt%
Tween 80) and conﬁrmed that at all ﬂow rates droplets are gener-
ated in every one of the 10,260 droplet generators (Supplementary
Movie 5). We found that the T-junction device could generate
droplets at a maximum dispersed ﬂow rate of ϕdmax= 1.5 L h−1
(Fig. 4c). We mass produced oil-in-water emulsion using this device
by using pressure-driven ﬂow and the size of emulsion droplets
could be changed by varying the ratio of the ﬂow rates of the
dispersed and continuous phases. Droplets were generated with sizes
that range from 46.2 µm (ϕd= 0.5 L h−1, ϕc= 4.5 L h−1) (Fig. 4d) to
33.2 µm (ϕd= 1.5 L h−1, ϕc= 12.8 L h−1) (Fig. 4e). The generated
droplets were highly monodisperse with the coefﬁcient of variation
CV <4% at a throughput of 80 billion droplets per h.
Large-scale manufacturing of polymer microparticles. To
demonstrate the power of this approach for the industrial scale
manufacturing of uniform solid particles, appropriate to use as an
injectable drug delivery system5,6, we generated micrometer scale
PCL microparticles, a biodegradable material approved by the US
FDA31. We achieved a production rate of 277 g h−1 (328 billion
particles per h) for particles with diameters ranging from 8–15 µm
with CV <5% (Supplementary Movie 6, Supplementary Movie 7).
Emulsion templates for the solid particles were fabricated on our
chip using a dispersed phase of DCM with either 4 wt% (ρE= 53.2 g
L−1) or 10 wt% (ρE= 133 g L−1) of PCL. The continuous phase was
deionized water with 2 wt/vol% of polyvinyl alcohol (PVA) (Fig. 5a).
These two phases were driven through the FFG-based VLDSI chip
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using pressure-driven ﬂow, collected, and then further processed
using roto-evaporation and lyophilization prior to being ana-
lyzed. Uniform DCM droplets were generated with sizes ranging
from 23 to 42 µm with CV <3% at a production rate of ϕd ≅ 2.09 L h
−1 (Fig. 5b). After the DCM was extracted (Fig. 5c), spherical, highly
monodispersed solid PCL polymer particles remain (Fig. 5d, e).
To test our chip’s ability to produce highly monodispersed
particles with a determined particle diameter, we generated four
different particle formulations. Using a dispersed phase of DCM
with 10 wt% PCL (ρE= 133 g L−1), we generated two pools of
particles, one with a diameter of dp= 11.2 µm (CV= 4.4%)
(Fig. 5f) and one with a diameter dp= 16.1 µm (CV= 4.4%)
(Fig. 5g), beginning with droplet templates with diameters of dT
= 23.2 µm (CV= 2.5%) and dT= 35.9 µm (CV= 1.4%), respec-
tively. Using a dispersed phase of DCM with 4 wt% PCL (ρE=
53.2 g L−1), we generated two populations of particles, one with a
diameter of dp= 8.4 µm (CV= 4.0%) (Fig. 5h) and one with a
diameter dp= 15.2 µm (CV= 3.6%) (Fig. 5i), beginning with
droplet templates with diameters dT= 24.5 µm (CV= 2.4%) and
dT= 42.7 µm (CV= 2.0%), respectively. The slight increase in
CV from droplets to particles came primarily from rare particles
that were deformed during post-processing off chip, and we
postulate that CV can be further improved by translating our
process to a continuous ﬂow liquid-liquid extraction system32.
We have produced as much as two gallons of DCM-PCL in water
emulsion droplets at a ﬂow rate of ϕd= 2.09 L h−1 with a run
time of 75 min without a single device failing. These tests were
limited by the size of our pressure vessels—1 gallon for dispersed,
3 gallons for continuous phase (Supplementary Fig. 5).
We compared the measured diameter of our microparticles dp
with their expected diameter d3p= dT3 (ρE/ρPCL) based on the
diameter of the emulsion template dT, the density of solid PCL
microparticle ρPCL= 1.143 g/mL, and the weight per volume
concentration of PCL in our emulsions ρE. We considered four
separate formulations, generated using a dispersed phase with
both ρE= 133 g L−1 (Fig. 5j) and ρE= 53.2 g L−1 (Fig. 5k).
Excellent agreement was found between the measured particle
diameters and the predicted diameters (R2= 0.99), suggesting the
particles prepared from the emulsions were non-porous. (Fig. 5l).
Discussion
We present a new platform to mass produce highly uniform
microparticles using a highly parallelized microﬂuidic device. By
developing a new 3D architecture, implemented entirely in a
monolithically fabricated silicon wafer with glass encapsulation, we
can generate polymer solid microparticles at a rate >1000× faster
than existing parallelized devices12,21,34. Moreover, if commercia-
lized and implemented using a 12-inch wafer34, a production rate
of 10 trillion droplets per h is feasible. In this paper, we system-
atically studied the effect of ﬂow rate on droplet uniformity and
demonstrated that the addition of high aspect ratio ﬂow resistors,
allows microﬂuidic droplet generators that can operate at high
production rates to be successfully parallelized without redesign.
Given the high value of therapeutics and the large mass of drug
particles that each VLSDI device could produce, we postulate that
these devices could be economically feasible for use in the
pharmaceutical industry21. We estimate that if these chips were
fabricated at-scale (>1000), then each wafer would cost on the
order of a hundred dollars. As an example, the current market for
anti-retroviral therapy (ART), for the 37 million people living
with HIV worldwide, is ~$24 billion35. To manufacture the entire
world’s supply of ART in the form of long-lasting microparticle-
based injectables, assuming 200 mg drug administration per day
per patient and a 200 g per h production rate and a fraction of
active ingredient in each particle of 10–70%, <100 of our chips
continuously running 24 h a day could provide the world’s sup-
ply. Moreover, due to the low cost and automated use of the
VLSDI design, it can be used for point-of-demand pharmaceu-
tical production at locations closer to the patient. An improved
solution for automated manufacturing of high-quality pharma-
ceutical formulations closer to the point of patient care can help
address current challenges, such as the shortage of generic
injectables36 associated with high manufacturing and storage
costs, which currently limit access to essential therapies for sepsis,
cancer, and other life threatening conditions.
Methods
VLSDI device fabrication. The VLSDI was fabricated at The Singh Center at The
University of Pennsylvania (Supplementary Fig. 2). The designs for all layers of the
VLSDI chips were designed in DraftSight (Dassault Systems). Four mask layers
were designed, droplet makers (Layer-1), underpass channels (Layer-2), vias
(Layer-3), and delivery channels (Layer-4). The designs ﬁles were written on
chrome-coated soda lime photomasks (AZ1500) using Heidelberg 66 plus mask
writer with a 10 mm write head. After exposure, the photomasks were developed in
MF 319 for 1 min and then in Chrome etchant for 1 min. Finally, the remaining
photoresist on the photomask is removed by plasma oxidation for 10 min in
Anatech SCE-106-barrel Asher.
All layers of the VLSDI chip were lithographically patterned and etched in a
single 4-inch double-side polished silicon wafer using DRIE (SPTS Rapier Si
DRIE). In the ﬁrst etch step, 16 µm of positive photoresist SPR 220.7 is spin-coated
on the front side of the silicon wafer, and exposed with the delivery channels
(Layer-4) photomask. After exposure, the wafer is left at room temperature for
rehydration for 24 h, then it is developed in MF 319 for 1 min. The wafer is then
etched in DRIE for an etch depth of 370 µm. The wafer is then cleaned in Acetone
and placed in nanostrip for 30 min and cleaned in DI water and dried in N2 gas. In
the second etch step, the wafer is ﬂipped and spin-coated with 12 µm SPR 220.7
positive photoresist. The wafer is then exposed with Via layer (Layer-3)
photomask, and left at room temperature for 12 h for rehydration, and then
developed in MF-319 for 1 min. The wafer is bonded to another silicon wafer
(carrier wafer) using crystal bond adhesive. The wafer is etched in DRIE for
through vias in the silicon wafer. The wafer is then placed on a hotplate at 65 °C,
and the carrier wafer is removed. The wafer is cleaned in acetone, and then
nanostrip, and then in DI water, and then dried in N2 gas. In the third etch step,
the wafer is spray-coated with 8 µm S1805 resist. The wafer is then exposed with
underpass channel (Layer-2) photomask, and then developed in MF 319. The wafer
is again bonded to carrier wafer using crystal bond. Underpass channels are etched
in DRIE for a 30 µm deep etch. The wafer is then cleaned in acetone, and then
nanostrip. In the ﬁnal etch step, the wafer is spray-coated with 4 µm S1805 resist,
and then exposed with the droplet maker photomask (Layer-1), and developed in
MF 319 for 1 min. The wafer is placed on a carrier wafer, and then etched for 23
µm deep in DRIE. The carrier wafer is removed by placing it on hotplate at 65 °C.
The 3D-etched silicon wafer is then placed in acetone and in nanostrip for 1 h.
Boroﬂoat33 glass wafers are laser micromachined with 1 mm holes using IPG
Photonics excimer laser. These vias serve as inlets and outlet connections for the
VLSDI chip.
The completely etched silicon wafer and plain Boroﬂoat33 glass wafer is cleaned in
acetone, Isopropyl alcohol (IPA), and deionzied water (DI) water for 10min each. The
wafers are then dried in a Spin Rinse dryer. The wafers are then placed in nanostrip for
half an hour and then placed in piranha solution for 2 h. Then, the wafers are cleaned
in water, dried in spin rinse dryer, and then bonded in an EVG 510 wafer bonder by
applying 600 V, and a pressure of 600N for 1 h. Once front side of wafers are bonded,
the bonded wafer and laser machined Boroﬂoat33 wafer are kept in Nanostrip for half
an hour and then in piranha solution for 2 h. The wafers are then placed in DI water
for 12 h to completely remove the the acid solution that may ﬁlled in the channels. The
wafers are then dried in spin rinse drier and bonded in EVG 510 wafer bonder with
pressure of 600N for 2 h.
Stainless steel compressed tube ﬁttings (1/8 tube OD) form McMaster Carr
(52245K609) are bonded to the glass wafer using chemically resistant epoxy from
master bond (EP41S-5). The epoxy is left to cure at room temperature for 4 days.
PTFE tubes of 1/8 OD were connected to the ﬁttings.
Experimental setup. Pressure-driven ﬂow is used to conduct the experiments.
Nitrogen pressure tanks were connected to 1-gallon and 3-gallon stainless steel
pressure vessels (Alloy products). The 1-gallon vessel is used for dispersed phase
and the 3-gallon vessel is used for continuous phase. The VLSDI chip is connected
to the pressure vessels using PTFE tubings. The VLSDI chip is housed in a custom-
built acrylic box and then mounted on to an xyz stage. Inline ﬁlters (McMaster
Carr: 9816K72) are used to ﬁlter debris in the continuous and dispersed phases. An
inline ﬂow meter (McMaster Carr: 5084K23) was used to measure the ﬂow rates for
the aqueous phase. To test hexadecane droplets in water, hexadecane of viscosity µ
= 3 cps was purchased from Alfa Aesar (Stock number: 43283-LW). Tween
80 surfactant was purchased from Fisher Scientiﬁc (catalog number:
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AC278630025). For mineral oil droplets in water, mineral oil with viscosity of µ=
30 cps was purchased from Sigma-Aldrich (product number: M3516).
Polymer microparticle synthesis. For the generation of polymer microparticles,
DCM solvent of viscosity µ= 0.43 cps was purchased from ﬁsher scientiﬁc (catalog
number: AC406920040), PCL was purchased from Sigma-Aldrich (product num-
ber: 440752) and PVA was purchased from Sigma-Aldrich (product number:
363170). The dispersed phase consisted of 10 wt% (133.3 g/L) or 4 wt% (53.2 g/L)
PCL in DCM. DCM of 2 L was mixed with the corresponding amount of PCL and
mixed on a magnetic stirrer for 1 h. For the continuous phase, 2 wt% of PVA (87%
hydrolyzed) was mixed with water at 95 °C for 12 h. Continuous phase of 9 L was
used for each experiment. The generated emulsion templates were collected in 4 L
glass beakers. To post-process the emulsion templates, 10 mL of emulsion tem-
plates were dispersed in 30 mL of water with PVA and placed in Rotovap for 5 min.
The precipitated polymer particles were washed thrice in water using centrifuge
and then dried in lyophilization unit for 24 h. Scanning electron microscope images
were obtained using JEOL 7500F HRSEM and Quanta 600 FEG SEM. An accel-
erating voltage of 5 kV is used to collect the SEM images.
Data availability. The authors declare that the data supporting the ﬁndings of this
study are available within the paper and its supplementary information ﬁles.
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Material Safety Data Sheet (MSDS) for  
BMP-2     
I. Identification:
Product name: BMP-2     
Product Catalog: 4697 
Manufacturer Supplier:  Cell Signaling Technology 
3 Trask Lane 
Danvers, MA 01923 USA 
978-867-2300 TEL 
978-867-2400 FAX 
978-578-6737 EMERGENCY TEL
II.  Composition/Information:
III. Hazard Identification: 
CAUTION: This product contains material of human origin and is not for use in humans. To 
the best of our knowledge, the chemical, physical, and toxicological properties of this material 
have not been established.
IV. First Aid Measures:
Inhalation: If inhaled, remove to fresh air. If breathing is difficult, get medical attention.  
Ingestion: If swallowed, wash out mouth with water provided person is conscious. Get  
medical attention.  
Skin exposure: In case of contact, immediately wash skin with soap and water for at least 15 
minutes. Remove contaminated clothing. Wash clothing before reuse. 
Eye exposure: In case of contact with eyes, immediately flush eyes with water for at least 15 
minutes. Get medical attention. 
V. Fire Fighting Measures: 
Flash Point: Data not available. 
Autoignition Temperature: Data not available. 
Explosion: Data not available. 
Fire extinguishing media: Water spray, dry chemical, alcohol foam, or carbon dioxide. 
Firefighting: Wear protective clothing and self-contained breathing apparatus to prevent 
contact with skin and eyes. May emit toxic fumes under fire conditions.
VI. Accidental Release Measures: Wear appropriate personal 
protective equipment as indicated in Section VIII. Sweep up material and avoid raising dust. 
Transfer to a closed chemical waste container for disposal. Wash spill site after material has 
been picked up for disposal.
VII. Handling And Storage:  
Storage: Store in tightly closed container at -20°C. 
Avoid contact with eyes, skin, and clothing. Wash thoroughly after handling.  
VIII. Exposure Controls/Personal:  
Ventilation System: A system of local and/or general exhaust is recommended.  
Skin Protection: Wear compatible chemical resistant gloves and protective clothing.  
Eye protection: Wear protective safety glasses or chemical safety goggles. Maintain eye 
wash fountain and quick-drench facilities in work area.
IX. Physical And Chemical Properties
X. Stability and Reactivity:
Stability: Very stable under normal conditions. 
Materials to avoid: Strong acids, strong bases. 
Hazardous Decomposition: Data not available.
XI. Toxicological Information:  
Acute Effects: Not established. May cause irritation inhaled, ingested or absorbed.  
Chronic Effects: Not established. May be harmful if inhaled, ingested or absorbed.
Potential Health Effects: Not established. 
Inhalation: May be harmful, may be irritating to mucous membranes and upper respiratory 
tract. 
Skin: May be harmful if absorbed through skin. May cause skin irritation.   
Eyes: May cause eye irritation. 
Ingestion: May be harmful if swallowed.
To the best of our knowledge, the chemical, physical, and toxicological properties of this mate-
rial have not been thoroughly investigated.
XII. Ecological Information: Data not available for this product. 
XIII. Disposal Considerations: Dispose of in accordance with 
federal, state, local environmental regulations.
XIV. Transport Information:
DOT: Proper Shipping Name: None.
Hazard Class: This substance is considered non-hazardous for transport. 
   
IATA: Proper Shipping Name: None.
Non-Hazardous for air transport: This substance is considered non-hazardous for air 
transport.
XV. Regulatory Information:  
EU Regulations/Classifications/Labeling Information: None.
US Regulatory Information:
 SARA Listed: No.
 Canada (WHMIS): DSL No, NDSL No.
XVI. Other Information:
This compound is sold only for research use only. It is not for use in humans. To the best of 
our knowledge, this document is accurate. It is intended to serve as a guide for safe use of this 
product in a laboratory setting by experienced personnel. The burden of safe use of this mate-
rial rests entirely with the user. Cell Signaling Technology, Inc., shall not be held liable for any 
damage resulting from the handling of or from contact with the above product. 
Substance Name: Bone morphogenetic protein 2    
Synonyms: recombinant human BMP-2, Dibotermin alfa
CAS#: 246539-15-1
Appearance: powder
pH: data not available
Melting Point: data not available
Boiling Point: data not available
Freezing Point: data not available
Volatile Organic Compounds: data not available
Solubility: data not available
NFPA Rating: Health: 1 Flammability: 0 Reactivity: 0
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SIGMA-ALDRICH sigma-aldrich.com 
SAFETY DATA SHEET 
Version 5.0 
Revision Date 11/02/2014 
Print Date 04/14/2019 
 
1. PRODUCT AND COMPANY IDENTIFICATION 
1.1 Product identifiers 
Product name : FGF-2 human 
 
Product Number : SRP4037 
Brand : Sigma 
   
1.2 Relevant identified uses of the substance or mixture and uses advised against 
Identified uses : Laboratory chemicals, Manufacture of substances 
1.3 Details of the supplier of the safety data sheet 
Company : Sigma-Aldrich 
3050 Spruce Street 
SAINT LOUIS MO  63103 
USA 
 
Telephone : +1 800-325-5832 
Fax : +1 800-325-5052 
1.4 Emergency telephone number 
Emergency Phone # : +1-703-527-3887 (CHEMTREC) 
 
2. HAZARDS IDENTIFICATION 
2.1 Classification of the substance or mixture 
 
Not a hazardous substance or mixture. 
2.2 GHS Label elements, including precautionary statements 
Not a hazardous substance or mixture. 
2.3 Hazards not otherwise classified (HNOC) or not covered by GHS 
Human source material. 
 
3. COMPOSITION/INFORMATION ON INGREDIENTS 
3.2 Mixtures 
Synonyms : FGF-2 
Fibroblast Growth Factor-basic 
HBGF-2 
Prostatropin 
 
 
No components need to be disclosed according to the applicable regulations. 
 
4. FIRST AID MEASURES 
4.1 Description of first aid measures 
If inhaled 
If breathed in, move person into fresh air. If not breathing, give artificial respiration. 
In case of skin contact 
Wash off with soap and plenty of water. 
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In case of eye contact 
Flush eyes with water as a precaution. 
If swallowed 
Never give anything by mouth to an unconscious person. Rinse mouth with water. 
4.2 Most important symptoms and effects, both acute and delayed 
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11 
4.3 Indication of any immediate medical attention and special treatment needed 
No data available 
 
5. FIREFIGHTING MEASURES 
5.1 Extinguishing media 
Suitable extinguishing media 
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. 
5.2 Special hazards arising from the substance or mixture 
Carbon oxides, Nitrogen oxides (NOx), Hydrogen chloride gas, Sodium oxides 
5.3 Advice for firefighters 
Wear self-contained breathing apparatus for firefighting if necessary. 
5.4 Further information 
No data available 
 
6. ACCIDENTAL RELEASE MEASURES 
6.1 Personal precautions, protective equipment and emergency procedures 
Avoid dust formation. Avoid breathing vapours, mist or gas. 
For personal protection see section 8. 
6.2 Environmental precautions 
No special environmental precautions required. 
6.3 Methods and materials for containment and cleaning up 
Clean up and decontaminate all materials for disposal, as well as contaminated surfaces, with an effective 
decontamination method such as autoclaving, incineration, or chemical disinfection.Sweep up and shovel. Keep in 
suitable, closed containers for disposal. 
6.4 Reference to other sections 
For disposal see section 13. 
 
7. HANDLING AND STORAGE 
7.1 Precautions for safe handling 
Further processing of solid materials may result in the formation of combustible dusts. The potential for combustible 
dust formation should be taken into consideration before additional processing occurs. 
Provide appropriate exhaust ventilation at places where dust is formed. 
For precautions see section 2.2. 
7.2 Conditions for safe storage, including any incompatibilities 
Keep container tightly closed in a dry and well-ventilated place.  
Recommended storage temperature -20 °C 
Storage class (TRGS 510): Non Combustible Solids 
7.3 Specific end use(s) 
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated 
 
8. EXPOSURE CONTROLS/PERSONAL PROTECTION 
8.1 Control parameters 
Components with workplace control parameters 
Contains no substances with occupational exposure limit values. 
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8.2 Exposure controls 
Appropriate engineering controls 
General industrial hygiene practice. 
Personal protective equipment 
Eye/face protection 
Use equipment for eye protection tested and approved under appropriate government standards such as 
NIOSH (US) or EN 166(EU). 
Skin protection 
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without 
touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after 
use in accordance with applicable laws and good laboratory practices. Wash and dry hands. 
 
Body Protection 
Choose body protection in relation to its type, to the concentration and amount of dangerous substances, and 
to the specific work-place., The type of protective equipment must be selected according to the concentration 
and amount of the dangerous substance at the specific workplace. 
Respiratory protection 
Respiratory protection is not required. Where protection from nuisance  levels of dusts are desired, use type 
N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and approved under 
appropriate government standards such as NIOSH (US) or CEN (EU). 
Control of environmental exposure 
No special environmental precautions required. 
 
9. PHYSICAL AND CHEMICAL PROPERTIES 
9.1 Information on basic physical and chemical properties 
a) Appearance Form: solid 
b) Odour No data available 
c) Odour Threshold No data available 
d) pH No data available 
e) Melting point/freezing 
point 
No data available 
f) Initial boiling point and 
boiling range 
No data available 
g) Flash point No data available 
h) Evaporation rate No data available 
i) Flammability (solid, gas) No data available 
j) Upper/lower 
flammability or 
explosive limits 
No data available 
k) Vapour pressure No data available 
l) Vapour density No data available 
m) Relative density No data available 
n) Water solubility No data available 
o) Partition coefficient: n-
octanol/water 
No data available 
p) Auto-ignition 
temperature 
No data available 
q) Decomposition 
temperature 
No data available 
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r) Viscosity No data available 
s) Explosive properties No data available 
t) Oxidizing properties No data available 
9.2 Other safety information 
No data available 
 
10. STABILITY AND REACTIVITY 
10.1 Reactivity 
No data available 
10.2 Chemical stability 
Stable under recommended storage conditions. 
10.3 Possibility of hazardous reactions 
No data available 
10.4 Conditions to avoid 
No data available 
10.5 Incompatible materials 
Strong oxidizing agents 
10.6 Hazardous decomposition products 
Other decomposition products - No data available 
In the event of fire: see section 5 
 
11. TOXICOLOGICAL INFORMATION 
11.1 Information on toxicological effects 
Acute toxicity 
No data available 
Inhalation: No data available 
Dermal: No data available 
No data available 
Skin corrosion/irritation 
No data available 
Serious eye damage/eye irritation 
No data available 
Respiratory or skin sensitisation 
No data available 
Germ cell mutagenicity 
No data available 
 
 
Carcinogenicity 
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as 
probable, possible or confirmed human carcinogen by IARC. 
ACGIH: No component of this product present at levels greater than or equal to 0.1% is identified as a 
carcinogen or potential carcinogen by ACGIH. 
NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a 
known or anticipated carcinogen by NTP. 
OSHA: No component of this product present at levels greater than or equal to 0.1% is identified as a 
carcinogen or potential carcinogen by OSHA. 
Reproductive toxicity 
No data available 
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No data available 
Specific target organ toxicity - single exposure 
No data available 
Specific target organ toxicity - repeated exposure 
No data available 
Aspiration hazard 
No data available 
Additional Information 
RTECS: Not available 
 
To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly 
investigated. 
 
 
12. ECOLOGICAL INFORMATION 
12.1 Toxicity 
No data available 
12.2 Persistence and degradability 
No data available 
12.3 Bioaccumulative potential 
No data available 
12.4 Mobility in soil 
No data available 
12.5 Results of PBT and vPvB assessment 
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted 
12.6 Other adverse effects 
No data available 
 
13. DISPOSAL CONSIDERATIONS 
13.1 Waste treatment methods 
Product 
Offer surplus and non-recyclable solutions to a licensed disposal company.  
Contaminated packaging 
Dispose of as unused product.  
 
14. TRANSPORT INFORMATION 
DOT (US) 
Not dangerous goods 
 
IMDG 
Not dangerous goods 
 
IATA 
Not dangerous goods 
 
15. REGULATORY INFORMATION 
SARA 302 Components 
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302. 
SARA 313 Components 
This material does not contain any chemical components with known CAS numbers that exceed the threshold (De 
Minimis) reporting levels established by SARA Title III, Section 313. 
SARA 311/312 Hazards 
No SARA Hazards 
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Massachusetts Right To Know Components 
No components are subject to the Massachusetts Right to Know Act. 
Pennsylvania Right To Know Components 
 
Protein 
CAS-No. 
 -  
Revision Date 
 
New Jersey Right To Know Components 
 
Protein 
CAS-No. 
 -  
Revision Date 
 
Sodium chloride 7647-14-5  
Tris (hydroxymethyl) aminomethane 77-86-1  
California Prop. 65 Components 
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other 
reproductive harm. 
 
 
 
16. OTHER INFORMATION 
HMIS Rating 
Health hazard: 1 
Chronic Health Hazard:  
Flammability: 0 
Physical Hazard 0 
NFPA Rating 
Health hazard: 1 
Fire Hazard: 0 
Reactivity Hazard: 0 
Further information 
Copyright 2014 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only. 
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a 
guide. The information in this document is based on the present state of our knowledge and is applicable to the 
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the 
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling 
or from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing 
slip for additional terms and conditions of sale. 
 
Preparation Information 
Sigma-Aldrich Corporation 
Product Safety – Americas Region 
1-800-521-8956 
 
Version: 5.0 Revision Date: 11/02/2014 Print Date: 04/14/2019 
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SIGMA-ALDRICH sigma-aldrich.com 
SAFETY DATA SHEET 
Version 4.5 
Revision Date 09/21/2017 
Print Date 11/10/2018 
 
1. PRODUCT AND COMPANY IDENTIFICATION 
1.1 Product identifiers 
Product name : D-(+)-Glucose 
 
Product Number : G8270 
Brand : Sigma 
   
CAS-No. : 50-99-7 
1.2 Relevant identified uses of the substance or mixture and uses advised against 
Identified uses : Laboratory chemicals, Synthesis of substances 
 
1.3 Details of the supplier of the safety data sheet 
Company : Sigma-Aldrich 
3050 Spruce Street 
SAINT LOUIS MO  63103 
USA 
 
Telephone : +1 800-325-5832 
Fax : +1 800-325-5052 
1.4 Emergency telephone number 
Emergency Phone # : +1-703-527-3887 (CHEMTREC) 
 
2. HAZARDS IDENTIFICATION 
2.1 Classification of the substance or mixture 
 
Not a hazardous substance or mixture. 
2.2 GHS Label elements, including precautionary statements 
Not a hazardous substance or mixture. 
2.3 Hazards not otherwise classified (HNOC) or not covered by GHS - none 
 
3. COMPOSITION/INFORMATION ON INGREDIENTS 
3.1 Substances 
Synonyms : Dextrose 
 
Formula : C6H12O6 
Molecular weight : 180.16 g/mol 
CAS-No. : 50-99-7 
EC-No. : 200-075-1 
 
No components need to be disclosed according to the applicable regulations. 
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4. FIRST AID MEASURES 
4.1 Description of first aid measures 
If inhaled 
If breathed in, move person into fresh air. If not breathing, give artificial respiration. 
In case of skin contact 
Wash off with soap and plenty of water. 
In case of eye contact 
Flush eyes with water as a precaution. 
If swallowed 
Never give anything by mouth to an unconscious person. Rinse mouth with water. 
4.2 Most important symptoms and effects, both acute and delayed 
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11 
 
4.3 Indication of any immediate medical attention and special treatment needed 
No data available 
 
5. FIREFIGHTING MEASURES 
5.1 Extinguishing media 
Suitable extinguishing media 
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. 
5.2 Special hazards arising from the substance or mixture 
No data available 
5.3 Advice for firefighters 
Wear self-contained breathing apparatus for firefighting if necessary. 
5.4 Further information 
No data available 
 
6. ACCIDENTAL RELEASE MEASURES 
6.1 Personal precautions, protective equipment and emergency procedures 
Avoid dust formation. Avoid breathing vapours, mist or gas. 
For personal protection see section 8. 
6.2 Environmental precautions 
No special environmental precautions required. 
6.3 Methods and materials for containment and cleaning up 
Sweep up and shovel. Keep in suitable, closed containers for disposal. 
6.4 Reference to other sections 
For disposal see section 13. 
 
7. HANDLING AND STORAGE 
7.1 Precautions for safe handling 
Further processing of solid materials may result in the formation of combustible dusts. The potential for combustible dust 
formation should be taken into consideration before additional processing occurs. 
Provide appropriate exhaust ventilation at places where dust is formed. 
For precautions see section 2.2. 
7.2 Conditions for safe storage, including any incompatibilities 
Keep container tightly closed in a dry and well-ventilated place.  
hygroscopic Keep in a dry place.  
7.3 Specific end use(s) 
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated 
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8. EXPOSURE CONTROLS/PERSONAL PROTECTION 
8.1 Control parameters 
Components with workplace control parameters 
Contains no substances with occupational exposure limit values. 
8.2 Exposure controls 
Appropriate engineering controls 
General industrial hygiene practice. 
Personal protective equipment 
Eye/face protection 
Use equipment for eye protection tested and approved under appropriate government standards such as 
NIOSH (US) or EN 166(EU). 
Skin protection 
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without 
touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after 
use in accordance with applicable laws and good laboratory practices. Wash and dry hands. 
 
Full contact 
Material: Nitrile rubber 
Minimum layer thickness: 0.11 mm 
Break through time: 480 min 
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M) 
 
Splash contact 
Material: Nitrile rubber 
Minimum layer thickness: 0.11 mm 
Break through time: 480 min 
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M) 
 
data source: KCL GmbH, D-36124 Eichenzell, phone +49 (0)6659 87300, e-mail sales@kcl.de, test method: 
EN374 
If used in solution, or mixed with other substances, and under conditions which differ from EN 374, contact the 
supplier of the CE approved gloves. This recommendation is advisory only and must be evaluated by an 
industrial hygienist and safety officer familiar with the specific situation of anticipated use by our customers. It 
should not be construed as offering an approval for any specific use scenario. 
 
Body Protection 
Choose body protection in relation to its type, to the concentration and amount of dangerous substances, and 
to the specific work-place., The type of protective equipment must be selected according to the concentration 
and amount of the dangerous substance at the specific workplace. 
Respiratory protection 
Respiratory protection is not required. Where protection from nuisance  levels of dusts are desired, use type 
N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and approved under 
appropriate government standards such as NIOSH (US) or CEN (EU). 
Control of environmental exposure 
No special environmental precautions required. 
 
9. PHYSICAL AND CHEMICAL PROPERTIES 
9.1 Information on basic physical and chemical properties 
a) Appearance Form: crystalline, powder 
Colour: white 
b) Odour No data available 
c) Odour Threshold No data available 
d) pH No data available 
e) Melting point/freezing 
point 
Melting point/range: 150 - 152 °C (302 - 306 °F) 
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f) Initial boiling point and 
boiling range 
No data available 
g) Flash point No data available 
h) Evaporation rate No data available 
i) Flammability (solid, gas) No data available 
j) Upper/lower 
flammability or 
explosive limits 
No data available 
k) Vapour pressure No data available 
l) Vapour density No data available 
m) Relative density No data available 
n) Water solubility soluble 
o) Partition coefficient: n-
octanol/water 
No data available 
p) Auto-ignition 
temperature 
No data available 
q) Decomposition 
temperature 
No data available 
r) Viscosity No data available 
s) Explosive properties No data available 
t) Oxidizing properties No data available 
9.2 Other safety information 
No data available 
 
10. STABILITY AND REACTIVITY 
10.1 Reactivity 
No data available 
10.2 Chemical stability 
Stable under recommended storage conditions. 
10.3 Possibility of hazardous reactions 
No data available 
10.4 Conditions to avoid 
No data available 
10.5 Incompatible materials 
Strong oxidizing agents 
10.6 Hazardous decomposition products 
Hazardous decomposition products formed under fire conditions. - Carbon oxides 
Other decomposition products - No data available 
In the event of fire: see section 5 
 
11. TOXICOLOGICAL INFORMATION 
11.1 Information on toxicological effects 
Acute toxicity 
LD50 Oral - Rat - 25,800 mg/kg 
Remarks: Behavioral:Coma. Cyanosis Diarrhoea 
 
Inhalation: No data available 
Dermal: No data available 
No data available 
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Skin corrosion/irritation 
No data available 
Serious eye damage/eye irritation 
No data available 
Respiratory or skin sensitisation 
No data available 
Germ cell mutagenicity 
Mouse 
lymphocyte  
Mutation in mammalian somatic cells. 
 
Carcinogenicity 
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as 
probable, possible or confirmed human carcinogen by IARC. 
ACGIH: No component of this product present at levels greater than or equal to 0.1% is identified as a 
carcinogen or potential carcinogen by ACGIH. 
NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a 
known or anticipated carcinogen by NTP. 
OSHA: No component of this product present at levels greater than or equal to 0.1% is identified as a 
carcinogen or potential carcinogen by OSHA. 
Reproductive toxicity 
No data available 
No data available 
Specific target organ toxicity - single exposure 
No data available 
Specific target organ toxicity - repeated exposure 
No data available 
Aspiration hazard 
No data available 
Additional Information 
RTECS: LZ6600000 
 
To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated. 
 
 
12. ECOLOGICAL INFORMATION 
12.1 Toxicity 
No data available 
12.2 Persistence and degradability 
No data available 
12.3 Bioaccumulative potential 
No data available 
12.4 Mobility in soil 
No data available 
12.5 Results of PBT and vPvB assessment 
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted 
12.6 Other adverse effects 
 
No data available 
 Sigma - G8270 Page 6  of  7 
 
13. DISPOSAL CONSIDERATIONS 
13.1 Waste treatment methods 
Product 
Offer surplus and non-recyclable solutions to a licensed disposal company.  
Contaminated packaging 
Dispose of as unused product.  
 
14. TRANSPORT INFORMATION 
DOT (US) 
Not dangerous goods 
 
IMDG 
Not dangerous goods 
 
 
IATA 
Not dangerous goods 
 
15. REGULATORY INFORMATION 
SARA 302 Components 
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302. 
SARA 313 Components 
This material does not contain any chemical components with known CAS numbers that exceed the threshold (De 
Minimis) reporting levels established by SARA Title III, Section 313. 
Massachusetts Right To Know Components 
No components are subject to the Massachusetts Right to Know Act. 
Pennsylvania Right To Know Components 
 
Glucose 
CAS-No. 
50-99-7 
Revision Date 
 
New Jersey Right To Know Components 
 
Glucose 
CAS-No. 
50-99-7 
Revision Date 
 
California Prop. 65 Components 
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other 
reproductive harm. 
 
 
16. OTHER INFORMATION 
HMIS Rating 
Health hazard: 0 
Chronic Health Hazard:  
Flammability: 0 
Physical Hazard 0 
NFPA Rating 
Health hazard: 0 
Fire Hazard: 0 
Reactivity Hazard: 0 
Further information 
Copyright 2016 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only. 
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a 
guide. The information in this document is based on the present state of our knowledge and is applicable to the 
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the 
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling 
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or from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing 
slip for additional terms and conditions of sale. 
 
Preparation Information 
Sigma-Aldrich Corporation 
Product Safety – Americas Region 
1-800-521-8956 
 
Version: 4.5 Revision Date: 09/21/2017 Print Date: 11/10/2018 
 
 
 
________________________________________________________________________________________________________________
Safety Data Sheet
SECTION 2: Hazards ident i f ic at ion
Not Hazardous
GHS - Classification 
Principle Routes of Exposure 
Potential Health Effects  
eyes May cause eye irritation with susceptible persons.
Signal Word
Not Hazardous
Health hazards 
Physical hazards 
Research Use Only.  Not for use in diagnostic procedures.
Not Hazardous
Identification of the substance or mixture  
24 hour Emergency Response:
________________________________________________________________________________________________________________
866-536-0631
301-431-8585
Outside of the U.S. +1-301-431-8585
Product code 21056023
Company/undertaking identification  
Country specific Emergency Number (if available):
SECTION 1: Ident i f ic at ion of  t he subst anc e/m ix t ure and of  t he c om pany/under t ak ing
21056023
Revision date
Product name  Iscove''s Modified Dulbecco''s Medium (IMDM), (1X),
liquid
Product name
Page  1 / 6
Iscove''s Modified Dulbecco''s Medium (IMDM), (1X), liquid
17-Jun-2015
+(55)-2139581449 (português)
www.lifetechnologies.com
Life Technologies
5250 Mainway Drive
Burlington, ONT
CANADA L7L 6A4
800/263-6236
Product code
Life Technologies
5791 Van Allen Way
PO Box 6482
Carlsbad, CA 92008
+1 760 603 7200
CHEMTREC Brazil (Rio De Janeiro)
Treat symptomatically.
Specific effects 
SECTION 5: Fi re f ight ing m easures
Suitable extinguishing media Water spray. Carbon dioxide (CO2). Foam. Dry chemical.
Target Organ Effects No known effects under normal use conditions
Special protective equipment for firefighters Wear self-contained breathing apparatus and protective
suit.
May cause skin irritation in susceptible persons.
SECTION 6: Ac c ident a l  re lease m easures
Carcinogenic effects None
Personal precautions Use personal protection equipment.
HMIS 
Methods for cleaning up Soak up with inert absorbent material.
Ingestion
Mutagenic effects
Environmental precautions  
None
May be harmful if swallowed.
Prevent further leakage or spillage if safe to do so.
Skin
SECTION 4: Fi rs t  a id  m easures
Reproductive toxicity None
Skin contact Rinse cautiously with water for several minutes. If symptoms occur, obtain medical
advice.
Eye contact Rinse immediately with plenty of water, also under the eyelids, for at least 15
minutes. If symptoms persist, call a physician.
Ingestion Never give anything by mouth to an unconscious person. If symptoms persist, call
a physician. Do not induce vomiting without medical advice.
Sensitization None
inhalation Remove to fresh air. If symptoms persist, call a physician. If not breathing, give
artificial respiration.
inhalation May be harmful by inhalation.
Notes to Physician
Sodium selenite
________________________________________________________________________________________________________________
10102-18-8 - <0.00011
We recommend handling all chemicals with caution.
21056023
SECTION 3: Com posi t ion/in form at ion on ingredient s
Revision date
Product name  Iscove''s Modified Dulbecco''s Medium (IMDM), (1X),
liquid
Flammability
Page  2 / 6
0
Health 0
17-Jun-2015
Chemical Name CAS-No
www.lifetechnologies.com
EINECS-No Weight %
Product code
Reactivity 0
ACGIH OEL (STEL)
SECTION 7: Handl ing and s t orage
Handling
Sodium selenite
Hand protection Impervious gloves.
0.2 mg/m3 None
Eye protection Wear safety glasses with side shields (or goggles).
0.2 mg/m3 None
Skin and Body Protection Lightweight protective clothing.
SECTION 8: Ex posure c ont ro ls /personal  prot ec t ion
Always wear reccommended Personal Protective Equipment. No special handling
advices are necessary.
Hygiene measures Handle in accordance with good industrial hygiene and safety practice.
Oxidizing properties No information available
Environmental exposure 
controls 
Prevent product from entering drains.
Water solubility No data available
Engineering measures Ensure adequate ventilation, especially in confined areas.
Viscosity No data available
Storage
SECTION 10: St ab i l i t y  and reac t iv i t y
Exposure Limits  
SECTION 9: Phys ic a l  and c hem ic a l  proper t ies
Keep in a dry, cool and well-ventilated place.
Personal Protective Equipment 
Stability Stable under normal conditions.
Materials to avoid No dangerous reaction known under conditions of normal use.
General information 
Personal Protective Equipment requirements are dependent on the user institution's risk assessment and are specific
to the risk assessment for each laboratory where this material may be used.
See Section 12 for more information.
Form Liquid
Appearance No information available
Chemical Name
________________________________________________________________________________________________________________
OSHA PEL
Odor No data available
Respiratory protection
Odor Threshold No data available
In case of insufficient ventilation, wear suitable respiratory equipment.
OSHA PEL (Ceiling) ACGIH OEL (TWA)
21056023
Revision date
°C  No data available
Product name  Iscove''s Modified Dulbecco''s Medium (IMDM), (1X),
liquid
Boiling point / boiling range
Page  3 / 6
°F  No data available
flash point
°C  No data available
°F  No data available
17-Jun-2015
°C  No data available
°F  No data available
www.lifetechnologies.com
°F  No data available
Melting point / melting range
Product code
°C  No data available
Autoignition Temperature
Biodegradation No information available
inhalation
Bioaccumulation No information available
May be harmful by inhalation
Chemical Name LD50 (oral,rat/mouse)
Ingestion May be harmful if swallowed
LD50 (dermal,rat/rabbit) LC50 (inhalation,rat/mouse)
SECTION 13: Disposal  c ons iderat ions
polymerization
Dispose of contents/containers in accordance with local regulations.
Carcinogenic effects None
Sodium selenite = 7 mg/kg (Rat)
SECTION 14: Transpor t  in form at ion
Mutagenic effects None
No data available No data available
IATA 
Reproductive toxicity None.
Proper Shipping Name No dangerous good in sense of these transport regulations
Acute Toxicity  
Hazardous polymerization does not occur.
Hazard Class None
Sensitization
Subsidiary class None
None
Packing group None
UN-No None
SECTION 11: Tox ic o log ic a l  in form at ion
Target Organ Effects No known effects under normal use conditions
________________________________________________________________________________________________________________
Principle Routes of Exposure 
Potential Health Effects 
Hazardous decomposition
products
None under normal use conditions.
eyes
SECTION 12: Ec olog ic a l  in form at ion
21056023
May cause eye irritation with susceptible persons
Revision date
Product name  Iscove''s Modified Dulbecco''s Medium (IMDM), (1X),
liquid
Page  4 / 6
Ecotoxicity No information available
17-Jun-2015
Skin May cause skin irritation in susceptible persons
www.lifetechnologies.com
Mobility No information available
Product code
SDS sections updated.
"The above information was acquired by diligent search and/or investigation and the recommendations are based on
prudent application of professional judgment. The information shall not be taken as being all inclusive and is to be
used only as a guide. All materials and mixtures may present unknown hazards and should be used with caution.
Since the Company cannot control the actual methods, volumes, or conditions of use, the Company shall not be held
liable for any damages or losses resulting from the handling or from contact with the product as described herein.
THE INFORMATION IN THIS SDS DOES NOT CONSTITUTE A WARRENTY, EXPRESSED OR IMPLIED,
INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PUPOSE"
SECTION 16: Ot her  in form at ion
End of Safety Data Sheet
Research Use Only.  Not for use in diagnostic procedures.
Reason for revision
CAS-No Weight % 
US State Regulations 
SARA 313 - Threshold Values 
TSCA
Sodium selenite
Chemical Name Massachusetts - RTK New Jersey - RTK Pennsylvania - RTK Illinois - RTK Rhode Island - RTK
10102-18-8 <0.00011
Sodium selenite Listed - Listed Listed Listed
1.0
US Federal Regulations 
California Proposition 65
This product does not contain any Proposition 65 chemicals.
________________________________________________________________________________________________________________
SECTION 15: Regulat ory  in form at ion
Clean Air Act, Section 112 Hazardous Air Pollutants (HAPs) (see 40 CFR 61)
This product contains the following HAPs:.
WHMIS Hazard Class
Non-controlled
Sodium selenite
 10102-18-8 (  <0.00011 )
This product has been classified in accordance with the hazard criteria of the Controlled Products Regulations (CPR) and the
MSDS contains all the information required by the CPR.
Listed
21056023
Revision date
Component 
Product name  Iscove''s Modified Dulbecco''s Medium (IMDM), (1X),
liquid
CAS-No 
Page  5 / 6
Weight % HAPS data 
SARA 313
This product contains the following toxic chemical(s) subject to the notification requirements of section 313 of Title III of the
Superfund Amendments and Reauthorization Act of 1986. This law requires certain manufacturers to report on annual emissions of
specified chemicals and chemical categories. Please note that if you repackage, or otherwise redistribute, this product to industrial
customers, a notice similar to this one should be sent to those customers:.
Component
17-Jun-2015
Sodium selenite
 10102-18-8 (  <0.00011 )
10102-18-8
www.lifetechnologies.com
<0.00011 Present (including any unique
chemical substance that contains
Selenium as part of its
infrastructure)
Product code
Chemical Name 
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SIGMA-ALDRICH sigma-aldrich.com 
SAFETY DATA SHEET 
Version 4.11 
Revision Date 06/26/2018 
Print Date 11/10/2018 
 
1. PRODUCT AND COMPANY IDENTIFICATION 
1.1 Product identifiers 
Product name : Potassium chloride 
 
Product Number : P9541 
Brand : Sigma 
   
CAS-No. : 7447-40-7 
1.2 Relevant identified uses of the substance or mixture and uses advised against 
Identified uses : Laboratory chemicals, Synthesis of substances 
 
1.3 Details of the supplier of the safety data sheet 
Company : Sigma-Aldrich 
3050 Spruce Street 
SAINT LOUIS MO  63103 
USA 
 
Telephone : +1 800-325-5832 
Fax : +1 800-325-5052 
1.4 Emergency telephone number 
Emergency Phone # : +1-703-527-3887 (CHEMTREC) 
 
2. HAZARDS IDENTIFICATION 
2.1 Classification of the substance or mixture 
 
Not a hazardous substance or mixture. 
2.2 GHS Label elements, including precautionary statements 
Not a hazardous substance or mixture. 
2.3 Hazards not otherwise classified (HNOC) or not covered by GHS - none 
 
3. COMPOSITION/INFORMATION ON INGREDIENTS 
3.1 Substances 
Formula : KCl 
Molecular weight : 74.55 g/mol 
CAS-No. : 7447-40-7 
EC-No. : 231-211-8 
Registration number : 01-2119539416-36-XXXX 
 
No components need to be disclosed according to the applicable regulations. 
 
 
 
 
4. FIRST AID MEASURES 
4.1 Description of first aid measures 
General advice 
Consult a physician. Show this safety data sheet to the doctor in attendance. 
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If inhaled 
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician. 
In case of skin contact 
Wash off with soap and plenty of water. Consult a physician. 
In case of eye contact 
Flush eyes with water as a precaution. 
If swallowed 
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician. 
4.2 Most important symptoms and effects, both acute and delayed 
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11 
 
4.3 Indication of any immediate medical attention and special treatment needed 
No data available 
 
5. FIREFIGHTING MEASURES 
5.1 Extinguishing media 
Suitable extinguishing media 
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. 
5.2 Special hazards arising from the substance or mixture 
No data available 
5.3 Advice for firefighters 
Wear self-contained breathing apparatus for firefighting if necessary. 
5.4 Further information 
No data available 
 
6. ACCIDENTAL RELEASE MEASURES 
6.1 Personal precautions, protective equipment and emergency procedures 
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Avoid breathing dust. 
For personal protection see section 8. 
6.2 Environmental precautions 
Do not let product enter drains. 
6.3 Methods and materials for containment and cleaning up 
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed containers for 
disposal. 
6.4 Reference to other sections 
For disposal see section 13. 
 
7. HANDLING AND STORAGE 
7.1 Precautions for safe handling 
Avoid formation of dust and aerosols.Further processing of solid materials may result in the formation of combustible 
dusts. The potential for combustible dust formation should be taken into consideration before additional processing 
occurs. 
Provide appropriate exhaust ventilation at places where dust is formed. 
For precautions see section 2.2. 
7.2 Conditions for safe storage, including any incompatibilities 
Keep container tightly closed in a dry and well-ventilated place.  
hygroscopic Keep in a dry place.  
Storage class (TRGS 510): 13: Non Combustible Solids 
7.3 Specific end use(s) 
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated 
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8. EXPOSURE CONTROLS/PERSONAL PROTECTION 
8.1 Control parameters 
Components with workplace control parameters 
Contains no substances with occupational exposure limit values. 
8.2 Exposure controls 
Appropriate engineering controls 
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at the end of 
workday. 
Personal protective equipment 
Eye/face protection 
Use equipment for eye protection tested and approved under appropriate government standards such as 
NIOSH (US) or EN 166(EU). 
Skin protection 
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without 
touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after 
use in accordance with applicable laws and good laboratory practices. Wash and dry hands. 
 
Full contact 
Material: Nitrile rubber 
Minimum layer thickness: 0.11 mm 
Break through time: 480 min 
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M) 
 
Splash contact 
Material: Nitrile rubber 
Minimum layer thickness: 0.11 mm 
Break through time: 480 min 
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M) 
 
data source: KCL GmbH, D-36124 Eichenzell, phone +49 (0)6659 87300, e-mail sales@kcl.de, test method: 
EN374 
If used in solution, or mixed with other substances, and under conditions which differ from EN 374, contact the 
supplier of the CE approved gloves. This recommendation is advisory only and must be evaluated by an 
industrial hygienist and safety officer familiar with the specific situation of anticipated use by our customers. It 
should not be construed as offering an approval for any specific use scenario. 
 
Body Protection 
Choose body protection in relation to its type, to the concentration and amount of dangerous substances, and 
to the specific work-place., The type of protective equipment must be selected according to the concentration 
and amount of the dangerous substance at the specific workplace. 
Respiratory protection 
Respiratory protection is not required. Where protection from nuisance  levels of dusts are desired, use type 
N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and approved under 
appropriate government standards such as NIOSH (US) or CEN (EU). 
Control of environmental exposure 
Do not let product enter drains. 
 
9. PHYSICAL AND CHEMICAL PROPERTIES 
9.1 Information on basic physical and chemical properties 
a) Appearance Form: powder 
Colour: white 
b) Odour No data available 
c) Odour Threshold No data available 
d) pH 7 
e) Melting point/freezing Melting point/range: 770 °C (1,418 °F) 
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point 
f) Initial boiling point and 
boiling range 
1,500 °C (2,732 °F) 
g) Flash point No data available 
h) Evaporation rate No data available 
i) Flammability (solid, gas) No data available 
j) Upper/lower 
flammability or 
explosive limits 
No data available 
k) Vapour pressure No data available 
l) Vapour density No data available 
m) Relative density 1.98 g/mL at 25 °C (77 °F) 
n) Water solubility soluble 
o) Partition coefficient: n-
octanol/water 
No data available 
p) Auto-ignition 
temperature 
No data available 
q) Decomposition 
temperature 
No data available 
r) Viscosity No data available 
s) Explosive properties No data available 
t) Oxidizing properties No data available 
9.2 Other safety information 
No data available 
 
10. STABILITY AND REACTIVITY 
10.1 Reactivity 
No data available 
10.2 Chemical stability 
Stable under recommended storage conditions. 
10.3 Possibility of hazardous reactions 
No data available 
10.4 Conditions to avoid 
Exposure to moisture 
10.5 Incompatible materials 
Strong acids, Strong oxidizing agents 
10.6 Hazardous decomposition products 
Hazardous decomposition products formed under fire conditions. - Hydrogen chloride gas, Potassium oxides 
Other decomposition products - No data available 
In the event of fire: see section 5 
 
11. TOXICOLOGICAL INFORMATION 
11.1 Information on toxicological effects 
Acute toxicity 
LD50 Oral - Rat - 2,600 mg/kg 
Remarks: (RTECS) 
 
Inhalation: No data available 
Dermal: No data available 
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No data available 
Skin corrosion/irritation 
No data available 
Serious eye damage/eye irritation 
Eyes - Rabbit 
Result: slight irritation 
 
Respiratory or skin sensitisation 
No data available 
Germ cell mutagenicity 
No data available 
 
Ames test 
Salmonella typhimurium  
Result: negative 
(National Toxicology Program) 
 
Carcinogenicity 
No data available 
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as 
probable, possible or confirmed human carcinogen by IARC. 
ACGIH: No component of this product present at levels greater than or equal to 0.1% is identified as a 
carcinogen or potential carcinogen by ACGIH. 
NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a 
known or anticipated carcinogen by NTP. 
OSHA: No component of this product present at levels greater than or equal to 0.1% is on OSHA’s 
list of regulated carcinogens. 
Reproductive toxicity 
No data available 
Specific target organ toxicity - single exposure 
No data available 
Specific target organ toxicity - repeated exposure 
No data available 
Aspiration hazard 
No data available 
Additional Information 
RTECS: TS8050000 
 
hyperkalemia, Nausea, Vomiting, Abdominal pain, Diarrhoea, Constipation., Paresthesia., Thirst, Dizziness, Rash, 
pruritus, Weakness, muscle cramps, minor psychiatric changes, minor visual changes 
To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated. 
 
 
12. ECOLOGICAL INFORMATION 
12.1 Toxicity 
 
Toxicity to fish static test LC50 - Pimephales promelas (fathead minnow) - 880 mg/l  - 96 h 
(OECD Test Guideline 203) 
 
Toxicity to daphnia and 
other aquatic 
invertebrates 
static test EC50 - Daphnia magna (Water flea) - > 440 mg/l  - 48 h 
(OECD Test Guideline 202) 
 
Toxicity to algae EC50 - Desmodesmus subspicatus (green algae) - > 100 mg/l  - 72 h 
(OECD Test Guideline 201) 
 
Toxicity to bacteria static test EC50 - activated sludge - > 1,000 mg/l  - 3 h 
(OECD Test Guideline 209) 
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12.2 Persistence and degradability 
The methods for determining biodegradability are not applicable to inorganic substances. 
12.3 Bioaccumulative potential 
No data available 
12.4 Mobility in soil 
No data available 
12.5 Results of PBT and vPvB assessment 
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted 
12.6 Other adverse effects 
 
13. DISPOSAL CONSIDERATIONS 
13.1 Waste treatment methods 
Product 
Offer surplus and non-recyclable solutions to a licensed disposal company.  
Contaminated packaging 
Dispose of as unused product.  
 
14. TRANSPORT INFORMATION 
DOT (US) 
Not dangerous goods 
 
IMDG 
Not dangerous goods 
 
 
IATA 
Not dangerous goods 
 
15. REGULATORY INFORMATION 
SARA 302 Components 
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302. 
SARA 313 Components 
This material does not contain any chemical components with known CAS numbers that exceed the threshold (De 
Minimis) reporting levels established by SARA Title III, Section 313. 
SARA 311/312 Hazards 
No SARA Hazards 
Massachusetts Right To Know Components 
No components are subject to the Massachusetts Right to Know Act. 
Pennsylvania Right To Know Components 
 
Potassium chloride 
CAS-No. 
7447-40-7 
Revision Date 
 
New Jersey Right To Know Components 
 
Potassium chloride 
CAS-No. 
7447-40-7 
Revision Date 
 
California Prop. 65 Components 
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other 
reproductive harm. 
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16. OTHER INFORMATION 
Further information 
Copyright 2016 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only. 
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a 
guide. The information in this document is based on the present state of our knowledge and is applicable to the 
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the 
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling 
or from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing 
slip for additional terms and conditions of sale. 
 
Preparation Information 
Sigma-Aldrich Corporation 
Product Safety – Americas Region 
1-800-521-8956 
 
Version: 4.11 Revision Date: 06/26/2018 Print Date: 11/10/2018 
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SIGMA-ALDRICH sigma-aldrich.com 
SAFETY DATA SHEET 
Version 5.3 
Revision Date 06/20/2018 
Print Date 11/10/2018 
 
1. PRODUCT AND COMPANY IDENTIFICATION 
1.1 Product identifiers 
Product name : Magnesium chloride hexahydrate 
 
Product Number : M2670 
Brand : Sigma-Aldrich 
   
CAS-No. : 7791-18-6 
1.2 Relevant identified uses of the substance or mixture and uses advised against 
Identified uses : Laboratory chemicals, Synthesis of substances 
 
1.3 Details of the supplier of the safety data sheet 
Company : Sigma-Aldrich 
3050 Spruce Street 
SAINT LOUIS MO  63103 
USA 
 
Telephone : +1 800-325-5832 
Fax : +1 800-325-5052 
1.4 Emergency telephone number 
Emergency Phone # : +1-703-527-3887 (CHEMTREC) 
 
2. HAZARDS IDENTIFICATION 
2.1 Classification of the substance or mixture 
 
Not a hazardous substance or mixture. 
2.2 GHS Label elements, including precautionary statements 
Not a hazardous substance or mixture. 
2.3 Hazards not otherwise classified (HNOC) or not covered by GHS - none 
 
3. COMPOSITION/INFORMATION ON INGREDIENTS 
3.1 Substances 
Formula : Cl2Mg · 6H2O 
Molecular weight : 203.30 g/mol 
CAS-No. : 7791-18-6 
EC-No. : 232-094-6 
Registration number : 01-2119485597-19-XXXX 
 
Hazardous components 
Component Classification Concentration 
Magnesium chloride hexahydrate 
      -  
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4. FIRST AID MEASURES 
4.1 Description of first aid measures 
General advice 
Move out of dangerous area. 
If inhaled 
If breathed in, move person into fresh air. If not breathing, give artificial respiration. 
In case of skin contact 
Wash off with soap and plenty of water. 
In case of eye contact 
Flush eyes with water as a precaution. 
If swallowed 
Never give anything by mouth to an unconscious person. Rinse mouth with water. 
4.2 Most important symptoms and effects, both acute and delayed 
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11 
 
4.3 Indication of any immediate medical attention and special treatment needed 
No data available 
 
5. FIREFIGHTING MEASURES 
5.1 Extinguishing media 
Suitable extinguishing media 
Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. 
5.2 Special hazards arising from the substance or mixture 
No data available 
5.3 Advice for firefighters 
Wear self-contained breathing apparatus for firefighting if necessary. 
5.4 Further information 
The product itself does not burn. 
 
6. ACCIDENTAL RELEASE MEASURES 
6.1 Personal precautions, protective equipment and emergency procedures 
Avoid dust formation. Avoid breathing vapours, mist or gas. 
For personal protection see section 8. 
6.2 Environmental precautions 
Do not let product enter drains. 
6.3 Methods and materials for containment and cleaning up 
Sweep up and shovel. Keep in suitable, closed containers for disposal. 
6.4 Reference to other sections 
For disposal see section 13. 
 
7. HANDLING AND STORAGE 
7.1 Precautions for safe handling 
Provide appropriate exhaust ventilation at places where dust is formed. 
For precautions see section 2.2. 
7.2 Conditions for safe storage, including any incompatibilities 
Keep container tightly closed in a dry and well-ventilated place.  
Moisture sensitive. Hygroscopic.  
Storage class (TRGS 510): 13: Non Combustible Solids 
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7.3 Specific end use(s) 
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated 
 
8. EXPOSURE CONTROLS/PERSONAL PROTECTION 
8.1 Control parameters 
Components with workplace control parameters 
Contains no substances with occupational exposure limit values. 
8.2 Exposure controls 
Appropriate engineering controls 
General industrial hygiene practice. 
Personal protective equipment 
Eye/face protection 
Use equipment for eye protection tested and approved under appropriate government standards such as 
NIOSH (US) or EN 166(EU). 
Skin protection 
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without 
touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after 
use in accordance with applicable laws and good laboratory practices. Wash and dry hands. 
 
Full contact 
Material: Nitrile rubber 
Minimum layer thickness: 0.11 mm 
Break through time: 480 min 
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M) 
 
Splash contact 
Material: Nitrile rubber 
Minimum layer thickness: 0.11 mm 
Break through time: 480 min 
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M) 
 
data source: KCL GmbH, D-36124 Eichenzell, phone +49 (0)6659 87300, e-mail sales@kcl.de, test method: 
EN374 
If used in solution, or mixed with other substances, and under conditions which differ from EN 374, contact the 
supplier of the CE approved gloves. This recommendation is advisory only and must be evaluated by an 
industrial hygienist and safety officer familiar with the specific situation of anticipated use by our customers. It 
should not be construed as offering an approval for any specific use scenario. 
 
Body Protection 
Choose body protection in relation to its type, to the concentration and amount of dangerous substances, and 
to the specific work-place., The type of protective equipment must be selected according to the concentration 
and amount of the dangerous substance at the specific workplace. 
Respiratory protection 
Respiratory protection is not required. Where protection from nuisance  levels of dusts are desired, use type 
N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and approved under 
appropriate government standards such as NIOSH (US) or CEN (EU). 
Control of environmental exposure 
Do not let product enter drains. 
 
9. PHYSICAL AND CHEMICAL PROPERTIES 
9.1 Information on basic physical and chemical properties 
a) Appearance Form: solid 
b) Odour No data available 
c) Odour Threshold No data available 
d) pH No data available 
e) Melting point/freezing No data available 
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point 
f) Initial boiling point and 
boiling range 
No data available 
g) Flash point No data available 
h) Evaporation rate No data available 
i) Flammability (solid, gas) No data available 
j) Upper/lower 
flammability or 
explosive limits 
No data available 
k) Vapour pressure No data available 
l) Vapour density No data available 
m) Relative density 1.570 g/cm3 
n) Water solubility No data available 
o) Partition coefficient: n-
octanol/water 
No data available 
p) Auto-ignition 
temperature 
No data available 
q) Decomposition 
temperature 
No data available 
r) Viscosity No data available 
s) Explosive properties No data available 
t) Oxidizing properties No data available 
9.2 Other safety information 
No data available 
 
10. STABILITY AND REACTIVITY 
10.1 Reactivity 
No data available 
10.2 Chemical stability 
Stable under recommended storage conditions. 
10.3 Possibility of hazardous reactions 
No data available 
10.4 Conditions to avoid 
Exposure to moisture may affect product quality. 
10.5 Incompatible materials 
Strong oxidizing agents 
10.6 Hazardous decomposition products 
Hazardous decomposition products formed under fire conditions. - Hydrogen chloride gas, Magnesium oxide 
Other decomposition products - No data available 
In the event of fire: see section 5 
 
11. TOXICOLOGICAL INFORMATION 
11.1 Information on toxicological effects 
Acute toxicity 
No data available 
Inhalation: No data available 
Dermal: No data available 
No data available 
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Skin corrosion/irritation 
No data available 
Serious eye damage/eye irritation 
No data available 
Respiratory or skin sensitisation 
No data available 
Germ cell mutagenicity 
No data available 
 
Carcinogenicity 
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as 
probable, possible or confirmed human carcinogen by IARC. 
ACGIH: No component of this product present at levels greater than or equal to 0.1% is identified as a 
carcinogen or potential carcinogen by ACGIH. 
NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a 
known or anticipated carcinogen by NTP. 
OSHA: No component of this product present at levels greater than or equal to 0.1% is on OSHA’s 
list of regulated carcinogens. 
Reproductive toxicity 
No data available 
No data available 
Specific target organ toxicity - single exposure 
No data available 
Specific target organ toxicity - repeated exposure 
No data available 
Aspiration hazard 
No data available 
Additional Information 
RTECS: OM2975000 
 
Vomiting, Diarrhoea, Abdominal pain, To the best of our knowledge, the chemical, physical, and toxicological properties 
have not been thoroughly investigated. 
 
Liver - Irregularities - Based on Human Evidence 
Liver - Irregularities - Based on Human Evidence 
 
12. ECOLOGICAL INFORMATION 
12.1 Toxicity 
No data available 
12.2 Persistence and degradability 
No data available 
12.3 Bioaccumulative potential 
No data available 
12.4 Mobility in soil 
No data available 
12.5 Results of PBT and vPvB assessment 
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted 
12.6 Other adverse effects 
 
No data available 
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13. DISPOSAL CONSIDERATIONS 
13.1 Waste treatment methods 
Product 
Offer surplus and non-recyclable solutions to a licensed disposal company.  
Contaminated packaging 
Dispose of as unused product.  
 
14. TRANSPORT INFORMATION 
DOT (US) 
Not dangerous goods 
 
IMDG 
Not dangerous goods 
 
 
IATA 
Not dangerous goods 
 
15. REGULATORY INFORMATION 
SARA 302 Components 
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302. 
SARA 313 Components 
This material does not contain any chemical components with known CAS numbers that exceed the threshold (De 
Minimis) reporting levels established by SARA Title III, Section 313. 
SARA 311/312 Hazards 
Chronic Health Hazard 
Massachusetts Right To Know Components 
No components are subject to the Massachusetts Right to Know Act. 
Pennsylvania Right To Know Components 
 
Magnesium chloride hexahydrate 
CAS-No. 
7791-18-6 
Revision Date 
 
New Jersey Right To Know Components 
 
Magnesium chloride hexahydrate 
CAS-No. 
7791-18-6 
Revision Date 
 
California Prop. 65 Components 
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other 
reproductive harm. 
 
 
16. OTHER INFORMATION 
Further information 
Copyright 2016 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only. 
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a 
guide. The information in this document is based on the present state of our knowledge and is applicable to the 
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the 
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling 
or from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing 
slip for additional terms and conditions of sale. 
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SIGMA-ALDRICH sigma-aldrich.com 
SAFETY DATA SHEET 
Version 5.8 
Revision Date 08/01/2018 
Print Date 11/10/2018 
 
1. PRODUCT AND COMPANY IDENTIFICATION 
1.1 Product identifiers 
Product name : Sodium chloride 
 
Product Number : S9888 
Brand : Sigma-Aldrich 
   
CAS-No. : 7647-14-5 
1.2 Relevant identified uses of the substance or mixture and uses advised against 
Identified uses : Laboratory chemicals, Synthesis of substances 
 
1.3 Details of the supplier of the safety data sheet 
Company : Sigma-Aldrich 
3050 Spruce Street 
SAINT LOUIS MO  63103 
USA 
 
Telephone : +1 800-325-5832 
Fax : +1 800-325-5052 
1.4 Emergency telephone number 
Emergency Phone # : +1-703-527-3887 (CHEMTREC) 
 
2. HAZARDS IDENTIFICATION 
2.1 Classification of the substance or mixture 
 
Not a hazardous substance or mixture. 
2.2 GHS Label elements, including precautionary statements 
Not a hazardous substance or mixture. 
2.3 Hazards not otherwise classified (HNOC) or not covered by GHS - none 
 
3. COMPOSITION/INFORMATION ON INGREDIENTS 
3.1 Substances 
Formula : ClNa 
Molecular weight : 58.44 g/mol 
CAS-No. : 7647-14-5 
EC-No. : 231-598-3 
Registration number : 01-2119485491-33-XXXX 
 
No components need to be disclosed according to the applicable regulations. 
 
 
 
 
4. FIRST AID MEASURES 
4.1 Description of first aid measures 
If inhaled 
If breathed in, move person into fresh air. If not breathing, give artificial respiration. 
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In case of skin contact 
Wash off with soap and plenty of water. 
In case of eye contact 
Flush eyes with water as a precaution. 
If swallowed 
Never give anything by mouth to an unconscious person. Rinse mouth with water. 
4.2 Most important symptoms and effects, both acute and delayed 
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11 
 
4.3 Indication of any immediate medical attention and special treatment needed 
No data available 
 
5. FIREFIGHTING MEASURES 
5.1 Extinguishing media 
Suitable extinguishing media 
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. 
5.2 Special hazards arising from the substance or mixture 
No data available 
5.3 Advice for firefighters 
Wear self-contained breathing apparatus for firefighting if necessary. 
5.4 Further information 
No data available 
 
6. ACCIDENTAL RELEASE MEASURES 
6.1 Personal precautions, protective equipment and emergency procedures 
Avoid dust formation. Avoid breathing vapours, mist or gas. 
For personal protection see section 8. 
6.2 Environmental precautions 
Do not let product enter drains. 
6.3 Methods and materials for containment and cleaning up 
Sweep up and shovel. Keep in suitable, closed containers for disposal. 
6.4 Reference to other sections 
For disposal see section 13. 
 
7. HANDLING AND STORAGE 
7.1 Precautions for safe handling 
Further processing of solid materials may result in the formation of combustible dusts. The potential for combustible dust 
formation should be taken into consideration before additional processing occurs. 
Provide appropriate exhaust ventilation at places where dust is formed. 
For precautions see section 2.2. 
7.2 Conditions for safe storage, including any incompatibilities 
Keep container tightly closed in a dry and well-ventilated place.  
Storage class (TRGS 510): 13: Non Combustible Solids 
7.3 Specific end use(s) 
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated 
 
8. EXPOSURE CONTROLS/PERSONAL PROTECTION 
8.1 Control parameters 
Components with workplace control parameters 
Contains no substances with occupational exposure limit values. 
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8.2 Exposure controls 
Appropriate engineering controls 
General industrial hygiene practice. 
Personal protective equipment 
Eye/face protection 
Use equipment for eye protection tested and approved under appropriate government standards such as 
NIOSH (US) or EN 166(EU). 
Skin protection 
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without 
touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after 
use in accordance with applicable laws and good laboratory practices. Wash and dry hands. 
 
Full contact 
Material: Nitrile rubber 
Minimum layer thickness: 0.11 mm 
Break through time: 480 min 
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M) 
 
Splash contact 
Material: Nitrile rubber 
Minimum layer thickness: 0.11 mm 
Break through time: 480 min 
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M) 
 
data source: KCL GmbH, D-36124 Eichenzell, phone +49 (0)6659 87300, e-mail sales@kcl.de, test method: 
EN374 
If used in solution, or mixed with other substances, and under conditions which differ from EN 374, contact the 
supplier of the CE approved gloves. This recommendation is advisory only and must be evaluated by an 
industrial hygienist and safety officer familiar with the specific situation of anticipated use by our customers. It 
should not be construed as offering an approval for any specific use scenario. 
 
Body Protection 
Choose body protection in relation to its type, to the concentration and amount of dangerous substances, and 
to the specific work-place., The type of protective equipment must be selected according to the concentration 
and amount of the dangerous substance at the specific workplace. 
Respiratory protection 
Respiratory protection is not required. Where protection from nuisance  levels of dusts are desired, use type 
N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and approved under 
appropriate government standards such as NIOSH (US) or CEN (EU). 
Control of environmental exposure 
Do not let product enter drains. 
 
9. PHYSICAL AND CHEMICAL PROPERTIES 
9.1 Information on basic physical and chemical properties 
a) Appearance Form: solid 
Colour: colourless 
b) Odour No data available 
c) Odour Threshold No data available 
d) pH 7 
e) Melting point/freezing 
point 
Melting point/range: 801 °C (1,474 °F) 
f) Initial boiling point and 
boiling range 
1,413 °C (2,575 °F) 
g) Flash point No data available 
h) Evaporation rate No data available 
i) Flammability (solid, gas) No data available 
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j) Upper/lower 
flammability or 
explosive limits 
No data available 
k) Vapour pressure 1.33 hPa (1.00 mmHg) at 865 °C (1,589 °F) 
l) Vapour density No data available 
m) Relative density 2.1650 g/cm3 
n) Water solubility 358 g/l at 20 °C (68 °F) - soluble 
o) Partition coefficient: n-
octanol/water 
No data available 
p) Auto-ignition 
temperature 
No data available 
q) Decomposition 
temperature 
No data available 
r) Viscosity No data available 
s) Explosive properties No data available 
t) Oxidizing properties No data available 
9.2 Other safety information 
No data available 
 
10. STABILITY AND REACTIVITY 
10.1 Reactivity 
No data available 
10.2 Chemical stability 
Stable under recommended storage conditions. 
10.3 Possibility of hazardous reactions 
No data available 
10.4 Conditions to avoid 
No data available 
10.5 Incompatible materials 
Strong oxidizing agents 
10.6 Hazardous decomposition products 
Hazardous decomposition products formed under fire conditions. - Hydrogen chloride gas, Sodium oxides 
Other decomposition products - No data available 
In the event of fire: see section 5 
 
11. TOXICOLOGICAL INFORMATION 
11.1 Information on toxicological effects 
Acute toxicity 
LD50 Oral - Rat - 3,550 mg/kg 
 
LC50 Inhalation - Rat - 1 h - > 42,000 mg/m3 
 
LD50 Dermal - Rabbit - > 10,000 mg/kg 
 
No data available 
Skin corrosion/irritation 
No data available 
Serious eye damage/eye irritation 
No data available 
Respiratory or skin sensitisation 
No data available 
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Germ cell mutagenicity 
No data available 
 
Carcinogenicity 
No data available 
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as 
probable, possible or confirmed human carcinogen by IARC. 
ACGIH: No component of this product present at levels greater than or equal to 0.1% is identified as a 
carcinogen or potential carcinogen by ACGIH. 
NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a 
known or anticipated carcinogen by NTP. 
OSHA: No component of this product present at levels greater than or equal to 0.1% is on OSHA’s 
list of regulated carcinogens. 
Reproductive toxicity 
No data available 
Specific target organ toxicity - single exposure 
No data available 
Specific target organ toxicity - repeated exposure 
No data available 
Aspiration hazard 
No data available 
Additional Information 
RTECS: VZ4725000 
 
Vomiting, Diarrhoea, Dehydration and congestion may occur in internal organs. Hypertonic salt solutions can produce 
inflammatory reactions in the gastrointestinal tract., To the best of our knowledge, the chemical, physical, and 
toxicological properties have not been thoroughly investigated., Nausea 
 
 
12. ECOLOGICAL INFORMATION 
12.1 Toxicity 
 
Toxicity to fish LC50 - Lepomis macrochirus (Bluegill) - 5,840 mg/l  - 96 h 
 
Toxicity to daphnia and 
other aquatic 
invertebrates 
NOEC - Daphnia (water flea) - 1,500 mg/l  - 7 d 
 
 LC50 - Daphnia magna (Water flea) - 1,661 mg/l  - 48 h 
12.2 Persistence and degradability 
12.3 Bioaccumulative potential 
No data available 
12.4 Mobility in soil 
No data available 
12.5 Results of PBT and vPvB assessment 
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted 
12.6 Other adverse effects 
 
13. DISPOSAL CONSIDERATIONS 
13.1 Waste treatment methods 
Product 
Offer surplus and non-recyclable solutions to a licensed disposal company.  
Contaminated packaging 
Dispose of as unused product.  
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14. TRANSPORT INFORMATION 
DOT (US) 
Not dangerous goods 
 
IMDG 
Not dangerous goods 
 
 
IATA 
Not dangerous goods 
 
15. REGULATORY INFORMATION 
SARA 302 Components 
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302. 
SARA 313 Components 
This material does not contain any chemical components with known CAS numbers that exceed the threshold (De 
Minimis) reporting levels established by SARA Title III, Section 313. 
SARA 311/312 Hazards 
No SARA Hazards 
Massachusetts Right To Know Components 
No components are subject to the Massachusetts Right to Know Act. 
Pennsylvania Right To Know Components 
 
Sodium chloride 
CAS-No. 
7647-14-5 
Revision Date 
 
New Jersey Right To Know Components 
 
Sodium chloride 
CAS-No. 
7647-14-5 
Revision Date 
 
California Prop. 65 Components 
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other 
reproductive harm. 
 
 
16. OTHER INFORMATION 
Further information 
Copyright 2016 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only. 
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a 
guide. The information in this document is based on the present state of our knowledge and is applicable to the 
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the 
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling 
or from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing 
slip for additional terms and conditions of sale. 
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 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING
Product Identifier
Material Name:  Neumega
Trade Name: NEUMEGA
Synonyms: Oprelvekin; Recombinant Interleukin-11, Neumega, Recombinant IL-11
Chemical Family: Not determined
Relevant Identified Uses of the Substance or Mixture and Uses Advised Against
Intended Use: Pharmaceutical product
Details of the Supplier of the Safety Data Sheet
2. HAZARDS IDENTIFICATION
Classification of the Substance or Mixture
GHS - Classification Not classified as hazardous
US OSHA Specific - Classification
Physical Hazard:   Combustible Dust
EU Classification:
EU Indication of danger: Not classified
Label Elements
Signal Word: Warning
Hazard Statements: May form combustible dust concentrations in air
Other Hazards
Australian Hazard Classification
(NOHSC):
Non-Hazardous Substance.  Non-Dangerous Goods.
Note: This document has been prepared in accordance with standards for workplace safety, which
requires the inclusion of all known hazards of the product or its ingredients regardless of the
potential risk.  The precautionary statements and warning included may not apply in all cases.
Your needs may vary depending upon the potential for exposure in your workplace.
_______________________________________________________________________________________________________
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Revision date: 11-Apr-2015
Pfizer Inc
Pfizer Pharmaceuticals Group
 235 East 42nd Street
New York, New York 10017
1-800-879-3477
Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161
Version: 2.1
Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
         SAFETY DATA SHEET
Emergency telephone number:
International CHEMTREC (24 hours): +1-703-527-3887
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3. COMPOSITION / INFORMATION ON INGREDIENTS
Hazardous
Ingredient CAS Number EU
EINECS/ELINCS
List
EU Classification GHS
Classification
%
Hydrochloric Acid 7647-01-0 231-595-7 T; R23
C; R35
Press. Gas
Skin Corr. 1A; H314
Acute Tox. 3; H331
**
Glycine 56-40-6 200-272-2 Not Listed Not Listed *
Oprelvekin 145941-26-0 Not Listed Not Listed Not Listed 5.2 mg/vial
Ingredient CAS Number EU
EINECS/ELINCS
List
EU Classification GHS
Classification
%
Sodium phosphate, monobasic 7558-80-7 231-449-2 Not Listed Not Listed *
Sodium phosphate, dibasic 7558-79-4 231-448-7 Not Listed Not Listed *
Additional Information: * Proprietary
** to adjust pH
Ingredient(s) indicated as hazardous have been assessed under standards for workplace
safety.
In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has
been withheld as a trade secret.
For the full text of the  R phrases and CLP/GHS abbreviations mentioned in this Section, see Section 16
4. FIRST AID MEASURES
Description of First Aid Measures
Eye Contact: Flush with water while holding eyelids open for at least 15 minutes.  Seek medical attention
immediately.
Skin Contact: Remove contaminated clothing.  Flush area with large amounts of water.  Use soap.  Seek
medical attention.
Ingestion: Never give anything by mouth to an unconscious person.  Wash out mouth with water.  Do not
induce vomiting unless directed by medical personnel.  Seek medical attention immediately.
Inhalation: Remove to fresh air and keep patient at rest.  Seek medical attention immediately.
Most Important Symptoms and Effects, Both Acute and Delayed
Symptoms and Effects of
Exposure:
For information on potential signs and symptoms of exposure, See Section 2 - Hazards
Identification and/or Section 11 - Toxicological Information.
Medical Conditions
Aggravated by Exposure:
None known
Indication of the Immediate Medical Attention and Special Treatment Needed
Notes to Physician: None
5. FIRE FIGHTING MEASURES
Extinguishing Media: Extinguish fires with CO2, extinguishing powder, foam, or water.
Special Hazards Arising from the Substance or Mixture
_______________________________________________________________________________________________________
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Revision date: 11-Apr-2015
Material Name:  Neumega
Version: 2.1
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Hazardous Combustion
Products:
Formation of toxic gases is possible during heating or fire.
Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.
Advice for Fire-Fighters
During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.
6. ACCIDENTAL RELEASE MEASURES
Personal Precautions, Protective Equipment and Emergency Procedures
Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8).  Minimize exposure.
Environmental Precautions
Place waste in an appropriately labeled, sealed container for disposal.  Care should be taken to avoid environmental release.
Methods and Material for Containment and Cleaning Up
Measures for Cleaning /
Collecting:
Contain the source of spill if it is safe to do so.  Collect spilled material by a method that
controls dust generation.  A damp cloth or a filtered vacuum should be used to clean spills of
dry solids.  Clean spill area thoroughly.
Additional Consideration for
Large Spills:
Non-essential personnel should be evacuated from affected area.  Report emergency
situations immediately.  Clean up operations should only be undertaken by trained personnel.
7. HANDLING AND STORAGE
Precautions for Safe Handling
Restrict access to work area. Avoid open handling. Ground and bond all bulk transfer equipment. Use appropriate engineering
controls to maintain exposures below the B-OEB taking all applicable routes of exposure into consideration. Minimize dust
generation and accumulation.  Avoid inhalation and contact with skin, eye, and clothing. When handling, use appropriate
personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. A change area to
facilitate 'good laboratory/manufacturing' decontamination practices is recommended. Releases to the environment should be
avoided.  Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent
occupational exposure or environmental releases.  Potential points of process emissions of this material to the atmosphere
should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.
Conditions for Safe Storage, Including any Incompatibilities
Storage Conditions: Store as directed by product packaging.
Specific end use(s): Pharmaceutical drug product
8. EXPOSURE CONTROLS / PERSONAL PROTECTION
Control Parameters
Refer to available public information for specific member state Occupational Exposure Limits.
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Australia PEAK 5 ppm
7.5 mg/m3
Material Name:  Neumega
Austria OEL - MAKs 5 ppm
8 mg/m3
Version: 2.1
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Belgium OEL - TWA 5 ppm
8 mg/m3
Hydrochloric Acid
Bulgaria OEL - TWA 5 ppm
8.0 mg/m3
ACGIH Ceiling Threshold Limit: 2 ppm
Revision date: 11-Apr-2015
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8. EXPOSURE CONTROLS / PERSONAL PROTECTION
The Biotherapeutic Occupational Exposure Band (B-OEB) is an acceptable daily intake (ADI) range, based on available hazard data
with appropriate safety factors applied.  Engineering control measures should be utilized to bring exposures into the relevant B-OEB;
supplementary administrative controls and personal protective equipment are to be used to achieve exposure control to the bottom of
the band.
Exposure Controls
_______________________________________________________________________________________________________
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Lithuania OEL - TWA 5 ppm
8 mg/m3
Material Name:  Neumega
Luxembourg OEL - TWA 5 ppm
8 mg/m3
Germany - TRGS 900 - TWAs
Malta OEL - TWA 5 ppm
8 mg/m3
2 ppm
3 mg/m3
Version: 2.1
Netherlands OEL - TWA 8 mg/m3
Page 4 of 9
Poland OEL - TWA 5 mg/m3
Germany (DFG) - MAK 2 ppm
3.0 mg/m3
Portugal OEL - TWA 5 ppm
8 mg/m3
Romania OEL - TWA 5 ppm
8 mg/m3
Cyprus OEL - TWA
Slovakia OEL - TWA 5 ppm
8.0 mg/m3
Greece OEL - TWA 5 ppm
7 mg/m3
Slovenia OEL - TWA 5 ppm
8 mg/m3
5 ppm
8 mg/m3
Spain OEL - TWA 5 ppm
7.6 mg/m3
Hungary OEL - TWA
Switzerland OEL -TWAs 2 ppm
3.0 mg/m3
8 mg/m3
Vietnam OEL - TWAs 5 mg/m3
Glycine
Ireland OEL - TWAs 5 ppm
8 mg/m3
Latvia OEL - TWA 5 mg/m3
Czech Republic OEL - TWA 8 mg/m3
Oprelvekin
Italy OEL - TWA 5 ppm
8 mg/m3
Pfizer Occupational Exposure
Band (OEB):
B-OEB 4 (control exposure to the range of 10 µg/day to <100 µg/day)
Revision date: 11-Apr-2015
Japan - OELs - Ceilings 5 ppm
7.5 mg/m3
Latvia OEL - TWA 5 ppm
8 mg/m3
Estonia OEL - TWA 5 ppm
8 mg/m3
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8. EXPOSURE CONTROLS / PERSONAL PROTECTION
Engineering Controls: Engineering controls should be used as the primary means to control exposures.  Use process
containment, local exhaust ventilation, biosafety cabinet, or other engineering controls to
maintain airborne levels within the B-OEB range. It is recommended that all operations be fully
enclosed and no air recirculated.
Personal Protective
Equipment:
Refer to applicable national standards and regulations in the selection and use of personal
protective equipment (PPE).
Hands: Wear impervious, disposable gloves as minimum protection (double recommended).
Eyes: Wear safety glasses as minimum protection.
Skin: Wear impervious protective clothing when handling this compound. Full body protection
recommended (scale dependent).
Respiratory protection: If airborne exposures are within or exceed the Biotherapeutic Occupational Exposure Band (B-
OEB) range, wear an appropriate respirator with a protection factor sufficient to control
exposures to the bottom of the B-OEB range.
9. PHYSICAL AND CHEMICAL PROPERTIES
Solvent Solubility: No data available
Water Solubility: No data available
pH: No data available.
Melting/Freezing Point (°C): No data available
Boiling Point (°C): No data available.
Partition Coefficient: (Method, pH, Endpoint, Value)
Decomposition Temperature (°C): No data available.
Evaporation Rate (Gram/s): No data available
Vapor Pressure (kPa): No data available
Vapor Density (g/ml): No data available
Relative Density: No data available
Viscosity: No data available
Flammablity:
Autoignition Temperature (Solid) (°C): No data available
Flammability (Solids): No data available
Flash Point (Liquid) (°C): No data available
Upper Explosive Limits (Liquid) (% by Vol.): No data available
Lower Explosive Limits (Liquid) (% by Vol.): No data available
_______________________________________________________________________________________________________
WB00005
Molecular Formula: Mixture
Sodium phosphate, dibasic
No data available
Molecular Weight: Mixture
Sodium phosphate, monobasic
Revision date: 11-Apr-2015
No data available
Physical State: Lyophilized powder
Hydrochloric Acid
Material Name:  Neumega
No data available
Color: No data available.
Oprelvekin
Version: 2.1
No data available
Odor: No data available.
Glycine
Page 5 of 9
No data available
Odor Threshold: No data available.
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10. STABILITY AND REACTIVITY
Reactivity: No data available
Chemical Stability: Stable under normal conditions of use.
Possibility of Hazardous Reactions
Oxidizing Properties: No data available
Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.
Incompatible Materials: As a precautionary measure, keep away from strong oxidizers
Hazardous Decomposition
Products:
No data available
11. TOXICOLOGICAL INFORMATION
Information on Toxicological Effects
General Information: The information included in this section describes the potential hazards of the individual
ingredients.
Known Clinical Effects: Serious allergic reactions, including anaphylaxis, have been reported.  Common adverse
effects include effects on cardiovascular system, fluid retention, swelling of the face, changes
in blood pressure, irregular heartbeat (cardiac arrhythmia), visual disturbances, decreased red
blood cell count (anemia), stroke.
Acute Toxicity: (Species, Route, End Point, Dose)
Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable
at the highest dose used in the test.
Irritation / Sensitization: (Study Type, Species, Severity)
Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)
Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))
Genetic Toxicity: (Study Type, Cell Type/Organism, Result)
_______________________________________________________________________________________________________
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13 Week(s)      Monkey      Subcutaneous  1  µg/kg/day      NOAEL      Liver
Oprelvekin
13 Week(s)      Dog      Oral  30  mg/kg/day      NOAEL      No effects at maximum dose
Skin Irritation     Severe
26 Week(s)      Rat      Subcutaneous  2000  ug/kg/day      NOAEL      No effects at maximum dose
Eye Irritation     Severe
Rat     Intravenous     Minimum Lethal Dose     >  10  mg/kg
Revision date: 11-Apr-2015
Oprelvekin
Material Name:  Neumega
Fertility and Embryonic Development      Rat      Subcutaneous10  ug/kg/day      NOAEL      Developmental toxicity, Fetotoxicity,
Maternal toxicity
Oprelvekin
Fertility and Embryonic Development      Rabbit      Subcutaneous  1  ug/kg/day      NOAEL      Fetotoxicity, Fetal mortality, Maternal
Toxicity
Version: 2.1
4 Week(s)      Monkey      Subcutaneous10  µg/kg/day      LOAEL      Liver
Page 6 of 9
28 Day(s)      Rat      Subcutaneous  1000  µg/kg/day      NOAEL      No effects at maximum dose
Hydrochloric Acid
         SAFETY DATA SHEET
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11. TOXICOLOGICAL INFORMATION
Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.
12. ECOLOGICAL INFORMATION
Environmental Overview: Environmental properties have not been investigated. Releases to the environment should be
avoided.
Toxicity: No data available
Persistence and Degradability: No data available
Bio-accumulative Potential: No data available
Mobility in Soil: No data available
13. DISPOSAL CONSIDERATIONS
Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations.  Member State
specific and Community specific provisions must be considered.  Considering the relevant
known environmental and human health hazards of the material, review and implement
appropriate technical and procedural waste water and waste disposal measures to prevent
occupational exposure and environmental release.  It is recommended that waste minimization
be practiced.  The best available technology should  be utilized to prevent environmental
releases. This may include destructive techniques for waste and wastewater.
14. TRANSPORT INFORMATION
The following refers to all modes of transportation unless specified below.
Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.
15. REGULATORY INFORMATION
Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture
_______________________________________________________________________________________________________
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Revision date: 11-Apr-2015
IARC: Group 3 (Not Classifiable)
In Vitro Mammalian Cell Mutagenicity       Mouse Lymphoma      Negative
Material Name:  Neumega
In Vivo Micronucleus      Mouse Bone Marrow      Negative
Version: 2.1
Page 7 of 9
Oprelvekin
In Vitro Bone Marrow Metaphase Analysis      Human Lymphocytes      Negative
Hydrochloric Acid
         SAFETY DATA SHEET
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15. REGULATORY INFORMATION
Canada - WHMIS: Classifications
WHMIS hazard class:
None required
_______________________________________________________________________________________________________
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Hydrochloric Acid
Material Name:  Neumega
CERCLA/SARA 313 Emission reporting 1.0 %
Australia (AICS):
CERCLA/SARA Hazardous Substances
and their Reportable Quantities:
5000 lb
2270 kg
Present
CERCLA/SARA - Section 302 Extremely Hazardous
TPQs
500 lb
Sodium phosphate, monobasic
CERCLA/SARA - Section 302 Extremely Hazardous
Substances EPCRA RQs
5000 lb
EU EINECS/ELINCS List 231-449-2
California Proposition 65 Not Listed
Version: 2.1
Inventory - United States TSCA - Sect. 8(b) Present
Sodium phosphate, dibasic
Australia (AICS): Present
Standard for the Uniform Scheduling
for Drugs and Poisons:
Schedule 5
Schedule 6
CERCLA/SARA 313 Emission reporting
EU EINECS/ELINCS List 231-595-7
CERCLA/SARA 313 Emission reporting Not Listed
Glycine
Not Listed
Page 8 of 9
CERCLA/SARA 313 Emission reporting Not Listed
CERCLA/SARA Hazardous Substances
and their Reportable Quantities:
California Proposition 65 Not Listed
5000 lb
2270 kg
Inventory - United States TSCA - Sect. 8(b) Present
Australia (AICS): Present
California Proposition 65 Not Listed
EU EINECS/ELINCS List 200-272-2
California Proposition 65
Oprelvekin
Not Listed
CERCLA/SARA 313 Emission reporting Not Listed
Inventory - United States TSCA - Sect. 8(b) Present
California Proposition 65 Not Listed
EU EINECS/ELINCS List Not Listed
Australia (AICS): Present
Revision date: 11-Apr-2015
EU EINECS/ELINCS List 231-448-7
Inventory - United States TSCA - Sect. 8(b) Present
         SAFETY DATA SHEET
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16. OTHER INFORMATION
Text of R phrases and GHS Classification abbreviations mentioned in Section 3
Acute toxicity, oral-Cat.3; H331 - Toxic if inhaled
Specific target organ toxicity, single exposure; Narcotic effects-Cat.3; H335 - May cause respiratory irritation
Skin corrosion/irritation-Cat.1A; H314 - Causes severe skin burns and eye damage
T - Toxic
C - Corrosive
R23 - Toxic by inhalation.
R35 - Causes severe burns.
Data Sources: Pfizer proprietary drug development information. Publicly available toxicity information. Safety
data sheets for individual ingredients.
Reasons for Revision: Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking.
Updated Section 2 - Hazard Identification.
Revision date: 11-Apr-2015
Prepared by:
Product Stewardship Hazard Communication
Pfizer Global Environment, Health, and Safety Operations
Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it
is without warranty of any kind, expressed or implied.  If data for a hazard are not included in this document there is no known
information at this time.
End of Safety Data Sheet
_______________________________________________________________________________________________________
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Version: 2.1
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Revision date: 11-Apr-2015
Material Name:  Neumega
Each vial of Plasbumin-25 is heat-treated at 60°C for 10 hours against the possibility of transmitting the hepatitis viruses.
Additionally, the manufacturing process was investigated for its capacity to decrease the infectivity of an experimental
agent of transmissible spongiform encephalopathy (TSE), considered as a model for the variant Creutzfeldt-Jakob disease
(vCJD) and Creutzfeldt-Jakob disease (CJD) agents.(11-14) The production steps from Pooled Plasma to Effluent IV-1 in
the Plasbumin-25 manufacturing process have been shown to decrease TSE infectivity of that experimental model agent
(a total of !7.0 logs). These studies provide reasonable assurance that low levels of vCJD/CJD agent infectivity, if present
in the starting material, would be removed.
CLINICAL PHARMACOLOGY
Each 20 mL vial of Plasbumin-25 supplies the oncotic equivalent of approximately 100 mL citrated plasma; 50 mL supplies
the oncotic equivalent of approximately 250 mL citrated plasma.
When administered intravenously to an adequately hydrated subject, the oncotic (colloid osmotic) effect of  20 mL
Plasbumin-25 is such that it will draw approximately a further 70 mL of fluid from the extravascular tissues into the
circulation within 15 minutes,(1) thus increasing the total blood volume and reducing both hemoconcentration and whole
blood viscosity. Accordingly, the main clinical indications are for hypoproteinemic states involving reduced oncotic
pressure, with or without accompanying edema.(2) Plasbumin-25 can also be used as a plasma volume expander.
Albumin is a transport protein and it may be useful in severe hemolytic disease in the neonate who is awaiting exchange
transfusion. The infused albumin may reduce the level of free bilirubin in the blood.(2,3) This could also be of importance
in acute liver failure where albumin might serve the dual role of supporting plasma oncotic pressure, as well as binding
excessive plasma bilirubin.(2)
INDICATIONS AND USAGE
Emergency Treatment of Hypovolemic Shock
Plasbumin-25 is hyperoncotic and on intravenous infusion will expand the plasma volume by an additional amount, three
to four times the volume actually administered, by withdrawing fluid from the interstitial spaces, provided the patient is
normally hydrated interstitially or there is interstitial edema.(1) If the patient is dehydrated, additional crystalloids must be
given,(4) or alternatively, Albumin (Human) 5%, USP (Plasbumin®-5) should be used. The patient’s hemodynamic
response should be monitored and the usual precautions against circulatory overload observed. The total dose should not
exceed the level of albumin found in the normal individual, i.e., about 2 g per kg body weight in the absence of active
bleeding. Although Plasbumin-5 is to be preferred for the usual volume deficits, Plasbumin-25 with appropriate crystalloids
may offer therapeutic advantages in oncotic deficits or in long-standing shock where treatment has been delayed.(2)
Removal of ascitic fluid from a patient with cirrhosis may cause changes in cardiovascular function and even result in hypo-
volemic shock. In such circumstances, the use of an albumin infusion may be required to support the blood volume.(2)
Burn Therapy
An optimal therapeutic regimen with respect to the administration of colloids, crystalloids, and water following extensive
burns has not been established. During the first 24 hours after sustaining thermal injury, large  volumes of crystalloids are
infused to restore the depleted extracellular fluid volume. Beyond 24 hours Plasbumin-25 can be used to maintain plasma
colloid osmotic pressure.
Hypoproteinemia With or Without Edema
During major surgery, patients can lose over half of their circulating albumin with the attendant complications of oncotic
deficit.(2,4,5) A similar situation can occur in sepsis or intensive care patients. Treatment with Plasbumin-25 may be of
value in such cases.(2)
Adult Respiratory Distress Syndrome (ARDS)(2,5)
This is characterized by deficient oxygenation caused by pulmonary interstitial edema complicating shock and postsurgical
conditions. When clinical signs are those of hypoproteinemia with a fluid volume overload, Plasbumin-25 together with a
diuretic may play a role in therapy.
Cardiopulmonary Bypass(2,6)
With the relatively small priming volume required with modern pumps, preoperative dilution of the blood using albumin
and crystalloid has been shown to be safe and well-tolerated. Although the limit to which the hematocrit and plasma protein
concentration can be safely lowered has not been defined, it is common practice to adjust the albumin and crystalloid
pump prime to achieve a hematocrit of 20% and a plasma albumin concentration of 2.5 g per 100 mL in the patient.
Acute Liver Failure(2)
In the uncommon situation of rapid loss of liver function with or without coma, administration of albumin may serve the
double purpose of supporting the colloid osmotic pressure of the plasma as well as binding excess plasma bilirubin.
Neonatal Hemolytic Disease(2,3)
The administration of Plasbumin-25 may be indicated prior to exchange transfusion, in order to bind free bilirubin, thus
lessening the risk of kernicterus. A dosage of 1 g/kg body weight is given about 1 hour prior to exchange transfusion.
Caution must be observed in hypervolemic infants.
Sequestration of Protein Rich Fluids(7)
This occurs in such conditions as acute peritonitis, pancreatitis, mediastinitis, and extensive cellulitis. The magnitude of
loss into the third space may require treatment of reduced volume or oncotic activity with an infusion of albumin.
Erythrocyte Resuspension(2)
Albumin may be required to avoid excessive hypoproteinemia, during certain types of exchange transfusion, or with the
use of very large volumes of previously frozen or washed red cells. About 25 g of albumin per liter of erythrocytes is
commonly used, although the requirements in preexistent hypoproteinemia or hepatic impairment can be greater.
Plasbumin-25 is added to the isotonic suspension of washed red cells immediately prior to transfusion.
Acute Nephrosis(2)
Certain patients may not respond to cyclophosphamide or steroid therapy. The steroids may even aggravate the underlying
edema. In this situation a loop diuretic and 100 mL Plasbumin-25 repeated daily for 7 to 10 days may be helpful in
controlling the edema and the patient may then respond to steroid treatment.
Renal Dialysis(2)
Although not part of the regular regimen of renal dialysis, Plasbumin-25 may be of value in the treatment of shock or
hypotension in these patients. The usual volume administered is about 100 mL, taking particular care to avoid fluid
overload as these patients are often fluid overloaded and cannot tolerate substantial volumes of salt solution.
Situations in Which Albumin Administration is Not Warranted(2)
In chronic nephrosis, infused albumin is promptly excreted by the kidneys with no relief of the chronic edema or effect on
the underlying renal lesion. It is of occasional use in the rapid “priming” diuresis of nephrosis. Similarly, in hypoproteinemic
states associated with chronic cirrhosis, malabsorption, protein losing enteropathies, pancreatic insufficiency, and
undernutrition, the infusion of albumin as a source of protein nutrition is not justified.
CONTRAINDICATIONS
Certain patients, e.g., those with a history of congestive cardiac failure, renal insufficiency or stabilized chronic anemia,
are at special risk of developing circulatory overload. A history of an allergic reaction to albumin is a specific contra-
indication to usage.
WARNINGS
Plasbumin-25 is made from human plasma. Products made from human plasma may contain infectious agents, such
as viruses, and, theoretically, the Creutzfeldt-Jakob Disease (CJD) agent that can cause disease. The theoretical risk
for transmission of CJD is considered extremely remote. No cases of transmission of viral diseases or CJD have ever
3036465
3036465 (Rev. 9/2014)
Albumin (Human) 25%, USP
Plasbuminw-25
DESCRIPTION
Albumin (Human) 25%, USP (Plasbumin®-25) is made from large pools of human venous plasma by the Cohn cold ethanol
fractionation process. Part of the fractionation may be performed by another licensed manufacturer. It is prepared in
accordance with the applicable requirements established by the U.S. Food and Drug Administration.
Plasbumin-25 is a 25% sterile solution of albumin in an aqueous diluent. The preparation is stabilized with 0.02 M sodium
caprylate and 0.02 M acetyltryptophan. The aluminum content of the product is not more than 200 µg/L. The approximate
sodium content of the product is 145 mEq/L. Plasbumin-25 is clear, slightly viscous, almost colorless to pale yellow, amber
or green. It contains no preservative. Plasbumin-25 must be administered intravenously.
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been identified for albumin. The risk that such products will transmit an infectious agent has been reduced by
screening plasma donors for prior exposure to certain viruses, by testing for the presence of certain current virus
infections, and by inactivating and/or removing certain viruses. Despite these measures, such products can still
potentially transmit disease. There is also the possibility that unknown infectious agents may be present in such
products. Individuals who receive infusions of blood or plasma products may develop signs and/or symptoms of some
viral infections, particularly hepatitis C. ALL infections thought by a physician possibly to have been transmitted by
this product should be reported by the physician or other healthcare provider to Grifols Therapeutics Inc. [1-800-520-
2807]. 
The physician should discuss the risks and benefits of this product with the patient, before prescribing or adminis-
tering it to the patient.
As with any hyperoncotic protein solution likely to be administered in large volumes, severe hemolysis and acute renal
failure may result from the inappropriate use of Sterile Water for Injection as a diluent for Albumin (Human), 25%.
Acceptable diluents include 0.9% Sodium Chloride or 5% Dextrose in Water. Please refer to the DOSAGE AND ADMINIS-
TRATION section for recommended diluents.
Solutions which have been frozen should not be used. Do not use if turbid. Do not begin administration more than 4 hours
after the container has been entered. Partially used vials must be discarded. Vials which are cracked or which have been
previously entered or damaged should not be used, as this may have allowed the entry of microorganisms. Albumin
(Human) 25%, USP (Plasbumin®-25) contains no preservative.
PRECAUTIONS
General
Patients should always be monitored carefully in order to guard against the possibility of circulatory overload. Plasbumin-25
is hyperoncotic, therefore, in the presence of dehydration, albumin must be given with or followed by addition of fluids.(4)
In hemorrhage the administration of albumin should be supplemented by the transfusion of whole blood to treat the relative
anemia associated with hemodilution.(8) When circulating blood volume has been reduced, hemodilution following the
administration of albumin persists for many hours. In patients with a normal blood volume, hemodilution lasts for a much
shorter period.(4,9,10)
The rapid rise in blood pressure which may follow the administration of a colloid with positive oncotic activity necessitates
careful observation to detect and treat severed blood vessels which may not have bled at the lower blood pressure.
Drug Interactions
Plasbumin-25 is compatible with whole blood, packed red cells, as well as the standard carbohydrate and electrolyte
solutions intended for intravenous use. It should, however, not be mixed with protein hydrolysates, amino acid solutions
nor those containing alcohol.
Pregnancy Category C
Animal reproduction studies have not been conducted with Plasbumin-25. It is also not known whether Plasbumin-25 can
cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Plasbumin-25 should be
given to a pregnant woman only if clearly needed.
Pediatric Use
Safety and effectiveness in the pediatric population have not been established.
ADVERSE REACTIONS
Adverse reactions to albumin are rare. Such reactions may be allergic in nature or due to high plasma protein levels from
excessive albumin administration. Allergic manifestations include urticaria, chills, fever, and changes in respiration, pulse
and blood pressure.
DOSAGE AND ADMINISTRATION
Plasbumin-25 should always be administered by intravenous infusion. Plasbumin-25 may be administered either undiluted
or diluted in 0.9% Sodium Chloride or 5% Dextrose in Water. If sodium restriction is required, Plasbumin-25 should only
be administered either undiluted or diluted in a sodium-free carbohydrate solution such as 5% Dextrose in Water.
A number of factors beyond our control could reduce the efficacy of this product or even result in an ill effect following its
use. These include improper storage and handling of the product after it leaves our hands, diagnosis, dosage, method of
administration, and biological differences in individual patients. Because of these factors, it is important that this product
be stored properly and that the directions be followed carefully during use.
Hypovolemic Shock—For treatment of hypovolemic shock, the volume administered and the speed of infusion should be
adapted to the response of the individual patient.
Burns—After a burn injury (usually beyond 24 hours) there is a close correlation between the amount of albumin infused
and the resultant increase in plasma colloid osmotic pressure. The aim should be to maintain the plasma albumin concen-
tration in the region of 2.5 ! 0.5 g per 100 mL with a plasma oncotic pressure of 20 mm Hg (equivalent to a total plasma
protein concentration of 5.2 g per 100 mL).(2) This is best achieved by the intravenous administration of Plasbumin-25.
The duration of therapy is decided by the loss of protein from the burned areas and in the urine. In addition, oral or
parenteral feeding with amino acids should be initiated, as the long-term administration of albumin should not be
considered as a source of nutrition.
Hypoproteinemia With or Without Edema—Unless the underlying pathology responsible for the hypoproteinemia can be
corrected, the intravenous administration of Plasbumin-25 must be considered purely symptomatic or supportive (see
section Situations in Which Albumin Administration is Not Warranted).(2) The usual daily dose of albumin for adults is
50 to 75 g and for children 25 g. Patients with severe hypoproteinemia who continue to lose albumin may require larger
quantities. Since hypoproteinemic patients usually have approximately normal blood volumes, the rate of administration of
Plasbumin-25 should not exceed 2 mL per minute, as more rapid injection may precipitate circulatory embarrassment and
pulmonary edema.
Other dosage recommendations are given under the specific indications referred to above.
Preparation for Administration
Remove seal to expose stopper. Always swab stopper top immediately with a suitable antiseptic prior to entering vial.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration,
whenever solution and container permit.
Only 16 gauge needles or dispensing pins should be used with 20 mL vial sizes and larger. Needles or dispensing pins
should only be inserted within the stopper area delineated by the raised ring. The stopper should be penetrated perpen-
dicular to the plane of the stopper within the ring.
HOW SUPPLIED
Plasbumin-25 is available in 20 mL, 50 mL, and 100 mL rubber-stoppered vials. Each single dose vial contains albumin in
the following approximate amounts:
STORAGE
Store at room temperature not exceeding 30°C (86°F). Do not freeze. Do not use after expiration date.
CAUTION
& only
U.S. federal law prohibits dispensing without prescription.
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Size
20 mL
50 mL
100 mL
Grams Albumin
5.0
12.5
25.0
NDC Number
13533-692-16
13533-692-20
13533-692-71
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Revision Date  23-Oct-2018
72302 72304 72305 72308 -  Y-27632 (Dihydrochloride) Revision Number  2
1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND OF THE
COMPANY/UNDERTAKING
Product identifier 
Product Name Y-27632 (Dihydrochloride)
Other means of identification 
Catalog Number 72302 72304 72305 72308
Document Number DX21101
Synonyms 4-[(1R)-1-aminoethyl]-N-4-pyridinyl-trans-cyclohexanecarboxamide, dihydrochloride;
Recommended use of the chemical and restrictions on use 
Recommended Use Laboratory chemicals
STEMCELL TECHNOLOGIES INC.’S QUALITY MANAGEMENT SYSTEM IS CERTIFIED TO ISO 13485. PRODUCTS ARE FOR RESEARCH
USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED.
Details of the supplier of the safety data sheet 
Emergency telephone number 
Emergency Telephone 1-800-667-0322
2. HAZARDS IDENTIFICATION
Classification 
This chemical is considered hazardous by the 2012 OSHA Hazard Communication Standard (29 CFR 1910.1200)
Acute toxicity - Oral Category 4
Acute toxicity - Dermal Category 4
Acute toxicity - Inhalation (Dusts/Mists) Category 4
Hazards not otherwise classified (HNOC)  
Not applicable
Label elements 
Manufacturer/Supplier
STEMCELL Technologies Canada Inc.
Suite 500 - 1618 Station Street
Vancouver, British Columbia V6A 1B6 Canada
_____________________________________________________________________________________________
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72302 72304 72305 72308 -  Y-27632 (Dihydrochloride) Revision Number  2
Precautionary Statements - Prevention
Wash face, hands and any exposed skin thoroughly after handling
Do not eat, drink or smoke when using this product
Wear protective gloves/protective clothing
Avoid breathing dust/fume/gas/mist/vapors/spray
Use only outdoors or in a well-ventilated area
IF ON SKIN: Wash with plenty of water and soap
Call a POISON CENTER or doctor if you feel unwell
Take off contaminated clothing and wash it before reuse
IF INHALED: Remove person to fresh air and keep comfortable for breathing
Call a POISON CENTER or doctor if you feel unwell
IF SWALLOWED: Call a POISON CENTER or doctor if you feel unwell
Rinse mouth
Precautionary Statements - Disposal
Dispose of contents/container to an approved waste disposal plant
Other Information  
Not applicable
Unknown acute toxicity 100 % of the mixture consists of ingredient(s) of unknown toxicity
0 % of the mixture consists of ingredient(s) of unknown acute oral toxicity
0 % of the mixture consists of ingredient(s) of unknown acute dermal toxicity
100 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (gas)
100 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (vapor)
0 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (dust/mist)
3. COMPOSITION/INFORMATION ON INGREDIENTS
Warning
Hazard statements  
Harmful if swallowed
Harmful in contact with skin
Harmful if inhaled
Appearance  Crystalline Physical state  Solid
_____________________________________________________________________________________________
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Odor  No information available
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72302 72304 72305 72308 -  Y-27632 (Dihydrochloride) Revision Number  2
Substance 
Synonyms 4-[(1R)-1-aminoethyl]-N-4-pyridinyl-trans-cyclohexanecarboxamide, dihydrochloride;.
Chemical name CAS No. Weight-%
4-[(1R)-1-aminoethyl]-N-pyridin-4-ylcyclohexane-1-c
arboxamide;dihydrochloride
129830-38-2 100
*The exact percentage (concentration) of composition has been withheld as a trade secret.
4. FIRST AID MEASURES
Description of first aid measures
General advice Show this safety data sheet to the doctor in attendance.
Inhalation If breathing has stopped, give artificial respiration. Get medical attention immediately.
Remove to fresh air. If symptoms persist, call a physician.
Eye contact Rinse thoroughly with plenty of water for at least 15 minutes, lifting lower and upper eyelids.
Consult a physician.
Skin contact Wash off immediately with plenty of water for at least 15 minutes. If symptoms persist, call a
physician.
Ingestion Do NOT induce vomiting. Clean mouth with water and drink afterwards plenty of water.
Never give anything by mouth to an unconscious person. Get medical attention.
Self-protection of the first aider Ensure that medical personnel are aware of the material(s) involved, take precautions to
protect themselves and prevent spread of contamination. Avoid breathing
dust/fume/gas/mist/vapors/spray. Use personal protective equipment as required. See
section 8 for more information.
Most important symptoms and effects, both acute and delayed  
Symptoms Coughing and/ or wheezing. Difficulty in breathing.
Indication of any immediate medical attention and special treatment needed  
Note to physicians Treat symptomatically.
5. FIRE-FIGHTING MEASURES
Suitable Extinguishing Media Use extinguishing measures that are appropriate to local circumstances and the
_____________________________________________________________________________________________
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surrounding environment.
Unsuitable extinguishing media CAUTION: Use of water spray when fighting fire may be inefficient.
Specific hazards arising from the
chemical
No information available.
Explosion data
Sensitivity to Mechanical Impact None.
Sensitivity to Static Discharge None.
Special protective equipment for
fire-fighters
Firefighters should wear self-contained breathing apparatus and full firefighting turnout
gear. Use personal protection equipment.
6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures  
Personal precautions Avoid contact with skin, eyes or clothing. Ensure adequate ventilation. Use personal
protective equipment as required. Avoid generation of dust. Do not breathe dust.
Other Information Refer to protective measures listed in Sections 7 and 8.
Environmental precautions  
Environmental precautions Prevent further leakage or spillage if safe to do so.
Methods and material for containment and cleaning up  
Methods for containment Prevent further leakage or spillage if safe to do so.
Methods for cleaning up Pick up and transfer to properly labeled containers.
Prevention of secondary hazards Clean contaminated objects and areas thoroughly observing environmental regulations.
7. HANDLING AND STORAGE
Precautions for safe handling
Advice on safe handling Handle in accordance with good industrial hygiene and safety practice. Avoid contact with
skin, eyes or clothing. Ensure adequate ventilation. Avoid breathing
dust/fume/gas/mist/vapors/spray. Avoid generation of dust. Do not eat, drink or smoke
when using this product.
_____________________________________________________________________________________________
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Storage Conditions Keep containers tightly closed in a dry, cool and well-ventilated place. Keep out of the reach
of children. Store locked up.
8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters  
Exposure Limits The following ingredients are the only ingredients of the product above the cut-off level (or
level that contributes to the hazard classification of the mixture) which have an exposure
limit applicable in the region for which this safety data sheet is intended or other
recommended limit. At this time, the other relevant constituents have no known exposure
limits from the sources listed here.
Appropriate engineering controls
Engineering controls Showers
Eyewash stations
Ventilation systems.
Individual protection measures, such as personal protective equipment
Eye/face protection Wear safety glasses with side shields (or goggles).
Hand protection Wear suitable gloves.
Skin and body protection Wear suitable protective clothing. Long sleeved clothing.
Respiratory protection No protective equipment is needed under normal use conditions. If exposure limits are
exceeded or irritation is experienced, ventilation and evacuation may be required.
General hygiene considerations Avoid contact with skin, eyes or clothing. Wear suitable gloves and eye/face protection.
Avoid breathing dust/fume/gas/mist/vapors/spray. Do not eat, drink or smoke when using
this product.
9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties  
Physical state Solid
Appearance Crystalline
Color No information available
Odor No information available
_____________________________________________________________________________________________
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Odor threshold No information available
Explosive properties No information available
Oxidizing properties No information available
Other Information  
Softening point No information available
Molecular weight 320.3
Molecular formula C14H21N3O · 2HCl
VOC Content (%) No information available
Liquid Density No information available
Bulk density No information available
10. STABILITY AND REACTIVITY
Reactivity No information available.
Chemical stability Stable under normal conditions.
Possibility of hazardous reactions None under normal processing.
Hazardous polymerization Hazardous polymerization does not occur.
Conditions to avoid Excessive heat.
Incompatible materials Strong oxidizing agents.
Property Values  Remarks  • Method  
pH No data available None known
Melting point / freezing point No data available None known
Boiling point / boiling range No data available None known
Flash point No data available None known
Evaporation rate No data available None known
Flammability (solid, gas) No data available None known
Flammability Limit in Air None known
Upper flammability limit: No data available
Lower flammability limit: No data available
Vapor pressure No data available None known
Vapor density No data available None known
Relative density No data available None known
Water solubility No data available None known
Solubility in other solvents ~10 mg/mL in PBS (pH 7.2); ~5 mg/mL
in EtOH; ~30 mg/mL in DMSO; ~20
mg/mL in DMF;
None known
Partition coefficient No data available None known
Autoignition temperature No data available None known
Decomposition temperature No data available None known
Kinematic viscosity No data available None known
Dynamic viscosity No data available None known
_____________________________________________________________________________________________
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Hazardous decomposition products Carbon dioxide (CO2). Carbon monoxide. Hydrogen chloride gas. Nitrogen oxides (NOx).
11. TOXICOLOGICAL INFORMATION
Information on likely routes of exposure  
Product Information
Inhalation Specific test data for the substance or mixture is not available. Harmful by inhalation.
(based on components).
Eye contact Specific test data for the substance or mixture is not available.
Skin contact May be harmful if absorbed through the skin. Harmful in contact with skin. (based on
components).
Ingestion Specific test data for the substance or mixture is not available. Harmful if swallowed. (based
on components).
Symptoms related to the physical, chemical and toxicological characteristics  
Symptoms Coughing and/ or wheezing.
Numerical measures of toxicity  
Acute toxicity
The following values are calculated based on chapter 3.1 of the GHS document  .
ATEmix (oral) 500.00  mg/kg
ATEmix (dermal) 1,100.00  mg/kg
ATEmix (inhalation-dust/mist) 1.50  mg/l
Unknown acute toxicity 100 % of the mixture consists of ingredient(s) of unknown toxicity
0 % of the mixture consists of ingredient(s) of unknown acute oral toxicity
0 % of the mixture consists of ingredient(s) of unknown acute dermal toxicity
100 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (gas)
100 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (vapor)
0 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (dust/mist)
Delayed and immediate effects as well as chronic effects from short and long-term exposure  
Skin corrosion/irritation No information available.
Serious eye damage/eye irritation No information available.
Respiratory or skin sensitization No information available.
_____________________________________________________________________________________________
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Germ cell mutagenicity No information available.
Carcinogenicity No information available.
Reproductive toxicity No information available.
STOT - single exposure No information available.
STOT - repeated exposure No information available.
Aspiration hazard No information available.
12. ECOLOGICAL INFORMATION
Ecotoxicity The environmental impact of this product has not been fully investigated.
Persistence and degradability No information available.
Bioaccumulation There is no data for this product.
Other adverse effects No information available.
13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Waste from residues/unused
products
Dispose of in accordance with local regulations. Dispose of waste in accordance with
environmental legislation.
Contaminated packaging Do not reuse empty containers.
14. TRANSPORT INFORMATION
Note: Transport in accordance with local, state, and federal regulations.
DOT Not regulated
TDG Not regulated
_____________________________________________________________________________________________
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MEX Not regulated
ICAO (air) Not regulated
IATA Not regulated
IMDG Not regulated
RID Not regulated
ADR Not regulated
ADN Not regulated
15. REGULATORY INFORMATION
International Inventories 
TSCA Does not comply
DSL/NDSL Does not comply
EINECS/ELINCS Does not comply
ENCS Does not comply
IECSC Does not comply
KECL Does not comply
PICCS Does not comply
AICS Does not comply
 Legend:
 TSCA  - United States Toxic Substances Control Act Section 8(b) Inventory
 DSL/NDSL  - Canadian Domestic Substances List/Non-Domestic Substances List
 EINECS/ELINCS  - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances
 ENCS  - Japan Existing and New Chemical Substances
 IECSC  - China Inventory of Existing Chemical Substances
 KECL  - Korean Existing and Evaluated Chemical Substances
 PICCS  - Philippines Inventory of Chemicals and Chemical Substances
 AICS  - Australian Inventory of Chemical Substances
US Federal Regulations 
SARA 313
Section 313 of Title III of the Superfund Amendments and Reauthorization Act of 1986 (SARA).  This product does not contain any
chemicals which are subject to the reporting requirements of the Act and Title 40 of the Code of Federal Regulations, Part 372.
SARA 311/312 Hazard Categories 
Acute health hazard Yes
Chronic Health Hazard No
Fire hazard No
Sudden release of pressure hazard No
Reactive Hazard No
_____________________________________________________________________________________________
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CWA (Clean Water Act)
This product does not contain any substances regulated as pollutants pursuant to the Clean Water Act (40 CFR 122.21 and 40
CFR 122.42).
CERCLA
This material, as supplied, does not contain any substances regulated as hazardous substances under the Comprehensive
Environmental Response Compensation and Liability Act (CERCLA) (40 CFR 302) or the Superfund Amendments and
Reauthorization Act (SARA) (40 CFR 355).  There may be specific reporting requirements at the local, regional, or state level
pertaining to releases of this material.
US State Regulations 
California Proposition 65
This product does not contain any Proposition 65 chemicals.
U.S. State Right-to-Know Regulations
US State Regulations This product does not contain any substances regulated by state right-to-know regulations
U.S. EPA Label Information  
EPA Pesticide Registration Number Not applicable
16. OTHER INFORMATION, INCLUDING DATE OF PREPARATION OF THE LAST REVISION
Prepared By, Quality Control. STEMCELL Technologies Canada Inc.
Revision Date 23-Oct-2018
Revision Note No information available.
Disclaimer
The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the
date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage,
transportation, disposal and release and is not to be considered a warranty or quality specification. The information
relates only to the specific material designated and may not be valid for such material used in combination with any other
materials or in any process, unless specified in the text. STEMCELL Technologies Inc. shall not be held liable for any
damage resulting from handling or from contact with the product.
End of Safety Data Sheet
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1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE
COMPANY/UNDERSTANDING
1.1  Product identifier
Product Name: Nplate
Common Name: Romiplostim
Chemical Name: Not Applicable
Synonyms: No information available
1.2  Relevant identified uses of the substance or mixture and uses advised against
Recommended Use: Pharmaceutical
Uses advised against: No information available
2. HAZARDS IDENTIFICATION
Emergency Overview
Pharmaceutical product intended for clinical and manufacturing purposes only.  Product contains romiplostim (a Fc
fusion protein that is expressed by recombinantly engineered E. coli) an active pharmaceutical ingredient for
treatment of immune (idiopathic) thrombocytompenic purpura (ITP).  Dosage contents may pose a health hazard only
if significant absorption occurs (e.g., inhalation after major spill or leak).  Avoid inhalation, skin contact, eye contact
and accidental ingestion. Does not meet GHS classification criteria and therefore is not classified.
2.1  - Classification of the drug substance or mixture (drug product in final form, not applicable)
REGULATION (EC) No 1272/2008
Not classified
Classification according to EU Directives 67/548/EEC or 1999/45/EC
For the full text of the  R phrases mentioned in this Section, see Section 16
2.2  Label elements
Not classified
2.3  Other Hazards  No information available
Manufacturer:
Amgen Inc.
One Amgen Center Drive
Thousand Oaks, California  91320-1799
1-805-447-7233
1-805-447-1000
Emergency Telephone Number:
Chemtrec
NORTH AMERICA 1-800-424-9300,
INTERNATIONAL 1-703-527-3887
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3. COMPOSITION/INFORMATION ON INGREDIENTS
3.1  Substances
Ingredients: Proprietary information
Chemical Name: Not Applicable
CAS-No: 267639-76-9
Single use vial containing 125 µg of NplateÒ supplied as a lyophilized dosage form with:
CAS Number: Amount
Romiplostin 267639-76-9 230 µg
Mannitol 87-78-5 18 mg
Sucrose 57-50-1 9 mg
Histidine 71-00-1 0.7 mg
Polysorbate 20 9005-64-5 0.02 mg
Single use vial containing 250 µg of NplateÒ supplied as a lyophilized dosage form with:
CAS Number: Amount
Romiplostin 267639-76-9 375 µg
Mannitol 87-78-5 30 mg
Sucrose 57-50-1 15 mg
Histidine 71-00-1 1.2 mg
Polysorbate 20 9005-64-5 0.03 mg
Single use vial containing 500 µg of NplateÒ supplied as a lyophilized dosage form with:
CAS Number: Amount
Romiplostin 267639-76-9 625 µg
Mannitol 87-78-5 50 mg
Sucrose 57-50-1 25 mg
Histidine 71-00-1 1.9 mg
Polysorbate 20 9005-64-5 0.05 mg
4. FIRST AID MEASURES
4.1  Description of first-aid measures
Eye Contact: In the case of contact with eyes, rinse immediately with plenty of water and seek medical
advice.
Skin Contact: Wash off immediately with soap and plenty of water removing all contaminated clothes and
shoes. Consult a physician if necessary.
Inhalation: Move to fresh air. If symptoms persist, call a physician.
Ingestion: If symptoms persist, call a physician. Do not induce vomiting without medical advice. Never
give anything by mouth to an unconscious person.
Notes to Physician: Treat symptomatically.
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5. FIRE-FIGHTING MEASURES
5.1  Extinguishing media
Flammable Properties: Not applicable.
Extinguishing Media: Use extinguishing measures that are appropriate to local circumstances and the
surrounding environment.
5.2  Special hazards arising from the substance or mixture
Hazardous Combustion Products: No information available.
5.3  Advice for firefighters
Protective Equipment and
Precautions for Firefighters:
As in any fire, wear self-contained breathing apparatus pressure-demand, NIOSH
(approved) and full protective gear.
6. ACCIDENTAL RELEASE MEASURES
6.1  Personal precautions, protective equipment and emergency procedures
Spill Procedures: If material is released or spilled, cordon off spill area.  Take proper precautions to minimize
exposure by using appropriate personal protective equipment in cleaning up a spill.  If in
powder form, wet down spilled material to minimize airborne dispersion.  Soak up material
with absorbent e.g., paper towels, and wash spill area thoroughly with appropriate cleaning
materials. Dispose of collected material in accordance with applicable waste disposal
regulations. Avoid release to the environment.
7. HANDLING AND STORAGE
7.1  Precautions for Safe Handling
Handling and Storage: Avoid contact with skin, eyes  or clothing.  Do not eat, drink or smoke in work areas.  Use
adequate ventilation to minimize exposure.  Wash hands, face and other potentially
exposed areas immediately after handling this material.  Remove contaminated clothing
prior to entering eating areas.  Clean protective equipment thoroughly after each use. Store
in a well ventilated area.
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8. EXPOSURE CONTROLS/PERSONAL PROTECTION
8.1  Control parameters
Occupational Exposure Limit: No exposure guidelines established by ACGIH, NIOSH or OSHA.  Amgen recommends an
occupational exposure limit  (OEL) of 40 µg/m3 as an 8-hour time weighted average over a
40-hour work  week.  The OEL is designed as an acceptable airborne concentration of a
substance for which it is believed that workers may be repeatedly exposed day after day
without adverse health effects. Nplate Ò has been classified per Amgen's Hazard
Classification System as an Occupational Exposure Band 3 compound (20 µg/m3 - 100
µg/m3).
Engineering Controls: When practicable, handle material in enclosed processes or in processes with effective
local exhaust ventilation or within a chemical hood.
8.2  Exposure controls
Personal Protective Equipment
Eye/face Protection: Wear safety glasses with side shields, chemical splash goggles, or safety glasses with side
shields and a full-face shield to prevent contact with eyes.  The choice of protection should
be based on the job activity and potential for exposure to the eyes and face.
Skin Protection: Use gloves or other appropriate personal protective equipment if skin contact with
formulation is possible.  Wear lab coat or other protective over garment if splashing is
possible.  The choice of protection should be based on the job activity and potential for skin
contact.
Respiratory Protection: When possible, handle material in enclosed processes or containers.  If it is properly
handled with effective local exhaust ventilation or containment, respiratory protection may
not be needed.  For procedures involving larger quantities or dust/aerosol generating
procedures such as weighing or a large transfer of liquids, an air-purifying respirator with
NIOSH approval for dusts and mists may be needed.  The choice of protection should be
based on the job activity and the potential for exposure.
Other: Wash hands, face and other potentially exposed areas after handling material (especially
before eating, drinking or smoking).  Clean protective equipment thoroughly after each use.
8.3  Environmental exposure controls
Environmental Exposure Controls Avoid release to the environment.
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9. PHYSICAL AND CHEMICAL PROPERTIES
Appearance: White
Physical State: Lyophilized powder
Molecular Weight: ~60 kD
Odor: No information available
Odor Threshold: No information available
pH:  5.0  (when reconstituted)
Melting Point: No information available
Flash Point: Not applicable
Evaporation Rate: No information available
Lower explosive limit: No information available
Upper explosive limit: No information available
Vapor Pressure: Not applicable
Vapor Density (air = 1): Not applicable
Relative density: No information available
Water Solubility: No information available
Partition Coefficient (log Kow): No information available
Viscosity: No information available
10. STABILITY AND REACTIVITY
10.1 Reactivity No information available
10.2 Chemical stability Stable
10.3 Possibility of hazardous
reactions
No information available
10.4  Conditions to avoid No Information available
10.5  Incompatible materials No information available
10.6 Hazardous
decomposition products
No information available
10.7 Other information None
Dust Explosion Properties: No information available
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11. TOXICOLOGICAL INFORMATION
11.1  Information on toxicological effects
Acute Toxicity: No information available
Skin corrosion/irritation: No information available
Serious eye damage/eye irritation: No information available
Respiratory or skin sensitization: No information available
Germ cell mutagenicity: No information available
Carcinogenicity: No information available
Reproductive toxicity: Even though this does not meet GHS classification, the following data is available:
developmental toxicity has been observed from subcutaneous administration in animal
studies.  In mice increased postimplantation loss occurred at the same dose as a reduction
in maternal weight gain.
STOT - single exposure: Even though this does not meet GHS classification, the following data is available: Single
dose toxicity and safety pharmacology studies with NplateÒ administered parenterally did
not identify any adverse effects. However, pharmacodynamic effects of increased platelet
count, increased spleen to body weight ratio, and increased extramedullary hematopoiesis
were observed.
STOT - repeated exposure: Even though this does not meet GHS classification, the following data is available: Four
week, multiple-dose toxicology studies with NplateÒ were conducted in rats, and rhesus and
cynomolgus monkeys. The drug was generally well-tolerated at doses up to 100 μg/kg
(rats) or 5,000 μg/kg (monkeys). In general, findings were related to the thrombopoietic
activity of NplateÒ and included extramedullary hematopoiesis, femoral and sternal bone
hyperostosis, marrow myelofibrosis (rats only), and megakaryocytosis. All findings reversed
or were absent after a 4-week recovery period.  Single doses of NplateÒ have been
effective in increasing platelet counts above baseline values without any identified safety
issues in healthy humans. In clinical trials, the most common treatment-related events
among patients with immune thrombocytopenia purpura (ITP) were headache, myalgia, and
injection site bruising.
Target organs include: Blood, bone, central nervous system (CNS), gastrointestinal tract
(GI), Musculoskeletal
Aspiration Hazard: No information available
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12. ECOLOGICAL INFORMATION
12.1  Toxicity
Ecotoxicity effects: No information available
12.2  Persistence and degradability
Persistence/Degradability: No information available
12.3  Bioaccumulative potential
Bioaccumulation/ Accumulation: No information available
12.4  Mobility in soil
Mobility in Environmental Media: No information available
12.5  Results of PBT and vPvB assessment
Results of PBT and vPvB assessment:  No information available
12.6  Other adverse effects
Other Adverse Effects: No information available
13. DISPOSAL CONSIDERATIONS
13.1  Waste treatment methods
Waste Disposal Method: Dispose of waste according to prescribed federal, state, local and competent authority
guidelines.
14. TRANSPORT INFORMATION
DOT Not regulated by U.S. DOT or IATA
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15. REGULATORY INFORMATION
15.1  Safety, health and environmental regulations/legislation specific for the substance or mixture
International Inventories
TSCA: -
EINECS/ELINCS -
DSL/NDSL -
PICCS: -
ENCS: -
CHINA: -
AICS: -
KECL: -
Legend
TSCA - United States Toxic Substances Control Act Section 8(b) Inventory
EINECS/ELINCS - European Inventory of Existing Commercial Chemical Substances/EU List of Notified Chemical Substances
DSL/NDSL - Canadian Domestic Substances List/Non-Domestic Substances List
PICCS - Philippines Inventory of Chemicals and Chemical Substances
ENCS - Japan Existing and New Chemical Substances
IECSC - China Inventory of Existing Chemical Substances
AICS - Australian Inventory of Chemical Substances
KECL - Korean Existing and Evaluated Chemical Substances
State Regulations
California Proposition 65: This product does not contain any Proposition 65 chemicals.
15.2  Chemical safety assessment
No CSA has been conducted.
16. OTHER INFORMATION
Text of R phrases mentioned in Section 2
No information available
Revision Number: 5
The above information is based on data available to us and is believed to be correct. Since the information may be
applied under conditions beyond our control and with which we may be unfamiliar, we do not assume any responsibility
for the results of its use and all persons receiving it must make their own determination of the effects, properties and
protections, which pertain to their particular conditions.
No representation, warranty, or guarantee, express or implied (including a warranty of fitness or merchantability for a
particular purpose), is made with respect to the materials, the accuracy of this information, the results to be obtained
from the use thereof, or the hazards connected with the use of the material. Caution should be used in the handling and
use of the material because it may be biologically active.
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SIGMA-ALDRICH sigma-aldrich.com 
SAFETY DATA SHEET 
Version 3.6 
Revision Date 07/01/2014 
Print Date 04/14/2019 
 
1. PRODUCT AND COMPANY IDENTIFICATION 
1.1 Product identifiers 
Product name : Stem Cell Factor, human 
 
Product Number : S7901 
Brand : Sigma 
   
1.2 Relevant identified uses of the substance or mixture and uses advised against 
Identified uses : Laboratory chemicals, Manufacture of substances 
1.3 Details of the supplier of the safety data sheet 
Company : Sigma-Aldrich 
3050 Spruce Street 
SAINT LOUIS MO  63103 
USA 
 
Telephone : +1 800-325-5832 
Fax : +1 800-325-5052 
1.4 Emergency telephone number 
Emergency Phone # : +1-703-527-3887 (CHEMTREC) 
 
2. HAZARDS IDENTIFICATION 
2.1 Classification of the substance or mixture 
 
Not a hazardous substance or mixture. 
2.2 GHS Label elements, including precautionary statements 
Not a hazardous substance or mixture. 
2.3 Hazards not otherwise classified (HNOC) or not covered by GHS - none 
 
3. COMPOSITION/INFORMATION ON INGREDIENTS 
3.1 Substances 
Synonyms : c-Kit ligand 
SCF 
 
 
Hazardous components 
Component Classification Concentration 
Stem Cell Factor human 
      -  
 
4. FIRST AID MEASURES 
4.1 Description of first aid measures 
General advice 
Move out of dangerous area. 
If inhaled 
If breathed in, move person into fresh air. If not breathing, give artificial respiration. 
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In case of skin contact 
Wash off with soap and plenty of water. 
In case of eye contact 
Flush eyes with water as a precaution. 
If swallowed 
Never give anything by mouth to an unconscious person. Rinse mouth with water. 
4.2 Most important symptoms and effects, both acute and delayed 
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11 
4.3 Indication of any immediate medical attention and special treatment needed 
no data available 
 
5. FIREFIGHTING MEASURES 
5.1 Extinguishing media 
Suitable extinguishing media 
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. 
5.2 Special hazards arising from the substance or mixture 
Nature of decomposition products not known. 
5.3 Advice for firefighters 
Wear self contained breathing apparatus for fire fighting if necessary. 
5.4 Further information 
no data available 
 
6. ACCIDENTAL RELEASE MEASURES 
6.1 Personal precautions, protective equipment and emergency procedures 
Avoid dust formation. Avoid breathing vapours, mist or gas. 
For personal protection see section 8. 
6.2 Environmental precautions 
Do not let product enter drains. 
6.3 Methods and materials for containment and cleaning up 
Sweep up and shovel. Keep in suitable, closed containers for disposal. 
6.4 Reference to other sections 
For disposal see section 13. 
 
7. HANDLING AND STORAGE 
7.1 Precautions for safe handling 
Provide appropriate exhaust ventilation at places where dust is formed. 
For precautions see section 2.2. 
7.2 Conditions for safe storage, including any incompatibilities 
Keep container tightly closed in a dry and well-ventilated place.  
Recommended storage temperature: -20 °C 
 Keep in a dry place.  
7.3 Specific end use(s) 
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated 
 
8. EXPOSURE CONTROLS/PERSONAL PROTECTION 
8.1 Control parameters 
Components with workplace control parameters 
Contains no substances with occupational exposure limit values. 
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8.2 Exposure controls 
Appropriate engineering controls 
General industrial hygiene practice. 
Personal protective equipment 
Eye/face protection 
Use equipment for eye protection tested and approved under appropriate government standards such as 
NIOSH (US) or EN 166(EU). 
Skin protection 
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without 
touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after 
use in accordance with applicable laws and good laboratory practices. Wash and dry hands. 
 
Body Protection 
Choose body protection in relation to its type, to the concentration and amount of dangerous substances, and 
to the specific work-place., The type of protective equipment must be selected according to the concentration 
and amount of the dangerous substance at the specific workplace. 
Respiratory protection 
Respiratory protection is not required. Where protection from nuisance  levels of dusts are desired, use type 
N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and approved under 
appropriate government standards such as NIOSH (US) or CEN (EU). 
Control of environmental exposure 
Do not let product enter drains. 
 
9. PHYSICAL AND CHEMICAL PROPERTIES 
9.1 Information on basic physical and chemical properties 
a) Appearance Form: powder 
b) Odour no data available 
c) Odour Threshold no data available 
d) pH no data available 
e) Melting point/freezing 
point 
no data available 
f) Initial boiling point and 
boiling range 
no data available 
g) Flash point no data available  
h) Evapouration rate no data available 
i) Flammability (solid, gas) no data available 
j) Upper/lower 
flammability or 
explosive limits 
no data available 
k) Vapour pressure no data available 
l) Vapour density no data available 
m) Relative density no data available 
n) Water solubility no data available 
o) Partition coefficient: n-
octanol/water 
no data available 
p) Auto-ignition 
temperature 
no data available 
q) Decomposition 
temperature 
no data available 
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r) Viscosity no data available 
s) Explosive properties no data available 
t) Oxidizing properties no data available 
9.2 Other safety information 
no data available 
 
10. STABILITY AND REACTIVITY 
10.1 Reactivity 
no data available 
10.2 Chemical stability 
Stable under recommended storage conditions. 
10.3 Possibility of hazardous reactions 
no data available 
10.4 Conditions to avoid 
no data available 
10.5 Incompatible materials 
Strong acids, Strong bases 
10.6 Hazardous decomposition products 
Other decomposition products - no data available 
In the event of fire: see section 5 
 
11. TOXICOLOGICAL INFORMATION 
11.1 Information on toxicological effects 
Acute toxicity 
no data available 
Inhalation: no data available 
Dermal: no data available 
no data available 
Skin corrosion/irritation 
no data available 
Serious eye damage/eye irritation 
no data available 
Respiratory or skin sensitisation 
no data available 
Germ cell mutagenicity 
no data available 
 
Carcinogenicity 
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as 
probable, possible or confirmed human carcinogen by IARC. 
ACGIH: No component of this product present at levels greater than or equal to 0.1% is identified as a 
carcinogen or potential carcinogen by ACGIH. 
NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a 
known or anticipated carcinogen by NTP. 
OSHA: No component of this product present at levels greater than or equal to 0.1% is identified as a 
carcinogen or potential carcinogen by OSHA. 
Reproductive toxicity 
no data available 
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no data available 
Specific target organ toxicity - single exposure 
no data available 
Specific target organ toxicity - repeated exposure 
no data available 
Aspiration hazard 
no data available 
Additional Information 
RTECS: Not available 
 
To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly 
investigated. 
 
Stomach - Irregularities - Based on Human Evidence 
Stomach - Irregularities - Based on Human Evidence 
 
12. ECOLOGICAL INFORMATION 
12.1 Toxicity 
no data available 
12.2 Persistence and degradability 
no data available 
12.3 Bioaccumulative potential 
no data available 
12.4 Mobility in soil 
no data available 
12.5 Results of PBT and vPvB assessment 
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted 
12.6 Other adverse effects 
 
no data available 
 
13. DISPOSAL CONSIDERATIONS 
13.1 Waste treatment methods 
Product 
Offer surplus and non-recyclable solutions to a licensed disposal company.  
Contaminated packaging 
Dispose of as unused product.  
 
14. TRANSPORT INFORMATION 
DOT (US) 
Not dangerous goods 
 
IMDG 
Not dangerous goods 
 
IATA 
Not dangerous goods 
 
15. REGULATORY INFORMATION 
SARA 302 Components 
SARA 302: No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302. 
SARA 313 Components 
SARA 313: This material does not contain any chemical components with known CAS numbers that exceed the 
threshold (De Minimis) reporting levels established by SARA Title III, Section 313. 
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SARA 311/312 Hazards 
Chronic Health Hazard 
Massachusetts Right To Know Components 
No components are subject to the Massachusetts Right to Know Act. 
Pennsylvania Right To Know Components 
 
Stem Cell Factor human 
CAS-No. 
 -  
Revision Date 
 
New Jersey Right To Know Components 
 
Stem Cell Factor human 
CAS-No. 
 -  
Revision Date 
 
California Prop. 65 Components 
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other 
reproductive harm. 
 
 
 
16. OTHER INFORMATION 
HMIS Rating 
Health hazard: 0 
Chronic Health Hazard: * 
Flammability: 0 
Physical Hazard 0 
NFPA Rating 
Health hazard: 0 
Fire Hazard: 0 
Reactivity Hazard: 0 
Further information 
Copyright 2014 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only. 
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a 
guide. The information in this document is based on the present state of our knowledge and is applicable to the 
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the 
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling 
or from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing 
slip for additional terms and conditions of sale. 
 
Preparation Information 
Sigma-Aldrich Corporation 
Product Safety – Americas Region 
1-800-521-8956 
 
Version: 3.6 Revision Date: 07/01/2014 Print Date: 04/14/2019 
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Material Safety Data Sheet – Sodium Citrate   
 
SECTION I · PRODUCT IDENTIFICATION 
 
CHEMTREC – 24HR Emergency Telephone 1-800-424-9300 
Manufacturers Address: Information Phone: (912) 443-6702   
916 West Lathrop Avenue Date Prepared: 24 Sept 08  
Savannah, Georgia 31415 Preparer:  F.Spaeth   
   
  
Synonym: Citric Acid 
Chemical Family: Organic Solid 
 
SECTION II · HAZARDOUS INGREDIENTS 
 
CHEMICAL NAME           CAS Number            %WT TLV  PEL 
 
Sodium Citrate 68-04-2 90-100 Not Established 
 
SECTION III · HAZARDOUS IDENTIFICATION 
   
Potential Acute Health Effects: None known. 
Potential Chronic Health Effects: None known. 
 
 
SECTION IV · PHYSICAL and CHEMICAL PROPERTIES 
 
Boiling Point Range:  Decomposes.     Vapor Density (Air=1): N/A 
pH: ~8.0      Vapor Pressure (mmHg): N/A 
Solubility In Water: Very soluble.     VOC %:  0 
Appearance/Odor: White granular solid with no odor.   Density: 1.7 
Melting Point/Freezing Point: 302 OF 
  
SECTION V · FIRE FIGHTING MEASURES 
 
Flash Point: Not considered a fire hazard.  
Auto Ignition: Not applicable.     
Extinguishing Media: Use measures suitable for extinguishing surrounding fire. 
Flammable Limits: Lower:  N/A    Upper:  N/A 
Fire Fighting Procedures:  Do not fight surrounding fire without a positive pressure self-contained breathing apparatus 
(SCBA) and full bunker firefighter’s protective clothing. 
Unusual Fire and Explosion Hazards: Dust dispersed in air in sufficient concentrations, and the presence of an ignition 
source is a potential dust explosion hazard.  
 
 
SECTION VI · STABILITY AND REACTIVITY 
 
Stability: Stable.  
Conditions to Avoid: Moisture, heat, flames, dust accumulation and ignition sources.   
Incompatibility: Avoid contact with strong oxidizers.   
Hazardous Decomposition Products: Oxides of carbon.  
Hazardous Polymerization: Will not occur. 
 
0 
1 
 
0 
NFPA Rating 
0- Minimal   1- Slight   2- Moderate 
3- Serious      4- Extreme
 
 
 
Colonial Chemical Solutions, Inc. 
 Page 2of 3
 
 
SECTION VII · STORAGE AND HANDLING 
 
Precautions To Be Taken In Handling and Storage: Always store in tightly sealed, properly labeled, original container. 
Store in a cool, dry well ventilated area. Avoid dust accumulation. Observe all warnings and precautions listed on the 
label for this product. 
 
SECTION VIII · HEALTH AND FIRST AID 
 
Skin:  Possible irritation of the skin on prolonged contact. 
Eyes: Dust may cause mechanical irritation.      
Inhalation: Inhalation of large amounts of dust may cause irritation to the respiratory tract.   
Ingestion: Extremely large oral dosages may produce gastrointestinal distress     
 
FIRST AID PROCEDURES: 
Eyes: Flush with large amounts of cool running water for at least 15 minutes. Seek medical attention as necessary.  
Skin: Flush excess material off.  Wash skin with soap and water. If irritation persists seek medical attention. 
Inhalation: For excessive inhalation remove to fresh air. If breathing is difficult seek medical attention. 
Ingestion: Have patient drink several glasses of water. Get medical attention if large doses were consumed. 
    
 
SECTION IX · EXPOSURE CONTROLS / PERSONAL PROTECTION 
 
Eye Protection: Goggles, safety glasses with side shields are recommended.  
Respiratory Protection: Where adequate ventilation is not available an approved respirator (NIOSH type N95) must be 
worn.  
Skin Protection: Wear chemically impervious clothing and gloves. 
Ventilation: General Mechanical ventilation to prevent dust accumulation and exposure below TLV control limits.  
Protective Clothing: Selection depends on potential exposure conditions and may include gloves, boots, apron, 
coveralls and long sleeved clothing.  
Other Equipment: Eye wash station and drench shower in close proximity are advised 
 
SECTION X · ACCIDENTAL RELEASE MEASURES 
 
Ventilate area of spill. Wear appropriate PPE as specified in Section IX.  Sweep up and containerize for reclamation or 
disposal.  Avoid dust dispersal during clean up operation. 
 
SECTION XI · DISPOSAL CONSIDERATIONS 
 
Whatever cannot be salvaged should be managed in an appropriate and approved waste disposal facility. Processing 
use or contamination of this product may alter its waste classification.  State and local disposal regulations may differ 
from federal regulations. Dispose of container and unused contents in accordance with federal, state and local 
requirements. 
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SECTION XII · TRANSPORTAION 
 
Proper Shipping Name:   Not Regulated by The U.S. DOT 
Hazard Class:    
UN Number:   
Packaging Group:    
Labels:  
 
SECTION XIII · TOXICOLOGY 
 
Carcinogenicity: Not listed. 
Mutagenicity:  No data available. 
Reproductive:  No data available. 
Sensitization:  Not considered a sensitizer 
 
SECTION XIV · REGULATORY 
 
 
RMP/PSM:             Not listed 
CERCLA-RQ:        None established 
EPCRA 311/312:   No. 
EPCRA 313:          No 
FIFRA:                   No documented information available. 
RCRA-CODE:       No Hazardous Waste Identification. 
TSCA:                 Listed 
 
 
SECTION XV · OTHER INFORMATION 
 
The information contained on this Material Safety Data Sheet is considered accurate as of the date of publication. It is 
not necessarily all inclusive nor fully adequate in every circumstance. The suggestions should not be confused with, nor 
followed in violation of applicable laws, regulations, rules or insurance requirements. No warranty, express or implied, of 
merchantability, fitness, accuracy of data, or the results to be obtained from the use thereof is made. The vendor 
assumes no responsibility for injury or damages resulting from the inappropriate use of this product. 
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SIGMA-ALDRICH sigma-aldrich.com 
SAFETY DATA SHEET 
Version 3.8 
Revision Date 05/11/2016 
Print Date 11/10/2018 
 
1. PRODUCT AND COMPANY IDENTIFICATION 
1.1 Product identifiers 
Product name : Vascular Endothelial Growth Factor, human 
 
Product Number : V7259 
Brand : Sigma 
   
CAS-No. : 127464-60-2 
1.2 Relevant identified uses of the substance or mixture and uses advised against 
Identified uses : Laboratory chemicals, Synthesis of substances 
 
1.3 Details of the supplier of the safety data sheet 
Company : Sigma-Aldrich 
3050 Spruce Street 
SAINT LOUIS MO  63103 
USA 
 
Telephone : +1 800-325-5832 
Fax : +1 800-325-5052 
1.4 Emergency telephone number 
Emergency Phone # : +1-703-527-3887 (CHEMTREC) 
 
2. HAZARDS IDENTIFICATION 
2.1 Classification of the substance or mixture 
 
Not a hazardous substance or mixture. 
2.2 GHS Label elements, including precautionary statements 
Not a hazardous substance or mixture. 
2.3 Hazards not otherwise classified (HNOC) or not covered by GHS - none 
 
3. COMPOSITION/INFORMATION ON INGREDIENTS 
3.1 Substances 
Synonyms : VEGF 
 
CAS-No. : 127464-60-2 
 
No components need to be disclosed according to the applicable regulations. 
 
4. FIRST AID MEASURES 
4.1 Description of first aid measures 
If inhaled 
If breathed in, move person into fresh air. If not breathing, give artificial respiration. 
In case of skin contact 
Wash off with soap and plenty of water. 
In case of eye contact 
Flush eyes with water as a precaution. 
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If swallowed 
Never give anything by mouth to an unconscious person. Rinse mouth with water. 
4.2 Most important symptoms and effects, both acute and delayed 
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11 
 
4.3 Indication of any immediate medical attention and special treatment needed 
No data available 
 
5. FIREFIGHTING MEASURES 
5.1 Extinguishing media 
Suitable extinguishing media 
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. 
5.2 Special hazards arising from the substance or mixture 
No data available 
5.3 Advice for firefighters 
Wear self-contained breathing apparatus for firefighting if necessary. 
5.4 Further information 
No data available 
 
6. ACCIDENTAL RELEASE MEASURES 
6.1 Personal precautions, protective equipment and emergency procedures 
Avoid dust formation. Avoid breathing vapours, mist or gas. 
For personal protection see section 8. 
6.2 Environmental precautions 
Do not let product enter drains. 
6.3 Methods and materials for containment and cleaning up 
Sweep up and shovel. Keep in suitable, closed containers for disposal. 
6.4 Reference to other sections 
For disposal see section 13. 
 
7. HANDLING AND STORAGE 
7.1 Precautions for safe handling 
Provide appropriate exhaust ventilation at places where dust is formed. 
For precautions see section 2.2. 
7.2 Conditions for safe storage, including any incompatibilities 
Keep container tightly closed in a dry and well-ventilated place.  
Recommended storage temperature -20 °C 
 Keep in a dry place.  
7.3 Specific end use(s) 
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated 
 
8. EXPOSURE CONTROLS/PERSONAL PROTECTION 
8.1 Control parameters 
Components with workplace control parameters 
Contains no substances with occupational exposure limit values. 
8.2 Exposure controls 
Appropriate engineering controls 
General industrial hygiene practice. 
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Personal protective equipment 
Eye/face protection 
Use equipment for eye protection tested and approved under appropriate government standards such as 
NIOSH (US) or EN 166(EU). 
Skin protection 
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without 
touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after 
use in accordance with applicable laws and good laboratory practices. Wash and dry hands. 
 
Full contact 
Material: Nitrile rubber 
Minimum layer thickness: 0.11 mm 
Break through time: 480 min 
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M) 
 
Splash contact 
Material: Nitrile rubber 
Minimum layer thickness: 0.11 mm 
Break through time: 480 min 
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M) 
 
data source: KCL GmbH, D-36124 Eichenzell, phone +49 (0)6659 87300, e-mail sales@kcl.de, test method: 
EN374 
If used in solution, or mixed with other substances, and under conditions which differ from EN 374, contact the 
supplier of the CE approved gloves. This recommendation is advisory only and must be evaluated by an 
industrial hygienist and safety officer familiar with the specific situation of anticipated use by our customers. It 
should not be construed as offering an approval for any specific use scenario. 
 
Body Protection 
Choose body protection in relation to its type, to the concentration and amount of dangerous substances, and 
to the specific work-place., The type of protective equipment must be selected according to the concentration 
and amount of the dangerous substance at the specific workplace. 
Respiratory protection 
Respiratory protection is not required. Where protection from nuisance  levels of dusts are desired, use type 
N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and approved under 
appropriate government standards such as NIOSH (US) or CEN (EU). 
Control of environmental exposure 
Do not let product enter drains. 
 
9. PHYSICAL AND CHEMICAL PROPERTIES 
9.1 Information on basic physical and chemical properties 
a) Appearance Form: powder 
b) Odour No data available 
c) Odour Threshold No data available 
d) pH No data available 
e) Melting point/freezing 
point 
No data available 
f) Initial boiling point and 
boiling range 
No data available 
g) Flash point No data available 
h) Evaporation rate No data available 
i) Flammability (solid, gas) No data available 
j) Upper/lower 
flammability or 
explosive limits 
No data available 
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k) Vapour pressure No data available 
l) Vapour density No data available 
m) Relative density No data available 
n) Water solubility No data available 
o) Partition coefficient: n-
octanol/water 
No data available 
p) Auto-ignition 
temperature 
No data available 
q) Decomposition 
temperature 
No data available 
r) Viscosity No data available 
s) Explosive properties No data available 
t) Oxidizing properties No data available 
9.2 Other safety information 
No data available 
 
10. STABILITY AND REACTIVITY 
10.1 Reactivity 
No data available 
10.2 Chemical stability 
Stable under recommended storage conditions. 
10.3 Possibility of hazardous reactions 
No data available 
10.4 Conditions to avoid 
No data available 
10.5 Incompatible materials 
Strong acids, Strong bases 
10.6 Hazardous decomposition products 
Hazardous decomposition products formed under fire conditions. - Nature of decomposition products not known. 
Other decomposition products - No data available 
In the event of fire: see section 5 
 
11. TOXICOLOGICAL INFORMATION 
11.1 Information on toxicological effects 
Acute toxicity 
No data available 
Inhalation: No data available 
Dermal: No data available 
No data available 
Skin corrosion/irritation 
No data available 
Serious eye damage/eye irritation 
No data available 
Respiratory or skin sensitisation 
No data available 
Germ cell mutagenicity 
No data available 
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Carcinogenicity 
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as 
probable, possible or confirmed human carcinogen by IARC. 
ACGIH: No component of this product present at levels greater than or equal to 0.1% is identified as a 
carcinogen or potential carcinogen by ACGIH. 
NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a 
known or anticipated carcinogen by NTP. 
OSHA: No component of this product present at levels greater than or equal to 0.1% is identified as a 
carcinogen or potential carcinogen by OSHA. 
Reproductive toxicity 
No data available 
No data available 
Specific target organ toxicity - single exposure 
No data available 
Specific target organ toxicity - repeated exposure 
No data available 
Aspiration hazard 
No data available 
Additional Information 
RTECS: Not available 
 
To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly 
investigated. 
 
 
12. ECOLOGICAL INFORMATION 
12.1 Toxicity 
No data available 
12.2 Persistence and degradability 
No data available 
12.3 Bioaccumulative potential 
No data available 
12.4 Mobility in soil 
No data available 
12.5 Results of PBT and vPvB assessment 
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted 
12.6 Other adverse effects 
 
No data available 
 
13. DISPOSAL CONSIDERATIONS 
13.1 Waste treatment methods 
Product 
Offer surplus and non-recyclable solutions to a licensed disposal company.  
Contaminated packaging 
Dispose of as unused product.  
 
14. TRANSPORT INFORMATION 
DOT (US) 
Not dangerous goods 
 
IMDG 
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Not dangerous goods 
 
IATA 
Not dangerous goods 
 
15. REGULATORY INFORMATION 
SARA 302 Components 
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302. 
SARA 313 Components 
This material does not contain any chemical components with known CAS numbers that exceed the threshold (De 
Minimis) reporting levels established by SARA Title III, Section 313. 
SARA 311/312 Hazards 
No SARA Hazards 
Massachusetts Right To Know Components 
No components are subject to the Massachusetts Right to Know Act. 
Pennsylvania Right To Know Components 
 
Vascular Endothelial Growth Factor human 
CAS-No. 
127464-60-2 
Revision Date 
 
New Jersey Right To Know Components 
 
Vascular Endothelial Growth Factor human 
CAS-No. 
127464-60-2 
Revision Date 
 
California Prop. 65 Components 
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other 
reproductive harm. 
 
 
 
16. OTHER INFORMATION 
HMIS Rating 
Health hazard: 0 
Chronic Health Hazard:  
Flammability: 0 
Physical Hazard 0 
NFPA Rating 
Health hazard: 0 
Fire Hazard: 0 
Reactivity Hazard: 0 
Further information 
Copyright 2016 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only. 
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a 
guide. The information in this document is based on the present state of our knowledge and is applicable to the 
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the 
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling 
or from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing 
slip for additional terms and conditions of sale. 
 
Preparation Information 
Sigma-Aldrich Corporation 
Product Safety – Americas Region 
1-800-521-8956 
 
Version: 3.8 Revision Date: 05/11/2016 Print Date: 11/10/2018 
XDR Single-Use Bioreactors
DATA SHEET
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Introduction
The XDR Single-Use Bioreactor is a fully-integrated system that deliv-
ers proven stirred-tank performance across a wide range of cell lines. 
Single use technology eliminates time consuming and costly clean in 
place (CIP), steam in place (SIP) and cleaning validation procedures. The 
system’s turnkey design enables fast installation and startup as well as 
rapid batch-to-batch turnover and increased process flexibility com-
pared to fixed stainless steel hard piped vessels.
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sign enables each XDR to oper ate down to 20% of maximum working 
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additional seed reactor and related costs. Each reactor system includes 
a stainless steel vessel, vital process instrumentation, state-of-the-art 
control automation, and an optimized single-use bioreactor bag assem-
bly. For high-density microbial applications, ask about the XDR-50 Turbo 
SYSTEM SNAPSHOT
u	Fully-integrated, turnkey GMP system 
u	Proven, scalable stirred tank performance 
across a wide range of cell lines
u	Single-use design eliminates CIP/SIP
u	Operating volumes of 10L to 2,000L
u	Essential process instrumentation included 
and fully characterized
u	Integrated temperature control and dimpled 
vessel jacket for efficient heat transfer
u	Powerful, user-friendly control system 
u	Predictive modeling and Xcellerex process 
expertise eliminates start-up headaches and 
ensures process efficiency
model.
uEfficient, Convenient Vessel Design  The vessel features a dimpled jacket  
heat transfer surface for efficient heating and cooling, a high performance bottom-
mounted magnetic drive agitator system that facilitates loading and coupling of 
the single-use bag assembly, load cells for weight measurement, an exhaust filter  
heater box, flexible hoses for the heat transfer fluid, and a tubing manager.
uCritical Process Instrumentation   Mass flow controllers,  
peristaltic pumps, and probe transmitters are built into the  
cabinet adjacent to the vessel, and an external temperature  
control unit is available as an option for process heating/cooling. 
5IFTZTUFNSFRVJSFTPOMZHBTFT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full functionality.
XDR 2000 u
agitator includes a HDPE bottom mounted impeller and a 
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steel disks and optional drilled holes that together impart 
the system with tremendous flexibility crucial for today’s cell 
culture processes. Xcellerex also maintains multiple supply 
sources to guard against supply chain disruptions.
 
Expert process support from Xcellerex   With years 
of experience running and supporting GMP biomanufactur-
ing operations, Xcellerex designed the XDR system to deliver 
complete process control from the mo ment each system 
starts up. No other single-use bioreactor is available with the 
XDR’s depth of characterization, process support, and GMP-
SFBEJOFTT9DFMMFSFYJTVOJRVFMZBCMFUPEFMJWFSDSJUJDBMDPOUSPM
automation with instrumentation, functionality, pro cess mod-
eling, tech transfer, and scalability.
Key XDR Advantages
u 5:1 turndown means each XDR can operate at 20% of maximum working 
volume, doing the work of multiple reactors
u True plug-and-play performance:  Connect gases and power and get 
started
u Robust, self-installing magnetically-driven bottom-mount  impeller:   
No rotating seals, insertable shafts and connection hassles
u Jacketed vessel ensures uniform temperature distribution throughout 
reactor
u Flexible control systems automate temperature shifts, feeds, changes to 
sparge composition   
u Multiple probe configurations available, including pH, DO, CO2, and 
biomass
u Accurate gas control using mass flow controllers on all systems (optional 
MFC for headspace on XDR50)
u Bag material sourced from multiple manufacturers for supply chain security
u Single-use design eliminates time consuming CIP, SIP and cleaning valida-
tions procedures
u XDR Single Use Reactor Systems are Factory Acceptance Tested (FAT) prior 
to delivery and Site Acceptance Tested (SAT) upon installation
u Each XDR Single Use Reactor System is shipped with a Turnover Package 
which includes XDR Operating Manual, System Specifications, FAT  
commissioning report, system drawings, component operating manuals, 
calibration records, and optional IQ/OQ protocols
u Xcellerex process experience and know how is built into every XDR 
System:  our process development expertise ensures that the process is 
up and running right the first time
u Xcellerex offers extensive XDR-specific predictive modeling and expert 
scale-up support
u Enhanced sparge control and CO2 stripping capabilities not offered on 
other single use systems
u Designed and fully characterized to deliver scalable cGMP processes from 
10L to 2000L
u Xcellerex has years of cGMP manufacturing experience operating the XDR 
system.  GMP product made in the XDR is currently being used in clinical 
trials and commercial XDR facilities are currently being prepared for com-
missioning.
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uPowerful, User-Friendly Controls  The XDR is 
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 
featuring intuitive pro cess controls, 
data historian, and robust automa-
tion hardware/software. The system 
enables precise process control, 
and offers convenient real-time 
trending and other valuable data. 
When coupled with Xcellerex’s 
process development experience 
and predictive modeling support, 
the XDR control platform assures optimized first-run 
process performance and reliability through tech 
transfer and scale-up.
uRobust Single-Use Components  The XDR irradiated 
TJOHMFVTFCBHBTTFNCMZDPOTJTUTPGB641$MBTT7*-%1&
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sampling and probe ports, a disposable pressure sensor, 
filtered gas lines, and high-functioning agitator system. The 
SYSTEM SPECIFICATIONS
XDR-50 XDR-200 XDR-500 XDR-1000 XDR-2000
BIOREACTOR
Max Working Volume (L) 50 200 500 1000 2000
Min Working Volume (L) 10 40 100 200 400
Volume turn-down ratio 5:1 5:1 5:1 5:1 5:1
Tank ID (in) 12 22 30 38 48
H/D 2.5 1.5 1.5 1.5 1.5
Vessel Material of Construction Jacketed 304 SS Jacketed 304 SS Jacketed 304 SS Jacketed 304 SS Jacketed 304 SS
Filter Heater Box 1 1 1 1 1
Bag Hoist NA NA NA Automated Automated
Impeller Bottom mounted, magnetically-driven, single-use impeller integrated with bag assembly
Impeller type M40E
Impeller diameter (in) 8 8 10 12 16
Di/Dt 0.67 0.36 0.33 0.33 0.33
Impeller location Center 900 150 off center 150 off center 150 off center 150 off center
Sparger
Standard Stanless steel sintered disks Stanless steel sintered disks Stanless steel sintered disks Stanless steel sintered disks Stanless steel sintered disks
Optional
Drilled Hole Drilled Hole Drilled Hole Drilled Hole Drilled Hole
CO2 stripping CO2 stripping CO2 stripping CO2 stripping CO2 stripping
PROCESS INSTRUMENTATION
pH probes 1 2 2 2 2
DO probes 1 2 2 2 2
MFCs (Brooks)
Standard 4 4 4 4 4
Additional (optional) 2 2 2 2 2
Pumps 3 Pumps are standard.     Additional pumps are available as an option
Temperature Control Unit Optional:  3 kw heater Optional:  9 kw heater
Optional:  3 kw heater/ 
0.5 ton chiller combo Optional:  9 kw heater/ 1.5 hp chiller combo
Load Cells 3 4 4 4 4
Utility Requirements Process gases  /  110V, single phase, 60 hz  /  TCU:  230V, 3 phase, 60 hz (EU: 380V, 3 phase, 50 hz)
E-Stop Integrated Safety Circuit for pumps, agitator, TCU, and filter heater
CONTROL UNIT (see page 5 for additional detail)
Integrated Control Panel Built to GAMP5 standards/ 21 CFR Part 11 Compliant
Hardware Rockwell/ Allen Bradley
Operator Interface Wonderware HMI
Data Historian Wonderware
Programming Rockwell Allen Bradley/Wonderware Archestra
NOTE:  This document describes standard systems and commonly requested options. Additional custom-engineered systems are also available to meet unique application needs. Ask your Xcellerex representative for details.
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All	speciﬁcations	are	subject	to	change	without	notice.
PERFORMANCE CONTROL SPECIFICATIONS
XDR-50 XDR-200 XDR-500 XDR-1000 XDR-2000
pH Range 2-12 pH units 
Accuracy  ± 0.05 pH units
DO Range 0-100% atmospheric saturation 
Accuracy  ± 1.0% of setpoint
Sparge Rate (slpm) Air* 0-5 0-5 0-10 0-10 0-20
*Additional MFC/sparge 
ranges can be supplied 
based on application 
requirements
02* 0-5 0-5 0-10 0-10 0-20
C02* 0-5 0-5 0-10 0-10 0-20
Air Headsweep* 0-10 0-10 0-20 0-20 0-25
Temperature Range 4-60 0C 
Accuracy ± 0.1 0C
Bag Pressure Range 0 - 30 psig    (0 - 2068 mbar)
Accuracy ± 0.1 psig  (± 6.89 mbar)
Agitation (rpm) 0-360 0-360 0-250 0-140 0-115
Load Cell Accuracy ± 0.02% of max bag volume
NOTE:   For high-density microbial applications, please ask about the XDR-50 Turbo system.
SYSTEM DIMENSIONS
XDR-50 XDR-200 XDR-500 XDR-1000 XDR-2000
Width (Vessel & Instrumentation) 43.375 in(111 cm)
52.25 in
(133 cm)
57 in 
(145 com)
64 in 
(163 cm)
23.375 in 
(182 cm)
Depth (Vessel & Instrumentation) 28 in(71 cm)
37 in 
(94 cm)
48 in 
(122 cm)
52 in 
(132 cm)
61 in 
(155 cm)
Height (Vessel & Instrumentation) 73.5 in(187 cm)
85.125 
(216 cm)
93.75 in 
(238 cm)
115 in 
(292 cm)
140 in
(356 cm)
HMI Control Unit Dimensions:   23.375 in x 30.75 in x 56.75 in (60 cm x 78 cm x 144 cm)
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FULLY-INTEGRATED XDR BIOREACTOR BAG ASSEMBLY
 
USP Class VIt
-%1&øVJEDPOUBDUMBZFSt
Gamma Irradiatedt
Validation Guide t
 
 
Standard “off-the-shelf” designs impart flexibility for a wide range of 
cell  culture and microbial processes.
$VTUPNBQQMJDBUJPOTQFDJöDEFTJHOTBWBJMBCMFVQPOSFRVFTU
Each bag comes complete with:
 
C-flex tubing (for tube-to-tube aseptic welding)t
Aseptic connectorst
Multiple feed/addition linest
Harvest linet
Exhaust filtert
Sparge filtert
Overlay filtert
Pressure sensort
Sampling portst
Probe portst
Thermowell (for temperature probe)t
Proprietary XDR impeller/sparge systemt
All	speciﬁcations	are	subject	to	change	without	notice.
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CONTROL AUTOMATION PLATFORM
The XDR Control Platform is comprised of a Rockwell/Allen Bradley controller with Wonderware HMI 
and data historian. The platform delivers precise process control and offers a level of flexibility and 
convenience that is unmatched in the industry.
In addition to robust control architecture, the XDR features a highly intuitive user interface that speeds 
operator training and efficiency.
uIntuitive, Powerful Interface
The XDR control system user interface was designed to provide fast and easy, yet comprehensive 
control over process configuration to the operator.  The easy-to-read screens enable dynamic adjust-
ment to key variables, and enable the operator to review complete configuration schemes at a glance. 
The high clarity touchscreen display provides an intuitive, visual interface that operators can use with 
confidence.  (See Screen 1)
The XDR system enables rapid understanding and interpretation of active control strategies through 
the use of graphical symbols.  (See Screen 2)
In addition, set-point automation tables enable the easy automation of set-point changes, permitting 
live adjustments to ramp or step to new value.  (See Screen 3)
uPowerful Control Strategies for Fast Response, Tight Control
t Cascade control strategies of pH, DO, and volume result in very tight control of critical process 
conditions. 
t Flexible closed loop control of critical process parameters support improved yields:
 t"HJUBUJPO t4QBSHF
 t(BTNJYJOH t(BTPWFSMBZ
 t-JRVJEBEEJUJPOBOESFNPWBM t5FNQFSBUVSF
 tQ) t%0(See Screen 4)
 t8FJHIU
t %ZOBNJDSFDPOöHVSJOHPGDBTDBEFDPOUSPMMPPQTFOBCMFTFYDFQUJPOBMQSPDFTTøFYJCJMJUZ  
uComprehensive, Real-Time Data Capture, Reporting and Trending
t 5IFSFBMUJNFEBUBIJTUPSJBODBQUVSFTBMMQSPDFTTQBSBNFUFSTBOEUJNFTBOEPòFST 
accessible look-up.
t &YQPSUPGEBUBUPPUIFSNBTUFSEBUBSFQPTJUPSZTZTUFNTJTTVQQPSUFEXJUICVJMUJOGVODUJPOBMJUZ
t 3FBMUJNFBMBSNJOHQSPUFDUTQSPDFTTJOUFHSJUZBOEIFMQTBWPJEMPTUCBUDIFT
t "MMBMBSNTBSFMPHHFEUPEBUBCBTF
Screen 1 - System Overview
Screen 2 - Cascade Loop Control
Screen 3 -Set Point Automation Tables
Screen 4 - DO Strategy Set-Up Screen
XDR PERFORMANCE DATA
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CHO Process -Titer Data
XDR vs 10L glass reactor
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CHO Perfuson Process-Cell Culture Data
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Figure 1:  CHO Process - Titer Data  (XDR vs. 10L Glas  Reactor)
Figure 2:  CHO Process - Viability Data  (XDR vs. 10L Glass Reactor)
Figure 3:  CHO Perfusion Process - Viability Data  (XDR vs. 10L Glass Reactor)
Figures 1-3 illustrate examples of first-run data 
for a series of CHO processes, demonstrating the 
XDR system’s ability to achieve immediate process 
equivalence.  Additional, extensive data is available 
on request.
FIGURE 1:    XDR achieved equivalent or better titer 
during scale-up from a 10 liter glass reactor to a 
200 L XDR to a 1000 liter XDR.
FIGURE 2:    XDR achieved equivalent or better cell 
viability during scale-up from a 10 liter glass reac-
tor to a 200L XDR to a 1000 liter XDR.
FIGURE 3:    XDR achieved process equivalence for 
a perfusion process at the 200L and 1000L scale.
Xcellerex, Inc. Toll Free: 1-866-Xcellerex
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FOR ADDITIONAL INFORMATION
To learn more about XDR Single-Use Bioreactors or other Xcellerex systems or services, 
please contact customer service at:
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DATA SHEET HyPerforma 2:1 50 L Single-Use Bioreactor
HyPerforma 2:1 50 L Single-Use Bioreactor 
• Integrally sealed ports in the S.U.B. BPC allow for 
addition of sensor probes and line sets
• Available in Thermo Scientific™ CX5-14 Film and 
Thermo Scientific™ Aegis™ 5-14 Film options
System options—adaptable to your needs
• Optional electrical box for agitation control
 – Temperature may be controlled from electrical box on 
S.U.B.s with resistive heater
 – Water-jacketed S.U.B.s require a separate external 
temperature control unit 
• Exhaust gas vent filter heaters
• Load cells
• Cable management tree
• Process control system
• See Table 12 for auxiliary components for S.U.B. control 
management; choose an open-architecture approach or 
a turnkey, ready-to-use Thermo Scientific™ S.U.B. system
The next generation of performance
The Thermo Scientific™ HyPerforma™ Single-Use Bioreactor 
(S.U.B.) provides enhanced functionality, ease of use, 
and efficiency. The complete HyPerforma S.U.B. system 
consists of a bioreactor tank and Thermo Scientific™ 
HyPerforma™ S.U.B. BioProcess Container (BPC) for 
the 50 L size with a 2:1 turndown ratio. The upgraded 
HyPerforma S.U.B. maintains traditional stirred-tank 
bioreactor design principles, including specific height-to-
diameter ratios and optimized mixer location that deliver 
optimum performance for cell density, viability, and 
scalability from process development through production.
This data sheet provides information on the 50 L S.U.B. 
system, which includes the tank and standard S.U.B. 
BPC. The BPC utilizes dual-sparger configurations with a 
porous-frit sparger and drilled-hole or open-pipe sparger 
that have been rigorously tested to provide high kLa values 
and optimal CO2 stripping for improved pH control and 
decreased foaming.
The S.U.B. system consists of the following 
components:
S.U.B. hardware unit—available in open-architecture or 
integrated format
• Complete mixing system with a choice of water jacket or 
resistive heater
• Drive shaft inserts into the S.U.B. BPC through the mixing 
drive motor and locks into the BPC agitator assembly
S.U.B. BPC—supplied sterile and ready to use
• Agitator assembly is a single-use (polyethylene) impeller 
with a bearing-and-seal assembly linked to an external 
mixer drive
• Dual gas spargers available with either drilled-hole or 
open-pipe sparger and standard porous-frit sparger
• Exhaust (vent) filter
Standard S.U.B. hardware units
The 50 L standard S.U.B. hardware units are available in 
the following confi gurations (Table 1).
• Water jacket with DC motor
• Water jacket with AC motor
• Resistive heater with DC motor
• Resistive heater with AC motor
Additional options are listed in Tables 3–7.
1. Exhaust vent fi lter holder
2. Mixing assembly with shield
3. Bearing port receiver with clamp
4. Mixer motor
5. Stainless steel (304) outer support container
6. Electrical control panel (optional)
7. Water jacket (3/8 in. dimpled) or resistive blanket 
(side and bottom)
8. Leveling casters
9. Bleed valve (water jacketed models only)
10. 1.5 in. tri-clamp water inlet/outlet ports (water jacketed 
models only)
11. Standard tool set: 3/8 in. x 150 in.-lb square torque 
wrench; load cell and motor cap lockout wrench
12. Drive shaft (stored)
13. Probe hanger bracket
14. Probe access windows
15. Cart assembly
16. Liquid sight windows
17. Bottom cutouts/pins for BPC attachment and alignment
1
3
2
4
5
6
7
8
9
11
16
17
12
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14
15
10
Design features
Side view
Note: Load cells are available as optional components.
Front view
Table 1. 50 L standard S.U.B. hardware unit with casters 
(leveling feet).
Description Cat. No.
Resistive, DC motor SUB0050.9001
Water jacketed, DC motor SUB0050.9002
Resistive, 120 VAC, AC motor SUB0050.9003
Water jacketed, 120 VAC, AC motor SUB0050.9004
Resistive, 240 VAC, AC motor SUB0050.9005
Water jacketed, 240 VAC, AC motor SUB0050.9006
Figure 1. 50 L S.U.B. hardware unit with water jacket or resistive heater.
Table 2. 50 L S.U.B. system specifi cations.
Specifi cations for AC and DC motors, resistive and water jacketed
AC motor DC motor
Resistive Water jacketed Resistive Water jacketed
B
io
re
ac
to
r 
ge
om
et
ry
Rated liquid working volume 50 L
Minimum liquid working volume 25 L
Total bioreactor volume (liquid and gas) 65.5 L
BPC chamber diameter 34.9 cm (13.75 in.)
BPC chamber shoulder height 80 cm (31.5 in.)
Liquid height at rated working volume 52.1 cm (20.5 in.)
Fluid geometry at working volume (height:diameter ratio) 1.5:1
Overall bioreactor geometry (height:diameter ratio) 1.9:1
Tank baffl es No
Im
p
el
le
r
Impeller (quantity x blade count) 1 x 3
Impeller scaling (impeller diameter/tank diameter) 1/3
Impeller blade pitch (angle) 45°
Impeller diameter 11.11 cm (4.375 in.)
Impeller calculated power number (N) 2.1
A
gi
ta
tio
n
Maximum mixing rate 30–200 rpm
Nominal agitation rating (power/volume) 20 W/m3
Nominal agitation 50% working volume: 145 rpm
100% working volume: 183 rpm
Nominal tip speed 103.9 cm/s (204.6 ft/min)
Counterclockwise mixing fl ow direction Down-pumping
Agitation shaft resolved angle 19.6°
Agitation shaft centerline offset 1.9 cm (0.75 in.)
Overall drive shaft length 76.2 cm (30 in.)
Drive shaft diameter 1.27 cm (0.5 in.)
Drive shaft poly-sheath outside diameter 2.54 cm (1 in.)
Impeller clearance from tank bottom 11.75 cm (4.63 in.)
Front viewTop view
Figure 2. 50 L S.U.B. hardware unit dimensions.
22.3 in. 
(57 cm)
cart width
78.2 in. (199 cm) fi lter height
55.5 in. (141 cm) motor height
46.2 in. (117 cm) tank height
17.5 in. (45 cm) tank bottom
6.1 in. (16 cm) cart height
0 in. (0 cm)
21.4 in. (54 cm)
cart length
34.0 in. (86 cm)
overall length
37.1 in. (94 cm)
overall width
13.8 in. (35 cm)
electrical
box width
Table 2. 50 L S.U.B. system specifications (continued).
Specifications for AC and DC motors, resistive and water jacketed
AC motor DC motor
Resistive Water jacketed Resistive Water jacketed
M
ot
o
r
Agitation motor drive (type, voltage, phase),  
AC motor only
Induction, 208 VAC, 3 –
Agitation motor drive (type, voltage), DC motor only – Brushless, 48 VDC
Motor power rating (AC motor) 0.25 hp (186.4 W) –
Motor power rating (DC motor) – 0.268 hp (200 W)
Motor torque rating 82 in.-lb (9.5 N-m) –
Gear reduction 10:1
Programmable VFD, remote panel interface, power 
fault auto restart 
Standard –
Motor communication methods (for external 
controller)
0–10 V, 4–20 mA, ModBus –
Te
m
p
er
at
ur
e 
co
nt
ro
l
R
es
is
ti
ve
 h
ea
te
r
Programmable PID temperature controller Standard – Standard –
Solid state relay (discrete voltage signal) 24–240 V AC/DC – 24–240 V AC/DC –
Heater power rating (total) 455.7 W – 455.7 W –
Heater power rating (sides) 360 W – 360 W –
Heater power rating (bottom) 95.7 W – 95.7 W –
Approximate liquid heat-up time (5–37°C) 4.32 hr – 4.32 hr –
W
at
er
 ja
ck
et
Jacket area: full/half volume (ft2) – 4.4/2 – 4.4/2
Jacket volume – 2.4 L – 2.4 L
Jacket flow rate at 50 psi (3.4 bar) – 136 L/min – 136 L/min
Process connection – 1.5 in. sanitary tri-clamp –
1.5 in. sanitary 
tri-clamp
Nominal heating/cooling load (W) – 500 W – 500 W
Approximate liquid heat-up time (5–37°C) – 1.7 hr – 1.7 hr
M
is
c.
RTD or thermocouple, 1/8 in. (3.18 mm) OD RTD: Pt-100 (standard)
S
up
p
o
rt
 
co
nt
ai
ne
r
Overall width 94.2 cm (37.1 in.) with E-Box 56.5 cm (22.25 in.)
Overall length 84.3 cm (33.2 in.) with E-Box 77 cm (30.3 in.)
Overall height 198.6 cm (78.2 in.)
Dry skid weight (mass) 134.3 kg (296 lb) 115.7 kg (255 lb) 134.3 kg (296 lb) 115.7 kg (255 lb)
Wet skid weight, rated working volume (mass) 184.2 kg (406.2 lb) 165.7 kg (365.2 lb) 184.2 kg (406.2 lb) 165.7 kg (365.2 lb)
G
en
er
al
Ceiling height required for drive shaft loading 213.4 cm (84 in.)
Electrical power supply requirement (voltage,  
phase, current) 120/240 VAC, single, 20/10 A Dependent on controller
Tested system reliability (minimum) 0.9 at 90%
pH and DO probe, autoclavable type (Applisens™, 
Broadley James™, Mettler Toledo™, Finesse™) 12 mm diameter x 215–235 mm insertion length x 13.5 PG (pipe) thread
Noise level < 70 dB at 1.5 m
R
ec
o
m
m
en
d
ed
 o
p
er
at
in
g 
p
ar
am
et
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s
Operating temperature range Ambient to 40 ± 0.1°C (104 ± 0.2°F)
Motor speed 30–200 rpm
Volume range 25–50 L
Maximum BioProcess Container pressure 0.5 psi (0.03 bar)
Continuous operating time 21 days mixing time at nominal volume only
 
System options 
Table 3 lists available options for the 50 L S.U.B.
• Sparger support line (Figure 3)—keeps gas lines in an 
upright position for optimal gas transfer
• Heavy-duty tubing clamps (Figure 4)—used for each 
probe port not in use, eliminating process fluid holdup
• Sterile sampling manifolds—available in 50 mL size for 
off-line sample retention
• Load cells (Figure 5)—Mettler Toledo™ FlexMount™ 
load cells allow for reading of batch liquid weight; three 
load cells are mounted with summing box on the S.U.B. 
hardware unit
• Bioreactor probe assemby (Figure 6)—required for 
each sterile electrochemical probe insertion
• Autoclave tray (Figure 7)—aids in holding the probe 
assembly during the autoclave process
• S.U.B. temperature sample port (Figure 8)—
provides off-line temperature probe calibration prior to 
system startup
• Cable management tree (Figure 9)—allows the end 
user to organize the S.U.B. BPC tubing lines for operator 
ease of use
Table 3. 50 L S.U.B. system options.
Description Cat. No.
Cable management tree SV50992.01
Load cell with summation box, without display SV50988.01
Autoclave tray SV50177.01
Kleenpak™ bioreactor probe assembly SH30720.01
AseptiQuik™ bioreactor probe assembly SH30720.02
Sparger line support SV50177B.19
Heavy-duty tubing clamp (each) SV20664.01
Heavy-duty tubing clamps (10 pack) SV20664.03
Sterile sampling manifold with Luer lock (each) SH30845.01
Sterile sampling manifold with Luer lock 
(10 pack)
SH30845.02
S.U.B. temperature/sample port SV20750.01
 
Additional information on autoclave tray:
• Fabricated from stainless steel
• Contains plastic carry handle for easy transport right out 
of the autoclave
• Positions probes on 15% incline for greater longevity
• Prevents probe bellows from collapsing 
during sterilization
• Accommodates two probes
Autoclave tray
Handle
Figure 7. Autoclave tray for probe kits. Figure 9. Cable management tree.
Figure 3. Sparger  
support line.
Figure 4. Heavy-duty  
tubing clamps.
Figure 5. Load cells. Figure 6. Bioreactor probe assembly.
Figure 8. S.U.B. temperature sample port.
Probe
Bioreactor probe 
assembly
Vent heaters 
Vent heaters aid in reducing moisture buildup on exhaust 
filters from system off-gassing. Vent heaters are factory 
preset at 50°C to allow for condensation to return to the 
vessel. Recommended gassing strategies of the S.U.B. 
system are in the S.U.B. Validation Guide. Table 4 lists 
available vent heaters.
Table 4. Vent heater required for each exhaust filter on the  
S.U.B. BPC.
Description Cat. No.
100–120 VAC, power cord, for Pall KA3 filter SV50191.11
200–240 VAC, power cord, for Pall KA3 filter SV50191.13
100–120 VAC, for Meissner 10 in. filter, 
United States and Japan
SV50191.16
200–240 VAC, for Meissner 10 in. filter, 
United Kingdom
SV50191.17
200–240 VAC, for Meissner 10 in. filter, 
Europe CEE 7/7
SV50191.18
200–240 VAC, for Meissner 10 in. filter, IEC320 
power cord
SV50191.19
 
Table 5. Harsh mount load cell display options.
Description Cat. No.
Mettler Toledo IND331 display, with analog 
interface (STD), 120 VAC U.S. line cord/plug
SV50177.306
Mettler Toledo IND331 display, with Allen-
Bradley RIO interface, 120 VAC U.S. line 
cord/plug
SV50177.307
Mettler Toledo IND331 display, with DeviceNet 
interface, 120 VAC U.S. line cord/plug
SV50177.308
Mettler Toledo IND331 display, with Ethernet/
IP and Modbus TCP interface, 120 VAC U.S. 
line cord/plug
SV50177.309
Mettler Toledo IND331 display, with Profibus 
interface, 120 VAC U.S. line cord/plug
SV50177.310
 
Table 6. Available spare parts list.
Description Cat. No.
DC motor SV50237.07
AC motor SV50237.16
Drive shaft SV50177.34
RTD 120 in. with Bulgin connector SV50177.363
Probe holders SV50177.23
Autoclave tray (stainless steel with plastic 
carry handle)
SV50177.01
Adjustable filter bracket SV50177.313
 
Table 7. Standard 50 L dual sparger S.U.B. BPCs.
Film Dual sparger configuration Cat. No.
CX5-14 film Open-pipe and porous-frit 
spargers
SH30774.01
Aegis5-14 film Open-pipe and porous-frit 
spargers
SH30972.01
CX5-14 film Drilled-hole and porous-frit 
spargers
SH30985.01
Aegis5-14 film Drilled-hole and porous-frit 
spargers
SH30999.01
 
Table 8. Standard 50 L S.U.B. BPC packaging.
Outer packaging Supplied "flat-packed"
Two polyethylene outer layers 
Label Description
Product code
Lot number
Expiry date on outer packaging and 
shipping container
Sterilization Irradiation (25–40 kGy) inside 
outer packaging
Shipping 
container
Durable cardboard carton
Documentation Certificate of Analysis provided with each 
lot for each delivery
 
Harsh mount load cell display 
Required for weight readout from the Mettler Toledo™ 
summing box, various signal output options are provided 
for external control monitoring (Table 5). More information 
can be found in the Load Cell Data Sheet.
Spare parts 
Table 6 lists the available spare parts of the 50 L 
S.U.B. systems.
Standard 50 L dual sparger S.U.B. BPC systems 
Table 7 shows the available dual sparger options for the 
50 L S.U.B. BPC system in either configuration: open-pipe 
and porous-frit spargers (Figure 10, Table 9) or drilled-hole 
and porous-frit spargers (Figure 11, Table 10). Standard 
S.U.B. BPC packaging is shown in Table 8. 
Table 9. Specifications for the standard 50 L dual-sparger S.U.B. BPC with open-pipe and porous-frit spargers.
Line Description Tubing set (inner diameter x outer diameter x length) End treatment
1 Overlay gas sparger 1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex™ tubing x 6 in. (15 cm) 
0.2 µm hydrophobic vent filter with 
Emflon™ II membrane
2 Inoculum addition
1/4 (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x 60 in. (152 cm) reduced to 
1/8 in. (3.2 mm) x 1/4 in. (6.4 mm) C-Flex tubing x 12 in. (30 cm)
Plugged
3–6 Probe ports (4) 1/2 in. (12.7 mm) tube ports
Kleenpak aseptic connectors—
KPCHT series (female)
7
Thermowell/small-
volume sample
Thermowell adapter for 1/4 in. (6.4 mm) diameter
1/8 in. (3.2 mm) x 1/4 in. (6.4 mm) C-Flex tubing x 18 in. (46 cm)
SterilEnz™ pouch with injection site 
assembly
8 Bottom drain harvest
1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 60 in. (152 cm) reduced 
to 3/8 in. (9.5 mm) x 5/8 in. (15.9 mm) C-Flex tubing x 12 in. (30 cm) splits to
1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x 12 in. (30 cm) reduced 
to 1/8 in. (3.2 mm) x 1/4 in. (6.4 mm) C-Flex tubing x 12 in. (30 cm) and
3/8 in. (9.5 mm) x 5/8 in. (15.9 mm) C-Flex tubing x 12 in. (30 cm)
Plugged
3/8 in. MPC insert
9 Base addition
1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x 6 in. (15 cm) reduced to
1/8 in. (3.2 mm) x 1/4 in. (6.4 mm) C-Flex tubing x 60 in. (152 cm)
Plugged
10, 11 Feed lines
3/8 in. (9.5 mm) x 5/8 in. (15.9 mm) C-Flex tubing x 60 in. (152 cm) splits to
1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x 12 in. (30 cm) reduced 
to 1/8 in. (3.2 mm) x 1/4 in. (6.4 mm) C-Flex tubing x 12 in. (30 cm) and
3/8 in. (9.5 mm) x 5/8 in. (15.9 mm) C-Flex tubing x 12 in. (30 cm)
SteriEnz pouch with injection site 
assembly, 3/8 in. MPC body
12 Exhaust line
1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 6 in. (15 cm) splits to
1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 6 in. (15 cm) and
1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 10 in. (25 cm) 
Kleenpak aseptic connector—KPCHT 
series (female)
Kleenpak 0.2 µm exhaust vent filter
13
Open-pipe macro 
sparger
1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x 3 in. (8 cm) connected 
to check valve and 1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x 
48 in. (122 cm)
0.2 µm hydrophobic vent filter with 
Emflon II membrane
14
Porous-frit micro 
sparger
1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x 6 in. (15 cm) connected 
to check valve and 1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x 
48 in. (122 cm)
Hydrophobic vent filter with Emflon II 
membrane
Front face
Back face
2. Inoculum addition
Impeller
3–6. Probe ports (4)
8. Bottom drain harvest
7. Thermowell/small volume sample
1. Overlay gas sparger
12. Exhaust line
9. Base addition
14. Porous-frit micro sparger
13. Open-pipe macro sparger
11. Feed line
10. Feed line
Figure 10. Standard 50 L dual-sparger S.U.B. BPC with open-pipe and porous-frit spargers.
Table 10. Specifi cations for the standard 50 L dual-sparger S.U.B. BPC with drilled-hole and porous-frit spargers.
Line Description Tubing set (inner diameter x outer diameter x length) End treatment
1 Overlay gas sparger 1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x 6 in. (15 cm) 
Hydrophobic vent fi lter with Emfl on II 
membrane, connected to 6 in. (15 cm) 
C-Flex tubing
2 Inoculum addition
1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x 60 in. (152 cm) 
reduced to 1/8 in. (3.2 mm) x 1/4 in. (6.4 mm) C-Flex tubing x 12 in. 
(30 cm)
Plugged
3–6 Probe ports (4) 1/2 in. (12.7 mm) tube ports
Kleenpak aseptic connectors—
KPCHT series (female)
7
Thermowell/
small-volume sample
Thermowell adapter for 1/4 in. (6.4 mm) diameter 
1/8 in. (3.2 mm) x 1/4 in. (6.4 mm) C-Flex tubing x 18 in. (46 cm)
SterilEnz pouch with injection 
site assembly
8
Bottom drain
harvest
1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 60 in. (152 cm) 
reduced to 3/8 in. (9.5 mm) x 5/8 in. (15.9 mm) C-Flex tubing x 12 in. 
(30 cm) splits to 1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x 
12 in. (30 cm) reduced to 1/8 in. (3.2 mm) x 1/4 in. (6.4 mm) C-Flex 
tubing x 12 in. (30 cm) and 3/8 in. (9.5 mm) x 5/8 in. (15.9 mm) C-Flex 
tubing x 12 in. (30 cm)
Plugged
3/8 in. MPC insert
9 Base addition
1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x 6 in. (15 cm) 
reduced to 1/8 in. (3.2 mm) x 1/4 in. (6.4 mm) C-Flex tubing x 60 in. 
(152 cm)
Plugged
10, 11 Feed lines
3/8 in. (9.5 mm) x 5/8 in. (15.9 mm) C-Flex tubing x 60 in. (152 cm) 
splits to 1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x 12 in. 
(30 cm) reduced to 1/8 in. (3.2 mm) x 1/4 in. (6.4 mm) C-Flex tubing x 
12 in. (30 cm) and 3/8 in. (9.5 mm) x 5/8 in. (15.9 mm) C-Flex tubing x 
12 in. (30 cm)
SteriEnz pouch with injection site 
assembly, 3/8 in. MPC body
12 Exhaust line
1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 8 in. (20 cm) 
connected to 1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 6 in. 
(15 cm) and 1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 10 in. 
(25 cm) 
Kleenpak aseptic connector—
KPCHT series (female)
Kleenpak 0.2 µm exhaust 
vent fi lter
13
Drilled-hole macro sparger
3.5 in. (8.9 cm) disk with 
360 x 0.178 mm (0.007 in.) 
holes
1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x 3 in. (8 cm) 
connected to check valve and 1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) 
C-Flex tubing x 38 in. (97 cm)
Meissner Steridyne™ 0.2 µm 
hydrophobic fi lter connected to 6 in. 
(15 cm) C-Flex tubing
14
Porous-frit micro sparger
12 mm diameter 
(25 µm pores)
1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x 6 in. (15 cm) 
connected to check valve and 1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) 
C-Flex tubing x 35 in. (89 cm)
Meissner Steridyne 0.2 µm 
hydrophobic fi lter connected to 6 in. 
(15 cm) C-Flex tubing
Front face
Back face
Figure 11. Standard 50 L dual-sparger S.U.B. BPC with drilled-hole and porous-frit spargers.
2. Inoculum addition
Impeller
3–6. Probe ports (4)
8. Bottom drain harvest
7. Thermowell/small volume sample
1. Overlay gas sparger
12. Exhaust line
9. Base addition
14. Porous-frit micro sparger
13. Drilled-hole macro sparger
11. Feed line
10. Feed line
Table 11. Custom 50 L S.U.B. BPC options.
Category Options/capability Notes
Tubing type Thermoplastic elastomers: C-Flex, PharMed™, 
PharmaPure™ tubing
Platinum-cured silicone
PVC 
More information is available in the Tubing 
Selection Guide
Tubing size Ranging from 1/8 to 1 in. (0.318 to 2.54 cm) ID, in 
customer-specified lengths
More information is available in the Tubing 
Selection Guide
Connectors Luers, quick connects, SIP connectors, tri-clamp, aseptic 
connectors, sterile connectors, steam-to, steam-through, 
sample ports, plugs
More information is available in the 
Connector Selection Guide. Note: 
Reusable probe port connections use 
Kleenpak connector only
Probe ports Additional ports: second row of four The reusable probe port connection uses 
a Kleenpak connector only
Disposable sensors Pressure sensor: PendoTECH and Finesse Solutions 
DO and pH: Finesse Solutions and PreSens
pH: Mettler Toledo
Choice of qualified sensors available
Additional probe ports Limited engineer-to-order customization only Qualified location on second row of probe 
ports only
Port sizes Limited engineer-to-order customization only Dependent on location in BPC and fit with 
hardware (e.g., 1 in. (2.54 cm) port on 
harvest line)
Rearrangement of lines 
on existing ports
Limited customization possible (e.g., moving sample/
thermowell port to a probe tube port, or swapping overlay 
inlet line with supplement line)
Dependent on location in BPC and fit with 
hardware
Sparger Dual sparger (macro open-pipe or drilled-hole and  
micro porous-frit) standard
Sparger locations are fixed
Diptube lines Limited customization possible Length cannot interfere with impeller  
and shaft
Overlay and sparger line 
filters
Filter options available from standard component library Choice of qualified filters available
Vent filters Standard is Pall or Meissner 0.2 µm exhaust vent filter Filters must be compatible with available 
vent filter heater configurations
Vent filter tubing length Extended filter height above the S.U.B. BPC is  
made to order
Must be compatible with a vent filter 
bracket option
Filters on media and 
supplement inlets
Limited engineer-to-order customization only; choice of 
filters used to sterilize incoming media or supplements  
are available
Choice of qualified filters available
 
Custom S.U.B. BPC Options 
Table 11 lists available custom 50 L S.U.B. BPC system 
options. Not all options are available for all ports. For 
additional information, please see the selection guides in 
the single-use products catalog.
Find out more at thermofisher.com/sut
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Table 12. Recommended S.U.B. parts list for first-time operators.
Description Quantity Cat. No./auxiliary part
S.U.B. hardware unit 1 Type to be configured
S.U.B. BPC 3 Type to be configured
Bioreactor probe assembly (nonsterile for use in autoclave) 12 SH30720.01
Heavy-duty tubing clamp 12 SV20664.01
Autoclave tray for autoclaving probe assemblies 1 SV50177.01
Auxiliary parts supporting the single-use bioreactor 
(supplied by end user or requested turnkey)
Necessary for gas flow control, DO, and pH set points 1 Bioreactor control system
Autoclavable probe (13 mm x 13.5 PG thread with 195–235 mm insertion length) * DO probe
Autoclavable probe (13 mm x 13.5 PG thread with 195–235 mm insertion length) * pH probe
Tubing welder, steam-in-place system, sterilizer, or laminar flow hood * Sterile/aseptic connection 
Used for fluid transfer between linesets on the containers * Stand-alone peristaltic pump
Necessary for water jacket temperature controls (not provided) * Temperature control unit (TCU)
 * Quantity based on needs.
External controller options 
The HyPerforma S.U.B. offers an open architecture or 
turnkey system. An open architecture system allows you 
to use any control system of your choice. The capital 
investment can be reduced by using a control system 
already utilized in your facility. A turnkey system is a ready-
to-use, out-of-the-box system with a choice of dedicated 
controls from Finesse Solutions or Applikon. These 
systems work on PC, DeltaV, Allen Bradley, or Siemens 
formats. Contact your local sales representative for 
more information.
1DATA SHEET 5:1 Single-Use Bioreactor 
 HyPerforma 5:1 250 L 
Single-Use Bioreactor
The HyPerforma S.U.B. system consists of 
the following components:
• S.U.B. hardware unit available in turnkey format
• Complete mixing system with water jacket
• Drive shaft inserts into the S.U.B. BPC through the mixing 
drive motor and locks into the BPC agitator assembly
Introduction
The Thermo Scientifi c™ HyPerforma™ Single-Use Bioreactor 
(S.U.B.) provides state-of-the-art functionality, ease of use, 
and effi ciency. The complete HyPerforma S.U.B. system 
consists of a bioreactor tank and HyPerforma S.U.B. 
BioProcess Container (BPC), which is available in 
50, 100, 250, 500, 1,000, and 2,000 L sizes. The 
redesigned HyPerforma S.U.B. maintains traditional 
stirred-tank bioreactor design principles, including specifi c 
height-to-diameter ratios and optimized mixer location that 
deliver optimum cell viability, performance, and scalability 
from process development through production. Design 
is optimized for the 250 L bioreactor tank, which allows 
for mixing at a 5:1 turndown ratio. Advantages of the 5:1 
system include: 
• Streamlining bioprocesses by reducing seed vessel 
requirements and maximizing process vessel usage
• Seed vessels at 20% volume then feed up to full volume
• Reduce cell transfers and associated adaptation
• Reduce the number of single-use BPC usage
This data sheet provides information on the HyPerforma 
5:1 250 L S.U.B. system, which includes the tank and 
standard S.U.B. BPC. The BPC utilizes dual-sparger 
design for cultures at nominal volume and a crossfl ow 
sparger strategically positioned just above the 20% 
liquid volume for seed cultures. Both sparge designs 
have been rigorously tested to provide high kLa values 
and optimal CO2 stripping for improved pH control and 
decreased foaming.
2Standard HyPerforma 5:1 S.U.B. hardware units
The 250 L standard 5:1 S.U.B. hardware units are available 
in the configurations below.
• 250 L jacketed S.U.B. with a 5:1 turndown ratio, AC 
motor, no E-box, and load cells without display
• 250 L jacketed S.U.B. with a 5:1 turndown ratio, AC 
motor, 120 VAC, E-box, and analog load cells
• 250 L jacketed S.U.B. with a 5:1 turndown ratio, AC 
motor, 240 VAC, E-box, and analog load cells
Top viewFront view
Table 1. 250 L standard 5:1 S.U.B. hardware unit with 
casters (leveling feet).
Description Cat. No.
250 L jacketed S.U.B. with a 5:1 
turndown ratio, AC motor, 120 VAC, 
no E-box, and analog load cells
SUB0250.8300
250 L jacketed S.U.B. with a 5:1 
turndown ratio, AC motor, 120 VAC, 
E-box, and analog load cells
SUB0250.8301
250 L jacketed S.U.B. with a 5:1 
turndown ratio, AC motor, 240 VAC, 
E-box, and analog load cells
SUB0250.8302
Figure 1. 250 L 5:1 S.U.B. hardware unit dimensions.
S.U.B. BPC (gamma-irradiated and ready to use)
• Agitator assembly is a single-use (polyethylene)  
impeller with a bearing/seal assembly linked to an 
external mixer drive
• Dual gas spargers available with crossflow and  
drilled-hole design
• Vent filter outlet for system exhaust
• Integrally sealed ports in the S.U.B. BPC allow for 
additional sensor probes and line sets
• Available in Thermo Scientific™ CX5-14 film and  
Aegis™ 5-14 Film options
System options (adaptable to your needs)
• Optional electrical box for remote agitation control
 – HyPerforma 5:1 S.U.B.s require a separate external 
temperature control unit
• Exhaust gas vent filter heaters
• Load cells
• Cable management tree
• Process control system
• See the ordering information for auxiliary components 
for S.U.B. control management. Choose an open 
architecture approach or a turnkey “ready-to-use” 
Thermo Scientific™ HyPerforma™ S.U.B. system
Additional options are listed in Tables 3–7.
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Back viewFront view
1. Exhaust vent filter holder (optional)
2. Mixing assembly with shield
3. Mixer motor
4. Bearing port receiver with clamp
5. Liquid sight windows
6. Electrical control panel (optional) 
7. Probe hanger bracket
8. Probe access windows
9. Leveling casters
10. Load cells
11.  Standard tool set: 3/8 in. x 150 in.-lb. square torque  
 wrench, load cell, and motor cap lockout wrench
12. Cable management tree
13. Drive shaft (stored)
14. Stainless steel (grade 304) outer support container
15. Bleed valve
16. 3/8 in. dimpled jacket (side)
17.  Cart assembly
18. Bottom cutouts/pins for BPC attachment/alignment
19. Quick-connect water inlet/outlet ports
Design features
Figure 2. 250 L 5:1 S.U.B. hardware unit.
4 AC motor DC motor
B
io
re
ac
to
r 
ge
om
et
ry
Rated liquid working volume 250 L
Minimum liquid working volume 50 L
Total reactor volume (liquid and gas) 316 L
BPC chamber diameter 59.7 cm (23.5 in)
BPC chamber shoulder height 115.6 cm (45.5 in)
Liquid height at rated working volume 91.4 cm (36 in)
Fluid geometry at working volume (height:diameter ratio) 1.5:1
Overall reactor geometry (height:diameter ratio) 1.9:1
Tank baffles No
G
en
er
al
Ceiling height required for drive shaft loading 267.46 cm (105.3 in)
Electrical power supply requirement (voltage, phase, current) 120/240 VAC, single, 20/10 A Dependent on controller
pH & dissolved oxygen (DO) probe, autoclavable type 12 mm diameter x 215-235 mm insertion length  x 13.5 PG (pipe) thread
Noise level < 70 dB at 1.5 m
Im
p
el
le
r
Impeller (quantity x blade count) 1 x 3
Impeller scaling (impeller diameter/tank diameter) 1/3
Impeller blade pitch (angle) 45°
Impeller diameter 20 cm (7.88 in)
Impeller, calculated power number (N) 2.1
A
gi
ta
tio
n
Maximum mixing rate 30-150 rpm
Nominal agitation rating, power/volume ratio 20 W/m3
Nominal agitation, 20% working volume 69 rpm
Nominal agitation, 50% working volume 93 rpm
Nominal agitation, 100% working volume 117 rpm
Nominal tip speed 123.6 cm/s (243.3 ft./min)
Counterclockwise mixing flow direction Down-pumping
Agitation shaft resolved angle 16.5°
Agitation shaft centerline offset 3.3 cm (1.3 in.)
Overall drive shaft length 120.9 cm (47.6 in.)
Drive shaft diameter 1.27 cm (0.5 in.)
Drive shaft poly-sheath outside diameter 2.54 cm (1 in.)
Impeller clearance from tank bottom 6.91 cm (2.72 in.)
Table 2. 250 L Standard 5:1 S.U.B. system specifications.
5 AC motor DC motor
M
ot
or
Agitation motor drive (type, voltage, phase), AC motor only Induction, 208 VAC,  3 phase –
Agitation motor drive (type, voltage), DC motor only – Brushless, 48 VDC
Motor power rating (AC motor) 186.4 W (0.25 hp) –
Motor power rating (DC motor) – 400 W (0.268 hp)
Motor torque rating 11.5 Nm (102 in.-lb.) –
Gear reduction 12.5:1 –
Programmable Variable-frequency drive (VFD), remote 
panel interface, power fault auto restart Standard –
Motor communication methods (for external controller) 0–10 V, 4–20 mA, Modbus –
Te
m
p
er
at
ur
e 
co
nt
ro
l
Jacket area: full/half volume 13.6/5.8 ft2
Jacket volume 8.6 L
Jacket flow rate at 3.4 bar (50 psi) 136 L/min
Process connection 1.5 in. sanitary tri-clamp
Nominal heating/cooling load (W) 2,500 W
Approximate liquid heat-up time (5–37°C), 20% volume 1.1 hr
Approximate liquid heat-up time (5–37°C), 100% volume 3.4 hr
Resistance temperature detector (RTD) or thermocouple,  
3.18 mm (1/8 in.) OD RTD: Pt-100 (standard)
S
up
p
or
t c
on
ta
in
er Overall width
112.8 cm (44.4 in.)  
with E-Box 68.5 cm (27 in.)
Overall length 102.2 cm (40.25 in.)  with E-Box 96.9 cm (38.15 in.)
Overall height 215.5 cm (84.8 in.)
Dry skid weight (mass) 223.6 kg (493 lb.)
Wet skid weight-rated working volume (mass) 473.6 kg (1044 lb.)
R
ec
om
m
en
de
d 
op
er
at
in
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m
et
er
s
Operating temperature range Ambient to 40 ± 0.1°C (104 ± 0.2°F)
Motor speed 30–150 rpm
Volume range 50–250 L
Maximum bag pressure 0.03 bar (0.5 psi)
Continuous operating time 21 days mixing time at nominal volume only
Table 2. 250 L Standard 5:1 S.U.B. specifications (continued).
6System options
Table 3 lists available S.U.B. system options for the  
250 L size. The figures referenced below appear on  
pages 6 and 7.
• Bioreactor probe assembly (Figure 3)—required for 
each sterile electrochemical probe insertion. New CPC 
AseptiQuik™ connector is used on probe assembly 
SH30720.02 and mating probe belt on S.U.B. BPC  
for connection
• Sparge line support (Figure 4)—keeps gas lines in an 
upright position for optimal gas transfer
• Heavy-duty tubing clamp (Figure 5)—used for each 
probe port not in use, eliminating process fluid holdup
• Autoclave tray for probe kits (Figure 6)—aids in holding 
the probe assembly during the autoclave process
• Additional information on autoclave tray:
 – Fabricated from stainless steel
 – Plastic carry handle for easy transport right out  
of the autoclave
 – Positions probes on 15% incline for greater  
probe/membrane longevity
 – Will restrain probe bellows from collapsing  
during sterilization
 – Probe holder accommodates two probes
• S.U.B. temperature sample port (Figure 7)— 
provides in-situ temperature monitoring during  
culture process
• Load cells (Figure 8)—Mettler-Toledo™ Flexmount™ load 
cells allow for batch liquid-weight reading and three load 
cells; three load cells are mounted with summing box on 
the S.U.B. hardware unit
Table 3. 250 L S.U.B. system options.
Description Cat. No.
Cable management tree SV50992.02
Load cell with summation box,  
without display SV50988.02
Autoclave tray SV50177.01
Bioreactor probe assembly with  
CPC AseptiQuik connector  
(nonsterile for use in autoclave)
SH30720.02
Sparge line support SV50177B.19
Heavy-duty tubing clamp (each) SV20664.01
Heavy-duty tubing clamp  
(10 per pack) SV20664.04
Sterile sampling manifold with luer 
lock (each) SH30845.01
Sterile sampling manifold with luer 
lock (10 per pack) SH30845.02
S.U.B. temperature/sample port SV20750.01
PendoTECH pressure sensor SH31134.01
Finesse pressure sensor SH31134.02
Figure 5. Heavy-duty tubing clamp.Figure 4. Sparge line support.
Figure 3. Bioreactor probe assembly.
Figure 6. Autoclave tray for probe kits.
Handle
Autoclave 
tray
Probe 
assembly
7Figure 8. Load cells.
Figure 7. S.U.B. Temperature sample port.
Figure 9. Cable management tree.
• Cable management tree (Figure 9)—allows the end  
user to organize the S.U.B. BPC tubing lines for  
operator ease of use. 
• Sterile sampling manifolds—available in 50 and  
100 mL sizes for off-line sample retention.
Vent heaters
Vent heaters aid in reducing moisture buildup in  
exhaust filters from system off-gassing. Vent heaters  
are factory-preset at 50°C, allowing for condensation to 
return to the vessel. Recommended gassing strategies of 
the S.U.B. system are in the S.U.B. Validation Guide.  
Table 4 lists available vent heaters.
Table 4. Vent heater required for each exhaust filter 
on S.U.B. BPC.
Description Cat. No.
120 VAC, 99.6 W, Meissner™  
10 in. series 46 vent filter heater,  
preset temperature bulb, IEC 320 C14
SV50191.33
240 VAC, 99.6 W, Meissner 
10 in. series 46 vent filter heater,  
preset temperature bulb, IEC 320 C14
SV50191.34
120 VAC, 99.6 W, Meissner  
10 in. series 46 vent filter heater, 
integrated, M12–4 pin connector*
SV50191.47
240 VAC, 99.6 W, Meissner  
10 in. series 46 vent filter heater, 
integrated, M12–4 pin connector*
SV50191.48
120 VAC, 23.8 W, Pall™ Kleenpak™  
KA3 series 46 vent filter heater,  
preset temperature bulb, IEC 320 C14
SV50191.31
240 VAC, 30.3 W, Pall Kleenpak  
KA3 series 46 vent filter heater,  
preset temperature bulb, IEC 320 C14
SV50191.32
120 VAC, 23.8 W, Pall Kleenpak  
KA3 series 46 vent filter heater, 
integrated, M12–4 pin connector*
SV50191.45
240 VAC, 30.3 W, Pall Kleenpak  
KA3 series 46 vent filter heater, 
integrated, M12–4 pin connector*
SV50191.46
* Require integration to a third party controller, which allows vent heater control through system HMI.
8Harsh mount load cell display
Required for remote weight readout from a Mettler-Toledo™ 
summing box, various signal output options are provided 
for external control monitoring (Table 5). More information 
can be found in the Load Cell Data Sheet.
Table 5. Harsh mount load cell display options.
Description Cat. No.
Mettler-Toledo™ IND331 display, with 
analog interface (STD), 120 VAC
U.S. line cord/plug
SV50177.306
Mettler-Toledo IND331 display, with 
Allen-Bradley RIO interface,
120 VAC U.S. line cord/plug
SV50177.307
Mettler-Toledo IND331 display, with 
device net interface, 120 VAC
U.S. line cord/plug
SV50177.308
Mettler-Toledo IND331 display, with 
ethernet/IP and Modbus TCP
interface, 120 VAC U.S. line cord/plug
SV50177.309
Mettler-Toledo IND331 display, with 
Profibus interface, 120 VAC U.S. line 
cord/plug
SV50177.310
Spare parts
Table 6 lists the available spare parts of the 250 L S.U.B. 
systems. Spare parts are for standard reference only; 
configured S.U.B. tank drawings will be provided with a 
spare parts list specific to the S.U.B. tank ordered. 
Table 6. Available spare parts.
Description Cat. No.
DC motor SV50237.07
AC motor SV50237.16
Drive shaft SV50959.11
RTD 304.8 cm (120 in) with  
Bulgin connector SV50177.363
Probe holders SV50177.23
Probe kit autoclave (SST with  
plastic carry handle) SV50177.01
Adjustable filter bracket SV50177.313
Figure 10. Harsh mount load cell display.
9Table 7. 250 L Standard 5:1 S.U.B. BPC packaging.
Outer packaging Supplied “flat-packed”
Two polyethylene outer layers
Label Description
Product code
Lot number
Expiry date on outer packaging and shipping container
Sterilization Irradiation (25–40 kGy) inside outer packaging
Shipping container Durable cardboard carton
Documentation Certificate of Analysis provided with each lot for delivery
Figure 11. Standard 250 L 5:1 S.U.B. BPC.
Table 8. 250 L Standard 5:1 S.U.B. BPCs.
Film Cat. No.
CX5-14 film SH31074.01
Aegis5-14 film SH31075.01
250 L Standard 5:1 S.U.B. BPC systems
Table 8 shows the available standard 250 L S.U.B. BPC 
system options with drilled-hole, crossflow, and overlay 
spargers. Standard S.U.B. BPC packaging is shown in 
Table 7.
* See standard drawing specifications below. 
Impeller
5. Bottom drain 
harvest
1-4. Probe 
ports (4)
7. Thermowell/
small volume 
sample
6. Crossflow 
sparger
Back face
12. Base addition
11. Overlay gas sparger
13-14. Feed lines
15. Drilled hole 
sparger
9. Inoculum 
addition
8. Exhaust line
10. Pressure 
sensor port
Front face
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Table 9. 250 L Standard 5:1 S.U.B. BPC specifications.
Description Tubing set (inner diameter x outer diameter x length)  End treatment
1–4. Probe ports (4) 12.7 mm (1/2 in.) tube ports
CPC AseptiQuik  
aseptic connectors
5. Bottom drain harvest
12.7 mm (1/2 in) ID x 19.1 mm (3/4 in.) OD C-Flex x 152 cm (60 in). Reduced 
to 9.5 mm (3/8 in.) ID x 15.9 mm (5/8 in.) OD C-Flex x 30 cm (12 in.) Splits to 
6.4mm (1/4 in.) ID x 11.1 mm (7/16 in.) OD C-Flex x 30 cm (12 in.) Reduced to 
3.2 mm (1/8 in.) ID x 6.4 mm (1/4 in.) OD C-Flex x 30 cm (12 in.) and 9.5 mm 
(3/8 in.) ID x 15.9 mm (5/8 in.) OD C-Flex x 30 cm (12 in.)
Plugged 9.5 mm  
(3/8 in.) MPC insert
6. Crossflow sparger
6.4 mm (1/4 in.) x 11.1 mm (7/16 in.) C-Flex tubing x 8 cm (3 in.) Connected  
to check valve and 6.4 mm (1/4 in.) x 11.1 mm (7/16 in.) C-Flex tubing x  
183 cm (72 in.)
Meissner Steridyne  
50 mm filter
7.
Thermowell/small 
volume sample
Thermowell adapter for 6.4 mm (1/4 in.) diameter 3.2 mm (1/8 in.) x 
6.4 mm (1/4 in.) C-Flex tubing x 46 cm (18 in.)
SterilEnz pouch  
with injection  
site assembly
8. Exhaust line
19.1 mm (3/4 in.) x 25.4 mm (1 in.) C-Flex tubing x 30 cm (12 in.) Splits to  
19.1 mm (3/4 in.) x 25.4 mm (1 in.) x 15 cm (6 in.) and 19.1 mm (3/4 in.) x  
25.4 mm (1 in.) C-Flex tubing x 15 cm (6 in.)
AseptiQuik 
G connector 
(genderless), (2) 
Meissner Ultracap  
0.2 µm hydrophobic 
filters
9. Inoculum addition
6.4 mm (1/4 in.) x 11.1 mm (7/16 in.) C-Flex tubing x 152 cm (60 in.) Reduced 
to 3.2 mm (1/8 in.) x 6.4 mm (1/4 in.) C-Flex tubing x 30 cm (12 in.)
Plugged
10. Pressure sensor port 12.7 mm (1/2 in.) x 19.1 mm (3/4 in.) C-Flex tubing x 8 cm (3 in.)
CPC AseptiQuik 
aseptic connector
11. Overlay gas sparger  6.4 mm (1/4 in.) x 11.1 mm (7/16 in.) C-Flex tubing x 15 cm (6 in.)
Meissner Steridyne 
0.2 micron 
hydrophobic filter 
connected to 15 cm 
(6 in.) C-Flex
12. Base addition
6.4 mm (1/4 in.) x 11.1 mm (7/16 in.) C-Flex tubing x 15 cm (6 in.) Reduced  
to 3.2 mm (1/8 in.) x 6.4 mm (1/4 in.) C-Flex tubing x 152 cm (60 in.)
Plugged
13–14. Feed lines
9.5 mm (3/8 in.) x 15.9 mm (5/8 in.) C-Flex tubing x 152 cm (60 in.) Splits to 
6.4 mm (1/4 in.) x 11.1 mm (7/16 in.) C-Flex tubing x 30 cm (12 in.) Reduced 
to 3.2 mm (1/8 in.) x 6.4 mm (1/4 in.) C-Flex tubing x 30 cm (12 in.) and  
9.5 mm (3/8 in.) x 15.9 mm (5/8 in.) C-Flex tubing x 30 cm (12 in.) 
SteriEnz pouch with 
injection site
assembly 9.5 mm 
(3/8 in.) MPC body
15.
Drilled-hole sparger 
12.2 cm (4.8 in.) disk 
with 760 x 0.233 mm 
(0.009 in.) holes
6.4 mm (1/4 in.) ID x 11.1 mm (7/16 in.) OD C-Flex x 8 cm (3 in.) Connected  
to check valve and 6.4 mm (1/4 in.) ID x 11.1 mm (7/16 in.) OD C-Flex x  
150 cm (59 in).
Meissner Steridyne 
0.2 µm hydrophobic 
filter connected to  
15 cm (6 in.) C-Flex
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Custom S.U.B. BPC options
Table 10 lists available custom 250 L S.U.B. BPC system  
options. Not all options are available for all ports. For   
additional information, please see the selection guides in  
the S.U.B. BPC catalog.
Category Options/capability Notes
Tubing type
Thermoplastic elastomers: C-Flex™, Pharmed™, PharmaPure™ 
platinum cured silicone PVC
More information is available in 
the component selection guide
Tubing size
Ranging from 0.318 to 2.54 cm (1/8–1 in.) ID, in  
customer-specified lengths
More information is available in 
the component selection guide
Connectors
Luers, quick connects, SIP connectors, Tri-Clamp, aseptic 
connectors, sterile connectors, Steam-To, Steam-Through, sample 
ports, plugs, etc.
More information is available in 
the component selection guide
Probe ports Additional ports: second row of four
The reusable probe port 
connection uses a Kleenpak 
Connector only
Disposable sensors
Pressure sensor: PendoTECH and Finesse Solutions
DO and pH: Finesse Solutions and PreSens
pH: Mettler Toledo
Choice of qualified sensors 
available
Additional probe ports Limited engineer-to-order customization only
Qualified location on second row 
of probe ports only
Port sizes Limited engineer-to-order customization only
Dependent on location in BPC  
and fit with hardware (e.g., 2.54 
cm (1 in.) port on harvest line)
Re-arrangement of lines on 
existing ports
Limited customization possible, e.g., moving sample/thermowell 
port to a probe tube port, or swapping overlay inlet line with 
supplement line
Dependent on location in BPC 
and fit with hardware
Sparger
Dual sparger (macro-open pipe or drilled hole and  
micro-porous frit) standard
Sparger locations are fixed
Diptube lines Limited customization possible
Length cannot interfere with 
impeller and shaft
Overlay and sparger line 
filters
Filter options available from standard component library
Choice of qualified filters 
available
Vent filters Standard is Pall or Meissner 0.2 μm exhaust vent filter
Filters must be compatible with 
available vent filter
heater configurations
Vent filter tubing length Extended filter height above the S.U.B. BPC is make-to-order
Must be compatible with a vent 
filter bracket option
Filters on media and 
supplement inlets
Limited engineer-to-order customization only. Choice of filters 
used to sterilize incoming media or supplements are available
Choice of qualified filters 
available
Table 10. 250 L Custom 5:1 S.U.B. BPC options
Ordering information
Product Quantity Cat. No.
S.U.B. hardware unit 1 SUB0250.8300
S.U.B. BPC CX5-14 film 3 SH31074.01
S.U.B. BPC Aegis5-14 film 3 SH31075.01
Bioreactor probe assembly with CPC AseptiQuik™ (nonsterile for use in autoclave) 12 SH30720.02
Heavy-duty tubing clamp 12 SV20664.01
Autoclave tray for autoclaving probe accessories 1 SV50177.01
Auxiliary components supporting the HyPerforma S.U.B. (supplied by end user or requested turnkey)
Necessary for feed strategies, gas flow, DO, and pH control 1 Bioreactor control system
Autoclavable probe (13 mm x 13.5 PG thread with 195-235 mm insertion length) * DO probe
Autoclavable probe (13 mm x 13.5 PG thread with 195-235 mm insertion length) * pH probe
Tubing welder, steam-in-place, sterilizer, or laminar flow hood * Sterile/aseptic connection
Used for fluid transfer between linesets on the containers * Stand-alone peristaltic pump
Necessary for temperature controls (not provided) * Temperature control unit (TCU)
External controller options
The HyPerforma S.U.B. offers an open architecture or 
turnkey system. An open architecture system allows you 
to use any control system of your choice. The capital 
investment can be reduced by using a control system 
already utilized in your facility. A turnkey system is a  
ready-to-use, out-of-the-box system with a choice of 
dedicated controls from Finesse Solutions or Applikon. 
These systems work on Delta V™, Allen Bradley™, or 
Siemens™ formats. Contact your local sales representative 
for more information.
Find out more at thermofisher.com/sub
For Research Use or Further Manufacturing. Not for diagnostic use or direct administration into humans 
or animals. © 2018 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and it 
subsidiaries unless otherwise specified. C-Flex and PharMed are trademarks of Saint-Gobain. PharmaPure is a trademark of PharmaPure Tubing. 
Pall, Kleenpak, and Emflon are trademarks of Pall Corporation. SterilEnz is a trademark of PAW Bioscience Products, Inc. Steridyne is a trademark 
of Meissner Filtration Products, Inc. Specifications, terms, and pricing are subject to change. Not all products are available in all countries. Please 
consult your local sales representative for details. COL03057 0118
* Quantity based on needs
1DATA SHEET 5:1 Single-Use Bioreactor 
 HyPerforma 5:1 250 L 
Single-Use Bioreactor
The HyPerforma S.U.B. system consists of 
the following components:
• S.U.B. hardware unit available in turnkey format
• Complete mixing system with water jacket
• Drive shaft inserts into the S.U.B. BPC through the mixing 
drive motor and locks into the BPC agitator assembly
Introduction
The Thermo Scientifi c™ HyPerforma™ Single-Use Bioreactor 
(S.U.B.) provides state-of-the-art functionality, ease of use, 
and effi ciency. The complete HyPerforma S.U.B. system 
consists of a bioreactor tank and HyPerforma S.U.B. 
BioProcess Container (BPC), which is available in 
50, 100, 250, 500, 1,000, and 2,000 L sizes. The 
redesigned HyPerforma S.U.B. maintains traditional 
stirred-tank bioreactor design principles, including specifi c 
height-to-diameter ratios and optimized mixer location that 
deliver optimum cell viability, performance, and scalability 
from process development through production. Design 
is optimized for the 250 L bioreactor tank, which allows 
for mixing at a 5:1 turndown ratio. Advantages of the 5:1 
system include: 
• Streamlining bioprocesses by reducing seed vessel 
requirements and maximizing process vessel usage
• Seed vessels at 20% volume then feed up to full volume
• Reduce cell transfers and associated adaptation
• Reduce the number of single-use BPC usage
This data sheet provides information on the HyPerforma 
5:1 250 L S.U.B. system, which includes the tank and 
standard S.U.B. BPC. The BPC utilizes dual-sparger 
design for cultures at nominal volume and a crossfl ow 
sparger strategically positioned just above the 20% 
liquid volume for seed cultures. Both sparge designs 
have been rigorously tested to provide high kLa values 
and optimal CO2 stripping for improved pH control and 
decreased foaming.
2Standard HyPerforma 5:1 S.U.B. hardware units
The 250 L standard 5:1 S.U.B. hardware units are available 
in the configurations below.
• 250 L jacketed S.U.B. with a 5:1 turndown ratio, AC 
motor, no E-box, and load cells without display
• 250 L jacketed S.U.B. with a 5:1 turndown ratio, AC 
motor, 120 VAC, E-box, and analog load cells
• 250 L jacketed S.U.B. with a 5:1 turndown ratio, AC 
motor, 240 VAC, E-box, and analog load cells
Top viewFront view
Table 1. 250 L standard 5:1 S.U.B. hardware unit with 
casters (leveling feet).
Description Cat. No.
250 L jacketed S.U.B. with a 5:1 
turndown ratio, AC motor, 120 VAC, 
no E-box, and analog load cells
SUB0250.8300
250 L jacketed S.U.B. with a 5:1 
turndown ratio, AC motor, 120 VAC, 
E-box, and analog load cells
SUB0250.8301
250 L jacketed S.U.B. with a 5:1 
turndown ratio, AC motor, 240 VAC, 
E-box, and analog load cells
SUB0250.8302
Figure 1. 250 L 5:1 S.U.B. hardware unit dimensions.
S.U.B. BPC (gamma-irradiated and ready to use)
• Agitator assembly is a single-use (polyethylene)  
impeller with a bearing/seal assembly linked to an 
external mixer drive
• Dual gas spargers available with crossflow and  
drilled-hole design
• Vent filter outlet for system exhaust
• Integrally sealed ports in the S.U.B. BPC allow for 
additional sensor probes and line sets
• Available in Thermo Scientific™ CX5-14 film and  
Aegis™ 5-14 Film options
System options (adaptable to your needs)
• Optional electrical box for remote agitation control
 – HyPerforma 5:1 S.U.B.s require a separate external 
temperature control unit
• Exhaust gas vent filter heaters
• Load cells
• Cable management tree
• Process control system
• See the ordering information for auxiliary components 
for S.U.B. control management. Choose an open 
architecture approach or a turnkey “ready-to-use” 
Thermo Scientific™ HyPerforma™ S.U.B. system
Additional options are listed in Tables 3–7.
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Back viewFront view
1. Exhaust vent filter holder (optional)
2. Mixing assembly with shield
3. Mixer motor
4. Bearing port receiver with clamp
5. Liquid sight windows
6. Electrical control panel (optional) 
7. Probe hanger bracket
8. Probe access windows
9. Leveling casters
10. Load cells
11.  Standard tool set: 3/8 in. x 150 in.-lb. square torque  
 wrench, load cell, and motor cap lockout wrench
12. Cable management tree
13. Drive shaft (stored)
14. Stainless steel (grade 304) outer support container
15. Bleed valve
16. 3/8 in. dimpled jacket (side)
17.  Cart assembly
18. Bottom cutouts/pins for BPC attachment/alignment
19. Quick-connect water inlet/outlet ports
Design features
Figure 2. 250 L 5:1 S.U.B. hardware unit.
4 AC motor DC motor
B
io
re
ac
to
r 
ge
om
et
ry
Rated liquid working volume 250 L
Minimum liquid working volume 50 L
Total reactor volume (liquid and gas) 316 L
BPC chamber diameter 59.7 cm (23.5 in)
BPC chamber shoulder height 115.6 cm (45.5 in)
Liquid height at rated working volume 91.4 cm (36 in)
Fluid geometry at working volume (height:diameter ratio) 1.5:1
Overall reactor geometry (height:diameter ratio) 1.9:1
Tank baffles No
G
en
er
al
Ceiling height required for drive shaft loading 267.46 cm (105.3 in)
Electrical power supply requirement (voltage, phase, current) 120/240 VAC, single, 20/10 A Dependent on controller
pH & dissolved oxygen (DO) probe, autoclavable type 12 mm diameter x 215-235 mm insertion length  x 13.5 PG (pipe) thread
Noise level < 70 dB at 1.5 m
Im
p
el
le
r
Impeller (quantity x blade count) 1 x 3
Impeller scaling (impeller diameter/tank diameter) 1/3
Impeller blade pitch (angle) 45°
Impeller diameter 20 cm (7.88 in)
Impeller, calculated power number (N) 2.1
A
gi
ta
tio
n
Maximum mixing rate 30-150 rpm
Nominal agitation rating, power/volume ratio 20 W/m3
Nominal agitation, 20% working volume 69 rpm
Nominal agitation, 50% working volume 93 rpm
Nominal agitation, 100% working volume 117 rpm
Nominal tip speed 123.6 cm/s (243.3 ft./min)
Counterclockwise mixing flow direction Down-pumping
Agitation shaft resolved angle 16.5°
Agitation shaft centerline offset 3.3 cm (1.3 in.)
Overall drive shaft length 120.9 cm (47.6 in.)
Drive shaft diameter 1.27 cm (0.5 in.)
Drive shaft poly-sheath outside diameter 2.54 cm (1 in.)
Impeller clearance from tank bottom 6.91 cm (2.72 in.)
Table 2. 250 L Standard 5:1 S.U.B. system specifications.
5 AC motor DC motor
M
ot
or
Agitation motor drive (type, voltage, phase), AC motor only Induction, 208 VAC,  3 phase –
Agitation motor drive (type, voltage), DC motor only – Brushless, 48 VDC
Motor power rating (AC motor) 186.4 W (0.25 hp) –
Motor power rating (DC motor) – 400 W (0.268 hp)
Motor torque rating 11.5 Nm (102 in.-lb.) –
Gear reduction 12.5:1 –
Programmable Variable-frequency drive (VFD), remote 
panel interface, power fault auto restart Standard –
Motor communication methods (for external controller) 0–10 V, 4–20 mA, Modbus –
Te
m
p
er
at
ur
e 
co
nt
ro
l
Jacket area: full/half volume 13.6/5.8 ft2
Jacket volume 8.6 L
Jacket flow rate at 3.4 bar (50 psi) 136 L/min
Process connection 1.5 in. sanitary tri-clamp
Nominal heating/cooling load (W) 2,500 W
Approximate liquid heat-up time (5–37°C), 20% volume 1.1 hr
Approximate liquid heat-up time (5–37°C), 100% volume 3.4 hr
Resistance temperature detector (RTD) or thermocouple,  
3.18 mm (1/8 in.) OD RTD: Pt-100 (standard)
S
up
p
or
t c
on
ta
in
er Overall width
112.8 cm (44.4 in.)  
with E-Box 68.5 cm (27 in.)
Overall length 102.2 cm (40.25 in.)  with E-Box 96.9 cm (38.15 in.)
Overall height 215.5 cm (84.8 in.)
Dry skid weight (mass) 223.6 kg (493 lb.)
Wet skid weight-rated working volume (mass) 473.6 kg (1044 lb.)
R
ec
om
m
en
de
d 
op
er
at
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pa
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m
et
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s
Operating temperature range Ambient to 40 ± 0.1°C (104 ± 0.2°F)
Motor speed 30–150 rpm
Volume range 50–250 L
Maximum bag pressure 0.03 bar (0.5 psi)
Continuous operating time 21 days mixing time at nominal volume only
Table 2. 250 L Standard 5:1 S.U.B. specifications (continued).
6System options
Table 3 lists available S.U.B. system options for the  
250 L size. The figures referenced below appear on  
pages 6 and 7.
• Bioreactor probe assembly (Figure 3)—required for 
each sterile electrochemical probe insertion. New CPC 
AseptiQuik™ connector is used on probe assembly 
SH30720.02 and mating probe belt on S.U.B. BPC  
for connection
• Sparge line support (Figure 4)—keeps gas lines in an 
upright position for optimal gas transfer
• Heavy-duty tubing clamp (Figure 5)—used for each 
probe port not in use, eliminating process fluid holdup
• Autoclave tray for probe kits (Figure 6)—aids in holding 
the probe assembly during the autoclave process
• Additional information on autoclave tray:
 – Fabricated from stainless steel
 – Plastic carry handle for easy transport right out  
of the autoclave
 – Positions probes on 15% incline for greater  
probe/membrane longevity
 – Will restrain probe bellows from collapsing  
during sterilization
 – Probe holder accommodates two probes
• S.U.B. temperature sample port (Figure 7)— 
provides in-situ temperature monitoring during  
culture process
• Load cells (Figure 8)—Mettler-Toledo™ Flexmount™ load 
cells allow for batch liquid-weight reading and three load 
cells; three load cells are mounted with summing box on 
the S.U.B. hardware unit
Table 3. 250 L S.U.B. system options.
Description Cat. No.
Cable management tree SV50992.02
Load cell with summation box,  
without display SV50988.02
Autoclave tray SV50177.01
Bioreactor probe assembly with  
CPC AseptiQuik connector  
(nonsterile for use in autoclave)
SH30720.02
Sparge line support SV50177B.19
Heavy-duty tubing clamp (each) SV20664.01
Heavy-duty tubing clamp  
(10 per pack) SV20664.04
Sterile sampling manifold with luer 
lock (each) SH30845.01
Sterile sampling manifold with luer 
lock (10 per pack) SH30845.02
S.U.B. temperature/sample port SV20750.01
PendoTECH pressure sensor SH31134.01
Finesse pressure sensor SH31134.02
Figure 5. Heavy-duty tubing clamp.Figure 4. Sparge line support.
Figure 3. Bioreactor probe assembly.
Figure 6. Autoclave tray for probe kits.
Handle
Autoclave 
tray
Probe 
assembly
7Figure 8. Load cells.
Figure 7. S.U.B. Temperature sample port.
Figure 9. Cable management tree.
• Cable management tree (Figure 9)—allows the end  
user to organize the S.U.B. BPC tubing lines for  
operator ease of use. 
• Sterile sampling manifolds—available in 50 and  
100 mL sizes for off-line sample retention.
Vent heaters
Vent heaters aid in reducing moisture buildup in  
exhaust filters from system off-gassing. Vent heaters  
are factory-preset at 50°C, allowing for condensation to 
return to the vessel. Recommended gassing strategies of 
the S.U.B. system are in the S.U.B. Validation Guide.  
Table 4 lists available vent heaters.
Table 4. Vent heater required for each exhaust filter 
on S.U.B. BPC.
Description Cat. No.
120 VAC, 99.6 W, Meissner™  
10 in. series 46 vent filter heater,  
preset temperature bulb, IEC 320 C14
SV50191.33
240 VAC, 99.6 W, Meissner 
10 in. series 46 vent filter heater,  
preset temperature bulb, IEC 320 C14
SV50191.34
120 VAC, 99.6 W, Meissner  
10 in. series 46 vent filter heater, 
integrated, M12–4 pin connector*
SV50191.47
240 VAC, 99.6 W, Meissner  
10 in. series 46 vent filter heater, 
integrated, M12–4 pin connector*
SV50191.48
120 VAC, 23.8 W, Pall™ Kleenpak™  
KA3 series 46 vent filter heater,  
preset temperature bulb, IEC 320 C14
SV50191.31
240 VAC, 30.3 W, Pall Kleenpak  
KA3 series 46 vent filter heater,  
preset temperature bulb, IEC 320 C14
SV50191.32
120 VAC, 23.8 W, Pall Kleenpak  
KA3 series 46 vent filter heater, 
integrated, M12–4 pin connector*
SV50191.45
240 VAC, 30.3 W, Pall Kleenpak  
KA3 series 46 vent filter heater, 
integrated, M12–4 pin connector*
SV50191.46
* Require integration to a third party controller, which allows vent heater control through system HMI.
8Harsh mount load cell display
Required for remote weight readout from a Mettler-Toledo™ 
summing box, various signal output options are provided 
for external control monitoring (Table 5). More information 
can be found in the Load Cell Data Sheet.
Table 5. Harsh mount load cell display options.
Description Cat. No.
Mettler-Toledo™ IND331 display, with 
analog interface (STD), 120 VAC
U.S. line cord/plug
SV50177.306
Mettler-Toledo IND331 display, with 
Allen-Bradley RIO interface,
120 VAC U.S. line cord/plug
SV50177.307
Mettler-Toledo IND331 display, with 
device net interface, 120 VAC
U.S. line cord/plug
SV50177.308
Mettler-Toledo IND331 display, with 
ethernet/IP and Modbus TCP
interface, 120 VAC U.S. line cord/plug
SV50177.309
Mettler-Toledo IND331 display, with 
Profibus interface, 120 VAC U.S. line 
cord/plug
SV50177.310
Spare parts
Table 6 lists the available spare parts of the 250 L S.U.B. 
systems. Spare parts are for standard reference only; 
configured S.U.B. tank drawings will be provided with a 
spare parts list specific to the S.U.B. tank ordered. 
Table 6. Available spare parts.
Description Cat. No.
DC motor SV50237.07
AC motor SV50237.16
Drive shaft SV50959.11
RTD 304.8 cm (120 in) with  
Bulgin connector SV50177.363
Probe holders SV50177.23
Probe kit autoclave (SST with  
plastic carry handle) SV50177.01
Adjustable filter bracket SV50177.313
Figure 10. Harsh mount load cell display.
9Table 7. 250 L Standard 5:1 S.U.B. BPC packaging.
Outer packaging Supplied “flat-packed”
Two polyethylene outer layers
Label Description
Product code
Lot number
Expiry date on outer packaging and shipping container
Sterilization Irradiation (25–40 kGy) inside outer packaging
Shipping container Durable cardboard carton
Documentation Certificate of Analysis provided with each lot for delivery
Figure 11. Standard 250 L 5:1 S.U.B. BPC.
Table 8. 250 L Standard 5:1 S.U.B. BPCs.
Film Cat. No.
CX5-14 film SH31074.01
Aegis5-14 film SH31075.01
250 L Standard 5:1 S.U.B. BPC systems
Table 8 shows the available standard 250 L S.U.B. BPC 
system options with drilled-hole, crossflow, and overlay 
spargers. Standard S.U.B. BPC packaging is shown in 
Table 7.
* See standard drawing specifications below. 
Impeller
5. Bottom drain 
harvest
1-4. Probe 
ports (4)
7. Thermowell/
small volume 
sample
6. Crossflow 
sparger
Back face
12. Base addition
11. Overlay gas sparger
13-14. Feed lines
15. Drilled hole 
sparger
9. Inoculum 
addition
8. Exhaust line
10. Pressure 
sensor port
Front face
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Table 9. 250 L Standard 5:1 S.U.B. BPC specifications.
Description Tubing set (inner diameter x outer diameter x length)  End treatment
1–4. Probe ports (4) 12.7 mm (1/2 in.) tube ports
CPC AseptiQuik  
aseptic connectors
5. Bottom drain harvest
12.7 mm (1/2 in) ID x 19.1 mm (3/4 in.) OD C-Flex x 152 cm (60 in). Reduced 
to 9.5 mm (3/8 in.) ID x 15.9 mm (5/8 in.) OD C-Flex x 30 cm (12 in.) Splits to 
6.4mm (1/4 in.) ID x 11.1 mm (7/16 in.) OD C-Flex x 30 cm (12 in.) Reduced to 
3.2 mm (1/8 in.) ID x 6.4 mm (1/4 in.) OD C-Flex x 30 cm (12 in.) and 9.5 mm 
(3/8 in.) ID x 15.9 mm (5/8 in.) OD C-Flex x 30 cm (12 in.)
Plugged 9.5 mm  
(3/8 in.) MPC insert
6. Crossflow sparger
6.4 mm (1/4 in.) x 11.1 mm (7/16 in.) C-Flex tubing x 8 cm (3 in.) Connected  
to check valve and 6.4 mm (1/4 in.) x 11.1 mm (7/16 in.) C-Flex tubing x  
183 cm (72 in.)
Meissner Steridyne  
50 mm filter
7.
Thermowell/small 
volume sample
Thermowell adapter for 6.4 mm (1/4 in.) diameter 3.2 mm (1/8 in.) x 
6.4 mm (1/4 in.) C-Flex tubing x 46 cm (18 in.)
SterilEnz pouch  
with injection  
site assembly
8. Exhaust line
19.1 mm (3/4 in.) x 25.4 mm (1 in.) C-Flex tubing x 30 cm (12 in.) Splits to  
19.1 mm (3/4 in.) x 25.4 mm (1 in.) x 15 cm (6 in.) and 19.1 mm (3/4 in.) x  
25.4 mm (1 in.) C-Flex tubing x 15 cm (6 in.)
AseptiQuik 
G connector 
(genderless), (2) 
Meissner Ultracap  
0.2 µm hydrophobic 
filters
9. Inoculum addition
6.4 mm (1/4 in.) x 11.1 mm (7/16 in.) C-Flex tubing x 152 cm (60 in.) Reduced 
to 3.2 mm (1/8 in.) x 6.4 mm (1/4 in.) C-Flex tubing x 30 cm (12 in.)
Plugged
10. Pressure sensor port 12.7 mm (1/2 in.) x 19.1 mm (3/4 in.) C-Flex tubing x 8 cm (3 in.)
CPC AseptiQuik 
aseptic connector
11. Overlay gas sparger  6.4 mm (1/4 in.) x 11.1 mm (7/16 in.) C-Flex tubing x 15 cm (6 in.)
Meissner Steridyne 
0.2 micron 
hydrophobic filter 
connected to 15 cm 
(6 in.) C-Flex
12. Base addition
6.4 mm (1/4 in.) x 11.1 mm (7/16 in.) C-Flex tubing x 15 cm (6 in.) Reduced  
to 3.2 mm (1/8 in.) x 6.4 mm (1/4 in.) C-Flex tubing x 152 cm (60 in.)
Plugged
13–14. Feed lines
9.5 mm (3/8 in.) x 15.9 mm (5/8 in.) C-Flex tubing x 152 cm (60 in.) Splits to 
6.4 mm (1/4 in.) x 11.1 mm (7/16 in.) C-Flex tubing x 30 cm (12 in.) Reduced 
to 3.2 mm (1/8 in.) x 6.4 mm (1/4 in.) C-Flex tubing x 30 cm (12 in.) and  
9.5 mm (3/8 in.) x 15.9 mm (5/8 in.) C-Flex tubing x 30 cm (12 in.) 
SteriEnz pouch with 
injection site
assembly 9.5 mm 
(3/8 in.) MPC body
15.
Drilled-hole sparger 
12.2 cm (4.8 in.) disk 
with 760 x 0.233 mm 
(0.009 in.) holes
6.4 mm (1/4 in.) ID x 11.1 mm (7/16 in.) OD C-Flex x 8 cm (3 in.) Connected  
to check valve and 6.4 mm (1/4 in.) ID x 11.1 mm (7/16 in.) OD C-Flex x  
150 cm (59 in).
Meissner Steridyne 
0.2 µm hydrophobic 
filter connected to  
15 cm (6 in.) C-Flex
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Custom S.U.B. BPC options
Table 10 lists available custom 250 L S.U.B. BPC system  
options. Not all options are available for all ports. For   
additional information, please see the selection guides in  
the S.U.B. BPC catalog.
Category Options/capability Notes
Tubing type
Thermoplastic elastomers: C-Flex™, Pharmed™, PharmaPure™ 
platinum cured silicone PVC
More information is available in 
the component selection guide
Tubing size
Ranging from 0.318 to 2.54 cm (1/8–1 in.) ID, in  
customer-specified lengths
More information is available in 
the component selection guide
Connectors
Luers, quick connects, SIP connectors, Tri-Clamp, aseptic 
connectors, sterile connectors, Steam-To, Steam-Through, sample 
ports, plugs, etc.
More information is available in 
the component selection guide
Probe ports Additional ports: second row of four
The reusable probe port 
connection uses a Kleenpak 
Connector only
Disposable sensors
Pressure sensor: PendoTECH and Finesse Solutions
DO and pH: Finesse Solutions and PreSens
pH: Mettler Toledo
Choice of qualified sensors 
available
Additional probe ports Limited engineer-to-order customization only
Qualified location on second row 
of probe ports only
Port sizes Limited engineer-to-order customization only
Dependent on location in BPC  
and fit with hardware (e.g., 2.54 
cm (1 in.) port on harvest line)
Re-arrangement of lines on 
existing ports
Limited customization possible, e.g., moving sample/thermowell 
port to a probe tube port, or swapping overlay inlet line with 
supplement line
Dependent on location in BPC 
and fit with hardware
Sparger
Dual sparger (macro-open pipe or drilled hole and  
micro-porous frit) standard
Sparger locations are fixed
Diptube lines Limited customization possible
Length cannot interfere with 
impeller and shaft
Overlay and sparger line 
filters
Filter options available from standard component library
Choice of qualified filters 
available
Vent filters Standard is Pall or Meissner 0.2 μm exhaust vent filter
Filters must be compatible with 
available vent filter
heater configurations
Vent filter tubing length Extended filter height above the S.U.B. BPC is make-to-order
Must be compatible with a vent 
filter bracket option
Filters on media and 
supplement inlets
Limited engineer-to-order customization only. Choice of filters 
used to sterilize incoming media or supplements are available
Choice of qualified filters 
available
Table 10. 250 L Custom 5:1 S.U.B. BPC options
Ordering information
Product Quantity Cat. No.
S.U.B. hardware unit 1 SUB0250.8300
S.U.B. BPC CX5-14 film 3 SH31074.01
S.U.B. BPC Aegis5-14 film 3 SH31075.01
Bioreactor probe assembly with CPC AseptiQuik™ (nonsterile for use in autoclave) 12 SH30720.02
Heavy-duty tubing clamp 12 SV20664.01
Autoclave tray for autoclaving probe accessories 1 SV50177.01
Auxiliary components supporting the HyPerforma S.U.B. (supplied by end user or requested turnkey)
Necessary for feed strategies, gas flow, DO, and pH control 1 Bioreactor control system
Autoclavable probe (13 mm x 13.5 PG thread with 195-235 mm insertion length) * DO probe
Autoclavable probe (13 mm x 13.5 PG thread with 195-235 mm insertion length) * pH probe
Tubing welder, steam-in-place, sterilizer, or laminar flow hood * Sterile/aseptic connection
Used for fluid transfer between linesets on the containers * Stand-alone peristaltic pump
Necessary for temperature controls (not provided) * Temperature control unit (TCU)
External controller options
The HyPerforma S.U.B. offers an open architecture or 
turnkey system. An open architecture system allows you 
to use any control system of your choice. The capital 
investment can be reduced by using a control system 
already utilized in your facility. A turnkey system is a  
ready-to-use, out-of-the-box system with a choice of 
dedicated controls from Finesse Solutions or Applikon. 
These systems work on Delta V™, Allen Bradley™, or 
Siemens™ formats. Contact your local sales representative 
for more information.
Find out more at thermofisher.com/sub
For Research Use or Further Manufacturing. Not for diagnostic use or direct administration into humans 
or animals. © 2018 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and it 
subsidiaries unless otherwise specified. C-Flex and PharMed are trademarks of Saint-Gobain. PharmaPure is a trademark of PharmaPure Tubing. 
Pall, Kleenpak, and Emflon are trademarks of Pall Corporation. SterilEnz is a trademark of PAW Bioscience Products, Inc. Steridyne is a trademark 
of Meissner Filtration Products, Inc. Specifications, terms, and pricing are subject to change. Not all products are available in all countries. Please 
consult your local sales representative for details. COL03057 0118
* Quantity based on needs
DATA SHEET HyPerforma 2:1 2,000 L Single-Use Bioreactor
HyPerforma 2:1 2,000 L Single-Use Bioreactor 
• Integrally sealed ports in the S.U.B. BPC allow for 
addition of sensor probes and line sets
• Available in Thermo Scientifi c™ CX5-14 Film and 
Thermo Scientifi c™ Aegis™ 5-14 Film options
System options—adaptable to your needs
• Optional electrical box for remote agitation control
• Optional condenser system
• Exhaust gas vent fi lter heaters
• Load cell displays
• Cable management tree
• Process control system
• Mobile stairs
• See Table 12 for auxiliary components for S.U.B. control 
management; choose an open-architecture approach or 
a turnkey, ready-to-use Thermo Scientifi c™ S.U.B. system
The next generation of performance
The Thermo Scientifi c™ HyPerforma™ Single-Use Bioreactor 
(S.U.B.) provides enhanced functionality, ease of use, 
and effi ciency. The complete HyPerforma S.U.B. system 
consists of a bioreactor tank and Thermo Scientifi c™
HyPerforma™ S.U.B. BioProcess Container (BPC), which 
is available in 50, 100, 250, 500, 1,000, and 2,000 L sizes 
with a 2:1 turndown ratio. The redesigned HyPerforma 
S.U.B. maintains traditional stirred-tank bioreactor design 
principles including specifi c height-to-diameter ratios and 
optimized mixer location that deliver optimum cell viability, 
performance, and scalability from process development 
through production.
This data sheet provides information on the 2,000 L S.U.B. 
system, which includes the tank and standard S.U.B. 
BPC. The BPC utilizes dual-sparger confi gurations with a 
porous-frit sparger and drilled-hole or open-pipe sparger 
that have been rigorously tested to provide high kLa values 
and optimal CO2 stripping for improved pH control and 
decreased foaming.
The S.U.B. system consists of the following 
components:
S.U.B. hardware unit—available in turnkey format
• Complete mixing system with a water-jacketed vessel
• Drive shaft inserts into the S.U.B. BPC through the mixing 
drive motor and locks into the BPC agitator assembly
• Load cells
S.U.B. BPC—supplied sterile and ready to use
• Agitator assembly is a single-use (polyethylene) impeller 
with a bearing-and-seal assembly linked to an external 
mixer drive
• Dual gas spargers available with either drilled-hole or 
open-pipe sparger and standard porous-frit sparger
• Vent fi lter outlet for system exhaust
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Standard S.U.B. hardware units
2,000 L standard S.U.B. hardware units are available with 
a water jacket only with either a DC or AC motor. The 
Mettler Toledo™ FlexMount™ load cells allow for batch 
liquid-weight reading. Three load cells are mounted 
with summation box on the S.U.B. hardware unit. These 
hardware units do not include other options listed in 
Tables 3–7. Base part numbers listed in Table 1 will change 
depending upon which options are chosen.
1. Mixer motor
2. Mixing assembly with shield
3. Auxiliary E-stop assembly
4. Stainless steel outer support container 
5. Bag lift assembly
6. Standard tool set 
7. Load cell display
8. Control panel 
9. Load cell summation box
10. Load cells (3)
11. Probe access window
12. Probe clips
13. Water jacket
14. Bottom cutouts for BPC alignment
15. Sparge access plate
16. Jacket quick-connect couplings
17. Pneumatic bag lift control
Design features
Front/top view
Note: Load cells are standard on 2,000 L S.U.B. hardware units.
Back view
Table 1. 2,000 L standard S.U.B. hardware.
Description Cat. No.
Water jacketed, DC motor SUB2000.9002
Water jacketed, 240 VAC, AC motor SUB2000.9008
Figure 1. 2,000 L S.U.B. hardware unit with water jacket.
2
Design features
Top view
Front view
1/2 hp
15:1 ratio
gear motor
Figure 2. 2,000 L S.U.B. hardware unit dimensions.
25.2 in.
(64 cm)
small door
sensor probe
mount
58.9 in.
(150 cm)
63.7 in.
(162 cm)
50.5 in. 
(128 cm)
tank OD
135 in.
(343 cm)
11 ft 3 in. minimum
ceiling height
240 VAC
ETL/CE
compliant
102.4 in.
(260 cm)
tank
height
126.4 in.
(321 cm)
bag lift
height
Table 2. 2,000 L S.U.B. system specifications.
Specifications for water-jacketed systems with AC and DC motors
AC motor DC motor
B
io
re
ac
to
r 
ge
om
et
ry
Rated liquid working volume 2,000 L
Minimum liquid working volume 1,000 L
Total bioreactor volume (liquid and gas) 2,575 L
BPC chamber diameter 119.4 cm (47 in.)
BPC chamber shoulder height 229.9 cm (90.5 in.)
Liquid height at rated working volume 178.7 cm (70.4 in.)
Fluid geometry at working volume (height:diameter ratio) 1.5:1
Overall bioreactor geometry (height:diameter ratio) 1.9:1
Tank baffles No
Im
p
el
le
r
Impeller (quantity x blade count) 1 x 3
Impeller scaling (impeller diameter/tank diameter) 1/3
Impeller blade pitch (angle) 45°
Impeller diameter 39.8 cm (15.7 in.)
Impeller calculated power number (N) 2.1
A
gi
ta
tio
n
Maximum mixing rate Standard: 20–75 rpmCustom: up to 95 rpm above 90% working volume only
Nominal agitation rating (power/volume) 20 W/m3
Nominal agitation 50% working volume: 60 rpm100% working volume: 75 rpm
Nominal tip speed 154.9 cm/s (305 ft/min)
Counterclockwise mixing flow direction Down-pumping
Agitation shaft resolved angle 19.6°
Agitation shaft centerline offset 6.7 cm (2.6 in.)
Overall drive shaft length (two-piece and four-piece) 210.6 cm (82.9 in.)
Drive shaft diameter 1.9 cm (0.8 in.)
Drive shaft poly-sheath outside diameter 3.5 cm (1.4 in.)
Impeller clearance from tank bottom 39.8 cm (15.7 in.)
M
ot
or
Agitation motor drive (type, voltage, phase) AC  
motor only Induction, 208 VAC, 3 –
Agitation motor drive (type, voltage) DC motor only – Brushless, 48 VDC
Motor power rating (AC motor) 0.5 hp (372.8 W) –
Motor power rating (DC motor) –  0.536 hp (400 W) 
Motor torque rating  27.7 N-m (245 in.-lb) –
Gear reduction 15:1 20:1
Programmable VFD, remote panel interface, power fault 
auto restart Standard –
Motor communication methods (for external controller) 0–10 V, 4–20 mA, ModBus –
Table 2. 2,000 L S.U.B. system specifications (continued).
Specifications for water-jacketed systems with AC and DC motors
AC motor DC motor
Te
m
p
er
at
ur
e 
co
nt
ro
l
W
at
er
 ja
ck
et
Jacket area: full/half-volume 67.1/53.9 ft2
Jacket volume 44 L
Jacket flow rate at 50 psi (3.4 bar) 75 L/min
Process connection 1 in. male national pipe thread (NPT) nipple provided with  Hansen™ quick-connect check valves
Nominal heating/cooling load (W) 18,000 W
Approximate liquid heat-up time (5–37°C) 4 hr
M
is
c. RTD or thermocouple, 1/8 in.  
(3.18 mm) OD RTD: Pt-100 (standard)
S
up
p
or
t 
co
nt
ai
ne
r Overall width 179.7 cm (70.5 in.) with E-box 148.5 cm (58.5 in.)
Overall length 171.4 cm (67.5 in.)
Overall height 321 cm (126.4 in.)
Dry skid weight (mass) 962.1 kg (2,121 lb)
Wet skid weight, rated working volume (mass) 2,962.1 kg (6,530 lb)
G
en
er
al
Ceiling height required for 2-piece driveshaft loading 381 cm (150 in.)
Ceiling height required for 4-piece driveshaft loading 353.06 cm (139 in.)
Electrical power supply requirement (voltage, phase, 
current) 208–240 VAC, single, 10 A Dependent on controller
Tested system reliability (minimum) 0.9 at 90%
pH and DO probe, autoclavable type (Applisens™, 
Broadley James™, Mettler Toledo™) 12 mm diameter x 215–235 mm insertion length x 13.5 PG thread
Noise level < 70 dB at 1.5 m
Minimum acceleration and deceleration rate 60 seconds
R
ec
om
m
en
d
ed
 
op
er
at
in
g 
p
ar
am
et
er
s Operating temperature range Ambient to 40 ± 0.1°C (104 ± 0.2°F)
Motor speed Standard: 20–75 rpmCustom: up to 95 rpm above 90% working volume only
Volume range 1,000–2,000 L
Maximum BioProcess Container pressure 0.5 psi (0.03 bar)
Continuous operating time 21 days mixing time at nominal volume only
System options 
Table 3 lists available S.U.B. system options for the 
2,000 L size.
• Autoclave tray (Figure 3)—aids in holding the probe 
assembly during the autoclave process
• Sparger support line (Figure 4)—keeps gas lines in an 
upright position for optimal gas transfer
• Heavy-duty tubing clamps (Figure 5)—used for each 
probe port not in use, eliminating process fl uid holdup
• Sterile sampling manifolds—available in 50 and 
100 mL sizes for off-line sample retention
• Mobile stairs (Figure 6)—facilitates access to the 
bioreactor for top-mount drive shaft loading; the 2,000 L 
S.U.B. requires a platform for top-mount drive shaft 
loading (customer may provide their own solution)
• Bioreactor probe assemblies (Figure 7)—required for 
each sterile electrochemical probe insertion
• S.U.B. temperature sample port (Figure 8)—
provides off-line temperature probe calibration prior to 
system startup
• Condenser system (Figure 9)
Table 3. 2,000 L S.U.B. system options.
Description Cat. No.
Complete condenser system (120 V) including cart, 
chill plate and mounting post with fi lter brackets, 
TCU, and pump
SV50232.01
Complete condenser system (240 V) including cart, 
chill plate and mounting post with fi lter brackets, 
TCU, and pump
SV50232.02
Autoclave tray SV50177.01
Bioreactor probe assembly (nonsterile for use in 
autoclave) with KPC connector
SH30720.01
Bioreactor probe assembly (nonsterile for use in 
autoclave) with AseptiQuik™ connector
SH30720.02
Sparger line support SV50177.65
Heavy-duty tubing clamp (each) SV20664.01
Heavy-duty tubing clamps (10 pack) SV20664.03
Sterile sampling manifold with Luer lock (each) SH30845.01
Sterile sampling manifold with Luer lock (10 each) SH30845.02
S.U.B. temperature/sample port SV20750.01
Mobile stairs SV50935.01
Additional information on autoclave tray:
• Fabricated from stainless steel
• Contains plastic carry handle for easy transport right out 
of the autoclave
• Positions probes on 15% incline for greater longevity
• Prevents probe bellows from collapsing during 
sterilization
• Accommodates two probes
Autoclave tray
Handle
Probe
Bioreactor probe 
assembly
Figure 3. Autoclave tray for probe kits.
Figure 9. Condenser system.
Figure 4. Sparger support line. Figure 5. Heavy-duty tubing clamps.
Figure 7. Bioreactor probe assembly. Figure 8. S.U.B. temperature sample port.Figure 6. Mobile stairs.
Vent heaters 
Vent heaters aid in reducing moisture buildup in exhaust 
filters from system off-gassing. Vent heaters are factory-
preset at 50°C to allow condensation to return to the 
vessel. Recommended gassing strategies of the S.U.B. 
system are in the S.U.B. Validation Guide. Table 4 lists 
available vent heaters.
Note: Vent heater is not required if condenser system 
is purchased.
Table 5. Harsh mount load cell display options.
Description Cat. No.
Mettler Toledo IND331 display, with analog interface 
(STD), 120 VAC U.S. line cord/plug
SV50177.306
Mettler Toledo IND331 display, with Allen-Bradley 
RIO interface, 120 VAC U.S. line cord/plug
SV50177.307
Mettler Toledo IND331 display, with DeviceNet 
interface, 120 VAC U.S. line cord/plug
SV50177.308
Mettler Toledo IND331 display, with Ethernet/IP and 
Modbus TCP interface, 120 VAC U.S. line cord/plug
SV50177.309
Mettler Toledo IND331 display, with Profibus 
interface, 120 VAC U.S. line cord/plug
SV50177.310
 
Table 6. Available spare parts list.
Description Cat. No.
DC motor SV50237.22
AC motor SV50237.19
Drive shaft SV50177.155
RTD 120 in. with Bulgin connector SV50177.363
Probe holders SV50177.23
Autoclave tray (stainless steel with plastic 
carry handle)
SV50177.01
 
Table 8. Standard 2,000 L S.U.B. BPC packaging.
Outer packaging Supplied "flat-packed"
Two polyethylene outer layers 
Label Description
Product code
Lot number
Expiry date on outer packaging and 
shipping container
Sterilization Irradiation (25–40 kGy) inside outer packaging
Shipping container Durable cardboard carton
Documentation Certificate of Analysis provided with each lot 
for each delivery
 
Harsh mount load cell display 
Required for remote weight readout from the 
Mettler Toledo™ summing box, various signal output 
options are provided for external control monitoring 
(Table 5). More information can be found in the Load Cell 
Data Sheet.
Spare parts 
Table 6 lists the available spare parts of the 2,000 L 
S.U.B. systems.
Standard 2,000 L dual-sparger S.U.B. BPC systems 
Table 7 shows the available dual-sparger options for 
the 2,000 L S.U.B. BPC system in either configuration: 
open-pipe and porous-frit spargers (Figure 10, Table 9) or 
drilled-hole and porous-frit spargers (Figure 11, Table 10). 
Standard S.U.B. BPC packaging is shown in Table 8. 
Table 7. Standard 2,000 L dual-sparger S.U.B. BPCs.
Film Dual-sparger  configuration Condenser Cat. No. 
CX5-14 film Open-pipe and  
porous-frit spargers
No SH30774.07
CX5-14 film Open-pipe and  
porous-frit spargers
Yes SH30774.08
CX5-14 film Drilled-hole and 
porous-frit spargers
Yes SH30985.07
CX5-14 film Drilled-hole and 
porous-frit spargers
No SH30985.08
Aegis5-14 film Open-pipe and  
porous-frit spargers
No SH30972.07
Aegis5-14 film Open-pipe and  
porous-frit spargers
Yes SH30972.08
Aegis5-14 film Drilled-hole and 
porous-frit spargers
Yes SH30999.07
Aegis5-14 film Drilled-hole and 
porous-frit spargers
No SH30999.08
 
Table 4. Vent heater required for each exhaust filter on the  
S.U.B. BPC.
Description Voltage Controller Cat. No.
Meissner™ 10 in. series 
46 vent filter heater
120 VAC Preset SV50191.33
Meissner 10 in. series 46 
vent filter heater
240 VAC Preset SV50191.34
Meissner 10 in. series 46 
vent filter heater
120 VAC Integrated SV50191.47
Meissner 10 in. series 46 
vent filter heater
240 VAC Integrated SV50191.48
Pall™ Kleenpak™ KA3 
series 46 vent filter heater
120 VAC Preset SV50191.31
Pall Kleenpak KA3 series 
46 vent filter heater
240 VAC Preset SV50191.32
Pall Kleenpak KA3 series 
46 vent filter heater
120 VAC Integrated SV50191.45
Pall Kleenpak KA3 series 
46 vent filter heater
240 VAC Integrated SV50191.46
Figure 10. Standard 2,000 L dual-sparger S.U.B. BPC with open-pipe and porous-frit spargers. Available with or without the condenser assembly.
Table 9. Specifications for the standard 2,000 L dual-sparger S.U.B. BPC with open-pipe and porous-frit spargers.
Line Description Tubing set (inner diameter x outer diameter x length) End treatment
1 Overlay gas sparger
1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex™ tubing x 4 in. (10 cm) reduced to
 3/8 in. (9.5 mm) x 5/8 in. (15.9 mm) C-Flex tubing x 84 in. (213 cm)
Kleenpak™ Emflon™ II capsule and 
pressure transducer
2
Inoculum addition/
feed line
1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 3 in. (8 cm) reduced to
1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x 6 in. (15 cm) reduced to
1/8 in. (3.2 mm) x 1/4 in. (6.4 mm) C-Flex tubing x 84 in. (213 cm)
Plugged
3–7 Probe ports (5) 1/2 in. (12.7 mm) tube ports
Pall™ Kleenpak™ aseptic connectors 
(female)
8
Thermowell/
small-volume sample
Thermowell adapter for 1/4 in. (6.4 mm) diameter
1/8 in. (3.2 mm) x 1/4 in. (6.4 mm) C-Flex tubing x 24 in. (60 cm)
SterilEnz™ pouch with injection 
site assembly
9 Bottom drain harvest
3/4 in. (19.1 mm) x 1 in. (25.4 mm) C-Flex tubing x 48 in. (122 cm) splits to
1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 24 in. (61 cm) reduced to 
1/4 in. (6.4 mm) x 3/8 in. (9.5 mm) C-Flex tubing x 12 in. (30 cm) and 1/2 in. 
(12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 24 in. (61 cm)
1/4 in. MPC insert and Pall™ Kleenpak™ 
connector (male)
10 Base addition
1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 3 in. (8 cm) reduced to
1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x 84 in. (213 cm) reduced 
to 1/8 in. (3.2 mm) x 1/4 in. (6.4 mm) C-Flex tubing x 12 in. (30 cm)
Plugged
11 Feed line
1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 4 in. (10 cm) splits to
1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 10 in. (25 cm) and
1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 10 in. (25 cm)
SterilEnz pouch with injection site 
assembly and 3/8 in. MPC body
12 Exhaust line Condenser bag assembly (optional) –
13
Open-pipe macro 
sparger
1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x 72 in. (183 cm) reduced 
to check valve and 1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x 72 in. 
(183 cm)
Kleenpak Emflon II capsule
14
Porous-frit micro 
spargers (3), 12 mm 
diameter (25 µm 
pores)
(2x) 12 mm PDVF porous sparge inserts connected to
1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x 6 in. (15 cm) converge to 
one 1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x 72 in. (183 cm)
Kleenpak Emflon II capsule
15
Media fill/ 
auxiliary drain
3/4 in. (19.1 mm) x 1 in. (25.4 mm) C-Flex tubing x 84 in. (213 cm) splits to
1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 24 in. (61 cm) and
1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 24 in. (61 cm) 
Pall Kleenpak connectors (female)
16
Condensate 
return line
Condenser bag assembly (optional) –
17
Condenser 
bag assembly
Condenser bag assembly (optional) –
18 Tri-clamp port (3 in.) NA Gasket, end cap, and clamp
3–7. Probe ports (5)
9. Bottom drain harvest
15. Media fill/auxiliary drain
11. Feed line
8. Thermowell/ 
small-volume sample
8. Feed line
15. Media fill/auxiliary drain
Impeller
10. Base addition
1. Overlay gas sparger
2. Inoculum addition/feed line
9. Media fill
16. Condensate return line
12. Exhaust line
17. Condenser bag 
assemby (optional)
18. Tri-clamp port (3 in.)
14. Porous-frit  
micro spargers (3)
13. Open-pipe  
macro sparger
Front face
Back face
Figure 11. Standard 2,000 L dual-sparger S.U.B. BPC with drilled-hole and porous-frit spargers. Available with or without condenser assemblies.
Front face
Back face
6. Inoculum addition
Impeller
8–12. Probe ports (5)
4. Media fill/auxiliary drain
15. Drilled-hole macro sparger
2. Exhaust line
5. Base addition
14. Thermowell/small-volume sample
7. Overlay gas sparger
13. Feed line
13. Feed line
4. Media fill/auxiliary drain
4. Media fill
3. Condensate return line
2. Exhaust line
18. Tri-clamp 
port (3 in.)
15. Drilled-hole macro sparger
17. Bottom drain harvest
16. Porous-frit  
micro sparger (2)
Table 10. Specifications for the standard 2,000 L dual-sparger S.U.B. BPC with drilled-hole and porous-frit spargers.
Line Description Tubing set (inner diameter x outer diameter x length) End treatment
1
Condenser bag 
assemblies (2)
Condenser bag assembly (optional) –
2 Exhaust lines (2) Condenser bag assembly (optional) –
3 Condensate return line Condenser bag assembly (optional) –
4
Media fill/auxiliary drain 
lines
(3x) 3/4 in. (19.1 mm) x 1 in. (25.4 mm) C-Flex tubing x 84 in. (213 cm) splits 
to 1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 24 in. (61 cm) and
1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 24 in. (61 cm) 
Pall Kleenpak aseptic connectors 
(female)
5 Base addition
1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 3 in. (8 cm) reduced to
1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x 84 in. (213 cm) reduced 
to 1/8 in. (3.2 mm) x 1/4 in. (6.4 mm) C-Flex tubing x 12 in. (30 cm)
Plugged
6
Inoculum addition/
feed line
1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 3 in. (8 cm) reduced to
1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x 6 in. (15 cm) reduced to
1/8 in. (3.2 mm) x 1/4 in. (6.4 mm) C-Flex tubing x 84 in. (213 cm)
Plugged
7 Overlay gas sparger
1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 4 in. (10 cm) reduced to 
3/8 in. (9.5 mm) x 5/8 in. (15.9 mm) C-Flex tubing x 84 in. (213 cm)
Kleenpak Emflon II capsule
and pressure transducer
8–12 Probe ports (5) 1/2 in. (12.7 mm) tube ports
Pall Kleenpak aseptic connectors 
(female)
13 Feed lines
(2x) 1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 4 in. (10 cm) splits to 
1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 10 in. (25 cm) and
1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 10 in. (25 cm) 
SterilEnz pouch with injection site 
assembly and 3/8 in. MPC body
14
Thermowell/
small-volume sample
Thermowell adapter for 1/4 in. (6.4 mm) diameter 
1/8 in. (3.2 mm) x 1/4 in. (6.4 mm) C-Flex tubing x 24 in. (61 cm)
SterilEnz pouch with injection site 
assembly
16
Porous-frit micro sparger,
12 mm diameter (25 µm 
pores)
1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x 6 in. (15 cm) reduced to
check valve and 1/4 in. (6.4 mm) x 7/16 in. (11.1 mm) C-Flex tubing x  
72 in. (183 cm)
(2x) Meissner™ Steridyne™ 0.2 µm 
hydrophobic filter
17 Bottom drain harvest
3/4 in. (19.1 mm) x 1 in. (25.4 mm) C-Flex tubing x 48 in. (122 cm) splits to
1/2 in. (12.7 mm) x 34 in. (19.1 mm) C-Flex tubing x 24 in. (61 cm) reduced to 
1/4 in. (6.4 mm) x 3/8 in. (9.5 mm) C-Flex tubing x 12 in. (30 cm) and
1/2 in. (12.7 mm) x 3/4 in. (19.1 mm) C-Flex tubing x 24 in. (61 cm)
1/4 in. MPC insert and 
Pall Kleenpak connector (male) 
18 Tri-clamp port (3 in.) NA Gasket, end cap, and clamp
1. Condenser bag 
assemblies
Table 11. Custom 2,000 L S.U.B. BPC options.
Category Options/capability Notes
Tubing type Thermoplastic elastomers: C-Flex, PharMed™, 
PharmaPure™ tubing
Platinum-cured silicone
PVC 
More information is available in the Tubing 
Selection Guide
Tubing size Ranging from 1/8 to 1 in. (0.318 to 2.54 cm) ID, in 
customer-specified lengths
More information is available in the Tubing 
Selection Guide
Connectors Luers, quick-connects, SIP connectors, tri-clamp, aseptic 
connectors, sterile connectors, steam-to, steam-through, 
sample ports, plugs
More information is available in the 
Connector Selection Guide. Note: 
Reusable probe port connections use 
Kleenpak™ connector only
Probe ports Additional ports: second row of five The reusable probe port connection uses 
a Kleenpak connector only
Disposable sensors Pressure sensor: PendoTECH and Finesse Solutions 
DO and pH: Finesse Solutions and PreSens
pH: Mettler Toledo
Choice of qualified sensors available; 
PendoTECH pressure sensors come 
standard
Additional probe ports Limited engineer-to-order customization only To be designed
Port sizes Limited engineer-to-order customization only Dependent on location in BPC and fit with 
hardware (e.g., 1 in. (2.54 cm) port on 
harvest line)
Rearrangement of lines 
on existing ports
Limited customization possible (e.g., moving sample/
thermowell port to a probe tube port, or swapping overlay 
inlet line with supplement line)
Dependent on location in BPC and fit with 
hardware
Sparger Dual sparger (macro open-pipe or drilled-hole and  
micro porous-frit) standard
Sparger locations are fixed
Diptube lines Limited customization possible Length cannot interfere with impeller  
and shaft
Overlay and sparger line 
filters
Filter options available from standard component library Choice of qualified filters available
Vent filters Standard is Pall or Meissner 0.2 µm exhaust vent filter Filters must be compatible with available 
vent filter heater configurations
Vent filter tubing length Extended filter height above the S.U.B. BPC is  
made to order
Must be compatible with a vent filter 
bracket option
Filters on media and 
supplement inlets
Limited engineer-to-order customization only; choice of 
filters used to sterilize incoming media or supplements  
are available
Choice of qualified filters available
 
Custom S.U.B. BPC options 
Table 11 lists available custom 2,000 L S.U.B. BPC system 
options. Not all options are available for all ports. For 
additional information, please see the selection guides in 
the single-use products catalog.
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Table 12. Recommended S.U.B. parts list for first-time operators.
Description Quantity Cat. No./auxiliary part
S.U.B. hardware unit 1 Type to be configured
S.U.B. BPC 3 Type to be configured
Bioreactor probe assembly (nonsterile for use in autoclave) 12 SH30720.01
Heavy-duty tubing clamp 12 SV20664.01
Autoclave tray for autoclaving probe assemblies 1 SV50177.01
Auxiliary parts supporting the single-use bioreactor 
(supplied by end user or requested turnkey)
Necessary for gas flow control, DO, and pH set points 1 Bioreactor control system
Autoclavable probe (13 mm x 13.5 PG thread with 195–235 mm insertion length) * DO probe
Autoclavable probe (13 mm x 13.5 PG thread with 195–235 mm insertion length) * pH probe
Tubing welder, steam-in-place system, sterilizer, or laminar flow hood * Sterile/aseptic connection 
Used for fluid transfer between linesets on the containers * Stand-alone peristaltic pump
Necessary for water jacket temperature controls (not provided) * Temperature control unit (TCU)
* Quantity based on needs.
External controller options 
The HyPerforma S.U.B. offers an open-architecture or 
turnkey system. An open-architecture system allows you 
to use any control system of your choice. The capital 
investment can be reduced by using a control system 
already utilized in your facility. A turnkey system is a ready-
to-use, out-of-the-box system with a choice of dedicated 
controls from Finesse Solutions or Applikon. These 
systems work on PC, DeltaV, Allen-Bradley, or Siemens 
formats. Contact your local sales representative for 
more information.
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Components
Touchscreen
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Quick-release bag holder
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Optional components
pH Monitor
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O2/air mix controller
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CO2/air mix controller
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Analog output card
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Loadcell
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Linear electronic motor
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Technical information and specifications
WAVE Bioreactor 500/1000 system
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Components and materials of 
construction
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Cellbag bioreactor configurations, 
options and accessories
Cellbag with ReadyMate connectors
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Cellbag bioreactor accessories
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Optical sensing technologies
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QX^aTPRc^aBW^f]WTaTXbcWTQPVPSP_cTa^_cXRP[UXQTaRPQ[TPccPRWTSc^
cWTQPV_^ac
Table 3. >_cXRP[_7bT]b^ab_TRXUXRPcX^]b
_7\TPbdaT\T]caP]VT _7#$c^'$
_7R^]ca^[aP]VT _7%c^'
_7PRRdaPRh
fXcWX]R^]ca^[aP]VT
$_7fXcWX]!$_7Ua^\^UUbTc
RP[XQaPcX^]_7
 _7fXcWX]!$c^$_7Ua^\
^UUbTcRP[XQaPcX^]_7
>UUbTcRP[XQaPcX^]bW^d[SQTS^]TPccWTbTc_^X]c_7
Operating specifications
CWT2T[[QPVQX^aTPRc^aXbSTbXV]TSc^cWTU^[[^fX]V
b_TRX
RPcX^]b)
~ >_TaPcX]VcT\_TaPcdaTaP]VT) 2c^$2
~ <PgX\d\^_TaPcX]V_aTbbdaT) $_bXV QPa
Regulatory conformance
Sterility and endotoxin
2T[[QPVQX^aTPRc^abPaTbcTaX[XiTSQhVP\\PXaaPSXPcX^]Pc
!$c^#Z6h;^caT[TPbTaT`dXaTb+ !$4DT]S^c^gX]\;
STcTRcTS_TaQPV
Biocompatability
CTbcX]VXb_TaU^a\TS^]VP\\PXaaPSXPcTS
[\$Z6hP]S
QX^R^\_PcPQX[Xch\TTcbDB?2[PbbE81X^[^VXRP[CTbcbU^a
?[PbcXRbDB?''P]S8B> (("aT`dXaT\T]cbX]R[dSX]V)
~ 8B> (("#)7T\^[hbXbbcdShin vivoTgcaPRcX^]\TcW^S
~ 8B> (("$DB?'&)2hc^c^gXRXchbcdShdbX]V8B>T[dcX^]
\TcW^S
~ 8B> (("%DB?'')<dbR[TX\_[P]cPcX^]bcdShX]aPQQXc
~ 8B> ((" DB?'')0RdcTX]caPRdcP]T^dbaTPRcXeXch
bcdShX]aPQQXc
~ 8B> (("  DB?'')0RdcTbhbcT\XRc^gXRXchX]\^dbT
Table 4. >_cXRP[SXbb^[eTS^ghVT]bT]b^ab_TRXUXRPcX^]b
3Xbb^[eTS^ghVT]\TPbdaT\T]caP]VT c^!$PXabPcdaPcX^]
3Xbb^[eTS^ghVT]PRRdaPRh
fXcWX]R^]ca^[aP]VT
"PXabPcdaPcX^]PUcTa
RP[XQaPcX^]Pc+ PXa
bPcdaPcX^]
Table 5. >_TaPcX]Ve^[d\Tb
Bag size Minimum Maximum System
$\; $\; !$\; ! 
 ; $\; $\; ! 
!;  \;  ; ! P]S:Xc!
 ; $\; $; ! P]S:Xc!
!;  ;  ; !$P]S:Xc!
!!;  ;  ; !$P]S:Xc$
$; $; !$; !$P]S:Xc$
 ; $; $; !
!;  ;  ; !
$; $; !$; $ P]S:Xc$
 ;  ; $; $ P]S:Xc 
Table 2. 0RRTbb^aXTbPePX[PQ[TU^adbTfXcWbcP]SPaS2T[[QPVQX^aTPRc^ab
Accessory Use Compatibility
3>>?C_a^QT 3Xbb^[eTS^ghVT]_a^QT 3>>?C_a^QT\TPbdaT\T]c^USXbb^[eTS^ghVT])DbTfXcWP]h2T[[QPV
QX^aTPRc^acWPcWPbP]>ghfT[[!BPcdaPcTSPXac^!$8]R[dSTb5X[[Ta
:XcP]SITa^>ghVT]B^[dcX^]
5XQaP2T[\XRa^RPaaXTab <XRa^RPaaXTabc^_a^\^cTVa^fcW >][hPePX[PQ[T_aT[^PSTSX]c^PRT[[QPVRWP\QTa^UPSWTaT]cRT[[b=^c
PePX[PQ[TU^abT_PaPcT_daRWPbT
0XaUX[cTaWTPcTa 5^adbTfXcWPXaUX[cTabc^_aTeT]c
R^]ST]bPcX^]PRRd\d[PcX^]
DbT^]cWTTgWPdbcUX[cTacWPcXbPccPRWTSc^cWT2T[[QPV
AC3_a^QT CT\_TaPcdaT_a^QT 5^adbTfXcWPCT\_fT[[
ITa^>ghVT]B^[dcX^] 2P[XQaPcX^] 5^adbTfXcW>ghfT[[!P]S3>>?C_a^QT
#  !'($  "%04
Table 6. 2T[[QPVQX^aTPRc^abXiTbP]S^_cX^]b
Cellbag Code number Ports Description Ports Description
2T[[QPV$\; !'# !#  
_Pac]d\QTa)
21$<;  
 "$& 0XaX][TcUX[cTa
!#%' " %X]¾"'X]¾!X]bX[XR^]T]TTS[T[TbbbP\_[X]V
2T[[QPV ; !'# !!%'
_Pac]d\QTa)
21 ;  
 $  'X]¾ #X]¾"(X]25[TgUT\P[T[dTa
!% " %X]¾"'X]¾!X]bX[XR^]T]TTS[T[TbbbP\_[X]V
"& 0Xa^dc[TcUX[cTaRWTRZeP[eT
#' 0XaX][TcUX[cTa
2T[[QPV!; !'# !!%(
_Pac]d\QTa)
21!;  
  'X]¾ #X]¾"(X]25[TgUT\P[T[dTa $ 0XaX][TcUX[cTa
! =0 % 0Xa^dc[TcUX[cTaRWTRZeP[eT
" " %X]¾"'X]¾!X]bX[XR^]T]TTS[T[TbbbP\_[X]V &( =0
# =0
!'# !!&
>ghfT[[!eTabX^]
21!; !
  'X]¾ #X]¾"(X]25[TgUT\P[T[dTa $ 0XaX][TcUX[cTa
! " %X]¾"'X]¾!X]bX[XR^]T]TTS[T[TbbbP\_[X]V % 0Xa^dc[TcUX[cTaRWTRZeP[eT
" " %X]¾"'X]¾!X]bX[XR^]TUT\P[T[dTa & " %X]¾"'X]¾!X]bX[XR^]TUT\P[T[dTa
# >ghfT[[!U^a3>>?C_a^QT '( =0
!'# !!& 
bRaTfRP_eTabX^]
21!; "
  'X]¾ #X]¾"(X]25[TgUT\P[T[dTa $ 0XaX][TcUX[cTa
! " %X]¾"'X]¾!X]bX[XR^]T]TTS[T[TbbbP\_[X]V % 0Xa^dc[TcUX[cTaRWTRZeP[eT
" >ghfT[[!U^a3>>?C_a^QT & " %X]¾"'X]¾!X]bX[XR^]TUT\P[T[dTa
# BRaTfRP_"'# '( =0
!'# !"#!
_TaUdbX^]eTabX^]
21!; #
  'X]¾ #X]¾"(X]25[TgUT\P[T[dTa % 0Xa^dc[TcUX[cTaRWTRZeP[eT
! " %X]¾"'X]¾!X]bX[XR^]T]TTS[T[TbbbP\_[X]V & " %X]¾"'X]¾!X]bX[XR^]TUT\P[T[dTa
" HR^]]TRcX^]PccPRWTSc^_TaUdbX^]UX[cTa '( =0
# >ghfT[[!U^a3>>?C_a^QT 8]c ?TaUdbX^]UX[cTa
$ 0XaX][TcUX[cTa
!'# !"#"
5XQaP2T[eTabX^]
21!; &
  'X]¾ #X]¾"(X]25[TgUT\P[T[dTa % 0Xa^dc[TcUX[cTaRWTRZeP[eT
! " %X]¾"'X]¾!X]bX[XR^]T]TTS[T[TbbbP\_[X]V & " %X]¾"'X]¾!X]bX[XR^]TUT\P[T[dTa
" >ghfT[[!U^a3>>?C_a^QT '( =0
# BRaTfRP_"'# 8]c !V^U5XQaP2T[
$ 0XaX][TcUX[cTa
!'('#&#
_7>?CeTabX^]
21!;   
  'X]¾ #X]¾"(X]25[TgUT\P[T[dTa % 0Xa^dc[TcUX[cTaRWTRZeP[eT
! " %X]¾"'X]¾!X]bX[XR^]T]TTS[T[TbbbP\_[X]V & " %X]¾"'X]¾!X]bX[XR^]TUT\P[T[dTa
" " %X]¾"'X]¾!X]bX[XR^]TUT\P[T[dTa ' _7>?CbT]b^aQ^ShQ^cc^\^UQPV
#
$
>ghfT[[!U^a3>>?C_a^QT
0XaX][TcUX[cTa
( =0
!( !"$"
_7>?CP]S
bRaTfRP_eTabX^]
21!;  "
  'X]¾ #X]¾"(X]25[TgUT\P[T[dTa % 0Xa^dc[TcUX[cTaRWTRZeP[eT
! " %X]¾"'X]¾!X]bX[XR^]T]TTS[T[TbbbP\_[X]V & " %X]¾"'X]¾!X]bX[XR^]TUT\P[T[dTa
" >ghfT[[!U^a3>>?C_a^QT ' _7>?CbT]b^aQ^ShQ^cc^\^UQPV
#
$
BRaTfRP_"'#
0XaX][TcUX[cTa
( =0
!( !"$$
_7>?CP]S
_TaUdbX^]eTabX^]
21!;  #
  'X]¾ #X]¾"(X]25[TgUT\P[T[dTa % 0Xa^dc[TcUX[cTaRWTRZeP[eT
! " %X]¾"'X]¾!X]bX[XR^]T]TTS[T[TbbbP\_[X]V & " %X]¾"'X]¾!X]bX[XR^]TUT\P[T[dTa
" HR^]]TRcX^]PccPRWTSc^_TaUdbX^]UX[cTa ' _7>?CbT]b^aQ^ShQ^cc^\^UQPV
#
$
>ghfT[[!U^a3>>?C_a^QT
0XaX][TcUX[cTa
( =0
!'# " %
ATPSh<PcTeTabX^]
21!; ! 
  #X]¾& %X]¾"(X]25[TgATPSh<PcT $ 0XaX][TcUX[cTa
! " %X]¾"'X]¾!X]bX[XR^]T]TTS[T[TbbbP\_[X]V % 0Xa^dc[TcUX[cTaRWTRZeP[eT
" " %X]¾"'X]¾!X]bX[XR^]TUT\P[T[dTa & " %X]¾"'X]¾!X]bX[XR^]TUT\P[T[dTa
# >ghfT[[!U^a3>>?C_a^QT '( =0
!( $! !
3>>?C88P]S
_7>?CeTabX^]
21!; " 
 £X]¾& %X]¾"(X]25[TgATPSh<PcT $ 0XaX][TcUX[cTa
! £X]¾& %X]¾"(X]25[TgATPSh<PcT % 0Xa^dc[TcUX[cTaRWTRZeP[eT
" " %X]¾"'X]¾!X]bX[XR^]T]TTS[T[TbbbP\_[X]V & =0
#  'X]¾£X]¾!X]25[TghR^]]TRc^a
 'X]¾£X]¾ 'X]25[TgUT\P[T[dTa
' _7>?CbT]b^aQ^ShQ^cc^\^UQPV
( 3>>?C88bT]b^aQ^ShQ^cc^\^UQPV
!( $"&
3>>?C88
_7>?CP]S
bRaTfRP_eTabX^]
21!; ""
 £X]¾& %X]¾"(X]25[TgATPSh<PcT % 0Xa^dc[TcUX[cTaRWTRZeP[eT
! £X]¾& %X]¾"(X]25[TgATPSh<PcT &  'X]¾£X]¾!X]25[TghR^]]TRc^a
 'X]¾£X]¾ 'X]25[TgUT\P[T[dTa" " %X]¾"'X]¾!X]bX[XR^]T]TTS[T[TbbbP\_[X]V
# BRaTfRP_"'# ' _7>?CbT]b^aQ^ShQ^cc^\^UQPV
$ 0XaX][TcUX[cTa ( 3>>?C88bT]b^aQ^ShQ^cc^\^UQPV
!( $"'
3>>?C88
_7>?CP]S
_TaUdbX^]eTabX^]
21!; "#
 £X]¾& %X]¾"(X]25[TgATPSh<PcT % 0Xa^dc[TcUX[cTaRWTRZeP[eT
! £X]¾& %X]¾"(X]25[TgATPSh<PcT &  'X]¾£X]¾!X]25[TghR^]]TRc^a
 'X]¾£X]¾ 'X]25[TgUT\P[T[dTa" HR^]]TRcX^]PccPRWTSc^_TaUdbX^]UX[cTa
# " %X]¾"'X]¾!X]bX[XR^]T]TTS[T[TbbbP\_[X]V ' _7>?CbT]b^aQ^ShQ^cc^\^UQPV
$ 0XaX][TcUX[cTa ( 3>>?C88bT]b^aQ^ShQ^cc^\^UQPV
P8P7
P5 P6
P4P3
P1 P2
P8 P7
P5 P6
P4 P3
P1 P2
P8
P7
P6
P9
P5
P3 P4P1 P2
!'($  "%04  $
Table 6. 2T[[QPVQX^aTPRc^abXiTbP]S^_cX^]bR^]cX]dTS
Cellbag Code number Ports Description Ports Description
2T[[QPV ; !'# !!&'
_Pac]d\QTa)
21 ;  
  #X]¾& %X]¾"(X]25[TgUT\P[T<?2 % 0XaX][TcUX[cTa
!  'X]¾ #X]¾"(X]25[TgUT\P[T[dTa & 0Xa^dc[TcUX[cTaRWTRZeP[eT
" " %X]¾"'X]¾!X]bX[XR^]T]TTS[T[TbbbP\_[X]V '  =0
#$ =0
!'# !!&(
>ghfT[[!eTabX^]
21 ; !
  #X]¾& %X]¾"(X]25[TgUT\P[T<?2 % 0XaX][TcUX[cTa
!  'X]¾ #X]¾"(X]25[TgUT\P[T[dTa & 0Xa^dc[TcUX[cTaRWTRZeP[eT
" " %X]¾"'X]¾!X]bX[XR^]T]TTS[T[TbbbP\_[X]V ' " %X]¾"'X]¾!X]bX[XR^]TUT\P[T[dTa
# >ghfT[[!U^a3>>?C_a^QT (  =0
$ " %X]¾"'X]¾!X]bX[XR^]TUT\P[T[dTa
!'# !!'
bRaTfRP_eTabX^]
21 ; "
  #X]¾& %X]¾"(X]25[TgUT\P[T<?2 % 0XaX][TcUX[cTa
!  'X]¾ #X]¾"(X]25[TgUT\P[T[dTa & 0Xa^dc[TcUX[cTaRWTRZeP[eT
" " %X]¾"'X]¾!X]bX[XR^]T]TTS[T[TbbbP\_[X]V ' " %X]¾"'X]¾!X]bX[XR^]TUT\P[T[dTa
# >ghfT[[!U^a3>>?C_a^QT (  =0
$ BRaTfRP_"'#
!'# !"$#
_TaUdbX^]eTabX^]
21 ; #
 " %X]¾"'X]¾!X]bX[XR^]T]TTS[T[TbbbP\_[X]V % 0XaX][TcUX[cTa
!  'X]¾ #X]¾"(X]25[TgUT\P[T[dTa & 0Xa^dc[TcUX[cTaRWTRZeP[eT
" >ghfT[[!U^a3>>?C_a^QT ' " %X]¾"'X]¾!X]bX[XR^]TUT\P[T[dTa
# HR^]]TRcX^]PccPRWTSc^_TaUdbX^]UX[cTa (  =0
$ " %X]¾"'X]¾!X]bX[XR^]TUT\P[T[dTa 8]c ?TaUdbX^]UX[cTa
!'# !!' 
5XQaP2T[eTabX^]
21 ; &
  #X]¾& %X]¾"(X]25[TgUT\P[T<?2 % 0XaX][Tc
[cTa
!  'X]¾ #X]¾"(X]25[TgUT\P[T[dTa & 0Xa^dc[Tc
[cTaRWTRZeP[eT
" " %X]¾"'X]¾!X]bX[XR^]T]TTS[T[TbbbP\_[X]V ' " %X]¾"'X]¾!X]bX[XR^]TUT\P[T[dTa
# >ghfT[[!U^a3>>?C_a^QT (  =0
$ BRaTfRP_"'# 8]c  V^U5XQaP2T[
!'('#&(
_7>?CeTabX^]
21 ;   
  #X]¾& %X]¾"(X]25[TgUT\P[T<?2 % 0XaX][Tc
[cTa
!  'X]¾ #X]¾"(X]25[TgUT\P[T[dTa & 0Xa^dc[Tc
[cTaRWTRZeP[eT
" " %X]¾"'X]¾!X]bX[XR^]T]TTS[T[TbbbP\_[X]V ' " %X]¾"'X]¾!X]bX[XR^]TUT\P[T[dTa
# >ghfT[[!U^a3>>?C_a^QT ( _7>?CbT]b^aQ^ShQ^cc^\^UQPV
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'X]¾ #X]¾"(X]25[TgUT\P[T[dTa ' 0Xa^dc[TcUX[cTaRWTRZeP[eT
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 %X]¾"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5[TgUT\P[T<?2 & " %X]¾"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!  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!  'X]¾ 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" "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'X]¾!X]bX[XR^]T]TTS[T[TbbbP\_[X]V ( 0XaX]c[TcUX[cTa
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# " %X]¾"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# >ghfT[[!U^a3>>?C_a^QT   H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5[TgUT\P[T[dTa & 0XaX]c[TcUX[cTa
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# " %X]¾"'X]¾!X]bX[XR^]TUT\P[T[dTa ( _7>?CbT]b^aQ^ShQ^cc^\^UQPV
$ CT\_fT[[U^aAC3_a^QT   =0
!'# " (
ATPSh<PcTeTabX^]
21!!; ! 
  #X]¾& %X]¾"(X]25[TgATPSh<PcT % 0Xa^dc[TcUX[cTaRWTRZeP[eT
!  'X]¾ #X]¾"(X]25[TgUT\P[T[dTa & 0XaX][TcUX[cTa
" " %X]¾"'X]¾!X]bX[XR^]T]TTS[T[TbbbP\_[X]V ' >ghfT[[!U^a3>>?C_a^QT
# " %X]¾"'X]¾!X]bX[XR^]TUT\P[T[dTa (  =0
$ CT\_fT[[U^aAC3_a^QT
!( $! $
3>>?C88P]S
_7>?CeTabX^]
21!!; " 
 ! "'X]¾$'X]¾"(X]25[TgATPSh<PcT % 0XaX][TcUX[cTa
" " %X]¾"'X]¾!X]bX[XR^]T]TTS[T[TbbbP\_[X]V & 0Xa^dc[TcUX[cTaRWTRZeP[eT
#  'X]¾£X]¾!X]25[TghR^]]TRc^a
 'X]¾£X]¾ 'X]25[TgUT\P[T[dTa
' "'X]¾$'X]¾"(X]25[TgUT\P[T<?2
( _7>?CbT]b^aQ^ShQ^cc^\^UQPV
$ CT\_fT[[U^aAC3_a^QT   3>>?C88bT]b^aQ^ShQ^cc^\^UQPV
P8P7P6
P10
P4P3P2P1
P9P5
P8
P12
P7
P6
P10P9
P11
P5P3 P4P1 P2
!'($  "%04  &
Table 6. 2T[[QPVQX^aTPRc^abXiTbP]S^_cX^]bR^]cX]dTS
Cellbag Code number Ports Description Ports Description
2T[[QPV$; !'# !"#
_Pac]d\QTa)
21$;  
 
!
"
#&
 #X]¾& %X]¾"(X]25[TgUT\P[T<?2
 'X]¾ #X]¾"(X]25[TgUT\P[T[dTa
" %X]¾"'X]¾!X]bX[XR^]T]TTS[T[TbbbP\_[X]V
=0
'
(
  !
0Xa^dc[TcUX[cTaRWTRZeP[eT
0XaX][TcUX[cTa
=0
!'# !"$
>ghfT[[!eTabX^]
21$; !
 
!
"
#
$
%
 #X]¾& %X]¾"(X]25[TgUT\P[T<?2
 'X]¾ #X]¾"(X]25[TgUT\P[T[dTa
" %X]¾"'X]¾!X]bX[XR^]T]TTS[T[TbbbP\_[X]V
" %X]¾"'X]¾!X]bX[XR^]TUT\P[T[dTa
=0
" %X]¾"'X]¾!X]bX[XR^]TUT\P[T[dTa
&
'
(
 
   !
" %X]¾"'X]¾!X]bX[XR^]TUT\P[T[dTa
0Xa^dc[TcUX[cTaRWTRZeP[eT
0XaX][TcUX[cTa
>ghfT[[!U^a3>>?C_a^QT
=0
!'# !"'"
_TaUdbX^]eTabX^]
21$; #
 
!
"
#
$
%
 #X]¾& %X]¾"(X]25[TgUT\P[T<?2
 'X]¾ #X]¾"(X]25[TgUT\P[T[dTa
" %X]¾"'X]¾!X]bX[XR^]T]TTS[T[TbbbP\_[X]V
>ghfT[[!U^a3>>?C_a^QT
=0
" %X]¾"'X]¾!X]bX[XR^]TUT\P[T[dTa
&
'
(
 
   !
8]c
" %X]¾"'X]¾!X]bX[XR^]TUT\P[T[dTa
0Xa^dc[TcUX[cTaRWTRZeP[eT
0XaX][TcUX[cTa
HR^]]TRcX^]PccPRWTSc^_TaUdbX^]UX[cTa
=0
?TaUdbX^]UX[cTa
!'# !"%
5XQaP2T[eTabX^]
21$; &
 
!
"
#
$
%
 #X]¾& %X]¾"(X]25[TgUT\P[T<?2
 'X]¾ #X]¾"(X]25[TgUT\P[T[dTa
" %X]¾"'X]¾!X]bX[XR^]T]TTS[T[TbbbP\_[X]V
" %X]¾"'X]¾!X]bX[XR^]TUT\P[T[dTa
=0
" %X]¾"'X]¾!X]bX[XR^]TUT\P[T[dTa
&
'
(
 
   !
8]c
" %X]¾"'X]¾!X]bX[XR^]TUT\P[T[dTa
0Xa^dc[TcUX[cTaRWTRZeP[eT
0XaX][TcUX[cTa
>ghfT[[!U^a3>>?C_a^QT
=0
$V5XQaP2T[
!'('#(
_7>?CeTabX^]
21$;   
 
!
"
#
$
%
 #X]¾& %X]¾"(X]25[TgUT\P[T<?2
 'X]¾ #X]¾"(X]25[TgUT\P[T[dTa
" %X]¾"'X]¾!X]bX[XR^]T]TTS[T[TbbbP\_[X]V
" %X]¾"'X]¾!X]bX[XR^]TUT\P[T[dTa
=0
" %X]¾"'X]¾!X]bX[XR^]TUT\P[T[dTa
&
'
(
 
  
 !
" %X]¾"'X]¾!X]bX[XR^]TUT\P[T[dTa
0Xa^dc[TcUX[cTaRWTRZeP[eT
0XaX][TcUX[cTa
>ghfT[[!U^a3>>?C_a^QT
_7>?CbT]b^aQ^ShQ^cc^\^UQPV
=0
!( !#&
_7>?CP]S
_TaUdbX^]eTabX^]
21$;  #
 
!
"
#
$
%
 #X]¾& %X]¾"(X]25[TgUT\P[T<?2
 'X]¾ #X]¾"(X]25[TgUT\P[T[dTa
" %X]¾"'X]¾!X]bX[XR^]T]TTS[T[TbbbP\_[X]V
>ghfT[[!U^a3>>?C_a^QT
=0
" %X]¾"'X]¾!X]bX[XR^]TUT\P[T[dTa
&
'
(
 
  
 !
" %X]¾"'X]¾!X]bX[XR^]TUT\P[T[dTa
0Xa^dc[TcUX[cTaRWTRZeP[eT
0XaX][TcUX[cTa
HR^]]TRcX^]PccPRWTSc^_TaUdbX^]UX[cTa
_7>?CbT]b^aQ^ShQ^cc^\^UQPV
=0
!'# "!
ATPSh<PcTeTabX^]
21$; ! 
 
!
"
#
$
%
 #X]¾& %X]¾"(X]25[TgATPSh<PcT
 'X]¾ #X]¾"(X]25[TgUT\P[T[dTa
" %X]¾"'X]¾!X]bX[XR^]T]TTS[T[TbbbP\_[X]V
" %X]¾"'X]¾!X]bX[XR^]TUT\P[T[dTa
"'X]¾$'X]¾"(X]25[TgATPSh<PcT
" %X]¾"'X]¾!X]bX[XR^]TUT\P[T[dTa
&
'
(
 
   !
" %X]¾"'X]¾!X]bX[XR^]TUT\P[T[dTa
0Xa^dc[TcUX[cTaRWTRZeP[eT
0XaX][TcUX[cTa
>ghfT[[!U^a3>>?C_a^QT
=0
!( $! %
3>>?C88P]S
_7>?CeTabX^]
21$; " 
 !
"
#
$
%
"'X]¾$'X]¾"(X]25[TgATPSh<PcT
" %X]¾"'X]¾!X]bX[XR^]T]TTS[T[TbbbP\_[X]V
 'X]¾£X]¾!X]25[TghR^]]TRc^a
 'X]¾£X]¾ 'X]25[TgUT\P[T[dTa
"'X]¾$'X]¾"(X]25[TgUT\P[T<?2
=0
&
'
(
 
  
 !
" %¾"'¾ 'X]bX[XR^]TUT\P[T[dTa
0Xa^dc[TcUX[cTaRWTRZeP[eT
0XaX][TcUX[cTa
=0
_7>?CbT]b^aQ^ShQ^cc^\^UQPV
3>>?C88bT]b^aQ^ShQ^cc^\^UQPV
!( $###
3>>?C88
_7>?CP]S
_TaUdbX^]eTabX^]
21$; "#
 !
"
#
$
%
"'X]¾$'X]¾"(X]25[TgATPSh<PcT
" %X]¾"'X]¾!X]bX[XR^]T]TTS[T[TbbbP\_[X]V
"'X]¾$'X]¾"(X]25[TgUT\P[T<?2
 'X]¾£X]¾!X]25[TghR^]]TRc^a
 'X]¾£X]¾ 'X]25[TgUT\P[T[dTa
=0
&
'
(
 
  
 !
" %¾"'¾ 'X]bX[XR^]TUT\P[T[dTa
0Xa^dc[TcUX[cTaRWTRZeP[eT
0XaX][TcUX[cTa
HR^]]TRcX^]PccPRWTSc^_TaUdbX^]UX[cTa
_7>?CbT]b^aQ^ShQ^cc^\^UQPV
3>>?C88bT]b^aQ^ShQ^cc^\^UQPV
2T[[QPV ; !'# !"(&
>ghfT[[!eTabX^]
_Pac]d\QTa)
21 ; !
 
!
"
#
$
%
>ghfT[[!U^a3>>?C_a^QT
"'X]¾$'X]¾&'X]25[Tg\P[T<?2
" %X]¾"'X]¾!X]bX[XR^]TUT\P[T[dTa
" %X]¾"'X]¾!X]bX[XR^]T]TTS[T[TbbbP\_[X]V
 #X]¾& %X]¾&'X]25[Tg\P[T<?2
 'X]¾ #X]¾&'X]25[TgUT\P[T[dTa
&
'
(
 
  
 !
CT\_fT[[U^aAC3_a^QT
0XaX]c[TcUX[cTa
0Xa^dc[TcUX[cTafXSTQ^aTRWTRZeP[eT
0Xa^dc[TcUX[cTafXSTQ^aTRWTRZeP[eT
"'X]¾$'X]¾&'X]25[Tg\P[T<?2bX[XR^]TSX_cdQT
=0
!'('#( 
_7>?CeTabX^]
_Pac]d\QTa)
21 ;   
 
!
"
#
$
%
>ghfT[[!U^a3>>?C_a^QT
"'X]¾$'X]¾&'X]25[Tg\P[T<?2
" %X]¾"'X]¾!X]bX[XR^]TUT\P[T[dTa
" %X]¾"'X]¾!X]bX[XR^]T]TTS[T[TbbbP\_[X]V
 #X]¾& %X]¾&'X]25[Tg\P[T<?2
 'X]¾ #X]¾&'X]25[TgUT\P[T[dTa
&
'
(
 
  
 !
CT\_fT[[U^aAC3_a^QT
0XaX]c[TcUX[cTa
0Xa^dc[TcUX[cTafXSTQ^aTRWTRZeP[eT
0Xa^dc[TcUX[cTafXSTQ^aTRWTRZeP[eT
"'X]¾$'X]¾&'X]25[Tg\P[T<?2bX[XR^]TSX_cdQT
_7>?CbT]b^aQ^ShQ^cc^\^UQPV
2T[[QPV!; !'# !"((
>ghfT[[!eTabX^]
_Pac]d\QTa)
21!; !
 
!
"
#
$
%
>ghfT[[!U^a3>>?C_a^QT
"'X]¾$'X]¾&'X]25[Tg\P[T<?2
" %X]¾"'X]¾!X]bX[XR^]TUT\P[T[dTa
" %X]¾"'X]¾!X]bX[XR^]T]TTS[T[TbbbP\_[X]V
 #X]¾& %X]¾&'X]25[Tg\P[T<?2
 'X]¾ #X]¾&'X]25[TgUT\P[T[dTa
&
'
(
 
  
 !
CT\_fT[[U^aAC3_a^QT
0XaX]c[TcUX[cTa
0Xa^dc[TcUX[cTafXSTQ^aTRWTRZeP[eT
0Xa^dc[TcUX[cTafXSTQ^aTRWTRZeP[eT
"'X]¾$'X]¾&'X]25[Tg\P[T<?2bX[XR^]TSX_cdQT
=0
!'('#(!
_7>?CeTabX^]
_Pac]d\QTa)
21!;   
 
!
"
#
$
%
>ghfT[[!U^a3>>?C_a^QT
"'X]¾$'X]¾&'X]25[Tg\P[T<?2
" %X]¾"'X]¾!X]bX[XR^]TUT\P[T[dTa
" %X]¾"'X]¾!X]bX[XR^]T]TTS[T[TbbbP\_[X]V
 #X]¾& %X]¾&'X]25[Tg\P[T<?2
 'X]¾ #X]¾&'X]25[TgUT\P[T[dTa
&
'
(
 
  
 !
CT\_fT[[U^aAC3_a^QT
0XaX]c[TcUX[cTa
0Xa^dc[TcUX[cTafXSTQ^aTRWTRZeP[eT
0Xa^dc[TcUX[cTafXSTQ^aTRWTRZeP[eT
"'X]¾$'X]¾&'X]25[Tg\P[T<?2bX[XR^]TSX_cdQT
_7>?CbT]b^aQ^ShQ^cc^\^UQPV
2T[[QPVQX^aTPRc^abRP]QTRdbc^\XiTSc^bdXch^dab_TRXUXRRT[[Rd[cdaT_a^RTbb]TTSb>da?a^SdRcB_TRXP[XbcbfX[[f^aZfXcWh^dc^RaTPcTh^daRT[[Rd[cdaT
QPVU^adbTfXcWcWTF0E41X^aTPRc^abhbcT\
P8 P9 P10P7
P6
P4P3P2P1
P11
P12
P5
P8 P9
P11
P10
P7
P6P4P3P2P1
P12
P5
P8 P9
P11
P10
P7
P6P4P3P2P1
P12
P5
imagination at work
64X\PVX]PcX^]Pcf^aZP]S64\^]^VaP\PaTcaPST\PaZb^U6T]TaP[4[TRcaXR2^\_P]h
2T[[QPVATPSh2XaRdXcATPSh<PcTATPShC^?a^RTbbD;C0P]SF0E41X^aTPRc^aPaTcaPST\PaZb^U
647TP[cWRPaTR^\_P]XTb
1X^2[P\_XbPcaPST\PaZ^U7^[[P]S0__[XTSCTRW]^[^VXTb
25[TgXbPcaPST\PaZ^UBPX]c6^QPX]?TaU^a\P]RT?[PbcXRb
2;0E4XbPaTVXbcTaTScaPST\PaZ^U82D<TSXRP[8]R
5XQaP2T[XbPcaPST\PaZ^U2T[XcT2^a_^aPcX^]
ATPSh<PcTXbR^eTaTSQhDB_PcT]c]d\QTa%%&($!(1!^f]TSQh9^W]b^]1^[Th7^[SX]Vb;;2P]S
[XRT]bTSc^647TP[cWRPaTR^\_P]XTb
!(! !6T]TaP[4[TRcaXR2^\_P]h0[[aXVWcbaTbTaeTS
5Xabc_dQ[XbWTS9d]!(
0[[V^^SbP]SbTaeXRTbPaTb^[SbdQYTRcc^cWTcTa\bP]SR^]SXcX^]b^UbP[T^UcWTR^\_P]hfXcWX]
647TP[cWRPaTfWXRWbd__[XTbcWT\0R^_h^UcWTbTcTa\bP]SR^]SXcX^]bXbPePX[PQ[T^]aT`dTbc2^]cPRc
h^da[^RP[647TP[cWRPaTaT_aTbT]cPcXeTU^acWT\^bcRdaaT]cX]U^a\PcX^]
647TP[cWRPaTD:;X\XcTS0\TabWP\?[PRT;Xcc[T2WP[U^]c1dRZX]VWP\bWXaT7?&(=0D:
647TP[cWRPaT4da^_T6\Q7<d]iX]VTaBcaPbbT$3&(   5aTXQdaV6Ta\P]h
647TP[cWRPaT1X^BRXT]RTb2^a_'2T]cT]]XP[0eT]dT?>1^g "!&?XbRPcPfPh=9''$$ "!&DB0
647TP[cWRPaT9P_P]2^a_^aPcX^]BP]ZT]1[SV"!$ 7hPZd]X]RW^BWX]YdZdZdC^Zh^ %(&"9P_P]
!'($  "%04 #! !
5^a[^RP[^U
RTR^]cPRcX]U^a\PcX^]eXbXc
www.gelifesciences.com/contact
fffVT[XUTbRXT]RTbR^\aTPShc^_a^RTbb
647TP[cWRPaT1X^BRXT]RTb01
1YÝaZVPcP]"
&$ '#D__bP[P
BfTST]
Ordering information
Product Quantity Code number
2T[[QPV!;3>>?C88P]S_7>?C   !( $! #
2T[[QPV!;3>>?C88_7>?CP]SbRaTfRP_   !( $" "
2T[[QPV!;3>>?C88_7>?CP]S_TaUdbX^]   !( $" $
2T[[QPV!!;>ghfT[[!   !'# !" 
2T[[QPV!!;5XQaP2T[   !'# !""
2T[[QPV!!;_7>?C   !'('#'(
2T[[QPV!!;ATPSh<PcT   !'# " (
2T[[QPV!!;3>>?C88P]S_7>?C   !( $! $
2T[[QPV$;   !'# !"#
2T[[QPV$;>ghfT[[!   !'# !"$
2T[[QPV$;_TaUdbX^]   !'# !"'"
2T[[QPV$;5XQaP2T[   !'# !"%
2T[[QPV$;_7>?C   !'('#(
2T[[QPV$;_7>?CP]S_TaUdbX^]   !( !#&
2T[[QPV$;ATPSh<PcT   !'# "!
2T[[QPV$;3>>?C88P]S_7>?C   !( $! %
2T[[QPV$;3>>?C88_7>?CP]S_TaUdbX^]   !( $###
2T[[QPV ;>ghfT[[!   !'# !"(&
2T[[QPV ;_7>?C   !'('#( 
2T[[QPV!;>ghfT[[!   !'# !"((
2T[[QPV!;_7>?C   !'('#(!
2[PeTbP\_[X]VeP[eT
^]%#\\>325[TgcdQX]V   !'# !# !
?E2cdQX]VfXcW_aTbbX]_[dV   !'# !# "
CdQT:Xc?E2P]S
bX[XR^]TcdQX]VfXcWCR^]]TRc^ab   !'# !# #
2WTRZeP[eT!$;_PRZ^U!$   !'# !##(
2WTRZeP[eT !;_PRZ^U$   !'# !#$
>ghfT[[!   !'# !#$ 
Product Quantity Code number
2T[[QPV$\;   !'# !#  
2T[[QPV ;   !'# !!%'
2T[[QPV!;   !'# !!%(
2T[[QPV!;>ghfT[[!   !'# !!&
2T[[QPV!;bRaTfRP_   !'# !!& 
2T[[QPV!;_TaUdbX^]   !'# !"#!
2T[[QPV!;5XQaP2T[   !'# !"#"
2T[[QPV!;_7>?C   !'('#&#
2T[[QPV!;_7>?CP]SbRaTfRP_   !( !"$"
2T[[QPV!;_7>?CP]S_TaUdbX^]   !( !"$$
2T[[QPV!;ATPSh<PcT   !'# " %
2T[[QPV!;3>>?C88P]S_7>?C   !( $! !
2T[[QPV!;3>>?C88_7>?CP]SbRaTfRP_   !( $"&
2T[[QPV!;3>>?C88_7>?CP]S_TaUdbX^]   !( $"'
2T[[QPV ;   !'# !!&'
2T[[QPV ;>ghfT[[!   !'# !!&(
2T[[QPV ;bRaTfRP_   !'# !!'
2T[[QPV ;_TaUdbX^]   !'# !"$#
2T[[QPV ;5XQaP2T[   !'# !!' 
2T[[QPV ;_7>?C   !'('#&(
2T[[QPV ;_7>?CP]SbRaTfRP_   !( !"$&
2T[[QPV ;_7>?CP]S_TaUdbX^]   !( !"%
2T[[QPV ;ATPSh<PcT   !'# " &
2T[[QPV ;3>>?C88P]S_7>?C   !( $! "
2T[[QPV ;3>>?C88_7>?CP]SbRaTfRP_   !( $"(
2T[[QPV ;3>>?C88_7>?CP]S_TaUdbX^]   !( $" !
2T[[QPV!;   !'# !!'%
2T[[QPV!;>ghfT[[!   !'# !!'&
2T[[QPV!;bRaTfRP_   !'# !!''
2T[[QPV!;_TaUdbX^]   !'# !"$(
2T[[QPV!;5XQaP2T[   !'# !"% 
2T[[QPV!;_7>?CeTabX^]   !'('#'
2T[[QPV!;_7>?CP]SbRaTfRP_   !( !#$$
2T[[QPV!;_7>?CP]S_TaUdbX^]   !( !#%
2T[[QPV!;ATPSh<PcT   !'# " '
Related literature
5^aATVd[Pc^ahBd__^ac^][X]TeXbXcfffVT[XUTbRXT]RTbR^\abU
D_^]bdQbRaX_cX^]P]SP__a^eP[cWTfTQbXcTRP]QTdbTSc^
^QcPX]cWT2T[[QPVEP[XSPcX^]6dXST2WP]VT2^]ca^[=^cX
RPcX^]b
P]S2TacX
RPcTb^U@dP[Xch
Thermo Fisher Scientific 
combines digital control with
peristaltic pump technology 
to provide high-accuracy, 
maintenance and worry free 
performance to your chemical
feed applications. 
•   Menu-driven LCD graphical 
    interface provides easy system  
    set-up.
•   Loaded with a broad range of 
    remote control options—ideal  
    for automated process 
    applications.
•   The brushless motor driven by
    a PWM control is capable of a 
    flow range turndown of 
    380,000:1.
•   Other control capabilities 
    include programmable 
    dispensing by volume, time, 
    or copy modes with a 
    programmable delay 
    between cycles for 
    convenient, automated 
    dispensing.
•   Precise PWM speed control 
    (±0.1%) maximizes accuracy 
    and efficiency while the brush-
    less motor gives you quiet, 
    maintenance-free reliability.
•   Optimize system accuracy by 
    calibrating the pump system 
    in process. The calibration is 
    stored in memory—one 
    calibration value per tubing 
    size.
•   Program the drive via the 
    simple membrane keypad and
    multi-language display.
•   Reversible motor so you can 
    purge tubing before or after
    pumping.
•   IP33 rated ABS housing for 
    improved splash and dust 
    resistance.
Thermo Scientific
Masterflex
P/S Standard 
Digital Pump 
Systems 
M
asterflex
®
P/S
 Pum
p S
ystem
s 
P/S 1.1
 
RPM                                                                        Precision pump tubing High-performance precision pump tubing*
                                 P/S 13                 P/S 14                  P/S 16                 P/S 25 P/S 17                 P/S 18 P/S 15 P/S 24 P/S 35 P/S 36
                                                                                                                                                 0.17 to 1000 0.28 to 1700 .38 to 2300 0.48 to 2900
                                                                                                                                                 (0.18 to 1100) (0.30 to 1800) (0.43 to 2600) (0.57 to 3400)
                                                                                                                                                 0.033 to 170 0.057 to 280 0.077 to 380 0.096 to 480
                                                                                                                                                 (0.033 to 180) (0.057 to 300) (0.077 to 430) (0.096 to 580)
* Values in parentheses are with high-performance pump heads
0.02 to 100            0.001 to 6          0.004 to 21         0.016 to 80        0.033 to 170 0.057 to 280       0.077 to 380
0.1 to 600             0.006 to 36        0.021 to 130        0.08 to 480        0.17 to 1000 0.28 to 1700       0.38 to 2300
 
               Catalog number                            1300-3600-955           1300-3600-956            1300-3600-965            1300-3100-955            1300-3100-956          1300-3100-965
Included pump head                                               Easy-Load II                    Easy-Load II                High-Performance                Easy-Load II                     Easy-Load II             High-Performance
                                                                                (thin wall)                      (thick wall)                      (thick wall)                       (thin wall)                       (thick wall)                   (thick wall)
Number of heads accepted                                             2                                     2                                     1                                     4                                      4                                   1
RPM                                                                                                                             0.1 to 600                                                                                                                 0.02 to 100                 
External control – input                                                                                                                            0 to 20 mA, 0 to 10V; Scaleable
                                                                                                                                                START/STOP, DIR. (CW/CC), PRIME via contact closure                                         
                                                                                                                                                                  Remote / Local Enable Contact
                                                                                                                                                      Secondary Speed Control 0-20mA or 4-20mA
                                                                                                                                                                 Auxiliary Contact (Limit Switch)
External control – output                                                                                                                                4 to 20 mA, or 0 to 10 V                                                                     
Motor running logic N.O. or N.C. (1A @ 24V)
Tachometer output 5V, TTL pulse
Power supply output                                                                                                                                          24V, 150 mA
Voltage (50/60 Hz)                                                                                                                                      115/230 VAC (auto selected)
Motor type                                                                                                                 Brushless continuous duty, TENV*, DC, permanent lubricated bearings
Control type                                                                                                                                              PWM (Pulse Width Modulated)
Speed regulation (repeatability)                                                                                           ±0.1%; ±0.1 rpm @ 600 rpm;  %; ±0.21 rpm @ 100 rpm                                                                       
Operating temperature                                                                                                                                   0 to 40ºC (32 to 104ºF)
Storage temperature                                                                                                                                    –25 to 65ºC (–13 to 149ºF)
Housing materials                                                                                                                                    ABS, Powder-coated aluminum)
IP rating                                                                                                                                                                          IP33
Agency approvals                                                                                                                                                    ETL, cETL, CE
Controller dimensions (L x W x H)                                                                                                                            13.0 x 8 x 8                                                               
Shipping weight                                                                                                                                                           20 lbs.                                                  
Specifications & Ordering Information
Flow rates in mL/min (flow rates in parentheses can only be obtained with the High-Performance pump head)
Barrington, IL 60010
1-800-637-3739
1-847-381-7050
1-847-381-7053 fax
www.thermo.com/fluidhandling 
P/S 1.2
		
	
	
	
	
	
	
	
Note:	For	the	centrifuge	used	in	this	process,	the	equipment	specification	sheet	for	the	exact	unit	used	was	not	available.	In	this	case,	a	specification	sheet	for	a	similar	unit	of	the	same	make	but	different	size	was	used	to	give	an	idea	of	the	construction	and	function.	The	affected	unit	is	the	Alfa	Laval	MBPX	404S	separation	system,	in	lieu	of	which	an	Alfa	Laval	MBPX	810S	separation	system	specification	sheet	is	provided.	
Applications
The MBPX 810 separation system is based on the  
solids ejecting disc stack separator MBPX 810SGV-34CL 
in clarifier execution. It is equipped with variable discharge 
mechanism for timer triggered discharge of solids. 
It is used to remove suspended solids with particle sizes 
of approximately 0.5 to 500 µm from a liquid having lower 
specific gravity than the solids. The solids content is  
normally in the range of 0.1-10% by volume. 
The main applications are bacteria, rDNA products, 
enzymes, cell cultures and vaccines. 
Design features
The MBPX 810 separator is equipped with the following 
features
Variable partial discharge mechanism, allowing settable  s 
 discharge volume
Disc inlet for low shear acceleration of process media s 
Variable speed to facilitate performance opimizations 
A cooling system with a cooling jacket for the bowl  s 
 enclosure including the solids collecting receptacle,  
 and a cooling coil for the lubrication oil bath.  
Anchoring feet and vibration damperss 
All liquid wetted parts are in high grade stainless steels 
All liquid wetted elastomers are in FDA approved EPDMs 
Hygienic design of solids handling area with internal  s 
 spray  nozzles
Monitoring kit with sensors for bowl, speed, vibrations  s 
 and operating water pressure, and, as option, a cover  
 switch for preventing the motor from being started   
 unless the separator top part has been properly  
 mounted.
Choice of large or small disc stack to accommodate  s 
 low or high solids loading
Choice of low flow or high flow paring discs 
Enhanced surface finish to less than 0.8 µm Ra for  s 
 product contact parts, as an option. 
 
Complete system 
The MBPX 810 separation system is flexible and designed  
to meet industry standards. 
The separator is mounted on a fixed base frame with  s 
 process piping for service liquids and process liquids  
 entering and leaving the separator. 
Clamp connections for improved hygiene.s 
Control system with a plc and HMI, suitable for  s 
 connectivity (Profibus or Ethernet) with a supervising  
 control system
Automatic CIP possibilitiess 
Automatic flow control with magnetic flow meter and  s 
 flow regulating valve
Back-pressure controls 
Optional - turbidity monitoring, replacement buffer liquid  s 
 addition, solids receiving unit, mass flow meter (replacing  
 magnetic flow meter) and temperature sensor on  
 supernatant outlet provide enhanced installation flexibility  
 to customer
Enhanced documentation supporting cGMP qualification  s 
 is available and FAT is performed before shipping.
MBPX 810
Separation system for fermentation and biotech industries
How to contact Alfa Laval
Contact details for all countries  
are continually updated on our website. 
Please visit www.alfalaval.com to 
access the information direct.
PLS00087EN 1003
Fig. 1.  Typical bowl drawing for solids-ejecting centrifuge in timer-
triggered clarifier execution. Drawing details do not necessarily 
correspond to the centrifuge described.
Operating principles
The feed is introduced to the rotating centrifuge bowl (fig 1) 
from the top via a stationary inlet pipe (1), and is acceler-
ated by the disc inlet in a distributor (2) before entering the 
disc stack (3). It is between the discs that the separation 
takes place. The liquid phase moves towards the centre 
of the bowl, from where it is pumped out under pressure 
by means of a built-in paring disc (4). The heavier solids 
phase is collected at the bowl periphery, from where it is 
discharged intermittently via the centrifuge cyclone. The 
solids discharge is achieved by a hydraulic system below 
the separation space in the bowl, which at certain inter-
vals forces the sliding bowl bottom (5) to drop down, thus 
opening the solids ports (6) at the bowl periphery. The bowl 
is mounted on a vertical spindle (7) driven by a horizontally 
mounted motor, via a worm gear.
Utilities for MBPX 810 separation system
Electric power consumption, max. 17 kW 1)
Flushing & Operating water;  
max. momentary flow 3 000 l/h
Consumption   Up to abt. 200 l/h 2)
Cooling water,  
recommended flow 120 – 150 l/h
1) At a feed rate of 10 m3/h. Actual consumption depends on feed rate, feed   
 characteristics and applied back-pressure on liquid outlet. 
2) Consumption is very dependent on selected flushing regime & discharging  
 frequency.   
Shipping data (approximate)
Complete system with bowl and motor. Packed on pallet or 
in case 
Net weight    2 300 kg 
Gross weight pallet  2 400 kg   case  2 800 kg 
Volume                            pallet        8 m3  case   10.5 m3
Technical specification, MBPX 810 separation system
Max throughput capacity 8 or 15 m3/h 1)
Max solids handling capacity 360 or 540  l/h 2)
Feed temperature range 0 - 100 oC
Feed inlet pressure required, max. 250  kPa 3)
Liquid outlet pressure available upto 400 kPa 4)
Installed motor power 25 kW
Sound pressure 80 dB(A) 5)
 
1) Actual throughput capacity depends on amount and type of  solids in the  
 feed, viscosity and required degree of clarificaiton.
2) Wet solids. 
3) Valid for water at throughput capacity 3 m3/h, and at max. back-pressure  
 on liquid outlet.
4) Valid for water throughput capacity 3 m3/h.
5) According to EN ISO 4871.
2005 mm
1305 mm
2450 mm
March 10, 2016 1 SPC 00336-AW, V 3.0, DRAFT 7 
 
INTERCEPT® Blood System for Platelets –Dual Storage (DS) Processing Set 
 
Rx Only 
Caution: US Federal law restricts this device to sale by or on the order of a licensed healthcare practitioner 
 
March 10, 2016 
 
INTENDED USE 
 
The INTERCEPT Blood System for platelets is intended to be used for ex vivo preparation of pathogen-reduced 
Amicus apheresis platelet components suspended in 65% PAS-3/35% plasma, and Trima apheresis platelet 
components suspended in 100% plasma in order to reduce the risk of transfusion-transmitted infection (TTI), 
including sepsis, and to potentially reduce the risk of transfusion-associated graft versus host disease (TA-
GVHD). 
 
DEVICE DESCRIPTION 
 
The INTERCEPT Blood System for platelets, DS Processing Set, contains a sterile, non-pyrogenic, single-use, 
integrated, fluid path platelet processing set (INT2510) comprised of four key components (See Table 1) and an 
ultraviolet (UVA) illumination device (INT100) for the ex vivo preparation and storage of pathogen reduced  
apheresis platelet components.  The INT100 is a microprocessor controlled device designed to deliver a controlled 
amount of UVA light, wavelength 320 to 400 nm, to up to two illumination containers simultaneously.   The 
device is programmed to be able to control, deliver, record and store intensity and duration of light dose for each 
cycle. 
 
 Components of the INTERCEPT Platelet DS Processing Set (INT2510) Table 1
Component Description 
Amotosalen (S-59, psoralen derivative) 
solution container 
17.5 mL, 3 mM amotosalen in 0.924% NaCl packaged 
in a 20 mL, flexible, heat-sealed plastic container, with 
an integral light-protective overwrap and sleeve 
Illumination container Heat-sealed,  plastic bag 
Compound Adsorption Device (CAD) Immobilized beads (wafer) in mesh pouch 
Platelet storage containers Two platelet storage bags – 1300 mL storage capacity 
each 
 
The operating principle for the INTERCEPT Blood System for platelets is illustrated below (Figure 1). Platelets 
collected by apheresis in a container are sterile connected to the Platelet DS Processing Set [INT2510]. The 
platelets flow through the amotosalen container into the illumination container. The illumination container is 
placed into the INT100 illumination device for UVA treatment while being mixed with horizontal agitation. 
Inactivation of potential pathogen or leukocyte contaminants in platelet components is achieved through a 
photochemical treatment process. Amotosalen (S-59, psoralen derivative), a chemical capable of binding to 
nucleic acids is added to platelets. UVA illumination (320 – 400 nm wavelengths) of amotosalen-treated platelet 
components induces covalent cross-linking of any nucleic acids to which amotosalen is bound; thereby, 
preventing further replication.1  Treated platelets are then transferred to the CAD container to reduce the levels of 
residual amotosalen and free photoproducts. Finally, the platelet components are transferred through the in-line 
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filter to the storage container for use or storage at 20-24°C with continuous agitation for up to 5 days from the 
time of collection.  
 
Figure 1 INTERCEPT Blood System for Platelets and Treatment Process 
 
 
DEVICE PERFORMANCE 
 
The INTERCEPT Blood System inactivates a broad spectrum of enveloped and non-enveloped viruses, Gram-
positive and Gram-negative bacteria, spirochetes, parasites and leukocytes.2-22 There is no pathogen inactivation 
process that has been shown to eliminate all pathogens. Certain non-enveloped viruses (e.g., HAV, HEV, B19 and 
poliovirus) and Bacillus cereus spores have demonstrated resistance to the INTERCEPT process. 
 
 Viral Reduction (Enveloped)4-14  Table 2
Pathogen 
Platelets in PAS-3 
Log10 Reduction  
(pfu/mL)a 
Platelets in 100% 
Plasma 
Log10  
Reduction(pfu/mL)a  
HIV-1 IIIB, cell-associated ≥5.4 ≥ 4.7  
HIV-I IIIB, cell-free ≥5.6 d 
HIV-1 Z84 (clinical isolate)  ≥3.3 d 
HIV-2 CLB-20 (clinical isolate)  ≥2.4 d 
DHBVb ≥4.8 ≥4.3 
BVDVc ≥4.4  >3.3 
HTLV-I 4.7 d 
HTLV-II ≥5.1 d  
West Nile virus (WNV) ≥5.7 >3.7 
Cytomegalovirus (CMV) ≥4.9 d 
Pseudorabies virus (model for CMV) d ≥4.2 
Chikungunya virus (CHIKV) ≥5.7 >6.5 
Dengue virus (DENV) ≥4.3 3.6 
Influenza A virus ≥5.9 d 
a Based on input titer and post-treatment titer in 1 mL, data obtained in platelets in PAS-3 or plasma 
components unless otherwise noted 
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b DHBV model virus for HBV 
c BVDV model virus for HCV 
d = Not tested 
 Viral Reduction (Non-Enveloped)4,17 Table 3
Pathogen 
Platelets in PAS-3 
Log10  Reduction  
(pfu/mL)a 
Platelets in 100% 
Plasma 
Log10  Reduction 
(pfu/mL)a 
Calicivirus (model non-enveloped virus) 2.1 0.9 
Adenovirus ≥4.9 ≥5.3 
Blue tongue virus (model non-enveloped 
virus) 
4.4 b 
a Based on input titer and post-treatment titer in 1 mL, data obtained in platelet components in PAS-3 or 
plasma components unless otherwise noted  
b = Not tested 
 
 Bacterial Reduction15,16  Table 4
Pathogen 
Platelets in PAS-3 
Log10  Reduction  
(cfu/mL)a 
Platelets in 100% 
Plasma 
Log10  Reduction 
(cfu/mL)a, b 
Gram-Negative Bacteria  
Klebsiella pneumoniae 5.8 5.9 
Escherichia coli ≥6.3 >5.9 
Serratia marcescens ≥6.7c >7.1 
Pseudomonas aeruginosa ≥3.9 ≥6.8 
Salmonella choleriaesuis 6.2 >5.9 
Enterobacter cloacae 5.5 ≥6.0 
Yersinia enterocolitica ≥5.9 >6.3 
Gram-Positive Bacteria  
Staphylococcus epidermidis ≥6.1 >6.1 
Staphylococcus aureus ≥5.4 ≥6.1 
Listeria monocytogenes ≥6.3c >6.6 
Corynebacterium minutissimum ≥5.3 >6.4 
Streptococcus pyogenes ≥6.8 c >6.1 
Bacillus cereus (vegetative) ≥5.5 ≥5.6 
Bacillus cereus (spore forming) 3.7 c d 
Anaerobic Gram-Positive Bacteria and Spirochete Bacteria  
Bifidobacterium adolescentis ≥6.0 d 
Propionibacterium acnes ≥6.5 >6.7 
Clostridium perfringens (vegetative) ≥6.5 >6.0 
Lactobacillus species ≥6.4 >6.1 
Treponema pallidum ≥6.4 b 
Borrelia burgdorferi ≥6.8  b 
a Based on input titer and post-treatment titer in 1 mL, data obtained in platelet components in PAS-3 or 
plasma components unless otherwise noted 
b Study in progress 
c Based on culture of full platelet unit (300 mL) 
d = Not tested  
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 Protozoa Reduction19-21 Table 5
Pathogen 
Platelets in PAS-3 
Log10  Reduction  
(pfu or cfu/mL)a 
Platelets in 100% 
Plasma 
Log10  Reduction 
(pfu or cfu/mL)a 
Plasmodium falciparum ≥5.6 c 
Babesia microti ≥4.9 c 
Trypanosoma cruzi ≥5.3 >5.5 
Leishmania mexicana (metacyclic 
promastigote stage)  
≥5.0 b 
a Based on input titer and post-treatment titer in 1 mL, data obtained in platelet components in PAS-3 or 
plasma components unless otherwise noted 
b = Not tested 
c Study in progress 
 
The INTERCEPT process for platelets reduces a broad spectrum of bacteria by > 4 log10 (Table 4) to lower the 
risk of microbial contamination of blood components.21   Bacterial spores are resistant to inactivation by the 
INTERCEPT Blood System for platelets. 
 
Contaminating T cell activity is reduced by the INTERCEPT treatment, potentially lowering the risk of 
transfusion-associated graft versus host disease (TA-GVHD).22-27 Using a limiting dilution assay (LDA), platelets 
processed with the INTERCEPT Blood System exhibited a 4 log10 reduction of viable T-cells. Using a DNA 
modification assay, platelets processed with the INTERCEPT Blood System demonstrated an average of one 
amotosalen adduct every 83 base pairs in leukocytes. 
 
In vitro Characterization of Platelet Components Processed with the INTERCEPT Blood System. 
 
In vitro platelet function characteristics were evaluated in prospective, randomized, paired, controlled, in vitro 
studies in healthy subjects of INTERCEPT apheresis platelet components compared to unprocessed (control) 
platelet components.  Each study subject donated a single- or double-apheresis platelet component, during each of 
the two donation periods. Components from the platelet donations were randomized to produce INTERCEPT 
processed platelet components or control platelet components.  In vitro platelet function of the platelet 
components was evaluated on day 5 after apheresis donation. The physical and metabolic characteristics for 
evaluation included: component volume platelet count, platelet volume (MPV), pH22◦C, pO2, pCO2, HCO3, 
morphology, supernatant LDH activity, P-selectin, total ATP, extent of shape change, hypotonic shock response, 
supernatant glucose, and supernatant lactate.  Trima platelets suspended in 100% plasma were evaluated further. 
 
1. Storage in 65% PAS-3/35% Plasma: 
 
63 single-dose and double-dose Amicus platelet collections containing 2.9 - 8.0×1011 platelets in PAS-3 
treated with the INTERCEPT Blood System for platelets and stored for 5 days retained presumptively 
therapeutically effective platelet doses (mean of 3.7 x 1011 platelets and lower bound of the 95% 
confidence interval (CI) for the proportion of INTERCEPT processed platelet components retaining 
>3.0×1011 platelets was 78.3%) with an average dose recovery after INTERCEPT treatment of 91.19% 
(95% CI: 89.7%-92.7%), and with retention of adequate in vitro metabolic and functional properties 
(Table 6). 
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 In Vitro Platelet Function Characteristics of INTERCEPT (I) and Control (C) Table 6
Platelets in PAS-3 After 5 Days of Storage (Mean +/- SD (median) [range]; n=63) 
 INTERCEPT Control 
95% CI for 
Treatment 
Difference 
(I-C) 
INTERCEPT 
within  ± 20% of 
Control, 
# / N (%) 
Platelet Component Characteristics  
Component volume 
(mL) 
279±74 (327) 
[162-382] 
288±74 (317) 
[152-400] -14.4 to -3.7* 60/63 (95.2%) 
Platelet count (×103/µl) 1383±341(1368) [717-2002] 
1482±375 (1408) 
[730-2250] -148.1to -51.0* 53/63 (84.1%) 
Platelet dose (×1011 
cells/unit) 
3.7±0.8 (3.5) 
[2.5-6.1] 
4.0±0.6 (3.9) 
[2.3-5.5] -0.5 to -0.2* 51/63 (81.0%) 
MPV (fL)1 8.1±0.8 (8.1) [6.7-10.6] 
8.1±0.9 (8.0) 
[6.7-10.4] -0.1 to 0.2 58/58 (100%) 
Indices of Platelet Metabolism  
pH at 22°C 7.02±0.11(7.04) [6.78-7.20] 
7.03±0.12 (7.03) 
[6.73-7.25] -0.04 to 0.02 63/63 (100%)† 
pO2 (mm Hg) 
130±21(134) 
[66-168] 
124±20 (128) 
[70-154] -1.0 to 13.2 39/63 (61.9%) 
pCO2 (mm Hg) 
20±6 (20) 
[10-32] 
24±6 (24) 
[13-35] -4.4 to -2.4* 36/63 (57.1%) 
HCO3− (mmol/L)2 
3.2±1.1 (3.1) 
[1.0-5.3] 
3.8±1.3 (4.0) 
[2.0-7.0] -0.9 to -0.3* 23/60 (38.3%) 
Supernatant glucose 
(mg/dL)3 
21.5±24.0 (18.5) 
[0.0-127.8] 
15.5±23.3 (2.0) 
[0.0-120.6] 1.2 to 10.9* 29/61 (47.5%) 
Supernatant lactate 
(mmol/L) 
11±2 (11) 
[7-15] 
12±3 (13) 
[7-19] -1.99 to -0.82* 43/63 (68.3%) 
Total ATP 
(nmol/108 Plts) 
4.70±1.95 (4.20) 
[1.07-9.39] 
4.47±1.72 (4.28) 
[1.20-10.25] -0.22 to 0.70 24/63 (38.1%) 
Indices Correlating with In Vivo Recovery, Survival and Function  
Morphology 257±47 (249) [176-360] 
251±45 (246) 
[186-360] -3.1 to 14.6 52/63 (82.5%) 
Extent of Shape 
Change (ESC; %) 
12.2±8.1 (12.3) 
[1.0-49.0] 
11.9±9.1 (10.1) 
[0.0-32.6] -2.1 to 2.7 12/63 (19.0%) 
Hypotonic Shock 
Response (HSR; %) 
28±18 (28) 
[0-56] 
30±19 (30) 
[0-62] -4.8 to 1.9 32/63 (50.8%) 
Indices of Granular and Cytoplasmic Content Retention  
LDH activity (IU/L) 149±92 (118) [10-581] 
142±83 (115) 
[60-460] -10.9 to 26.4 29/63 (46.0%) 
LDH (IU/1012 Plts) 110±54 (100) [8-329] 
97±49 (82) 
[35-270] 0.1 to 25.8* 19/63 (30.2%) 
P-selectin (%)4 
36.98±16.22 
(31.75) 
[7.93-83.31] 
33.70±13.96 
(29.76) 
[9.28-74.47] 
0.21 to 6.35* 19/60 (31.7%) 
1n=58; 2n=60; 3n=61; 4n=60 
* Statistically significant difference (p<0.05) between INTERCEPT and Control  
†The analysis criterion is ≥ 6.2 for pH22°C. 
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2. Storage in 100% Plasma: 
 
a. 67 single-dose and double-dose Trima platelet collections suspended in 100% plasma containing  
3.1- 7.9×1011 platelets in 100% plasma treated with the INTERCEPT Blood System for platelets and 
stored for 5 days showed a mean platelet dose of 3.5 x 1011  (the lower bound of the 95% CI for the 
proportion of INTERCEPT processed platelet components retaining >3.0×1011 platelets/component 
was 67.6%) with an average dose recovery after INTERCEPT treatment of 86.7%, (95% CI: 85.7%-
87.7%). In vitro results are included in Table 7. 
 
 In Vitro Platelet Function Characteristics of INTERCEPT (I) and Control (C) Table 7
Platelets in 100% Plasma After 5 Days of Storage (Mean +/- SD (median) [range]; n=67) 
 INTERCEPT Control 
95% CI for 
Treatment 
Difference 
(I-C) 
INTERCEPT 
within  ± 20% of 
Control, 
# / N (%) 
Platelet Component Characteristics  
Component volume 
(mL) 
280.8±70.2 1 
[183.5-365.1] 
289.9±69.6 
[198.4-378.2] -14.4 to -4.0* 65/67 (97.0%) 
Platelet count (×103/µl) 1313±254
 1 
[795-1955] 
1420±261 
[883-1941] -148 to -69* 57/66 (86.4%) 
Platelet dose (×1011 
cells/unit) 
3.5±0.7 1 
[2.4-5.2] 
4.0±0.6 
[2.9-5.1] -0.5 to -0.3* 56/66 (84.8%) 
MPV (fL)1 7.3±1.0 [5.9-10.4] 
7.4±0.9 
[6.0-11.4] -0.3 to -0.0* 64/65 (98.5%) 
Indices of Platelet Metabolism 
pH at 22°C 7.2±0.3
1 
[5.7-7.5] 
7.4±0.1 
[7.1-7.6] -0.3 to -0.2* 66/67 (98.5%)† 
pO2 (mm Hg) 
131±171 
[69-175] 
121±18 
[56-158] 4 to 16* 48/67 (71.6%) 
pCO2 (mm Hg) 
31±71 
[19-46] 
30±5 
[ 20-43] 0 to 2* 60/67 (89.6%) 
HCO3− (mmol/L) 
7.6±2.71 
[0.3-13.0] 
11.3±2.0 
[7.0-17.0] -4.4 to -3.2* 15/66 (22.7%) 
Supernatant glucose 
(mg/dL) 
225±541 
[104-481] 
268±52 
[183-510] -54 to -32* 40/66 (60.6%) 
Supernatant lactate 
(mmol/L) 
11.2±3.91 
[5.8-26.6] 
8.3±2.1 
[4.6-13.9] 2.1 to 3.7* 21/66 (31.8%) 
Total ATP 
(nmol/108 Plts) 
4.6±1.41 
[0.8-7.8] 
5.0±2.0 
[1.4-13.1] -0.8 to 0.1 31/66 (47%) 
Indices Correlating with In Vivo Recovery, Survival and Function 
Morphology 307±39
1 
[203-367] 
299±42 
[185-366] -4 to 21 53/66 (80.3%) 
Extent of Shape 
Change (ESC; %) 
23.1±5.01 
[13.2-34.2] 
26.9±5.1 
[16.3-39.5] -4.7 to -3.2* 51/66 (77.3%) 
Hypotonic Shock 
Response (HSR; %) 
59±91 
[40-83] 
58±10 
[36-82] -2 to 3 54/66 (81.8%) 
Indices of Granular and Cytoplasmic Content Retention 
LDH activity (IU/L) 169±56
2 
[76 – 483] 
141±28 
[62 – 277] 16 to 42* 40/67 (59.7%) 
LDH (IU/1012 Plts) 130±4
1 
[55-307] 
102±27 
[49-252] 20 to 36* 28/66 (42.4%) 
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P-selectin (%) 20.5±8.5
1 
[3.8-44.6] 
14.3±6.1 
[2.4-35.4] 4.6 to 7.8* 19/66 (28.8%) 
1 n=66; 2 Value for one sample on Day 6  
* Statistically significant difference (p<0.05) between INTERCEPT and Control  
†The analysis criterion is ≥ 6.2 for pH22°C. 
 
 
 
b. 260 single-dose and double-dose Trima apheresis platelet collections suspended in 100% plasma 
containing platelet doses of 3.0 to 7.7×1011 platelets in 270 to 417 mL plasma with platelet count 
ranging from 963×103 to 1891×03 platelets/μL, and stored for 5 days were evaluated for pH22°C, 
platelet dose, and platelet dose recovery. Day 5 INTERCEPT Trima platelet components in 100% 
plasma contained, on average, 3.6×1011 platelets in 313 mL total volume with a lower bound of the 
95% CI for the proportion of INTERCEPT processed platelet components retaining >3.0×1011 
platelets of 85%. The dose and volume recovery post- INTERCEPT process were 86.5 ±5.0% and 
92.6 ±1.8% (95% CI for dose recovery: 85.9%-87.1% and 95% CI for volume recovery: 92.4%-
92.8%), respectively.  Summary of evaluation criteria for pH22°C, platelet dose, and platelet dose 
recovery are provided in Table 8 by INTERCEPT processing set. 
 
Table 8 Evaluation Criteria of INTERCEPT Trima Platelet Components Suspended in 100% Plasma 
by Processing Set 
 
Test 
Recommended 
Threshold and 
Criterion 
INTERCEPT 
Processing 
Set 
Proportion of INTERCEPT 
Components Meeting 
Threshold (#/N, [%]) 
1-Sided 
95% CI 
Day 5 
pH22°C 
≥ 6.2 
 
SV          24/24        [100%] ≥88.3% 
LV            9/9           [100%] ≥71.7% 
DS       230/231      [99.6%] ≥98.0% 
Day 5 
Dose 
≥ 3.0 × 1011 
 
SV          21/24        [87.5%] ≥70.8% 
LV            6/7           [85.7%] ≥47.9% 
DS       195/219      [89.0%] ≥84.9% 
Dose 
Recovery 
≥ 85% 
 
SV          23/24        [95.8%] ≥81.7% 
LV            4/9           [44.4%] ≥16.9% 
DS       127/225      [56.4%] ≥50.7% 
≥ 80% 
 
SV          24/24        [100%] ≥88.3% 
LV            9/9           [100%] ≥71.7% 
DS       212/225      [94.2%] ≥91.0% 
 
The proportion of platelet units of the DS set containing a platelet dose ≥ 3.0 x 1011 platelets on Day 5 
was 89.0% (195 out of 219), and the lower bound of the 95% CI for the proportion of units containing a 
platelet dose ≥ 3.0 x 1011 platelets was 84.9% (Table 8). 
 
The combined overall results of the two in-vitro studies described above show that INTERCEPT Trima platelets 
suspended in 100% plasma retain presumptively therapeutically effective mean platelet doses, with retention of 
adequate in vitro metabolic and functional properties. 
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CONTRAINDICATIONS 
 
• Contraindicated for preparation of platelet components intended for patients with a history of 
hypersensitivity reaction to amotosalen or other psoralens.   
 
• Contraindicated for preparation of platelet components intended for neonatal patients treated with 
phototherapy devices that emit a peak energy wavelength less than 425 nm, or have a lower bound of the 
emission bandwidth <375 nm, due to the potential for erythema resulting from interaction between 
ultraviolet light and amotosalen. 
 
Note: Information about these contraindications needs to be included in the labeling provided with 
transfusable platelets prepared using the INTERCEPT Blood System for platelets. 
 
 
WARNINGS AND PRECAUTIONS  
 
• Only INTERCEPT Processing Sets for platelets are approved for use with the INTERCEPT Blood 
System. Use only the INTERCEPT INT100 Illuminator for UVA illumination of amotosalen-treated 
platelet components.  No other source of UVA light may be used.  Please refer to the Operator’s Manual 
for the INT100 Illuminator. Discard any platelet components not exposed to the complete INT100 
illumination process. 
 
• Tubing components and container ports of the INTERCEPT Blood System contain polyvinyl chloride 
(PVC).  Di(2-ethylhexyl)phthalate (DEHP) is known to be released from PVC medical devices, and 
increased leaching can occur with extended storage or increased surface area contact.  Blood components 
will be in contact with PVC for a brief period of time (approx. 15 minutes) during processing.  The risks 
associated with DEHP released to into the blood components must be weighed against the benefits of 
therapeutic transfusion. 
 
• Pulmonary events:  Acute Respiratory Distress Syndrome (ARDS) 
 
INTERCEPT processed platelets may cause the following adverse reaction: Acute Respiratory Distress 
Syndrome (ARDS) 
 
An increased incidence of ARDS was reported in a randomized trial for recipients of INTERCEPT 
processed platelets, 5/318 (1.6%), compared to recipients of conventional platelet components (0/327).28  
Monitor patients for signs and symptoms of ARDS.  
 
Note: Information about these Warnings and Precautions needs to be included in the labeling provided 
with transfusable platelets prepared using the INTERCEPT Blood System for Platelets. 
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INSTRUCTIONS FOR USE 
 
Initial Setup 
Equipment Provided: One (1) INT2510 Dual Storage Processing Set 
Equipment Available Separately: INTERCEPT INT100 Illuminator 
Equipment Required But Not Provided: Sterile Connecting Device (SCD), Tube Sealer, Flatbed Agitator, 
Manual Tube Clamp (e.g., Hemostat) 
 
• INTERCEPT Processing Sets for platelets are for single use only.  Do not reuse sets or components 
of sets. 
   
• This process is designed to be a functionally closed system.  Treatment with INTERCEPT Blood System 
does not replace applicable standards for processing in open and closed systems.   
 
Blood Collection  
Leukocyte reduced platelets collected by apheresis are used.  Refer to Table 9 for specifications of the platelet 
products which are used with this processing set. 
 
Table 9 Platelet Collection and Processing Specifications for INTERCEPT Dual Storage  
Processing Set 
 Platelets in PAS-3 Platelets in 100% Plasma 
Collection Specifications 
Platelet Source Amicus 
Apheresis 
Amicus Apheresis Trima Apheresis Trima Apheresis 
Suspension 
Medium 
PAS-3 and 
plasma (32-47%) 
PAS-3 and plasma 
(32-47%) 
100% Plasma 100% Plasma 
Platelet Input 
Volume 
300 – 390 mL 375 – 420 mL 300 – 390 mL 375 – 420 mL 
Platelet Dose 3.0  – 6.0x1011 4.0 – 8.0x1011 3.0 – 5.2x1011 5.3 – 7.9x1011 
Platelet Count 0.8 – 2.0x109/mL 0.95 – 2.1x109/mL 0.8-1.7 x 109/mL 1.3-2.0 x 109/mL 
RBC Content < 4x106 RBC/mL < 4x106 RBC/mL < 4x106 RBC/mL < 4x106 RBC/mL 
Processing Specifications 
Number of 
Storage Bags 1 1 or 2 1 2 
CAD Time  6-16 Hrs 6-16 Hrs 12-24 Hrs 12-24 Hrs 
Maximum 
Storage  5 Days 5 Days 5 Days 5 Days 
 
Platelet Processing 
 
Platelets must be exposed to UVA light within 24 hours after collection. 
 
Refer to Figure 2 for labeling and identification of set components. 
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Figure 2 INTERCEPT Dual Storage Processing Set 
 
 
 
 
 
 
I. Amotosalen Addition 
NOTE:  Amotosalen in contact with skin may result in photosensitization in the presence of ultraviolet light.  
 If skin exposure occurs, flush exposed skin with water. 
 
1. Remove set from package. Unwrap only illumination container (  ) from organizer. 
2. Weld tubing from platelet collection container to amotosalen container (  ) tubing using SCD. 
3. Label storage container (  ) using appropriate donation identification.  
4. Hang platelet collection container and break cannula (  ) below amotosalen container (  ) to let 
amotosalen flow into illumination container (  ); visually verify amotosalen is present. 
5. Break cannula (  ) above amotosalen container (  ) to let platelets flow through amotosalen container 
(  ) into illumination container (  ). 
6. Ensure the platelets drain completely from initial platelet collection container into illumination container  
(  ) by expressing air from the illumination container (  ) into amotosalen container  
( ). 
7. When air is removed and platelets have fully drained back through tubing into illumination container  
(  ), manually clamp tubing above illumination container.  Mix illumination container thoroughly by 
gentle agitation to ensure complete mixing of amotosalen and platelets (Figure 3). 
 
Legend: 
• Containers 1,2,3 
• Amotosalen A 
• Cannulae B,C,D,E 
• Clamps F,G  
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Figure 3 Gently Agitate the Filled Illumination Container 
 
8. Open manual tube clamp and express a small amount of platelet and amotosalen mixture into tubing, 
filling about 1.5 inches of tubing.  Close manual clamp. 
9. Seal tubing between illumination container (  ) and amotosalen container (  ) within the 1.5 inches of 
tubing (See Figure 4).  
 
 
Figure 4 Heat Seal Filled Tubing Within 1.5 Inches 
 
 
10. Remove and discard empty platelet collection container, amotosalen container (  ) and excess tubing. 
 
II. Illumination 
Refer to INT100 Illuminator Operator’s Manual for detailed instructions.  
 
NOTE: The inactivation process requires unimpeded light transmission through tray and illumination container. 
The illumination container and tubing must be within the large compartment of the illuminator tray. Tray must be 
clean and free from labels or other material (see Figure 5). Illumination container should lay flat in order to 
ensure complete illumination.  
 
NOTE: During illumination, tubing must be held within large compartment of illumination tray (see below). 
 
  
Manual 
Tube Clamp 
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Figure 5 Proper Way to Load Processing Set Into the Illuminator Tray 
  
 
Corre
  Tubin
9 ct: 
g is correct length  
  and is placed completely   
  within the large area of tray    
  to receive UV exposure. 
 
Incorrect: 
  Tubing is too long and  
  protrudes outside of the 
x 
  large compartment   
  of illumination tray. 
Incorrect: 
  Labels on the illumination   
x 
  container may impede 
  exposure to UV light. 
Correct: 9 
  Labels, if present, are  
  located where they will not  
  block exposure to UV light. 
 
Corr
  Tray
 
9 ect: 
 is clean. 
Incorrect: 
  Air must be expressed  
  prior to treatment. 
 
x 
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III. Agitation with Compound Adsorption Device (CAD) 
Do not fold or bend CAD. 
1. Unwrap set from organizer. 
2. Hang platelets in illumination container (  ), break cannula (  ) and allow platelets to flow into CAD 
container (  ). 
3. Express air from CAD container (  ) into illumination container (  ).  Do not fold or bend CAD. 
4. Seal tubing close to inlet port of CAD container (  ). 
5. Remove and discard empty illumination container (  ) and excess tubing. 
6. Place CAD container (  ) flat on flatbed agitator with attached storage containers for 6-16 hours for 
Amicus platelets in PAS-3 or 12-24 hours for Trima platelets in 100% plasma.  Agitation rate must be at 
least 60 RPM.  Do not stop the process before the minimum time and do not extend the process beyond 
the maximum allowable time. 
7. Do not fold or place storage container (  ), in line filter, or any tubing under CAD container (  ) 
during agitation. 
 
IV. Transfer to Storage Container 
1. Remove platelets from agitator and hang platelets in CAD container (  ). 
2. Expel air from platelet sampling pouch into storage container and close clamps (  ). 
3. Break cannula (  ) at outlet of CAD container (  ) and allow platelets to flow into each of the two 
storage containers (  ). 
4. Express air from storage containers (  ) into CAD container (  ) and close clamp above the Y fitting. 
5. Redistribute volume between storage containers (  ) as needed. 
Note:  Steps 4 and 5 may be performed in the reverse order. 
6. Ensure appropriate donor identification is attached to each filled platelet storage container (  ). 
7. Seal tubing close to the outlet of the Y fitting as needed for each therapeutic dose of platelets.    
• For Amicus platelets in PAS-3:  If the input platelet dose to the INTERCEPT process is greater 
than or equal to 6.1x1011, the product should be stored in two separate containers.   
• For Trima platelets in 100% plasma:   
o If the input platelet dose to the INTERCEPT process is greater than or equal to 5.3x1011 
but smaller than 7.1 x 1011, the product should be stored in two connected containers. 
o If the input platelet dose to the INTERCEPT process is greater than or equal to 7.1x1011 
the product should be stored in two separate containers. 
8. Remove and discard empty CAD container (  ) and tubing. Place platelets on platelet agitator. 
 
The INTERCEPT treatment process is now complete. 
 
V. Sampling Platelet Product (optional) 
1. Mix INTERCEPT treated platelets by gently agitating platelet storage container. 
2. Open clamp ( ) to platelet sampling pouch and squeeze several times. 
3. Allow sampling pouch to fill with platelets. Seal tubing. 
4. Remove sample pouch. 
5. Transfer sample to appropriate laboratory tube immediately. 
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STORAGE AND HANDLING 
 
Processing Sets 
 
• Do not use if tamper-evident package has been opened, signs of deterioration are visible, fluid path 
closures are loose or not intact, cannulae are broken or if there is no fluid in the amotosalen solution 
container. 
• Protect the processing set package and tubing from sharp objects. Discard platelet product if there is a 
leak in the set during processing.  
• Keep processing sets in the light-protective, aluminum foil pouch until time of use.  Protect from direct 
sunlight and strong UVA light source. 
• Do not store processing set above 25°C.   
• Do not vent.   
• Do not freeze.   
• Unused processing sets may be stored for up to 20 days at room temperature (18 – 25oC) in the open 
aluminum foil pouch by folding and securing the open end of the pouch. Record the “Date Opened” and 
“Use By” date on the foil pouch label in the space provided. The processing sets removed from the 
aluminum foil pouch must be used within 8 hours. 
 
Platelet Components 
 
• Platelet components processed with the INTERCEPT Blood System must be stored in the platelet storage 
container provided in the INT2510 processing sets.  
• Processed platelet components may be stored at 20-24°C with continuous agitation for up to 5 days from 
the day of collection. 
 
NONCLINICAL TOXICOLOGY  
 
Nonclinical studies were conducted in mice, rats and dogs to evaluate the potential toxicity of single and repeated 
exposures to amotosalen, the synthetic psoralen derivative used in the INTERCEPT process to cross-link DNA 
and RNA.  A single, intravenous injection of amotosalen alone resulted in mortality in rats at doses equal to or 
greater than 100,000-fold the anticipated human clinical exposure from a single transfusion of INTERCEPT 
processed platelets as compared on a dose per kilogram body weight basis. Lower doses of amotosalen (12,000- 
or 60,000-fold greater than the anticipated human clinical exposure in dogs and rats, respectively) were not lethal, 
and resulted in transient clinical signs of toxicity (i.e. piloerection, inactivity, hunched posture and abnormal 
breathing in rats, and excessive salivation, swelling of the muzzle and eyelids, and non-lethal cardiac arrhythmias 
in dogs). No target organ toxicities were noted at necropsy.29  
 
Animal experiments with amotosalen provided no indication of an increased toxicological risk for the use of 
platelets treated using the INTERCEPT Blood System.  Repeat-dose toxicity studies in rats and dogs dosed by 
daily intravenous injection for 7 to 28 days with amotosalen, at doses with at least 30,000- and 10,000-fold, 
respectively, the anticipated clinical exposure from transfusion of 300 mL of INTERCEPT Blood System-
processed platelets showed no evidence of toxicity.29, 30 Transient, minor changes in hematology profiles with no 
correlating histopathology findings or major organ toxicities were reported in dogs dosed 3 times weekly for 13 
weeks with autologous platelets processed with the INTERCEPT Blood System, at a cumulative amotosalen 
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exposure of approximately 115-fold the anticipated clinical exposure following a single transfusion of 300 mL of 
INTERCEPT processed platelets.  
 
Amotosalen was rapidly eliminated in mice and rats with an initial plasma t1/2 of less than 1 hour. There was no 
evidence of amotosalen accumulation after repeated exposures over periods as long as 13 weeks. The primary 
route of excretion of amotosalen and its photoproducts was fecal.29 
 
No effects on fertility parameters were noted in male or female rats dosed with amotosalen. In studies evaluating 
the effects of amotosalen dosing of pregnant rats or rabbits on embryo-fetal or peri-postnatal development in 
pregnant rats and rabbits, and in one study dosing neonatal rats with amotosalen, there was no evidence of 
teratogenicity, or other reproductive or developmental toxicities.31 
 
No evidence of genotoxicity or mutagenicity was observed in the in vitro or in vivo mutagenicity studies of 
amotosalen. In transgenic mice heterozygous for the p53 tumor suppressor gene, there was no evidence of 
carcinogenicity after repeated three times weekly dosing with amotosalen for 6 months at cumulative weekly 
doses approximately 1200 times the daily human exposure from a single 300 mL transfusion of INTERCEPT 
Blood System-treated platelets.32 
 
CLINICAL STUDIES 
 
The safety and effectiveness of INTERCEPT processed platelets were investigated in 10 controlled clinical 
studies.33-42  A total of 844 study subjects received INTERCEPT processed platelets in these clinical studies.  
 
Three trials were conducted in healthy volunteers to measure the viability of INTERCEPT processed platelets and 
the clearance of residual amotosalen. 33,34  Three studies utilized small doses (15-20 mL) of radiolabelled platelets; 
and in one study a full therapeutic dose (300 mL) was administered.  All platelet components (PCs) were 
apheresis collections.  
 
The primary endpoint of the three studies with radiolabelled platelets was post-transfusion viability of autologous 
INTERCEPT processed platelets after 5 days of storage. Autologous platelets from healthy donors prepared with 
the prototype IBS System (no amotosalen reduction) and stored for 5 days before transfusion demonstrated mean 
post transfusion recovery 77.8 % of untreated PCs, and mean life span 74.5 % of untreated PCs. Similarly, 
autologous platelets from healthy donors prepared with the prototype IBS System (with amotosalen reduction) 
and stored for 5 days before transfusion demonstrated mean post transfusion recovery 84.5 % of untreated PCs 
and life span 80 % of untreated PCs. 
 
The primary endpoint of the full dose transfusion of INTERCEPT processed platelets was clearance of residual 
amotosalen.  Peak post transfusion amotosalen levels were < 1 ng/ml with clearance kinetics of residual 
amotosalen median terminal (T50 = 6.5 hr) with acceptable tolerability after rapid transfusion of a therapeutic 
platelet dose.34 
 
No clinically relevant adverse events were observed in healthy subjects exposed to small volumes of autologous 
radiolabeled platelets or after transfusion of 300 mL of autologous INTERCEPT treated platelet components. 
 
A randomized, controlled, double blind, parallel-group study to compare the therapeutic efficacy and safety of 
INTERCEPT processed apheresis platelet components to conventional apheresis platelet components using a non-
inferiority design was conducted in patients requiring 1 or more platelet transfusions to support hypoplastic 
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thrombocytopenia.35 The study was designed to assess the proportion of patients with Grade 2 bleeding during up 
to 28 days of platelet transfusion support.  A total of 645 patients (318 Test, 327 Reference) received a total of 
4719 platelet transfusions (2678 Test, 2041 Reference). There were 186/318 (58.5%) patients in the Test group 
and 188/327 (57.5%) patients in the Reference group with Grade 2 bleeding. The test result met the efficacy 
success criteria of the non-inferiority margin of 12.5%. Differences in mean number of transfusions, average 
interval between transfusions, rates of refractoriness, mean days with Grade 2 bleeding and mean count increment 
and corrected count increment at 1 and 24 hours were all statistically significantly different favoring the control 
group.  The targeted platelet transfusion dose was 3.7x1011.  Sixty percent of the subjects in the INTERCEPT 
processed platelet group received a platelet dose of less than 3x1011 compared to 36% in the control group.  
Additionally, subjects in the INTERCEPT processed platelet group received off-protocol transfusions (32 vs. 
15%) more often than the control group because of protocol violations.  In order to assess whether  the platelet 
dose could have impacted all these efficacy endpoint outcomes,  a post-hoc analyses on three different subsets of 
subjects: subjects who received transfusions dose of platelets ≥3x1011, subjects who received off-protocol 
transfusions, and subsets who received transfusions dose of platelets ≥3x1011 without any off-protocol 
transfusions was conducted.  In all the three subsets, a statistically significant difference was no longer seen in 
mean days with Grade 2 bleeding and in the mean number of platelet transfusions. Adjusting the platelet dose per 
unit to ≥3x1011 may overcome the differences of these outcomes seen in the original study analysis.36 
 
There were no differences between treatment groups in the frequencies of Grade 3 and Grade 4 adverse events, 
serious adverse events, or mortality. Statistically significant differences for increased incidence of four adverse 
events of Grade 3 and Grade 4 severity were observed among recipients of INTERCEPT processed platelets. 
These included: pneumonitis not otherwise specified (5 versus 0); ARDS (5 versus 0); hypocalcemia  
(21 versus 8); and syncope (6 versus 0). A subsequent blinded, retrospective analysis of patients with clinically 
significant pulmonary adverse events (n = 148) demonstrated no significant increase in incidence of acute lung 
injury (ALI), including ARDS.43  However a trend of increased ARDS in the patients receiving INTERCEPT 
processed platelets remained. The causality of these events remains uncertain and an increased risk of ARDS with 
the INTERCEPT processed platelets cannot be ruled out. 
 
Another randomized, double-blind, controlled, parallel-group trial was conducted to evaluate the efficacy and 
safety of apheresis INTERCEPT processed platelets prepared with the commercial INTERCEPT system 
compared to conventional apheresis PCs. A total of 43 adult hematology-oncology patients with hypoplastic 
thrombocytopenia (22 Test, 21 Reference) were enrolled at 3 study centers. INTERCEPT treatment was used in 
place of gamma irradiation for 93% of INTERCEPT PCs for prevention of TA-GVHD.  A total of 218 platelet 
components were transfused (103 Test and 115 Reference). The primary endpoint was the 1-hour platelet count 
increment.  There was no excess treatment related morbidity reported among patients supported with 
INTERCEPT processed platelet components. 
 
A single-arm, open label safety study of 560 INTERCEPT processed platelet transfusions in 51 adult patients with 
malignant hematology-oncology disorders, including HSCT was conducted to assess the frequency of acute 
transfusion reactions.38  Platelet concentrates were prepared from either apheresis collections or whole blood 
derived buffy coat platelets, treated with INTERCEPT in place of gamma irradiation, and stored up to 5 days 
prior to transfusion. The frequency of acute transfusion reactions was 1.6%. This study was small in size and 
uncontrolled therefore the rate of acute transfusion reactions cannot be compared with that for conventional 
platelets. 
 
A single-arm, open label observational study  to assess acute transfusion reactions using  apheresis “double unit” 
collections (5-6 x 1011) without gamma irradiation and stored up to 5 days was conducted in 46 adult hematology 
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patients with malignant disorders, including HSCT.39  A total of 551 INTERCEPT processed platelet transfusions 
were administered.in a Swiss Red Cross blood center.  The frequency of acute transfusion reactions was 2%. This 
study was small in size and uncontrolled therefore the rate of acute transfusion reactions cannot be compared with 
that for conventional platelets. 
  
Post-Marketing Studies  
 
Safety data were obtained from three hemovigilance (HV) programs in routine use without patient selection: the 
Cerus hemovigilance program and the regulatory surveillance programs in France and in Switzerland.44-57 
 
The populations monitored in the Cerus hemovigilance studies included 4,067 patients, where 59 patients were 
under the age of 1 year and 185 patients were 1-18 years of age.  51% of the patients enrolled in these studies 
were hematology-oncology patients, of which 12% were HSCT patients. Adverse events within 24 hours and 
serious adverse events within 7 days of platelet transfusion were reported.  The frequencies of adverse events 
attributed to INTERCEPT processed platelet transfusions were not increased compared to conventional platelet 
transfusions reported in European regulatory hemovigilance programs. 
 
Clinical Experience with Transfusion of INTERCEPT Platelets Suspended in 100% Plasma 
 
Cerus conducted an analysis of the CLI-HV 00079 study to support the current PMA supplement for the use of 
the INTERCEPT Blood System for platelets suspended in 100% plasma. The final report (CLI-HV 00079-2) 
included data for 502 INTERCEPT platelet components suspended in 100% plasma. This study was an 
observational safety study to detect adverse events (AEs) that if imputed as related to the transfusion were 
classified as transfusion reactions (TR). Adverse events related to failure of hemostasis in thrombocytopenic 
patients could be reported in this study. Five hundred and two INTERCEPT platelet components were 
administered to 169 patients. All patients received INTERCEPT platelet components for hematology-oncology 
related diseases including HSCT (99.4%) or surgery (0.6%).  
 
AEs were observed following transfusion of 5 INTERCEPT components (1.0%) in 4 patients (2.4%). No AEs 
were classified as “serious” (SAE) following transfusion of INTERCEPT PC. No adverse events related to 
bleeding or hemostatic failure were reported. The 4 patients who suffered an AE experienced chills (2 patients, 
1.2%), pain (1 patient, 0.6%), pyrexia (3 patients, 1.8%) and rash (1 patient, 0.6%). Based on a clinical causality 
assessment, these AEs were classified as febrile non-hemolytic transfusion reactions with expected signs and 
symptoms (pyrexia and rash), and HLA antibody associated with lower back pain. The patients recovered from 
these adverse events on the day of transfusion, no transfusions were interrupted due to any AE or transfusion 
reaction, and no patients died during the study. The types of AEs were representative of the types of events 
experienced by patients with transfusion-dependent thrombocytopenia and were consistent with the types of 
events commonly experienced by patients following transfusion of conventional platelet components according to 
published data and national hemovigilance programs. No transfusion related acute lung injury (TRALI), 
transfusion-related sepsis (TRS), or transfusion-associated graft versus host disease (TA-GVHD) were 
reported.  The frequencies of these AEs were comparable to historical data for conventional PCs 100% plasma.44-
57,58 Transfusions of INTERCEPT PCs were well tolerated during this observational study, and the study provides 
further clinical data to support the use of the INTERCEPT Blood System with platelets suspended in 100% 
plasma. 
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ANSM and Swissmedic Active HV Programs (France and Switzerland) 
 
Since 2009, INTERCEPT processed platelets suspended in PAS-3 (InterSol™) have been monitored in 
comparison to other types of platelet concentrates (suspended in PAS-3 or in 100% plasma) transfused in France  
and  Switzerland through a national hemovigilance program.48-57 In Switzerland, INTERCEPT processed platelets 
were phased into routine use during 2011, accounting for approximately 80% of all platelet concentrates 
transfused that year, and 100% of platelets produced thereafter.  No septic transfusion reactions due to bacterial 
contamination of platelets were observed after the introduction of INTERCEPT processed platelets in France or 
Switzerland. The number of TRALI reported to the HV systems during the years 2009-2013 is small, and the 
TRALI rates were similar in both groups. There were 6/187,142 TRALI cases per INTERCEPT processed platelet 
transfusions, for a TRALI rate of 0.33 per 10,000 platelet transfusion, compared to 37/1,109,135 TRALI cases per 
conventional platelet transfusions, for a rate of 0.32 per 10,000 platelet transfusions.  Limitations of the 
hemovigilance system include data collection that was limited to only transfusion associated AEs (TRALI, 
TACO, TAD, etc.) as assessed by the reporter.  
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